
<html lang="en"     class="pb-page"  data-request-id="8d6b1e94-7c95-4c49-a0cf-897f9d83b800"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-22;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.8b01161;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome" /></meta><meta name="dc.Creator" content="Stanley&#xA;C.  Xie" /></meta><meta name="dc.Creator" content="David L.  Gillett" /></meta><meta name="dc.Creator" content="Natalie J.  Spillman" /></meta><meta name="dc.Creator" content="Christopher  Tsu" /></meta><meta name="dc.Creator" content="Madeline R.  Luth" /></meta><meta name="dc.Creator" content="Sabine  Ottilie" /></meta><meta name="dc.Creator" content="Sandra  Duffy" /></meta><meta name="dc.Creator" content="Alexandra E.  Gould" /></meta><meta name="dc.Creator" content="Paul  Hales" /></meta><meta name="dc.Creator" content="Benjamin A.  Seager" /></meta><meta name="dc.Creator" content="Carlie L.  Charron" /></meta><meta name="dc.Creator" content="Frank  Bruzzese" /></meta><meta name="dc.Creator" content="Xiaofeng  Yang" /></meta><meta name="dc.Creator" content="Xiansi  Zhao" /></meta><meta name="dc.Creator" content="Shih-Chung  Huang" /></meta><meta name="dc.Creator" content="Craig A.  Hutton" /></meta><meta name="dc.Creator" content="Jeremy N.  Burrows" /></meta><meta name="dc.Creator" content="Elizabeth A.  Winzeler" /></meta><meta name="dc.Creator" content="Vicky M.  Avery" /></meta><meta name="dc.Creator" content="Lawrence R.  Dick" /></meta><meta name="dc.Creator" content="Leann  Tilley" /></meta><meta name="dc.Description" content="The Plasmodium proteasome represents a potential antimalarial drug target for compounds with activity against multiple life cycle stages. We screened a library of human proteasome inhibitors (pepti..." /></meta><meta name="Description" content="The Plasmodium proteasome represents a potential antimalarial drug target for compounds with activity against multiple life cycle stages. We screened a library of human proteasome inhibitors (pepti..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 29, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01161" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01161" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01161" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01161" /></link>
        
    
    

<title>Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01161" /></meta><meta property="og:title" content="Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0006.jpeg" /></meta><meta property="og:description" content="The Plasmodium proteasome represents a potential antimalarial drug target for compounds with activity against multiple life cycle stages. We screened a library of human proteasome inhibitors (peptidyl boronic acids) and compared activities against purified P. falciparum and human 20S proteasomes. We chose four hits that potently inhibit parasite growth and show a range of selectivities for inhibition of the growth of P. falciparum compared with human cell lines. P. falciparum was selected for resistance in vitro to the clinically used proteasome inhibitor, bortezomib, and whole genome sequencing was applied to identify mutations in the proteasome β5 subunit. Active site profiling revealed inhibitor features that enable retention of potent activity against the bortezomib-resistant line. Substrate profiling reveals P. falciparum 20S proteasome active site preferences that will inform attempts to design more selective inhibitors. This work provides a starting point for the identification of antimalarial drug leads that selectively target the P. falciparum proteasome." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01161"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01161">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01161&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01161&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01161&amp;href=/doi/10.1021/acs.jmedchem.8b01161" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 10053-10066</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01120" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01200" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Target Validation and Identification of Novel Boronate Inhibitors of the <i>Plasmodium falciparum</i> Proteasome</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Stanley C. Xie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stanley C. Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stanley%0AC.++Xie">Stanley C. Xie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David L. Gillett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David L. Gillett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+L.++Gillett">David L. Gillett</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Natalie J. Spillman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Natalie J. Spillman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Natalie+J.++Spillman">Natalie J. Spillman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher Tsu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher Tsu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Clinical R&D, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Tsu">Christopher Tsu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Madeline R. Luth</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Madeline R. Luth</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Host-Microbe Systems and Therapeutics Division, UC San Diego School of Medicine, La Jolla, California 92093, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Madeline+R.++Luth">Madeline R. Luth</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sabine Ottilie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sabine Ottilie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Host-Microbe Systems and Therapeutics Division, UC San Diego School of Medicine, La Jolla, California 92093, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sabine++Ottilie">Sabine Ottilie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sandra Duffy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sandra Duffy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sandra++Duffy">Sandra Duffy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alexandra E. Gould</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alexandra E. Gould</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Clinical R&D, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alexandra+E.++Gould">Alexandra E. Gould</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Hales</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Hales</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Clinical R&D, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Hales">Paul Hales</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Benjamin A. Seager</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benjamin A. Seager</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Benjamin+A.++Seager">Benjamin A. Seager</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carlie L. Charron</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carlie L. Charron</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carlie+L.++Charron">Carlie L. Charron</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Frank Bruzzese</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Frank Bruzzese</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Clinical R&D, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Frank++Bruzzese">Frank Bruzzese</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaofeng Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaofeng Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Clinical R&D, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaofeng++Yang">Xiaofeng Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiansi Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiansi Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Clinical R&D, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiansi++Zhao">Xiansi Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shih-Chung Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shih-Chung Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Clinical R&D, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shih-Chung++Huang">Shih-Chung Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Craig A. Hutton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Craig A. Hutton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Craig+A.++Hutton">Craig A. Hutton</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2353-9258" title="Orcid link">http://orcid.org/0000-0002-2353-9258</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeremy N. Burrows</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeremy N. Burrows</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicines for Malaria Venture, 1215 Meyrin, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeremy+N.++Burrows">Jeremy N. Burrows</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elizabeth A. Winzeler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elizabeth A. Winzeler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Host-Microbe Systems and Therapeutics Division, UC San Diego School of Medicine, La Jolla, California 92093, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth+A.++Winzeler">Elizabeth A. Winzeler</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4049-2113" title="Orcid link">http://orcid.org/0000-0002-4049-2113</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vicky M. Avery</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vicky M. Avery</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vicky+M.++Avery">Vicky M. Avery</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lawrence R. Dick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lawrence R. Dick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology Clinical R&D, Takeda Pharmaceuticals International Co., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lawrence+R.++Dick">Lawrence R. Dick</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Leann Tilley</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Leann Tilley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#0569716c6969607c45706b6c686069672b6061702b6470"><span class="__cf_email__" data-cfemail="2f435b4643434a566f5a4146424a434d014a4b5a014e5a">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Leann++Tilley">Leann Tilley</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9910-0199" title="Orcid link">http://orcid.org/0000-0001-9910-0199</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01161&amp;href=/doi/10.1021%2Facs.jmedchem.8b01161" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 10053–10066</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 29, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 July 2018</li><li><span class="item_label"><b>Published</b> online</span>29 October 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 21 November 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01161" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01161</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01161"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3103</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">29</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01161" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Stanley\nC.&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;L. Gillett&quot;},{&quot;first_name&quot;:&quot;Natalie&quot;,&quot;last_name&quot;:&quot;J. Spillman&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Tsu&quot;},{&quot;first_name&quot;:&quot;Madeline&quot;,&quot;last_name&quot;:&quot;R. Luth&quot;},{&quot;first_name&quot;:&quot;Sabine&quot;,&quot;last_name&quot;:&quot;Ottilie&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;Duffy&quot;},{&quot;first_name&quot;:&quot;Alexandra&quot;,&quot;last_name&quot;:&quot;E. Gould&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Hales&quot;},{&quot;first_name&quot;:&quot;Benjamin&quot;,&quot;last_name&quot;:&quot;A. Seager&quot;},{&quot;first_name&quot;:&quot;Carlie&quot;,&quot;last_name&quot;:&quot;L. Charron&quot;},{&quot;first_name&quot;:&quot;Frank&quot;,&quot;last_name&quot;:&quot;Bruzzese&quot;},{&quot;first_name&quot;:&quot;Xiaofeng&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Xiansi&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Shih-Chung&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Craig&quot;,&quot;last_name&quot;:&quot;A. Hutton&quot;},{&quot;first_name&quot;:&quot;Jeremy&quot;,&quot;last_name&quot;:&quot;N. Burrows&quot;},{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;A. Winzeler&quot;},{&quot;first_name&quot;:&quot;Vicky&quot;,&quot;last_name&quot;:&quot;M. Avery&quot;},{&quot;first_name&quot;:&quot;Lawrence&quot;,&quot;last_name&quot;:&quot;R. Dick&quot;},{&quot;first_name&quot;:&quot;Leann&quot;,&quot;last_name&quot;:&quot;Tilley&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;10053-10066&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01161&quot;},&quot;abstract&quot;:&quot;The Plasmodium proteasome represents a potential antimalarial drug target for compounds with activity against multiple life cycle stages. We screened a library of human proteasome inhibitors (peptidyl boronic acids) and compared activities against purified P. falciparum and human 20S proteasomes. We chose four hits that potently inhibit parasite growth and show a range of selectivities for inhibition of the growth of P. falciparum compared with human cell lines. P. falciparum was selected for resistance in vitro to the clinically used proteasome inhibitor, bortezomib, and whole genome sequencing was applied to identify mutations in the proteasome β5 subunit. Active site profiling revealed inhibitor features that enable retention of potent activity against the bortezomib-resistant line. Substrate profiling reveals P. falciparum 20S proteasome active site preferences that will inform attempts to design more selective inhibitors. This work provides a starting point for the identification of antimalarial drug lea&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01161&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01161" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01161&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01161" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01161&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01161" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01161&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01161&amp;href=/doi/10.1021/acs.jmedchem.8b01161" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01161" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01161" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01161%26sid%3Dliteratum%253Aachs%26pmid%3D30373366%26genre%3Darticle%26aulast%3DXie%26date%3D2018%26atitle%3DTarget%2BValidation%2Band%2BIdentification%2Bof%2BNovel%2BBoronate%2BInhibitors%2Bof%2Bthe%2BPlasmodium%2Bfalciparum%2BProteasome%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D22%26spage%3D10053%26epage%3D10066%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291528" title="Parasites">Parasites</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/jmcmar.2018.61.issue-22/20181121/jmcmar.2018.61.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/medium/jm-2018-01161a_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01161&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The <i>Plasmodium</i> proteasome represents a potential antimalarial drug target for compounds with activity against multiple life cycle stages. We screened a library of human proteasome inhibitors (peptidyl boronic acids) and compared activities against purified <i>P. falciparum</i> and human 20S proteasomes. We chose four hits that potently inhibit parasite growth and show a range of selectivities for inhibition of the growth of <i>P. falciparum</i> compared with human cell lines. <i>P. falciparum</i> was selected for resistance in vitro to the clinically used proteasome inhibitor, bortezomib, and whole genome sequencing was applied to identify mutations in the proteasome β5 subunit. Active site profiling revealed inhibitor features that enable retention of potent activity against the bortezomib-resistant line. Substrate profiling reveals <i>P. falciparum</i> 20S proteasome active site preferences that will inform attempts to design more selective inhibitors. This work provides a starting point for the identification of antimalarial drug leads that selectively target the <i>P. falciparum</i> proteasome.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75331" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75331" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Malaria remains a major health problem, threatening hundreds of millions of people and causing ∼440 000 deaths each year.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Current antimalarial control is highly dependent on artemisinin-based combination therapies (ACTs), which makes the emergence of artemisinin partial resistance extremely concerning.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a> Decreased ACT sensitivity delays the clearance of parasites from patients and leads to clinical failure, resulting in ∼50% treatment failure in regions where resistance is entrenched, compared with ∼2% failure in regions where resistance is rare.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> Replacement antimalarials are therefore urgently needed.</div><div class="NLM_p">The proteasome is a multisubunit enzyme complex that is responsible for proteostasis and for regulating key processes such as the cell cycle. It has a 20S catalytic core that includes two heptameric rings of β subunits. The β1 subunit provides caspase-like activity (cleaves after acidic residues), the β2 subunit trypsin-like activity (cleaves after basic residues), and the β5 subunit chymotrypsin-like activity (cleaves after nonpolar residues).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In cells exposed to oxidative stress or inflammatory cytokines, three of the active constitutive proteasome subunits are replaced by “immuno” subunits to form immunoproteasomes.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">Proteasome inhibitors show potential for the treatment of malaria, exhibiting parasiticidal activity against asexual blood stages, including young (ring stage) intraerythrocytic parasites, as well as sexual stage gametocytes and liver stage parasites,<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a> life stages that are resistant to most other chemotherapeutic agents. Moreover, inhibitors of the proteasome are active against both artemisinin-sensitive and -resistant parasites<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> and, indeed, strongly synergize artemisinin-mediated killing of <i>P. falciparum</i> in culture and <i>P. berghei</i> in vivo.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> To date, efforts to identify proteasome inhibitors as potential antimalarial compounds have concentrated on inhibitors with epoxyketone and vinyl sulfone warheads that bind irreversibly to the proteasome active site. A recent report examined noncovalent asparagine ethylenediamine (AsnEDA) inhibitors and revealed good cellular selectivity, but this class of inhibitors is not stable in vivo (half-life of ∼30 min) and thus is not active (when used alone) in a mouse model of malaria.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> If a potent, specific, and “drug-like” proteasome inhibitor could be identified, it would be a promising antimalarial compound in its own right and would be particularly effective in combination with artemisinins.</div><div class="NLM_p last">The reversible, covalent peptide boronate proteasome inhibitors bortezomib<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and ixazomib<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> are used clinically to treat multiple myeloma. Ixazomib is administered orally and offers a favorable efficacy/safety profile with weekly dosing delivered as a fixed dose.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> Bortezomib has been shown to have activity against <i>P. falciparum</i>,<a onclick="showRef(event, 'ref12 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref12 ref18 ref19">(12,18,19)</a> although it has not been formally demonstrated that this results from inhibition of the <i>P. falciparum</i> proteasome. In this work, we used in vitro directed evolution to generate bortezomib-resistant parasites, thereby validating the β5 subunit of the proteasome as the target. We screened a boronate peptide library to identify inhibitors of the growth of cultures of <i>P. falciparum</i> and selected compounds for further characterization. We show that inhibition of β5 activity is needed for potent antiplasmodial activity but that compounds that also inhibit β2 activity remain active against bortezomib-resistant parasites. Substrate profiling points to substrate preferences that can underpin the development of inhibitors with high specificity against <i>P. falciparum</i>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06827" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06827" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Establishment of an Assay of <i>P. falciparum</i> 20S Proteasome Activity</h3><div class="NLM_p">Purified <i>Pf</i>20S proteasome (see characterization in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S1A,B</a>) was activated using human proteasome activator complex (PA28αβ), and the activity was assessed using fluorogenic AMC-based substrates. Initial testing of a range of substrates (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S2A</a>) suggested the use of Ac-nLPnLD-AMC for caspase-like activity (β1 subunit), Ac-WLR-AMC for trypsin-like activity (β2 subunit), and Ac-WLA-AMC for chymotrypsin-like activity (β5 subunit). The activity of β2 and β5 subunits was completely abrogated by 0.8 μM carfilzomib (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S2B</a>), consistent with a previous report.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> By contrast, carfilzomib exhibited only weak inhibitory effect against <i>Pf</i>20S proteasome β1 activity (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S2B</a>).</div><div class="NLM_p last">To assess the level of proteasome activity contributed by the estimated human 20S proteasome contaminant (1 in 240), we compared the activity of 1 nM <i>Pf</i>20S with that of 0.005 nM human constitutive proteasome (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S2C</a>). Human β1c and β2c activities were not detected, and the fluorescence signal generated from β5c activity was only 2% of that from <i>Pf</i>20S β5.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Analysis of the Activities of Selected Compounds against <i>P. falciparum</i> and Mammalian Cell Lines</h3><div class="NLM_p">Peptide boronates from the library of the Takeda Oncology Company (Cambridge, MA, USA), were screened for inhibition of the growth of cultures of <i>P. falciparum</i> (3D7).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Further characterization of the compounds for activity against <i>Pf</i>20S and human 20S proteasome activity led to the selection of four compounds for further investigation, namely, malaria proteasome inhibitors (MPI-1, MPI-2, MPI-3, MPI-4; compounds <b>1</b>–<b>4</b>), as well as bortezomib itself (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). The pinane esters of MPI-1 to -4 (compounds <b>7</b>–<b>10)</b> were resynthesized and characterized in-house (see <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> and <a class="ref internalNav" href="#sec4" aria-label="Experimental Methods">Experimental Methods</a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Analysis of MPI-1, MPI-2, MPI-3, MPI-4 as inhibitors of the activity of purified <i>Pf</i>20S and human 20S proteasome, in fluorogenic peptide assays, revealed that they exhibit good inhibition of both β2 and β5 activities of <i>Pf</i>20S (MPI-3 and MPI-4) or more selective inhibition of β5 activity (MPI-1, MPI-2 and bortezomib) (as summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). MPI-3 and -4 are more active against <i>P. falciparum</i> β2 than human β2c or β2i. However, all four compounds were more active against the β1 and β5 activities of the human 20S isoforms (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). While the levels of selectivity are less dramatic than in a recent study of asparagine ethylenediamine (AsnEDA) inhibitors,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> those assays were performed in the presence of 0.5 μM WLW-vinyl sulfone, which acts synergistically with inhibitors of <i>Pf</i>20S β5.<a onclick="showRef(event, 'ref11 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref13">(11,13)</a></div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/medium/jm-2018-01161a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of MPI Pinane Esters<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01161&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc-<span class="smallcaps smallerCapital">l</span>-alanine, T3P, Et<sub>3</sub>N, DCM, room temperature, 73%; (b) 4 M HCl in dioxane, Et<sub>2</sub>O, DCM, room temperature, 93%; (c) (<i>R</i>)-(+)-<i>N</i>-acetylproline, T3P, Et<sub>3</sub>N, DCM, room temperature, 38%.</p></p></figure><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/medium/jm-2018-01161a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures, proteasome inhibition, and isobologram analysis of selected compounds. (A) Structures of MPI-1, MPI-2, MPI-3, and MPI-4 (compounds <b>1</b>–<b>4</b>). (B) GFP-DD transfectants were maintained in Shield-1 for 24 h before wash-out prior to setting up experiments. Trophozoites were re-exposed to Shield-1 or exposed to indicated compounds for 3 h. Results are representative of four independent experiments. (i) Cell extracts were analyzed by Western blot using anti-GFP or anti-<i>Pf</i>BiP as a loading control. (ii) GFP fluorescence measured by flow cytometry. Dotted line represents background (fluorescence of sample after washout of Shield-1). Data are the mean ± range/2 for the readings in technical duplicate from one experiment. Curves are fitted with the sigmoidal four-parameter model. (C) Isobologram analysis of the interaction of test compounds and DHA. Cam3.II (DHA resistant) parasites at very early ring stages were subjected to 3 h pulses in the presence of different combinations of DHA and test compounds. The left side of each panel presents the isobolograms for the test compound–DHA pair at the 50% LD<sub>50</sub>(3 h) level. The right side of each panel shows the influence of sublethal concentrations of the test compounds (indicated in figure) on the dose–response profile of DHA. Data shown are representative of three independent experiments. Error bars, where present, correspond to the range of technical duplicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01161&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Summary of Inhibitory Activities of Selected Compounds against Purified <i>P. falciparum</i> and Human 20S Proteasome<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="4" align="center">(A)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center"><i>Plasmodium falciparum</i> 20S proteasome IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">β1</th><th class="colsep0 rowsep0" align="center">β2</th><th class="colsep0 rowsep0" align="center">β5</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-1</td><td class="colsep0 rowsep0" align="left">3.19 ± 0.04</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">1.5 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-2</td><td class="colsep0 rowsep0" align="left">3.0 ± 0.5</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">2.9 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-3</td><td class="colsep0 rowsep0" align="left">1.78 ± 0.48</td><td class="colsep0 rowsep0" align="left">0.07 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.016 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-4</td><td class="colsep0 rowsep0" align="left">0.6 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.06 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.010 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bortezomib</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.08</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.3</td><td class="colsep0 rowsep0" align="left">0.053 ± 0.004</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="4" align="center">(B)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center"><i>Homo sapiens</i> 20S constitutive proteasome IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">β1c</th><th class="colsep0 rowsep0" align="center">β2c</th><th class="colsep0 rowsep0" align="center">β5c</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-1</td><td class="colsep0 rowsep0" align="left">3.4 ± 0.9</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.22 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-2</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.07</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.097 ± 0.009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-3</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.2</td><td class="colsep0 rowsep0" align="left">0.44 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.009 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-4</td><td class="colsep0 rowsep0" align="left">0.052 ± 0.004</td><td class="colsep0 rowsep0" align="left">0.68 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.0014 ± 0.0003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bortezomib</td><td class="colsep0 rowsep0" align="left">0.09 ± 0.02</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.006 ± 0.001</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="4" align="center">(C)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center"><i>Homo sapiens</i> 20S immunoproteasome IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">β1i</th><th class="colsep0 rowsep0" align="center">β2i</th><th class="colsep0 rowsep0" align="center">β5i</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-1</td><td class="colsep0 rowsep0" align="left">0.008 ± 0.002</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.028 ± 0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-2</td><td class="colsep0 rowsep0" align="left">0.013 ± 0.002</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.063 ± 0.008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-3</td><td class="colsep0 rowsep0" align="left">0.029 ± 0.005</td><td class="colsep0 rowsep0" align="left">0.13 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.005 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-4</td><td class="colsep0 rowsep0" align="left">0.005 ± 0.001</td><td class="colsep0 rowsep0" align="left">0.30 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.0013 ± 0.0002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bortezomib</td><td class="colsep0 rowsep0" align="left">0.005 ± 0.002</td><td class="colsep0 rowsep0" align="left">0.54 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.0020 ± 0.0004</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values of selected compounds against <i>Pf</i>20S proteasome (A), human constitutive proteasome (B), and immunoproteasome (C) are shown. Data represent the mean ± SEM for three independent experiments.</p></div></div></div><div class="NLM_p">MPI-4 was chosen for a detailed kinetic analysis because it exhibited some selectivity for <i>P. falciparum</i> β2 compared with human constitutive β2 (β2c) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>A,B). It shows very rapid and tight (<i>K</i><sub>i</sub> = 0.13 nM) binding to the human β5c but weaker affinity for <i>P. falciparum</i> β5 (<i>K</i><sub>i</sub> = 4.3 nM) (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S3B,D</a>). Binding to the human β2c is very weak (<i>K</i><sub>i</sub> = 487 nM), while binding to <i>P. falciparum</i> β2 is relatively stronger (<i>K</i><sub>i</sub> = 6.4 nM) (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S3A,C</a>).</div><div class="NLM_p">Peptide boronates are covalent, slowly reversible inhibitors,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> with bortezomib exhibiting a <i>t</i><sub>1/2</sub> value of ∼110 min for dissociation from the β5 site.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> We found that MPI-4 exhibited a similar <i>t</i><sub>1/2</sub> at the human β5c site (106 min, <i>K</i><sub>i</sub> = 0.1 nM) but only 2 min (<i>K</i><sub>i</sub> = 490 nM) at the β2c site (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S3A</a>), indicating it is only tightly bound at the human β5c site. In contrast, MPI-4 bound to both the β2 and β5 sites of <i>Pf</i>20S with high affinity (∼5 nM) and extended <i>t</i><sub>1/2</sub> (∼65 min). This indicates a key difference between the <i>P. falciparum</i> β2 and human β2c sites, potentially arising from the open conformation of the <i>P. falciparum</i> β2-binding pocket compared to the human proteasome,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> which might be exploited in the development of <i>Pf</i>20S selective inhibitors.</div><div class="NLM_p">Careful reanalysis of dose–response profiles (<i>n</i> = 3) against 3D7 parasites revealed 50% viability inhibitory concentration values of ∼0.06 μM for MPI-3, MPI-4 and bortezomib (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>A). MPI-1 and MPI-2 exhibited only ∼2-fold weaker parasite killing activity (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>A), despite their several-fold weaker activities against <i>P. falciparum</i> β5 and very poor activity against <i>P. falciparum</i> β2 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). This suggests that extended exposure to weaker inhibitors of β5 can still induce parasite killing.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Activity of Selected Compounds and Bortezomib against <i>P. falciparum</i> and Mammalian Cancer Cell Lines<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="5" align="center">(A)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center"><i>Pf</i>3D7 LD<sub>50</sub> (72 h) (μM)</th><th class="colsep0 rowsep0" align="center">HCT116 LD<sub>50</sub> (72 h) (μM)</th><th class="colsep0 rowsep0" align="center">HepG2 LD<sub>50</sub> (72 h) (μM)</th><th class="colsep0 rowsep0" align="center">selectivity (HepG2 LD<sub>50</sub>)/(<i>Pf</i>3D7 LD<sub>50</sub>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-1</td><td class="colsep0 rowsep0" align="left">0.12 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.79 ± 0.01</td><td class="colsep0 rowsep0" align="left">6.7 ± 3.2</td><td class="colsep0 rowsep0" align="left">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-2</td><td class="colsep0 rowsep0" align="left">0.16 ± 0.02</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.3</td><td class="colsep0 rowsep0" align="left">2.4 ± 0.73</td><td class="colsep0 rowsep0" align="left">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-3</td><td class="colsep0 rowsep0" align="left">0.065 ± 0.004</td><td class="colsep0 rowsep0" align="left">0.027 ± 0.002</td><td class="colsep0 rowsep0" align="left">0.26 ± 0.06</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-4</td><td class="colsep0 rowsep0" align="left">0.061 ± 0.007</td><td class="colsep0 rowsep0" align="left">0.025 ± 0.014</td><td class="colsep0 rowsep0" align="left">0.04 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bortezomib</td><td class="colsep0 rowsep0" align="left">0.06 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.006 ± 0.001</td><td class="colsep0 rowsep0" align="left">0.03 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.5</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="3" align="center">(B)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">Cam3.II<sup>R539T</sup> LD<sub>50</sub> (3 h) (μM)</th><th class="colsep0 rowsep0" align="center">Cam3.II<sup>Rev</sup> LD<sub>50</sub> (3 h) (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-1</td><td class="colsep0 rowsep0" align="left">0.82 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.9 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-2</td><td class="colsep0 rowsep0" align="left">1.5 ± 0.2</td><td class="colsep0 rowsep0" align="left">1.8 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-3</td><td class="colsep0 rowsep0" align="left">0.19 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.21 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-4</td><td class="colsep0 rowsep0" align="left">0.16 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.18 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bortezomib</td><td class="colsep0 rowsep0" align="left">0.12 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.18 ± 0.06</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup><sup>a</sup></sup><p class="last">(A) Analysis of toxicity against 3D7 parasites and mammalian cancer cell lines. Sorbitol-treated ring stage parasites were incubated with the compounds, and viability was assessed in the next cycle (at ∼72 h). Data represent the mean ± SEM for three independent experiments. HCT116 or HepG2 cells were incubated with the compounds for 72 h before the viability was measured. Data represent the mean ± SEM or half range for 2–4 independent experiments, each performed in triplicate (HCT116) or duplicate (HepG2). (B) Pulsed exposure analysis of inhibition of the growth and viability of artemisinin-sensitive and -resistant parasites. Synchronized early ring parasites (1–3 h p.i.) were exposed to compounds for 3 h, and viability was assessed in the next cycle. Data represent the mean ± SEM for three independent experiments.</p></div></div></div><div class="NLM_p">To investigate the ability of the compounds to inhibit <i>P. falciparum</i> proteasome activity in cells, we made use of transfectants expressing GFP fused to a destabilization domain (DD),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> which, when destabilized, is targeted for degradation in a proteasome-dependent manner. Addition of a protective ligand, Shield-1, stabilizes the fusion protein and prevents GFP-DD degradation, leading to an accumulation of full-length protein (as assessed by Western blotting) as well as an increase in the fluorescence signal from the GFP reporter (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>Bi,ii). Inhibition of the proteasome, using bortezomib, prevented GFP-DD degradation in the absence of Shield-1, as indicated by the accumulation of the full-length protein (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>Bi) and an increase in the fluorescence signal (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>Bii). Treatment with MPI-4 had a similar effect, while a higher concentration of MPI-1 was needed to produce the same level of inhibition of GFP-DD degradation (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>Bi,ii). These data are consistent with the novel inhibitors exerting their activity by disrupting proteasome-dependent degradation.</div><div class="NLM_p">Mutations in a Kelch domain protein of unclear function (K13-propeller; PF3D7_1343700) are associated with decreased artemisinin sensitivity in vivo<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and reduced sensitivity of very early ring stage parasites in a pulse assay format in vitro.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> We examined the activity of the novel proteasome inhibitors in a 3 h pulsed exposure against a K13 mutant field strain from Cambodia (Cam3.II<sup>R539T</sup>) and an isogenic line (Cam3.II<sup>rev</sup>), in which the <i>K13</i> wild-type genotype has been restored and sensitivity to dihydroartemisinin (DHA) regained.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> All compounds exhibited similar activity against K13 wild-type and mutant parasites (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>B). MPI-1 and MPI-2 showed relatively weaker activity than MPI-3 and MPI-4 in this 3 h pulse assay, suggesting a slower mode of action or a faster off-rate.</div><div class="NLM_p">We next examined the activities (72 h exposure) of the selected compounds against a colorectal carcinoma cell line, HCT116, that is particularly susceptible to proteasome inhibitors<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and against the human hepatoma cell line, HepG2, that has been used frequently to assess selectivity in the screening of antimalarial compounds.<a onclick="showRef(event, 'ref11 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref11 ref28 ref29">(11,28,29)</a> While bortezomib exhibited 2-fold higher potency against HepG2 compared with <i>P. falciparum</i>, MPI-1 was 56 times more effective against <i>P. falciparum</i> cultures compared to the HepG2 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>A). This represents a 112-fold improvement in selectivity relative to bortezomib. These data indicate that compounds that exhibit weaker binding to the human β5 subunit (see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) permit better tolerability while retaining reasonable activity against <i>P. falciparum</i>.</div><div class="NLM_p last">We have previously shown that the clinically used proteasome inhibitor, bortezomib, is a potent inhibitor of the growth of <i>P. falciparum</i> in culture and exhibits strong synergism with the clinically relevant artemisinin, DHA.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Similarly, both MPI-1 and MPI-4 exerted a pronounced synergistic interaction with DHA against the early ring stages of the K13 mutant isolate, Cam3.II<sup>R539T</sup> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> In Vitro Evolution of Bortezomib-Resistant Parasites and Validation of the Inhibitor Target</h3><div class="NLM_p">In an effort to confirm that the peptide boronates exert their antiplasmodial activity via direct binding to one or more proteasome subunits and to determine the residues that are important for the inhibitory activity, we selected <i>P. falciparum</i> for resistance to bortezomib, followed by whole genome sequencing. This approach has been used successfully to identify and characterize the targets of a number of antiparasitic compounds.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a></div><div class="NLM_p">Multiple cloned lines of 3D7 were subjected to gradually increasing concentrations of bortezomib over a period of about 30 weeks. Two independent resistant lines (B1, B2) were obtained (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S4</a>) and cloned by limiting dilution. The selected clones (B1a, B2a) exhibited an approximately 20-fold increase in the 50% inhibitory concentration (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>A). The resistance phenotype was stable to freezing and thawing of the parasite clones. Whole genome sequencing was performed on the parental <i>P. falciparum</i> 3D7 clone and three independent clones (B1a,b,c; B2a,b,c) from each of the resistant lines selected with bortezomib. These six genomes yielded on average 26 million (26 191 102) reads with an average read length of 100 bp. Of these, 99.1% mapped to the <i>P. falciparum</i> reference genome (PlasmoDB version 13.0). An average coverage of 87.4% was obtained with an average of 97.7% of the genome covered by five or more reads (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Table S1</a>). Aligning each sequence as well as the drug-sensitive parent clone sequence to the reference 3D7 line revealed that each of the B1 and B2 clones had acquired a single C → A/T nucleotide variant (at Pf3D7_10, position 441,641), while the B1 line had an additional T→ A variant (at Pf3D7_10, position 441,617). These changes are predicted to result in mutations in <i>Pf</i>20S β5 (line B1, Met45Ile and Leu53Phe; line B2, Met45Ile) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). The data also indicate a high degree of specificity: only two other newly emerged high-quality missense variants were detected among the 138 million bases scanned. These included a Gly425Asp change in in eukaryotic translation initiation factor 2 γ subunit (PF3D7_1410600, all B2 clones) and a Gln60His variant in a predicted dicarboxylate/tricarboxylate carrier protein (PF3D7_0823900) in one B2 clone (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Table S2</a>). No obvious copy number variants (CNVs) were observed in any of the selected lines.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/medium/jm-2018-01161a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Sequence analysis of bortezomib-resistant parasites. (A) Comparison of sequences of β5 subunits of human and <i>Pf</i>20S. Residue positions are calculated at the start of the processed protein, and the first residue (Thr 1) is shown in red and underlined. Mutations that have been selected in human and <i>P. falciparum</i> cell lines are highlighted in yellow and green, respectively. (B) Molecular model of β5 subunit of <i>Pf</i>20S (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fmg">5fmg</a>) illustrating the Met45 and Leu53 residues that are mutated upon selection for resistance to bortezomib. (C) Mutations are located close to the anticipated bortezomib-binding pocket. Met45 and Leu53 residues are colored in gray. Residues shown in bold and underlined in (A) or marked with asterisks (T1, G47, A49, and A50) in (C) are identical in the yeast and human proteasome β5 subunit and/or have been shown to form direct hydrogen bonding interactions with bortezomib.<a onclick="showRef(event, 'ref22 ref33'); return false;" href="javascript:void(0);" class="ref ref22 ref33">(22,33)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01161&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory Activity of Bortezomib and Selected Compounds against Bortezomib-Resistant Parasites<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center">(A)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parasite</th><th class="colsep0 rowsep0" align="center">LD<sub>50</sub> (72 h) (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3D7 parent</td><td class="colsep0 rowsep0" align="left">0.06 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3D7 B1a</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3D7 B2a</td><td class="colsep0 rowsep0" align="left">1.1 ± 0.1</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center">(B)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">bortezomib-resistant 3D7 B1 line LD<sub>50</sub> (72 h) (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-1</td><td class="colsep0 rowsep0" align="left">0.23 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-2</td><td class="colsep0 rowsep0" align="left">>2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-3</td><td class="colsep0 rowsep0" align="left">0.054 ± 0.007</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPI-4</td><td class="colsep0 rowsep0" align="left">0.077 ± 0.001</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup><sup>a</sup></sup><p class="last">(A) Full-cycle analysis of bortezomib inhibition of wild-type and bortezomib-resistant clones. Sorbitol-treated ring stage parasites were incubated with bortezomib for 72 h, and viability was assessed. Data represent the mean ± SEM for three independent experiments. (B) Full-cycle analysis of inhibition of bortezomib-resistant parasites. Sorbitol-treated ring stage parasites were incubated with the compounds for 72 h, and viability was assessed. Data represent the mean ± SEM for three independent experiments.</p></div></div></div><div class="NLM_p">In the yeast and human β5 subunit, the boron atom covalently interacts with the active site Thr1 and the interaction is further stabilized by the hydrogen bonding network between bortezomib and several closely located residues (i.e., Thr21, Gly47, Ala49, and Ala50).<a onclick="showRef(event, 'ref22 ref32'); return false;" href="javascript:void(0);" class="ref ref22 ref32">(22,32)</a> The proteasome β5 subunit in <i>P. falciparum</i> has the identical Gly47, Ala49 and Ala50 residues (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A,C). The structure of <i>Pf</i>20S has been solved using cryoEM (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fmg">5fmg</a>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> As illustrated in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C, the mutations are in residues that lie close to the expected bortezomib-binding pocket.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Met45 in the yeast and human β5 subunits has been shown to undergo a conformational change to drive induced fit binding of bortezomib into the S1 pocket in the β5 active site.<a onclick="showRef(event, 'ref22 ref32'); return false;" href="javascript:void(0);" class="ref ref22 ref32">(22,32)</a> Of interest, a Met45Val mutation is readily selected when human cells evolve resistance to bortezomib,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and the equivalent Met120Ile mutant was observed in some patients under prolonged treatment with bortezomib<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and was selected when yeast was rendered resistant to a peptide epoxyketone inhibitor with good activity against <i>P. falciparum</i>.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p">Overlay of the <i>Pf</i>20S β5 structure and the crystal structure of the human 20S with bound bortezomib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5lf3">5lf3</a>) reveals close conservation of the residues lining the active site (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S5A</a>). In the overlaid <i>Pf</i>20S structure, Met45 is positioned unfavorably with respect to the bortezomib P1 leucine (predicted distance 1.8 Å; <a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S5B</a>). This indicates that, as is the case for the yeast active site,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Met45 would need to be repositioned for bortezomib binding. PyMol<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> was used to model the Met45Ile mutation in silico (without energy minimization). The distance between the bortezomib P1 substituent (Leu) and Ile45 in <i>Pf</i>20S β5 is predicted to increase to 3.5 Å (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S5C</a>). The increased distance and the inflexibility of the branched β-carbon of Ile45 may alter the local conformation at this site and/or inhibit the conformational changes in the S1 pocket that are needed for induced fit bortezomib binding.</div><div class="NLM_p">Interestingly, clone B1a has an additional mutation (Leu53) in <i>Pf</i>20S β5 and exhibits a moderately higher level of resistance than clone B2a. This additional mutation is located close to Met45 in the proteasome structure. A mutation in Cys52 (which lies adjacent to the Leu53 residue in <i>P. falciparum</i>) has been observed in human cell lines selected for bortezomib. The Leu53Phe mutation places a bulky hydrophobic group close to the P1 pocket of <i>Pf</i>20S β5 (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S5D</a>) and may cause additional alterations in the local conformation of the active site that inhibit bortezomib binding. Taken together, these data confirm that the β5 activity of the <i>P. falciparum</i> proteasome is the main target of bortezomib.</div><div class="NLM_p last">We examined the abilities of the novel compounds to inhibit the growth of the bortezomib-resistant parasite line (B1). The resistant parasites showed very strong cross-resistance to MPI-2 and weaker (2-fold) cross-resistance to MPI-1 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>A, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>B). Interestingly, the bortezomib-resistant parasite line retained sensitivity to compounds MPI-3 and MPI-4, suggesting that co-inhibition of β2 activity can overcome the resistance phenotype. This is consistent with a recent study<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> that revealed marked synergism of inhibitors of <i>Pf</i>20S β2 and β5. The resource of bortezomib resistant parasites will provide a valuable underpinning for further efforts to design and validate inhibitors.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Active Site Probe Analysis of Proteasome Subunit Specificity</h3><div class="NLM_p">A fluorescent activity probe (BMV037) contains an epoxyketone peptidic scaffold based on carfilzomib.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> We synthesized BMV037 using a procedure modified from the published method<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Supporting Information</a>). We treated purified <i>Pf</i>20S (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) or intact <i>P. falciparum</i> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B) with different concentrations of the novel compounds. Residual proteasome activity in the treated purified <i>Pf</i>20S or in lysates generated from the treated intact <i>P. falciparum</i>-infected erythrocytes was detected using BMV037. In the absence of inhibitors, the β5 and β2 subunits are labeled most efficiently, with label also incorporated into the β1 subunit (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,B, left lanes), consistent with previous reports.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> Upon treatment of infected erythrocytes with bortezomib, preferential inhibition of the β5 activity is observed (as indicated by an increase in the ratio of β2 to β5 labeling), with some inhibition of β1 activity (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). This is consistent with activity assay results for the purified proteasome (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and similar to the profile of inhibition in human cells.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Similarly, MPI-1 and MPI-2 preferentially inhibited binding of the probe to the β5 subunit. By contrast, MPI-3 and MPI-4 inhibited both β2 and β5 activities (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,B).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/medium/jm-2018-01161a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Active site probe analysis of the proteasome subunit specificity of the selected compounds in 3D7 parent and bortezomib-resistant parasites. Purified <i>Pf</i>20S proteasome from wild-type 3D7 (A) and bortezomib-resistant (C) parasites or wild-type 3D7 (B) and bortezomib-resistant (D) trophozoite-infected erythrocytes were treated with compounds for 1 h, and activity-based probe (BMV037) labeling was performed (postlysis for the trophozoite samples). Fluorescent gel scans reveal subunits that remain active after treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01161&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next analyzed the specificity of the compounds against the active sites in purified human 20S proteasome preparations (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S6</a>). BMV037 was incorporated into all the catalytic sites of human constitutive proteasome and immunoproteasome (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S6</a>, left lanes), with a labeling profile similar to that observed in previous studies.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> In agreement with the inhibitory activities assessed using the fluorogenic assay (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>B,C), bortezomib preferentially inhibits the β1 and β5 subunits of the human constitutive proteasome and immunoproteasome (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S6</a>). Similarly, MPI-3 and MPI-4 exhibited preferential inhibition of the β1 and β5 subunits. Interestingly, despite MPI-3 exhibiting a low IC<sub>50</sub> value (9 nM) against β5 activity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>B), labeling of the human β1 and β5 subunits was still evident after the treatment with 1 μM MPI-3, especially for the constitutive proteasome. This could be caused by the higher reversibility of MPI-3. MPI-2 preferentially inhibited β1c and β5i and was the only compound that displayed differential inhibition of the constitutive proteasome and immunoproteasome. This differential specificity was not observed in the fluorogenic assay, probably due to the small differences in IC<sub>50</sub> values (<5-fold) between β1 and β5 sites. MPI-1 preferentially targeted the β5 subunits of both the constitutive proteasome and immunoproteasome but did not completely ablate binding of the probe to β5c, even at a concentration of 10 μM, again suggesting reversibility of binding.</div><div class="NLM_p">We examined the activity probe profile in bortezomib-resistant parasites. In the absence of inhibitors, BMV037 labeled all three subunits (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C,D), indicating that the carfilzomib-based probe is still able to bind, despite the changes to the β5 active site. As anticipated, bortezomib was unable to prevent binding of the probe in the resistant parasites, consistent with decreased binding of bortezomib to β5. The competition profile for MPI-3 was very similar in the bortezomib-resistant and wild-type parasites (compare <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C), consistent with the maintenance of activity of this compound against bortezomib-resistant parasites. Similarly, MPI-1 was still able to prevent BMV037 labeling of the β5 active site, consistent with the maintenance of substantive killing activity, while MPI-2 was no longer able to prevent BMV037 labeling of the β5 active site, consistent with the loss of parasite killing activity. Of particular interest, MPI-4 was able to completely inhibit BMV037 labeling of the β2 active site but did not prevent labeling of the β5 active site. This suggests that MPI-4 occupancy of the β5 active site is decreased. The maintenance of activity of this compound against bortezomib-resistant parasites suggests that strong inhibition of the β2 active site (plus potentially weaker, reversible inhibition of β5 activity) is sufficient for parasite killing. This is consistent with a previous study<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> showing that inhibitor occupancy of β2 can potentiate proteasome inhibition by weaker inhibitor binding to β5. This insight will guide efforts to generate inhibitors that are more refractory to the development of resistance.</div><div class="NLM_p last">Interestingly, a recent study examined the activity of AsnEDA β5 inhibitor<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and proposed the extension of the inhibitor to the S4 pocket which is solvent-exposed and formed by amino acid residues of β6. This points to different modes of binding that can be exploited to further enhance specificity. For example, extending the peptidyl boronic acid structures so that they access this pocket could result in improved activity.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Proteasome Substrate Profiling</h3><div class="NLM_p">To determine differences in substrate preference that could be exploited in further development of inhibitors that specifically target the <i>P. falciparum</i> proteasome, we screened a large library of AMC-based discrete tripeptide substrates (i.e., 5920 of 8800 theoretical Ac-P3-P2-P1-AMC substrates).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Positions adjacent to the cleavage site are referred to as the P3, P2, and P1 positions (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A–C and <a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">S7A,B</a>). The majority of the substrates are preferentially cleaved by the human constitutive proteasome and immunoproteasome (compare <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B, and <a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S7A</a>). The profile is generally less active and narrower for <i>Pf</i>20S; however, residues in some positions do confer some specificity toward <i>Pf</i>20S.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/medium/jm-2018-01161a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>Pf</i>20S and human 20S constitutive (c20S) proteasome substrate profiling and validation of active and selective substrates for <i>P. falciparum</i> proteasome. Human and <i>P. falciparum</i> proteasome activity was measured using a library of AMC-based tripeptide substrates to determine cleavage preferences for each P position. Substrate specificity at P1, P2, and P3 positions was examined for <i>Pf</i>20S (A) and human constitutive (B) proteasomes. The <i>Y</i>-axis shows the average cleavage rate. Correlation between substrate sequence at each position and average cleavage activity by the proteasome is displayed. Cleavage rate for each substrate is normalized to Ac-WLR-AMC activity (×1000). B indicates either aspartic acid or asparagine. O is pyrrolysine. (C) Selectivity for <i>Pf</i>20S proteasome compared with human constitutive proteasome. The ratio of <i>Pf</i>20S to human constitutive proteasome cleavage activity is plotted based on the residues at P1, P2, and P3 positions. (D) Validation of selected substrates with <i>Pf</i>20S and human constitutive proteasomes. The cleavage rate for each substrate is normalized to Ac-WLR-AMC activity (×1000). Data shown are the mean ± SEM from three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01161&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, <i>Pf</i>20S activity is enhanced for substrates with tryptophan (W) at both the P2 and P3 positions (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). By contrast, human 20S exhibited poor selectivity at P2 but also preferred tryptophan at P3 position (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B and <a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">S7A</a>). In human 20S, preference for tryptophan at P2 generally results from β2 or β5 activity, while it may select for β1 and β2 when it is at the P3 position. Aspartic acid (D), leucine (L), histidine (H), tryptophan (W), arginine (R), and tyrosine (Y) are all favored by <i>Pf</i>20S at the P1 position (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). The data are somewhat different from a previous study,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> which suggested that <i>Pf</i>20S prefers aromatic residues at P1 and P3 due to the more open conformation of the β2-binding pocket compared to the human proteasome. Our data suggest a broader preference profile at P1 and a preference for tryptophan at P3, but the preference for tyrosine or phenylalanine is not as pronounced. Substrate preferences for human constitutive proteasome and immunoproteasome were very similar (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B and <a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">S7A</a>). The only apparent difference was the increased tolerance of large hydrophobic residues (i.e., F, W, Y) by the immunoproteasome at the P1 and P2 positions.</div><div class="NLM_p">Because the proteasome harbors three different catalytic sites, it is difficult to pinpoint which β subunit is responsible for the cleavage of a particular substrate. Our <i>Pf</i>20S substrate profiling method has the advantage that P2 and P3 preferences can be assigned to a particular P1 residue and has previously been used to profile several other mammalian and bacterial proteasomes.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> It also can identify individual peptides with especially high activity or selectivity for one active site versus another, whereas these trends may be muted in pooled library approaches. Such substrates can be used directly in further biochemical assays.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><div class="NLM_p">Differences in the substrate profiles of <i>Pf</i>20S and human constitutive 20S are illustrated by the correlation plot of the substrate library (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Figure S8</a>), with many of the selective substrates associated with a high rate of cleavage by their respective targets. The <i>Pf</i>20S P3 preference for tryptophan (for β2 and β5) favors substrates such as WLR and WLA, while <i>Pf</i>20S P2 preference for tryptophan (for β1 and β2) favors substrates such as DWD and YWR. <i>Pf</i>20S β5 (P1 hydrophobic) strongly prefers P3 tryptophan over similar aromatic residues (such as phenylalanine/tyrosine) at P3 (e.g., WQL vs FQL, YQL). This overlaps with human 20S β5 specificity, which is permissive of these alternative P3 residues. <i>Pf</i>20S β2 (P1 basic) prefers P1 arginine over lysine with aromatic residues in P2 and P3 (e.g., FWR, YWR). In contrast, for human 20S, if P1 is basic (β2), a basic residue is also preferred at P3 with little selectivity in P2 (e.g., RQR, RLR), with KQY also favored, while if P1 is hydrophobic (β5), an aromatic residue is preferred at P3 (e.g., WLA). <i>Pf</i>20S β1 (P1 acidic) appears to have selectivity for hydrophobic or aromatic P2 or P3 residues. Several P1 His substrates (e.g., KWH, WMH) cannot be definitively ascribed to a particular subunit but appear highly active and selective for <i>Pf</i>20S. Taken together, these results suggest that significant differences exist between <i>Pf</i> 20S and human 20S, which might be exploited in the design of selective <i>Pf</i>20S inhibitors.</div><div class="NLM_p">Overall, the substrate profiling results are similar to a previous study<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> but with some important differences. The selectivity of <i>Pf</i>20S for tryptophan in P3 is consistent across the studies, but the preferred residue at P2 (W, M, Y) does not match well with the previous report,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> possibly due to poor selectivity in P2. The rank order of P1 preferred residues roughly corresponds to the previous report.</div><div class="NLM_p last">To validate these substrate preferences, we resynthesized a number of differentiating substrates based on their activity and selectivity for the <i>Pf</i>20S proteasome and directly compared their relative activities as substrates for <i>Pf</i>20S proteasome, human 20S constitutive proteasome, and immunoproteasome (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D and <a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">S7C</a>). The preference of <i>Pf</i>20S for histidine and arginine in P1 was confirmed, as well as the preference for tryptophan at P2 and P3. It is important to consider residue preferences at different position as a combination rather than individual preferences. For example, Ac-RQR-AMC (arginine at P1) is inactive for <i>Pf</i>20S but it is a good human proteasome β2 substrate. The preference for aspartate at P1 was not confirmed, possibly due to a problem with the quality of the substrates in the original library. The selectivity of a number of substrates for <i>Pf</i>20S was confirmed. For example, Ac-KWH-AMC and Ac-WWK-AMC appear both active and selective for <i>Pf</i>20S. Interestingly, both substrates have tryptophan at the P2 position. While the human immunoproteasome is more tolerant of large bulky side groups at P2 than the constitutive proteasome, <i>Pf</i>20S retained evident selectivity for these substrates. Thus, the higher inhibitory activity of MPI-3 and MPI-4 against <i>Pf</i>20S may reflect their bulky hydrophobic groups at P2 and P3, and the fact that the <i>Pf</i>20S β2 site is more hydrophobic than human 20S.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> While this manuscript was under review, another study was published that used substrate profiling to design optimized vinyl sulfone-based inhibitors.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> This work suggests that choice of an optimal electrophilic warhead can further enhance selectivity.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10115" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10115" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have identified potent inhibitors of the <i>P. falciparum</i> proteasome that have significant activity against both artemisinin-sensitive and -resistant parasites in culture. While preferential inhibition of <i>P. falciparum</i> β2 activity was readily achieved, we show that inhibition of <i>P. falciparum</i> β5 activity coupled with weaker or reversible activity against human β5 activity represents a signature that permits selective killing of <i>P. falciparum</i> compared with a mammalian line. We developed resistance to bortezomib in <i>P. falciparum</i> and show this is associated with mutations in the β5 active site. These mutations prevent binding of some but not other related peptide boronates, and we show that strong inhibition of the β2 active site permits retention of good antiplasmodial activity even in the context of weaker β5 inhibition. Deployment of proteasome inhibitors antimalarial drugs in combinations with drugs with a different mode of action will help avoid the development of resistance. We identified MPI-1 as a compound with good selectivity between <i>P. falciparum</i> and a mammalian cancer cell line and the ability to maintain reasonable activity against the bortezomib-resistant parasite line. We have identified amino acid residues at the P1, P2, and P3 that can confer selective binding to the <i>P. falciparum</i> proteasome, providing a path to further modification of the peptide boronate scaffold to generate more selective inhibitors.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Chemistry</h3><div class="NLM_p last">All reagents and solvents were used as obtained. <sup>1</sup>H NMR spectra were run on a 400 MHz Bruker spectrometer in the solvent indicated. Full assignment of the NMR peaks can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Supporting Information (Figure S9)</a>. LC/MS spectra were recorded on an LC or UPLC system connected to a mass spectrometer using reverse phase C18 columns. Various gradients and run times were selected in order to best characterize the compounds. Mobile phases were based on ACN/water or MeOH/water gradients and contained either 0.1% formic acid or 10 mM ammonium acetate (typical gradients of 100% mobile phase A (mobile phase A = 99% water + 1% ACN + 0.1% formic acid) to 100% mobile phase B (mobile phase B = 95% ACN + 5% water + 0.1% formic acid) at a flow rate of 1 mL/min for a 16.5 min LC run or 0.5 mL/min for a 5 min UPLC run). All compounds were determined to be >95% pure by <sup>1</sup>H NMR or LC/MS.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> BMV037 Fluorescent Probe</h3><div class="NLM_p last">BMV037 was prepared using a modification of the published procedure<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">Supporting Information</a> for details). <sup>1</sup>H NMR spectra were run on a 400 MHz Varian Inova spectrometer. LC/MS spectra were recorded on an Agilent RP-HPLC system connected to a mass spectrometer using a reverse phase C18 column. Compound purity was assessed using a C18 150 mm × 4.6 mm 5 μm column in gradient mode with eluent (buffer) A, 0.1% aq TFA, and buffer B, 0.1% TFA in ACN.</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> <i>tert</i>-Butyl ((<i>S</i>)-1-Oxo-1-(((<i>R</i>)-2-phenyl-1-((3a<i>S</i>,4<i>S</i>,6<i>S</i>,7a<i>R</i>)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[<i>d</i>][1,3,2]dioxaborol-2-yl)ethyl)amino)propan-2-yl)carbamate (<b>5</b>)</h3><div class="NLM_p last">To a solution of (<i>R</i>)-2-phenyl-1-((3a<i>S</i>,4<i>S</i>,6<i>S</i>,7a<i>R</i>)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[<i>d</i>][1,3,2]dioxaborol-2-yl)ethanamine 2,2,2-trifluoroacetate<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> (600 mg, 1.45 mmol) in DCM (12 mL) was added Boc-<span class="smallcaps smallerCapital">l</span>-alanine (330 mg, 1.74 mmol) followed by triethylamine (1.0 mL, 7.26 mmol), and the mixture was degassed with nitrogen for 5 min. 2,4,6-Tripropyl-1,3,5,2,4,6-trioxatriphosphorinane 2,4,6-trioxide (T3P) in EtOAc (1.67 M, 1.74 mL, 2.90 mmol) was added, and the reaction mixture was stirred at room temperature for 4 h, quenched by addition of saturated NaHCO<sub>3</sub>, and extracted with DCM three times. The combined organic phases were washed with water and brine. The DCM phase was dried over Na<sub>2</sub>SO<sub>4</sub>, and then the suspension was filtered and concentrated to dryness. The residue was purified by silica gel column chromatography, eluting with MeOH/DCM to give 500 mg (73% yield, 93% purity, LC/MS) of the desired product. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.29–7.35 (m, 2 H), 7.19–7.26 (m, 3 H), 6.27–6.48 (m, 1 H), 4.64–4.91 (m, 1 H), 4.29–4.37 (m, 1 H), 4.15–4.27 (m, 1 H), 3.15–3.29 (m, 1 H), 2.96–3.08 (m, 1 H), 2.77–2.87 (m, 1 H), 2.30–2.41 (m, 1 H), 2.13–2.23 (m, 1 H), 1.99–2.05 (m, 1 H), 1.83–1.92 (m, 2 H), 1.41–1.45 (m, 9 H), 1.39–1.41 (m, 3 H), 1.35–1.38 (m, 3 H), 1.29–1.32 (m, 4 H), 0.87 (s, 3 H).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> (<i>S</i>)-2-Amino-<i>N</i>-((<i>R</i>)-2-phenyl-1-((3a<i>S</i>,4<i>S</i>,6<i>S</i>,7a<i>R</i>)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[<i>d</i>][1,3,2]dioxaborol-2-yl)ethyl)propanamide Hydrochloride (<b>6</b>)</h3><div class="NLM_p last">To a solution of <b>5</b> (500 mg, 1.06 mmol) in DCM (7.0 mL) was added a solution of HCl in 1,4-dioxane (4 M, 1 mL, 5.32 mmol) slowly at room temperature, and the reaction mixture was stirred at room temperature for 1 day and then concentrated to dryness. To the residue was added Et<sub>2</sub>O, and the mixture was sonicated for 5 min. The resulting mixture was concentrated to dryness to give 400 mg (93% yield, 86% purity, LC/MS) of the desired product. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.20–7.32 (m, 5 H), 4.35 (d, <i>J</i> = 7.53 Hz, 1 H), 3.88 (d, <i>J</i> = 6.90 Hz, 1 H), 2.84–2.99 (m, 2 H), 2.33–2.41 (m, 2 H), 2.10–2.19 (m, 1 H), 1.99 (t, <i>J</i> = 5.40 Hz, 1 H), 1.80–1.92 (m, 2 H), 1.45 (d, <i>J</i> = 7.15 Hz, 3 H), 1.40 (s, 3 H), 1.31 (s, 3 H), 1.19 (d, <i>J</i> = 10.79 Hz, 1 H), 0.86–0.92 (m, 3 H).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (<i>R</i>)-1-Acetyl-<i>N</i>-((<i>S</i>)-1-oxo-1-(((<i>R</i>)-2-phenyl-1-((3a<i>S</i>,4<i>S</i>,6<i>S</i>,7a<i>R</i>)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[<i>d</i>][1,3,2]dioxaborol-2-yl)ethyl)amino)propan-2-yl)pyrrolidine-2-carboxamide (<b>7</b>, MPI-1 Pinane Ester)</h3><div class="NLM_p last">(<i>R</i>)-(+)-<i>N</i>-Acetylproline (102 mg, 0.65 mmol) and <b>6</b> (240 mg, 0.59 mmol) were dissolved in DCM (4.0 mL). To this solution was added triethylamine (0.25 mL, 1.77 mmol), and the mixture was degassed with nitrogen for 5 min. 2,4,6-Tripropyl-1,3,5,2,4,6-trioxatriphosphorinane 2,4,6-trioxide (T3P) in EtOAc (1.67 M, 0.70 mL, 1.18 mmol) was added, and the resulting mixture was stirred at room temperature for 4 h, quenched by addition of saturated NaHCO<sub>3</sub>, and extracted with DCM three times. The combined organic phases were washed with water and brine. The DCM phase was dried over Na<sub>2</sub>SO<sub>4</sub>, and then the suspension was filtered and concentrated to dryness. The residue was purified by reverse phase C18 silica gel column chromatography, eluting with ACN/H<sub>2</sub>O with 0.1% formic acid to give 115 mg (38% yield, 100% pure, LC/MS) of the desired product. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.44 (br s, 1H), 9.08 (br s, 1H), 7.38 (br d, <i>J</i> = 7.58 Hz, 2H), 7.05–7.19 (m, 3H), 4.73–4.86 (m, 1H), 4.09 (br d, <i>J</i> = 8.19 Hz, 1H), 3.93–4.03 (m, 1H), 3.51–3.73 (m, 2H), 3.27–3.33 (m, 1H), 3.00–3.12 (m, 1H), 2.74–2.87 (m, 1H), 2.15–2.23 (m, 1H), 2.11–2.15 (m, 1H), 2.08 (s, 3H), 1.93–2.04 (m, 2H), 1.80–1.88 (m, 1H), 1.71–1.80 (m, 1H), 1.65–1.70 (m, 1H), 1.58–1.64 (m, 1H), 1.46 (br s, 3H), 1.41–1.45 (m, 1H), 1.33 (s, 3H), 1.15 (s, 3H), 0.79 (br s, 3H), 0.33–0.50 (m, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 177.1, 172.6, 169.9, 140.2, 130.1, 127.2, 125.4, 83.2, 75.7, 60.2, 52.6, 48.7, 45.6, 44.0, 39.7, 37.9, 36.9, 35.2, 29.5, 29.4, 27.2, 25.4, 25.1, 24.0, 22.4, 16.3. [α]<sub>D</sub><sup>20</sup> −80 (<i>c</i> 0.1, MeOH).</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Procedure for the Synthesis of the Pinane Esters of MPI-2, MPI-3, and MPI-4 (Compounds <b>8</b>, <b>9</b>, and <b>10</b>)</h3><div class="NLM_p last">MPI-2, MPI-3, and MPI-4 pinane esters were synthesized using the same procedures described above or using analogous conditions, for instance, substituting TBTU as a coupling reagent for T3P in steps a and c (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Each compound was prepared using commercial or synthesized pinaneboronates.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a></div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (<i>S</i>)-1-Acetyl-<i>N</i>-((S)-1-(((<i>R</i>)-3-methyl-1-((3a<i>S</i>,4<i>S</i>,6<i>S</i>,7a<i>R</i>)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[<i>d</i>][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxopropan-2-yl)pyrrolidine-2-carboxamide (<b>8</b>, MPI-2 Pinane Ester)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.90 (br s, 1H), 7.08 (br d, <i>J</i> = 8.07 Hz, 1H), 4.61–4.76 (m, 1H), 4.41 (br t, <i>J</i> = 6.17 Hz, 1H), 4.23–4.32 (m, 1H), 3.60–3.75 (m, 1H), 3.46–3.58 (m, 1H), 2.82–2.93 (m, 1H), 2.28–2.35 (m, 1H), 2.12–2.19 (m, 3H), 2.09 (s, 3H), 2.00–2.06 (m, 2H), 1.95–2.00 (m, 1H), 1.87–1.93 (m, 1H), 1.78–1.86 (m, 1H), 1.61–1.76 (m, 1H), 1.34–1.44 (m, 8H), 1.31–1.34 (m, 1H), 1.24–1.30 (m, 3H), 0.81–0.94 (m, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 175.8, 171.7, 171.6, 84.4, 76.4, 60.6, 51.7, 48.4, 46.2, 40.1, 39.9, 39.8, 38.1, 36.1, 29.0, 28.5, 27.2, 26.3, 25.4, 24.9, 24.1, 23.2, 22.3, 21.7, 16.8. [α]<sub>D</sub><sup>20</sup> −88 (<i>c</i> 0.1, MeOH). 100% pure, LC/MS.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<i>S</i>)-<i>N</i>1-((<i>S</i>)-1-(((<i>R</i>)-3-Methyl-1-((3a<i>S</i>,4<i>S</i>,6<i>S</i>,7a<i>R</i>)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[<i>d</i>][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((4-methylphenyl)sulfonamido)-<i>N</i>4-neopentylsuccinamide (<b>9</b>, MPI-3 Pinane Ester)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.13–7.33 (m, 5H), 6.89–7.03 (m, 2H), 6.64–6.75 (m, 2H), 4.73–4.81 (m, 1H), 4.17–4.27 (m, 1H), 3.34–3.45 (m, 2H), 3.02–3.17 (m, 1H), 2.90–3.02 (m, 1H), 2.62–2.74 (m, 1H), 2.30–2.44 (m, 1H), 2.08–2.22 (m, 1H), 1.92–2.03 (m, 1H), 1.84–1.92 (m, 1H), 1.75–1.84 (m, 1H), 1.48–1.59 (m, 1H), 1.42–1.47 (m, 1H), 1.36–1.42 (m, 3H), 1.28–1.36 (m, 3H), 1.20–1.28 (m, 2H), 0.80–0.95 (m, 9H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 176.8, 174.4, 157.7, 137.5, 131.3, 130.6, 129.8, 128.2, 127.1, 116.6, 84.5, 77.6, 53.7, 52.9, 42.9, 42.4, 41.7, 41.5, 39.3, 38.9, 37.7, 29.9, 27.9, 27.6, 26.7, 24.7, 23.7, 22.4. 100% pure, LC/MS.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (<i>S</i>)-2-(2-(4-Hydroxyphenyl)acetamido)-<i>N</i>-((<i>R</i>)-3-methyl-1-((3a<i>S</i>,4<i>S</i>,6<i>S</i>,7a<i>R</i>)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[<i>d</i>][1,3,2]dioxaborol-2-yl)butyl)-3-phenylpropanamide (<b>10</b>, MPI-4 Pinane Ester)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.66 (br d, <i>J</i> = 8.19 Hz, 2H), 7.20–7.33 (m, 7H), 4.59 (br t, <i>J</i> = 7.15 Hz, 1H), 4.15–4.22 (m, 1H), 4.03 (br t, <i>J</i> = 6.42 Hz, 1H), 3.07 (br dd, <i>J</i> = 6.60, 13.82 Hz, 1H), 2.85–2.97 (m, 3H), 2.61–2.68 (m, 1H), 2.47–2.57 (m, 1H), 2.41–2.47 (m, 1H), 2.39 (s, 3H), 2.31–2.38 (m, 1H), 2.07–2.18 (m, 1H), 1.92–2.00 (m, 1H), 1.82–1.90 (m, 1H), 1.73–1.82 (m, 1H), 1.53–1.68 (m, 1H), 1.40–1.46 (m, 1H), 1.37 (s, 3H), 1.29 (s, 3H), 1.23–1.28 (m, 2H), 0.82–0.91 (m, 18H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 176.9, 172.6, 171.7, 145.1, 138.8, 137.7, 130.9, 130.6, 129.9, 128.4, 128.2, 84.4, 77.5, 55.0, 53.7, 53.0, 51.8, 42.7, 41.7, 41.5, 39.6, 39.3, 38.1, 37.8, 33.1, 30.0, 27.9, 27.8, 27.6, 26.6, 24.7, 23.7, 22.6, 21.7. [α]<sub>D</sub><sup>20</sup> −47.4 (<i>c</i> 0.1, MeOH). 97% pure, LC/MS.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>Plasmodium falciparum</i> Culture</h3><div class="NLM_p last"><i>P. falciparum</i> parasites used in this study were propagated in O+ human erythrocytes (Australian Red Cross Blood Service) in RPMI-1640, supplemented with GlutaMAX, 25 mM HEPES (Thermo Fisher Scientific), 5% (v/v) human serum (Australian Red Cross Blood Service), 0.25% (w/v) AlbuMAX II (Thermo Fisher Scientific), 10 μM <span class="smallcaps smallerCapital">d</span>-glucose, 22 μg/mL gentamycin (Sigma-Aldrich), and 0.5 mM hypoxanthine (Sigma-Aldrich) and incubated at 37 °C in an atmosphere of 1% O<sub>2</sub>, 5% CO<sub>2</sub>, and 94% N<sub>2</sub>. Cultures were monitored by Giemsa staining of methanol-fixed blood smears. Culture medium was replaced at least every 48 h, and parasitemia was maintained below 10% to ensure health of cultures. The GFP-DD reporter strain was kindly provided by Dr. Paul Gilson, Dr. Brendan Crabb, and Dr. Mauro F. Azevedo (Burnet Institute).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> HCT116 and HepG2 Cell Culture</h3><div class="NLM_p last">HCT-116 and HepG2 cells were obtained from the American Type Culture Collection and maintained as recommended by the supplier. Cells were cultured in the ATCC-formulated McCoy’s 5A medium or DMEM (Life Technologies, CA), supplemented with fetal bovine serum to a final concentration of 9–10%, and incubated at 37 °C in an atmosphere of 95% air and 5% CO<sub>2</sub>. Cellular toxicity assays were performed using Promega’s CellTiter-Glo assay system. Varying concentrations of the test compounds in 5% DMSO/95% PBS were dispensed into a 384-well plate and cells added to each well. The plates were incubated at 37 °C for 72 h, and the CellTiter-Glo assay to assess cell viability was performed as described by the manufacturer (Promega).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Assessment of Cellular Toxicity</h3><div class="NLM_p">For standard assays of antiplasmodial activity, sorbitol-treated ring stage parasites were incubated with the drugs for 72 h and viability was assessed in the second cycle.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Drug pulse assays were performed as described previously.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> For short pulse assays, tightly synchronized early ring stage parasites (1–3 h after invasion) at 0.2% hematocrit and 1–2% parasitemia were subjected to 3 h drug pulse at 37 °C and returned to culture until parasites reached trophozoite stage of the following cycle. Cells were then stained with 2 μM Syto-61 (Thermo Fisher Scientific), and their fluorescence was measured by flow cytometry (FACSCanto II cytometer; Becton Dickinson). Data were gated and analyzed using FCS Express software (version 3) to determine parasitemia of each sample. Viability represents the parasitemia normalized to untreated and “kill treated” controls, where “kill treated” refers to samples treated with 2 μM DHA for 48–72 h. Interactions between DHA and MPI-1 or MPI-4 against the K13 mutant (DHA resistant) Cam3.II <i>P. falciparum</i> strain, exposed to a 3 h pulsed treatment, were determined at 4 h after invasion as described previously.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p last">For human cell line activity assays, cellular toxicity assays were performed as described previously.<a onclick="showRef(event, 'ref23 ref48'); return false;" href="javascript:void(0);" class="ref ref23 ref48">(23,48)</a></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>P. falciparum</i> Proteasome Preparation and Assay Optimization</h3><div class="NLM_p"><i>P. falciparum</i> 20S proteasome was enriched from infected RBCs using a two-step chromatographic procedure.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Mass spectrometry revealed the presence of all 14 <i>Pf</i>20S proteasome subunits with multiple unique peptide fragments. To determine the level of human proteasome contamination in the purified samples, 7 μg of the purified <i>Pf</i>20S proteasome was reduced with DTT and alkylated with iodoacetamide. The sample was then subjected to SDS–PAGE, and the gel fraction containing 14–38 kDa bends was excised. In-gel digestion with trypsin was performed, and peptide content was analyzed by LC–MS/MS. The data were processed using Proteome Discoverer 1.4 employing a user-defined protein database containing human and <i>Pf</i>20S proteasome subunits.</div><div class="NLM_p last">Peptide pairs of human and <i>Pf</i>20S subunits with similar amino acid sequences were selected and used to estimate the amount of <i>P. falciparum</i> proteasome relative to human proteasome. Signal intensity (peak area) from multiple peptide pairs was determined. The signal intensity ratio of <i>Pf</i>20S to human 20S proteasome was 240:1 on average, indicating a level of contamination by human proteasome of less than 0.5%. Human proteasome and human proteasome activator complex, PA28αβ, were prepared as described previously.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Optimization experiments indicated that 1 nM <i>Pf</i>20S was sufficient to produce a strong and reliable signal in the presence of 24 nM PA28αβ, which was found to activate <i>Pf</i>20S maximally.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Proteasome Inhibitor Analysis</h3><div class="NLM_p last">Proteasome activity was determined using Ac-nLPnLD-AMC (Bachem) for caspase-like (β1) activity, Ac-WLR-AMC (custom, Anaspec, Freemont, CA) for trypsin-like (β2) activity, and Ac-WLA-AMC (custom, Anaspec, Freemont, CA) for chymotrypsin-like (β5) activity. Compounds with 3-fold dilutions from 10 μM (10 concentration points in duplicate) were plated out into black 1536-well plates. The reaction was initiated by adding the AMC substrates, PA28αβ, and 20S proteasome sequentially to the plates. 1 nM <i>Pf</i>20S proteasome, 24 nM PA28αβ, and 15 μM AMC substrates were incubated in the assay buffer (50 mM Tris, 5 mM MgCl<sub>2</sub>, 1 mM DTT, 0.01% BSA, pH 7.4) at 37 °C for 1 or 2 h. Release of AMC fluorophore (excitation, 360 nm; emission, 450 nm) was measured using a fluorescence microplate reader (FLUOstar, BMG Labtech). Slopes of AMC formation over the measurement period were determined for each compound concentration to assess the inhibitory effect (i.e., end-point assay). The same set of compounds was also tested for inhibitory activity against human 20S constitutive proteasome and immunoproteasome (Boston Biochem).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Labeling of Proteasome Catalytic Subunit by BMV037</h3><div class="NLM_p last"><i>P. falciparum</i> culture, purified <i>Pf</i>20S proteasomes, human constitutive proteasomes, or immunoproteasomes (Boston Biochem) were incubated with test compounds at 37 °C for 1 h. Treated parasite lysates (10 μg), <i>Pf</i>20S proteasomes (80 nM), human constitutive proteasomes (20 nM), or immuno-20S proteasomes (20 nM) were labeled with BMV037 (10 μM) at 37 °C for 2 h. Samples were mixed with SDS loading buffer and heated at 95 °C for 5 min. Samples for <i>P. falciparum</i> and human immuno-20S were run on 4–12% Bis-Tris acrylamide gels using MES SDS running buffer (Thermo Fisher Scientific). Human constitutive 20S samples were run on a 10% Bis-Tris acrylamide gel using MOPS SDS running buffer (Thermo Fisher Scientific). Gels were imaged at the Cy5 channel on a Gel Doc XR+ Documentation System (Bio-Rad) or an Amersham Typhoon Trio imager (GE Healthcare Life Sciences).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Substrate Profiling</h3><div class="NLM_p last">5920 of 8800 theoretical Ac-P3-P2-P1-AMC substrates (2 μL reaction, 20 μM substrate) were assayed in black 1536-well plates with relevant controls: Ac-nLPnLD-AMC (β1), Ac-WLR-AMC (β2), Ac-WLA-AMC (β5). AMC (10 μM) was used as the fluorescence standard. <i>Pf</i>20S reaction condition: <i>Pf</i>20S (1 nM), human PA28 αβ (24 nM), in 50 mM Tris, pH 7.5, 5 mM MgCl<sub>2</sub>, 1 mM DTT, 0.01% BSA. Human 20S reaction condition: 0.25 nM human constitutive proteasome or immunoproteasome (Boston Biochem), PA28 αβ (24 nM) in 20 mM HEPES, pH 7.4, 0.5 mM EDTA, 0.01% BSA. The assays were read in kinetic mode at 37 °C using a BMG PHERAstar plate reader, and the rate data were normalized to activity obtained using the Ac-WLR-AMC substrate (=1000 units). For validation of substrate preferences, relevant Ac-P3-P2-P1-AMC substrates were resynthesized by CPC Scientific, CA, USA, and assayed for activity against human and <i>P. falciparum</i> 20S proteasomes in 96-well plates (80 μL reaction, 10 μM substrate) under the same reaction condition.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> In Silico Analysis</h3><div class="NLM_p last">All structure analysis was performed using PyMOL.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The structure of human 20S (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5lf3">5lf3</a>, chain K) was superimposed onto <i>P. falciparum</i> 20S (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fmg">5fmg</a>, chain L). The distances between atoms was measured using the Measurement Wizard feature, with bortezomib remaining in the position modeled by the human 20S bound state. Mutagenesis was performed using the Mutagenesis Wizard feature, with rotamers showing minimal clashes being selected. No energy minimization modeling was performed.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> In Vitro Evolution of Resistance to Bortezomib and Whole Genome Sequencing</h3><div class="NLM_p last">Prior to selection, an aliquot of the parental line was stocked as a reference for subsequent whole genome sequencing analysis. Several independent clones of <i>P. falciparum</i> 3D7 parasite line were cultured in Petri dishes exposed to increasing drug pressure for ∼30 weeks. Parasites were cloned by limiting dilution. For parasite extraction and genomic DNA isolation, cultures were scaled up to at least 4–5% parasitaemia, lysed in saponin, and genomic DNA was isolated using ISOLATE II Genomic DNA kit (Bioline). DNA libraries for each gDNA sample were prepared for sequencing using the Nextera XT kit as described previously.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Libraries were clustered and run on an Illumina HiSeq 2500 using the RapidRun mode, sequencing 100 base pairs in depth on either end. Paired-end reads were either aligned to the <i>P. falciparum</i> 3D7 reference genome (PlasmoDB version 13.0).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Measurement of GFP-DD Signal Using Flow Cytometry or Western Blotting</h3><div class="NLM_p last">Trophozoite-stage parasite cultures (GFP-DD parasites) at 5% hematocrit and 5% parasitemia were subjected to the drug treatment indicated in the figure legends at 37 °C. For flow cytometry analyses, culture samples were stained with 2 μM Syto-61 and adjusted to 0.1% hematocrit in PBS. Syto-61 and GFP fluorescence was recorded using the FACSCanto II cytometer (Becton Dickinson). Analysis was performed in FlowJo (version10). Parasites were gated based on parasite GFP fluorescence, and values reported are mean fluorescence. Data were fit by sigmoidal, nonlinear analyses using GraphPad Prism software. For Western blotting, trophozoite-stage parasites were isolated with 0.05% w/v saponin and pellets were washed in PBS, supplemented with EDTA-free protease inhibitor cocktail (Roche). Parasite pellets were solubilized in reducing SDS–PAGE sample buffer, boiled at 95 °C for 8 min, resolved by SDS–PAGE on a 4–12% Bis-Tris acrylamide gel (Life Technologies) using MOPS running buffer and transferred to nitrocellulose membrane (iBlot; Life Technologies). Membranes were blocked with 3.5% skim milk for 1 h at room temperature and probed with mouse anti-GFP (Roche; 1:1000) or mouse anti-<i>Pf</i>BiP (1:1000) overnight at 4 °C, followed by goat anti-mouse IgG-peroxidase (Chemicon-AP127P; 1:20 000) for 1 h at room temperature. Polyclonal mouse anti-<i>Pf</i>BiP was generated using recombinant <i>Pf</i>BiP at the WEHI Antibody Services. Blots were visualized using Clarity ECL substrate (BioRad).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01161" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35235" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35235" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01161" class="ext-link">10.1021/acs.jmedchem.8b01161</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Tables S1 and S2 listing sequencing statistics and summary of single nucleotide variants and insertion-deletions for bortezomib resistant <i>P. falciparum</i> clones; Figure S1–S9 showing purification of <i>Pf</i>20S proteasome; optimization of <i>Pf</i>20S proteasome activities; kinetic analysis of MPI-4; in vitro evolution of resistance to bortezomib; structure analysis of β5 mutations associated with bortezomib resistance; active site probe analysis of the selected compounds; proteasome substrate profiling of human 20S immunoproteasome and <i>P. falciparum</i> proteasome; substrate preferences of human constitutive and <i>Pf</i>20S proteasomes; NMR structural assignments of MPI compounds; synthesis of BMV037 (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_001.csv">jm8b01161_si_001.csv (1.72 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf">jm8b01161_si_002.pdf (2.07 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01161" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08012" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08012" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leann Tilley</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, Bio21 Molecular Science and
Biotechnology Institute, The University
of Melbourne, Melbourne, VIC 3010, Australia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9910-0199" title="Orcid link">http://orcid.org/0000-0001-9910-0199</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3d514954515158447d4853545058515f13585948135c48"><span class="__cf_email__" data-cfemail="513d25383d3d342811243f383c343d337f3435247f3024">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stanley
C. Xie</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, Bio21 Molecular Science and
Biotechnology Institute, The University
of Melbourne, Melbourne, VIC 3010, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David L. Gillett</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, Bio21 Molecular Science and
Biotechnology Institute, The University
of Melbourne, Melbourne, VIC 3010, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Natalie J. Spillman</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, Bio21 Molecular Science and
Biotechnology Institute, The University
of Melbourne, Melbourne, VIC 3010, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Tsu</span> - <span class="hlFld-Affiliation affiliation">Oncology
Clinical R&D, Takeda Pharmaceuticals
International Co., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Madeline R. Luth</span> - <span class="hlFld-Affiliation affiliation">Host-Microbe
Systems and Therapeutics Division, UC San
Diego School of Medicine, La Jolla, California 92093, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sabine Ottilie</span> - <span class="hlFld-Affiliation affiliation">Host-Microbe
Systems and Therapeutics Division, UC San
Diego School of Medicine, La Jolla, California 92093, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra Duffy</span> - <span class="hlFld-Affiliation affiliation">Griffith
Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexandra E. Gould</span> - <span class="hlFld-Affiliation affiliation">Oncology
Clinical R&D, Takeda Pharmaceuticals
International Co., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Hales</span> - <span class="hlFld-Affiliation affiliation">Oncology
Clinical R&D, Takeda Pharmaceuticals
International Co., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benjamin A. Seager</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biology, Bio21 Molecular Science and
Biotechnology Institute, The University
of Melbourne, Melbourne, VIC 3010, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carlie L. Charron</span> - <span class="hlFld-Affiliation affiliation">School
of Chemistry, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frank Bruzzese</span> - <span class="hlFld-Affiliation affiliation">Oncology
Clinical R&D, Takeda Pharmaceuticals
International Co., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaofeng Yang</span> - <span class="hlFld-Affiliation affiliation">Oncology
Clinical R&D, Takeda Pharmaceuticals
International Co., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiansi Zhao</span> - <span class="hlFld-Affiliation affiliation">Oncology
Clinical R&D, Takeda Pharmaceuticals
International Co., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shih-Chung Huang</span> - <span class="hlFld-Affiliation affiliation">Oncology
Clinical R&D, Takeda Pharmaceuticals
International Co., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Craig A. Hutton</span> - <span class="hlFld-Affiliation affiliation">School
of Chemistry, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2353-9258" title="Orcid link">http://orcid.org/0000-0002-2353-9258</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeremy N. Burrows</span> - <span class="hlFld-Affiliation affiliation">Medicines
for Malaria Venture, 1215 Meyrin, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth A. Winzeler</span> - <span class="hlFld-Affiliation affiliation">Host-Microbe
Systems and Therapeutics Division, UC San
Diego School of Medicine, La Jolla, California 92093, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4049-2113" title="Orcid link">http://orcid.org/0000-0002-4049-2113</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vicky M. Avery</span> - <span class="hlFld-Affiliation affiliation">Griffith
Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lawrence R. Dick</span> - <span class="hlFld-Affiliation affiliation">Oncology
Clinical R&D, Takeda Pharmaceuticals
International Co., Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>L.R.D. and L.T. contributed equally. S.C.X., D.L.G., N.J.S., C.T., S.O., S.D., A.E.G., P.H., F.B., X.Y., C.A.H., J.N.B., E.A.W., V.M.A., L.R.D., and L.T. designed the research. S.C.X., D.L.G., N.J.S., S.D., P.H., F.B., and X.Z. performed cellular and biochemical experiments. C.L.C. and C.A.H. synthesized the BMV037 probe. M.R.L., S.O., and E.A.W. performed whole genome sequencing. All authors analyzed data. S.C.X., L.R.D., and L.T. wrote the manuscript, with input from the other authors.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e2624-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66252" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66252" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Paul Gilson, Prof. Brendan Crabb, and Dr. Mauro F. Azevedo, Burnet Institute, for the DD-GFP parasite line, Dr. Snigdha Tiash, Dr. Mike Griffin, and Riley Metcalfe, University of Melbourne, and Dr. Hua Liao, Dr. Hirotake Mizutani, Takeda Pharmaceuticals, and Dr. Stephen Brand, Medicines for Malaria Venture, for advice and technical support. We thank Dr. Greg Blatch and Eva-Rachele Pesce, Victoria University, for providing recombinant <i>Pf</i>BiP. This work was supported by the National Health & Medical Research Council of Australia (Grants APP1092808, APP1072217) and the Global Health Innovation Technology Fund (GHIT Grant T2015-134). E.A.W. is supported by grants from the NIH (Grants 5R01AI090141 and R01AI103058) and by grants from the Bill and Melinda Gates Foundations (Grants OPP1086217, OPP1141300). We thank Medicines for Malaria Venture for ongoing support. We thank the Australian Red Cross Blood Bank for the provision of human red blood cells and serum.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviation Used</td></tr><tr><td class="NLM_term">ACT</td><td class="NLM_def"><p class="first last">artemisinin-based combination therapy</p></td></tr><tr><td class="NLM_term"><i>P. falciparum</i></td><td class="NLM_def"><p class="first last"><i>Plasmodium falciparum</i></p></td></tr><tr><td class="NLM_term"><i>P. berghei</i></td><td class="NLM_def"><p class="first last"><i>Plasmodium berghei</i></p></td></tr><tr><td class="NLM_term">AsnEDA</td><td class="NLM_def"><p class="first last">asparagine ethylenediamine</p></td></tr><tr><td class="NLM_term">PA28αβ</td><td class="NLM_def"><p class="first last">proteasome activator 28αβ</p></td></tr><tr><td class="NLM_term">Ac-xxx-AMC</td><td class="NLM_def"><p class="first last">acetyl-xxx-7-amino-4-methylcoumarin</p></td></tr><tr><td class="NLM_term">MPI</td><td class="NLM_def"><p class="first last">malaria proteasome inhibitor</p></td></tr><tr><td class="NLM_term">T3P</td><td class="NLM_def"><p class="first last">2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">CDCl<sub>3</sub></td><td class="NLM_def"><p class="first last">deuterated chloroform</p></td></tr><tr><td class="NLM_term">CD<sub>3</sub>OD</td><td class="NLM_def"><p class="first last">deuterated methanol</p></td></tr><tr><td class="NLM_term">LC/MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">Et<sub>2</sub>O</td><td class="NLM_def"><p class="first last">diethyl ether</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">β1/2/5c</td><td class="NLM_def"><p class="first last">constitutive proteasome β1/2/5 subunits</p></td></tr><tr><td class="NLM_term">β1/2/5i</td><td class="NLM_def"><p class="first last">immunoproteasome β1/2/5 subunits</p></td></tr><tr><td class="NLM_term">GFP-DD</td><td class="NLM_def"><p class="first last">green fluorescent protein–destabilization domain</p></td></tr><tr><td class="NLM_term">DHA</td><td class="NLM_def"><p class="first last">dihydroartemisinin</p></td></tr><tr><td class="NLM_term">HCT116</td><td class="NLM_def"><p class="first last">human colorectal carcinoma cell line</p></td></tr><tr><td class="NLM_term">HepG2</td><td class="NLM_def"><p class="first last">human hepatocellular carcinoma cell line</p></td></tr><tr><td class="NLM_term">CNV</td><td class="NLM_def"><p class="first last">copy number variant</p></td></tr><tr><td class="NLM_term">CryoEM</td><td class="NLM_def"><p class="first last">cryogenic electron microscopy</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</p></td></tr><tr><td class="NLM_term">RP-HPLC</td><td class="NLM_def"><p class="first last">reversed-phase high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">MOPS</td><td class="NLM_def"><p class="first last">3-(<i>N</i>-morpholino)propanesulfonic acid</p></td></tr><tr><td class="NLM_term">BiP</td><td class="NLM_def"><p class="first last">binding immunoglobulin protein</p></td></tr><tr><td class="NLM_term">Et<sub>3</sub>N</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 50 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <i>World
Malaria Report 2017</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva, Switzerland</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+World%0AMalaria+Report+2017%3B+World+Health+Organization%3A+Geneva%2C+Switzerland%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DWorld%250AMalaria%2520Report%25202017%26pub%3DWorld%2520Health%2520Organization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lwin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanpithakpong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringwald, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silamut, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhasivanon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindegardh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Socheat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Artemisinin resistance in <i>Plasmodium falciparum</i> malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0808859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1056%2FNEJMoa0808859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=19641202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1CrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=455-467&author=A.+M.+Dondorpauthor=F.+Nostenauthor=P.+Yiauthor=D.+Dasauthor=A.+P.+Phyoauthor=J.+Tarningauthor=K.+M.+Lwinauthor=F.+Arieyauthor=W.+Hanpithakpongauthor=S.+J.+Leeauthor=P.+Ringwaldauthor=K.+Silamutauthor=M.+Imwongauthor=K.+Chotivanichauthor=P.+Limauthor=T.+Herdmanauthor=S.+S.+Anauthor=S.+Yeungauthor=P.+Singhasivanonauthor=N.+P.+Dayauthor=N.+Lindegardhauthor=D.+Socheatauthor=N.+J.+White&title=Artemisinin+resistance+in+Plasmodium+falciparum+malaria&doi=10.1056%2FNEJMoa0808859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin resistance in Plasmodium falciparum malaria</span></div><div class="casAuthors">Dondorp, Arjen M.; Nosten, Francois; Yi, Poravuth; Das, Debashish; Phyo, Aung Phae; Tarning, Joel; Lwin, Khin Maung; Ariey, Frederic; Hanpithakpong, Warunee; Lee, Sue J.; Ringwald, Pascal; Silamut, Kamolrat; Imwong, Mallika; Chotivanich, Kesinee; Lim, Pharath; Herdman, Trent; Sam An, Sen; Yeung, Shunmay; Singhasivanon, Pratap; Day, Nicholas P. J.; Lindegardh, Niklas; Socheat, Duong; White, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-467</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Artemisinin-based combination therapies are the recommended first-line treatments of falciparum malaria in all countries with endemic disease.  There are recent concerns that the efficacy of such therapies has declined on the Thai-Cambodian border, historically a site of emerging antimalarial-drug resistance.  METHODS: In two open-label, randomized trials, we compared the efficacies of two treatments for uncomplicated falciparum malaria in Pailin, western Cambodia, and Wang Pha, northwestern Thailand: oral artesunate given at a dose of 2 mg per kg of body wt. per day, for 7 days, and artesunate given at a dose of 4 mg per kg per day, for 3 days, followed by mefloqine at two doses totaling 25 mg per kg.  We assessed in vitro and in vivo Plasmodium-falciparum susceptibility, artesunate pharmacokinetics, and mol. markers of resistance.  RESULTS: We studied 40 patients in each of the two locations.  The overall median parasite clearance times were 84 h (interquartile range, 60 to 96) in Pailin and 48 h (interquartile range, 36 to 66) in Wang Pha (P < 0.001).  Recrudescence confirmed by means of polymerase-chain-reaction assay occurred in 6 of 20 patients (30%) receiving artesunate monotherapy and 1 of 20 (5%) receiving artesunate-mefloqine therapy in Pailin, as compared with 2 of 20 (10%) and 1 of 20 (5%), resp., in Wang Pha (P = 0.31).  These markedly different parasitol. responses were not explained by differences in age, artesunate or dihydroartemisinin pharmacokinetics, results of isotopic in vitro sensitivity tests, or putative mol. correlates of P.falciparum drug resistance (mutations or amplifications of the gene encoding a multidrug resistance protein [PfMDR1] or mutations in the gene encoding sarco-endoplasmic reticulum calcium ATPase6 [PfSERCA]).  Adverse events were mild and did not differ significantly between the two treatment groups.  CONCLUSIONS: P.falciparum has reduced in vivo susceptibility to artesunate in western Cambodia as compared with northwestern Thailand.  Resistance is characterized by slow parasite clearance in vivo without corresponding redns. on conventional in vitro susceptibility testing.  Containment measures are urgently needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfVvi4ozTDSLVg90H21EOLACvtfcHk0lhbIm0ETgrRpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1CrsLk%253D&md5=ae3098a15e9fb82c80fa0ddd05378220</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0808859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0808859%26sid%3Dliteratum%253Aachs%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DYi%26aufirst%3DP.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DLwin%26aufirst%3DK.%2BM.%26aulast%3DAriey%26aufirst%3DF.%26aulast%3DHanpithakpong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DRingwald%26aufirst%3DP.%26aulast%3DSilamut%26aufirst%3DK.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DHerdman%26aufirst%3DT.%26aulast%3DAn%26aufirst%3DS.%2BS.%26aulast%3DYeung%26aufirst%3DS.%26aulast%3DSinghasivanon%26aufirst%3DP.%26aulast%3DDay%26aufirst%3DN.%2BP.%26aulast%3DLindegardh%26aufirst%3DN.%26aulast%3DSocheat%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DArtemisinin%2520resistance%2520in%2520Plasmodium%2520falciparum%2520malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D455%26epage%3D467%26doi%3D10.1056%2FNEJMoa0808859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkhoma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepniewska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGready, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ler Moo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Saai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lwin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhasivanon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span> <span> </span><span class="NLM_article-title">Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1960</span>– <span class="NLM_lpage">1966</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)60484-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FS0140-6736%2812%2960484-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=22484134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BC38rjtFehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1960-1966&author=A.+P.+Phyoauthor=S.+Nkhomaauthor=K.+Stepniewskaauthor=E.+A.+Ashleyauthor=S.+Nairauthor=R.+McGreadyauthor=C.+ler+Mooauthor=S.+Al-Saaiauthor=A.+M.+Dondorpauthor=K.+M.+Lwinauthor=P.+Singhasivanonauthor=N.+P.+Dayauthor=N.+J.+Whiteauthor=T.+J.+Andersonauthor=F.+Nosten&title=Emergence+of+artemisinin-resistant+malaria+on+the+western+border+of+Thailand%3A+a+longitudinal+study&doi=10.1016%2FS0140-6736%2812%2960484-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study</span></div><div class="casAuthors">Phyo Aung Pyae; Nkhoma Standwell; Stepniewska Kasia; Ashley Elizabeth A; Nair Shalini; McGready Rose; ler Moo Carit; Al-Saai Salma; Dondorp Arjen M; Lwin Khin Maung; Singhasivanon Pratap; Day Nicholas P J; White Nicholas J; Anderson Tim J C; Nosten Francois</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">9830</span>),
    <span class="NLM_cas:pages">1960-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Artemisinin-resistant falciparum malaria has arisen in western Cambodia.  A concerted international effort is underway to contain artemisinin-resistant Plasmodium falciparum, but containment strategies are dependent on whether resistance has emerged elsewhere.  We aimed to establish whether artemisinin resistance has spread or emerged on the Thailand-Myanmar (Burma) border.  METHODS:  In malaria clinics located along the northwestern border of Thailand, we measured six hourly parasite counts in patients with uncomplicated hyperparasitaemic falciparum malaria (≥4% infected red blood cells) who had been given various oral artesunate-containing regimens since 2001.  Parasite clearance half-lives were estimated and parasites were genotyped for 93 single nucleotide polymorphisms.  FINDINGS:  3202 patients were studied between 2001 and 2010.  Parasite clearance half-lives lengthened from a geometric mean of 2·6 h (95% CI 2·5-2·7) in 2001, to 3·7 h (3·6-3·8) in 2010, compared with a mean of 5·5 h (5·2-5·9) in 119 patients in western Cambodia measured between 2007 and 2010.  The proportion of slow-clearing infections (half-life ≥6·2 h) increased from 0·6% in 2001, to 20% in 2010, compared with 42% in western Cambodia between 2007 and 2010.  Of 1583 infections genotyped, 148 multilocus parasite genotypes were identified, each of which infected between two and 13 patients.  The proportion of variation in parasite clearance attributable to parasite genetics increased from 30% between 2001 and 2004, to 66% between 2007 and 2010.  INTERPRETATION:  Genetically determined artemisinin resistance in P falciparum emerged along the Thailand-Myanmar border at least 8 years ago and has since increased substantially.  At this rate of increase, resistance will reach rates reported in western Cambodia in 2-6 years.  FUNDING:  The Wellcome Trust and National Institutes of Health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9gTXdi_aNKUcLvDNbOD4DfW6udTcc2ea26UXyUg_XHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rjtFehsg%253D%253D&md5=9de4b3f2862332e0bf33d1d6612b06d0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960484-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960484-X%26sid%3Dliteratum%253Aachs%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DNkhoma%26aufirst%3DS.%26aulast%3DStepniewska%26aufirst%3DK.%26aulast%3DAshley%26aufirst%3DE.%2BA.%26aulast%3DNair%26aufirst%3DS.%26aulast%3DMcGready%26aufirst%3DR.%26aulast%3Dler%2BMoo%26aufirst%3DC.%26aulast%3DAl-Saai%26aufirst%3DS.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DLwin%26aufirst%3DK.%2BM.%26aulast%3DSinghasivanon%26aufirst%3DP.%26aulast%3DDay%26aufirst%3DN.%2BP.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DAnderson%26aufirst%3DT.%2BJ.%26aulast%3DNosten%26aufirst%3DF.%26atitle%3DEmergence%2520of%2520artemisinin-resistant%2520malaria%2520on%2520the%2520western%2520border%2520of%2520Thailand%253A%2520a%2520longitudinal%2520study%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26spage%3D1960%26epage%3D1966%26doi%3D10.1016%2FS0140-6736%2812%2960484-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepniewska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindegardh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span> <span> </span><span class="NLM_article-title">Artemisinin-resistant <i>Plasmodium falciparum</i> in Pursat province, western Cambodia: a parasite clearance rate study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">851</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(12)70181-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FS1473-3099%2812%2970181-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=22940027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BC38bjt1Cqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=851-858&author=C.+Amaratungaauthor=S.+Srengauthor=S.+Suonauthor=E.+S.+Phelpsauthor=K.+Stepniewskaauthor=P.+Limauthor=C.+Zhouauthor=S.+Maoauthor=J.+M.+Andersonauthor=N.+Lindegardhauthor=H.+Jiangauthor=J.+Songauthor=X.+Z.+Suauthor=N.+J.+Whiteauthor=A.+M.+Dondorpauthor=T.+J.+Andersonauthor=M.+P.+Fayauthor=J.+Muauthor=S.+Duongauthor=R.+M.+Fairhurst&title=Artemisinin-resistant+Plasmodium+falciparum+in+Pursat+province%2C+western+Cambodia%3A+a+parasite+clearance+rate+study&doi=10.1016%2FS1473-3099%2812%2970181-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study</span></div><div class="casAuthors">Amaratunga Chanaki; Sreng Sokunthea; Suon Seila; Phelps Erika S; Stepniewska Kasia; Lim Pharath; Zhou Chongjun; Mao Sivanna; Anderson Jennifer M; Lindegardh Niklas; Jiang Hongying; Song Jianping; Su Xin-zhuan; White Nicholas J; Dondorp Arjen M; Anderson Tim J C; Fay Michael P; Mu Jianbing; Duong Socheat; Fairhurst Rick M</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">851-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Artemisinin-resistant Plasmodium falciparum has been reported in Pailin, western Cambodia, detected as a slow parasite clearance rate in vivo.  Emergence of this phenotype in western Thailand and possibly elsewhere threatens to compromise the effectiveness of all artemisinin-based combination therapies.  Parasite genetics is associated with parasite clearance rate but does not account for all variation.  We investigated contributions of both parasite genetics and host factors to the artemisinin-resistance phenotype in Pursat, western Cambodia.  METHODS:  Between June 19 and Nov 28, 2009, and June 26 and Dec 6, 2010, we enrolled patients aged 10 years or older with uncomplicated falciparum malaria, a density of asexual parasites of at least 10,000 per μL of whole blood, no symptoms or signs of severe malaria, no other cause of febrile illness, and no chronic illness.  We gave participants 4 mg/kg artesunate at 0, 24, and 48 h, 15 mg/kg mefloquine at 72 h, and 10 mg/kg mefloquine at 96 h.  We assessed parasite density on thick blood films every 6 h until undetectable.  The parasite clearance half-life was calculated from the parasite clearance curve.  We genotyped parasites with 18 microsatellite markers and patients for haemoglobin E, α-thalassaemia, and a mutation of G6PD, which encodes glucose-6-phosphate dehydrogenase.  To account for the possible effects of acquired immunity on half-life, we used three surrogates for increased likelihood of exposure to P falciparum: age, sex, and place of residence.  This study is registered with ClinicalTrials.gov, number NCT00341003.  FINDINGS:  We assessed 3504 individuals from all six districts of Pursat province seeking treatment for malaria symptoms.  We enrolled 168 patients with falciparum malaria who met inclusion criteria.  The geometric mean half-life was 5·85 h (95% CI 5·54-6·18) in Pursat, similar to that reported in Pailin (p=0·109).  We identified two genetically different parasite clone groups: parasite group 1 (PG1) and parasite group 2 (PG2).  Non-significant increases in parasite clearance half-life were seen in patients with haemoglobin E (0·55 h; p=0·078), those of male sex (0·96 h; p=0·064), and in 2010 (0·68 h; p=0·068); PG1 was associated with a significant increase (0·79 h; p=0·033).  The mean parasite heritability of half-life was 0·40 (SD 0·17).  INTERPRETATION:  Heritable artemisinin resistance is established in a second Cambodian province.  To accurately identify parasites that are intrinsically susceptible or resistant to artemisinins, future studies should explore the effect of erythrocyte polymorphisms and specific immune responses on half-life variation.  FUNDING:  Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRI09wVfIhndi-bLEOO4dYpfW6udTcc2eYwDvpcZvnTNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bjt1Cqsg%253D%253D&md5=3bb047418e6093e6b0d6ef8227de797a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2812%2970181-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252812%252970181-0%26sid%3Dliteratum%253Aachs%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DPhelps%26aufirst%3DE.%2BS.%26aulast%3DStepniewska%26aufirst%3DK.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DJ.%2BM.%26aulast%3DLindegardh%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DX.%2BZ.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DAnderson%26aufirst%3DT.%2BJ.%26aulast%3DFay%26aufirst%3DM.%2BP.%26aulast%3DMu%26aufirst%3DJ.%26aulast%3DDuong%26aufirst%3DS.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26atitle%3DArtemisinin-resistant%2520Plasmodium%2520falciparum%2520in%2520Pursat%2520province%252C%2520western%2520Cambodia%253A%2520a%2520parasite%2520clearance%2520rate%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2012%26volume%3D12%26spage%3D851%26epage%3D858%26doi%3D10.1016%2FS1473-3099%2812%2970181-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sopha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Try, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blessborn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tullo, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span> <span> </span><span class="NLM_article-title">Dihydroartemisinin-piperaquine resistance in <i>Plasmodium falciparum</i> malaria in Cambodia: a multisite prospective cohort study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(15)00487-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FS1473-3099%2815%2900487-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=26774243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVWhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=357-365&author=C.+Amaratungaauthor=P.+Limauthor=S.+Suonauthor=S.+Srengauthor=S.+Maoauthor=C.+Sophaauthor=B.+Samauthor=D.+Dekauthor=V.+Tryauthor=R.+Amatoauthor=D.+Blessbornauthor=L.+Songauthor=G.+S.+Tulloauthor=M.+P.+Fayauthor=J.+M.+Andersonauthor=J.+Tarningauthor=R.+M.+Fairhurst&title=Dihydroartemisinin-piperaquine+resistance+in+Plasmodium+falciparum+malaria+in+Cambodia%3A+a+multisite+prospective+cohort+study&doi=10.1016%2FS1473-3099%2815%2900487-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study</span></div><div class="casAuthors">Amaratunga, Chanaki; Lim, Pharath; Suon, Seila; Sreng, Sokunthea; Mao, Sivanna; Sopha, Chantha; Sam, Baramey; Dek, Dalin; Try, Vorleak; Amato, Roberto; Blessborn, Daniel; Song, Lijiang; Tullo, Gregory S.; Fay, Michael P.; Anderson, Jennifer M.; Tarning, Joel; Fairhurst, Rick M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">357-365</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Artemisinin resistance in Plasmodium falciparum threatens to reduce the efficacy of artemisinin combination therapies (ACTs), thus compromising global efforts to eliminate malaria.  Recent treatment failures with dihydroartemisinin-piperaquine, the current first-line ACT in Cambodia, suggest that piperaquine resistance may be emerging in this country.  We explored the relation between artemisinin resistance and dihydroartemisinin-piperaquine failures, and sought to confirm the presence of piperaquine-resistant P falciparum infections in Cambodia.  In this prospective cohort study, we enrolled patients aged 2-65 years with uncomplicated P falciparum malaria in three Cambodian provinces: Pursat, Preah Vihear, and Ratanakiri.  Participants were given std. 3-day courses of dihydroartemisinin-piperaquine.  Peripheral blood parasite densities were measured until parasites cleared and then weekly to 63 days.  The primary outcome was recrudescent P falciparum parasitemia within 63 days.  We measured piperaquine plasma concns. at baseline, 7 days, and day of recrudescence.  We assessed phenotypic and genotypic markers of drug resistance in parasite isolates.  The study is registered with ClinicalTrials.gov, no. NCT01736319.  Between Sept 4, 2012, and Dec 31, 2013, we enrolled 241 participants.  In Pursat, where artemisinin resistance is entrenched, 37 (46%) of 81 patients had parasite recrudescence.  In Preah Vihear, where artemisinin resistance is emerging, ten (16%) of 63 patients had recrudescence and in Ratanakiri, where artemisinin resistance is rare, one (2%) of 60 patients did.  Patients with recrudescent P falciparum infections were more likely to have detectable piperaquine plasma concns. at baseline compared with non-recrudescent patients, but did not differ significantly in age, initial parasite d., or piperaquine plasma concns. at 7 days.  Recrudescent parasites had a higher prevalence of kelch13 mutations, higher piperaquine 50% inhibitory concn. (IC50) values, and lower mefloquine IC50 values; none had multiple pfmdr1 copies, a genetic marker of mefloquine resistance.  Dihydroartemisinin-piperaquine failures are caused by both artemisinin and piperaquine resistance, and commonly occur in places where dihydroartemisinin-piperaquine has been used in the private sector.  In Cambodia, artesunate plus mefloquine may be a viable option to treat dihydroartemisinin-piperaquine failures, and a more effective first-line ACT in areas where dihydroartemisinin-piperaquine failures are common.  The use of single low-dose primaquine to eliminate circulating gametocytes is needed in areas where artemisinin and ACT resistance is prevalent.  National Institute of Allergy and Infectious Diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd0RSM1qQzR7Vg90H21EOLACvtfcHk0ljxzWFu-TKF4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVWhsg%253D%253D&md5=b2b62ae0ef4f2b67f7446a2a5718654d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2815%2900487-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252815%252900487-9%26sid%3Dliteratum%253Aachs%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DSopha%26aufirst%3DC.%26aulast%3DSam%26aufirst%3DB.%26aulast%3DDek%26aufirst%3DD.%26aulast%3DTry%26aufirst%3DV.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DBlessborn%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DTullo%26aufirst%3DG.%2BS.%26aulast%3DFay%26aufirst%3DM.%2BP.%26aulast%3DAnderson%26aufirst%3DJ.%2BM.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26atitle%3DDihydroartemisinin-piperaquine%2520resistance%2520in%2520Plasmodium%2520falciparum%2520malaria%2520in%2520Cambodia%253A%2520a%2520multisite%2520prospective%2520cohort%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2016%26volume%3D16%26spage%3D357%26epage%3D365%26doi%3D10.1016%2FS1473-3099%2815%2900487-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spring, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanachayangkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somethy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Se, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ittiverakul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sia-ngam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntawunginn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arsanok, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buathong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaorattanakawee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ta-aksorn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanarat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundrakes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heng, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teja-isavadharm, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichyangkul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phann, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juliano, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meshnick, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chour, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanteri, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. L.</span></span> <span> </span><span class="NLM_article-title">Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(15)70049-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FS1473-3099%2815%2970049-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=25877962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFSgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=683-691&author=M.+D.+Springauthor=J.+T.+Linauthor=J.+E.+Manningauthor=P.+Vanachayangkulauthor=S.+Somethyauthor=R.+Bunauthor=Y.+Seauthor=S.+Channauthor=M.+Ittiverakulauthor=P.+Sia-ngamauthor=W.+Kuntawunginnauthor=M.+Arsanokauthor=N.+Buathongauthor=S.+Chaorattanakaweeauthor=P.+Gosiauthor=W.+Ta-aksornauthor=N.+Chanaratauthor=S.+Sundrakesauthor=N.+Kongauthor=T.+K.+Hengauthor=S.+Nouauthor=P.+Teja-isavadharmauthor=S.+Pichyangkulauthor=S.+T.+Phannauthor=S.+Balasubramanianauthor=J.+J.+Julianoauthor=S.+R.+Meshnickauthor=C.+M.+Chourauthor=S.+Promauthor=C.+A.+Lanteriauthor=C.+Lonauthor=D.+L.+Saunders&title=Dihydroartemisinin-piperaquine+failure+associated+with+a+triple+mutant+including+kelch13+C580Y+in+Cambodia%3A+an+observational+cohort+study&doi=10.1016%2FS1473-3099%2815%2970049-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study</span></div><div class="casAuthors">Spring, Michele D.; Lin, Jessica T.; Manning, Jessica E.; Vanachayangkul, Pattaraporn; Somethy, Sok; Bun, Rathvicheth; Se, Youry; Chann, Soklyda; Ittiverakul, Mali; Sia-ngam, Piyaporn; Kuntawunginn, Worachet; Arsanok, Montri; Buathong, Nillawan; Chaorattanakawee, Suwanna; Gosi, Panita; Ta-aksorn, Winita; Chanarat, Nitima; Sundrakes, Siratchana; Kong, Nareth; Heng, Thay Kheang; Nou, Samon; Teja-isavadharm, Paktiya; Pichyangkul, Sathit; Phann, Sut Thang; Balasubramanian, Sujata; Juliano, Jonathan J.; Meshnick, Steven R.; Chour, Char Meng; Prom, Satharath; Lanteri, Charlotte A.; Lon, Chanthap; Saunders, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">683-691</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dihydroartemisinin-piperaquine has been adopted as first-line artemisinin combination therapy (ACT) for multidrug-resistant Plasmodium falciparum malaria in Cambodia because of few remaining alternatives.  We aimed to assess the efficacy of std. 3 day dihydroartemisinin-piperaquine treatment of uncomplicated P falciparum malaria, with and without the addn. of primaquine, focusing on the factors involved in drug resistance.  In this observational cohort study, we assessed 107 adults aged 18-65 years presenting to Anlong Veng District Hospital, Oddar Meanchey Province, Cambodia, with uncomplicated P falciparum or mixed P falciparum/Plasmodium vivax infection of between 1000 and 200 000 parasites per μL of blood, and participating in a randomized clin. trial in which all had received dihydroartemisinin-piperaquine for 3 days, after which they had been randomly allocated to receive either primaquine or no primaquine.  The trial was halted early due to poor dihydroartemisinin-piperaquine efficacy, and we assessed day 42 PCR-cor. therapeutic efficacy (proportion of patients with recurrence at 42 days) and evidence of drug resistance from the initial cohort.  We did analyses on both the intention to treat (ITT), modified ITT (withdrawals, losses to follow-up, and those with secondary outcomes [eg, new non-recrudescent malaria infection] were censored on the last day of follow-up), and per-protocol populations of the original trial.  The original trial was registered with ClinicalTrials.gov, no. NCT01280162.  Between Dec 10, 2012, and Feb 18, 2014, we had enrolled 107 patients in the original trial.  Enrolment was voluntarily halted on Feb 16, 2014, before reaching planned enrollment (n=150) because of poor efficacy.  We had randomly allocated 50 patients to primaquine and 51 patients to no primaquine groups.  PCR-adjusted Kaplan-Meier risk of P falciparum 42 day recrudescence was 54% (95% CI 45-63) in the modified ITT anal. population.  We found two kelch13 propeller gene mutations assocd. with artemisinin resistance-a non-synonymous Cys580Tyr substitution in 70 (65%) of 107 participants, an Arg539Thr substitution in 33 (31%), and a wild-type parasite in four (4%).  Unlike Arg539Thr, Cys580Tyr was accompanied by two other mutations assocd. with extended parasite clearance (MAL10:688956 and MAL13:1718319).  This combination triple mutation was assocd. with a 5·4 times greater risk of treatment failure (hazard ratio 5·4 [95% CI 2·4-12]; p<0·0001) and higher piperaquine 50% inhibitory concn. (triple mutant 34 nM [28-41]; non-triple mutant 24 nM [1-27]; p=0·003) than other infections had.  The drug was well tolerated, with gastrointestinal symptoms being the most common complaints.  The dramatic decline in efficacy of dihydroartemisinin-piperaquine compared with what was obsd. in a study at the same location in 2010 was strongly assocd. with a new triple mutation including the kelch13 Cys580Tyr substitution.  3 Days of artemisinin as part of an artemisinin combination therapy regimen might be insufficient.  Strict regulation and monitoring of antimalarial use, along with non-pharmacol. approaches to malaria resistance containment, must be integral parts of the public health response to rapidly accelerating drug resistance in the region.  Armed Forces Health Surveillance Center/Global Emerging Infections Surveillance and Response System, Military Infectious Disease Research Program, National Institute of Allergy and Infectious Diseases, and American Society of Tropical Medicine and Hygiene/Burroughs Wellcome Fund.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFjkvNekrUMrVg90H21EOLACvtfcHk0ljxzWFu-TKF4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFSgu78%253D&md5=6150b25babe19f91eb5971e030327681</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2815%2970049-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252815%252970049-6%26sid%3Dliteratum%253Aachs%26aulast%3DSpring%26aufirst%3DM.%2BD.%26aulast%3DLin%26aufirst%3DJ.%2BT.%26aulast%3DManning%26aufirst%3DJ.%2BE.%26aulast%3DVanachayangkul%26aufirst%3DP.%26aulast%3DSomethy%26aufirst%3DS.%26aulast%3DBun%26aufirst%3DR.%26aulast%3DSe%26aufirst%3DY.%26aulast%3DChann%26aufirst%3DS.%26aulast%3DIttiverakul%26aufirst%3DM.%26aulast%3DSia-ngam%26aufirst%3DP.%26aulast%3DKuntawunginn%26aufirst%3DW.%26aulast%3DArsanok%26aufirst%3DM.%26aulast%3DBuathong%26aufirst%3DN.%26aulast%3DChaorattanakawee%26aufirst%3DS.%26aulast%3DGosi%26aufirst%3DP.%26aulast%3DTa-aksorn%26aufirst%3DW.%26aulast%3DChanarat%26aufirst%3DN.%26aulast%3DSundrakes%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DN.%26aulast%3DHeng%26aufirst%3DT.%2BK.%26aulast%3DNou%26aufirst%3DS.%26aulast%3DTeja-isavadharm%26aufirst%3DP.%26aulast%3DPichyangkul%26aufirst%3DS.%26aulast%3DPhann%26aufirst%3DS.%2BT.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DJuliano%26aufirst%3DJ.%2BJ.%26aulast%3DMeshnick%26aufirst%3DS.%2BR.%26aulast%3DChour%26aufirst%3DC.%2BM.%26aulast%3DProm%26aufirst%3DS.%26aulast%3DLanteri%26aufirst%3DC.%2BA.%26aulast%3DLon%26aufirst%3DC.%26aulast%3DSaunders%26aufirst%3DD.%2BL.%26atitle%3DDihydroartemisinin-piperaquine%2520failure%2520associated%2520with%2520a%2520triple%2520mutant%2520including%2520kelch13%2520C580Y%2520in%2520Cambodia%253A%2520an%2520observational%2520cohort%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2015%26volume%3D15%26spage%3D683%26epage%3D691%26doi%3D10.1016%2FS1473-3099%2815%2970049-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibitors: an expanding army attacking a unique target</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2Fj.chembiol.2012.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=22284358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=99-115&author=A.+F.+Kisselevauthor=W.+A.+van+der+Lindenauthor=H.+S.+Overkleeft&title=Proteasome+inhibitors%3A+an+expanding+army+attacking+a+unique+target&doi=10.1016%2Fj.chembiol.2012.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome Inhibitors: An Expanding Army Attacking a Unique Target</span></div><div class="casAuthors">Kisselev, Alexei F.; van der Linden, Wouter A.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-115</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Proteasomes are large, multisubunit proteolytic complexes presenting multiple targets for therapeutic intervention.  The 26S proteasome consists of a 20S proteolytic core and one or two 19S regulatory particles.  The 20S core contains three types of active sites.  Many structurally diverse inhibitors of these active sites, both natural product and synthetic, have been discovered in the last two decades.  One, bortezomib, is used clin. for treatment of multiple myeloma, mantle cell lymphoma, and acute allograft rejection.  Five more recently developed proteasome inhibitors are in trials for treatment of myeloma and other cancers.  Proteasome inhibitors also have activity in animal models of autoimmune and inflammatory diseases, reperfusion injury, promote bone and hair growth, and can potentially be used as anti-infectives.  In addn., inhibitors of ATPases and deubiquitinases of 19S regulatory particles have been discovered in the last decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKc-6qcZILhrVg90H21EOLACvtfcHk0ljZeG8Q4bWwsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cqsbc%253D&md5=a4eca9d710b209d5455c2eaa58dfd0bc</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DProteasome%2520inhibitors%253A%2520an%2520expanding%2520army%2520attacking%2520a%2520unique%2520target%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D99%26epage%3D115%26doi%3D10.1016%2Fj.chembiol.2012.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregerson, D. S.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasomes: structure, function, and antigen presentation</span>. <i>Prog. Mol. Biol. Transl Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-397863-9.00003-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FB978-0-12-397863-9.00003-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=22727420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2jtr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=75-112&author=D.+A.+Ferringtonauthor=D.+S.+Gregerson&title=Immunoproteasomes%3A+structure%2C+function%2C+and+antigen+presentation&doi=10.1016%2FB978-0-12-397863-9.00003-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasomes: structure, function, and antigen presentation</span></div><div class="casAuthors">Ferrington, Deborah A.; Gregerson, Dale S.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Molecular Biology and Translational Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">Proteasomal System in Aging and Disease</span>),
    <span class="NLM_cas:pages">75-112, 1 plate</span>CODEN:
                <span class="NLM_cas:coden">PNARC5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Immunoproteasomes contain replacements for the three catalytic subunits of std. proteasomes.  In most cells, oxidative stress and proinflammatory cytokines are stimuli that lead to elevated prodn. of immunoproteasomes.  Immune system cells, esp. antigen-presenting cells, express a higher basal level of immunoproteasomes.  A well-described function of immunoproteasomes is to generate peptides with a hydrophobic C terminus that can be processed to fit in the groove of MHC class I mols.  This display of peptides on the cell surface allows surveillance by CD8 T cells of the adaptive immune system for pathogen-infected cells.  Functions of immunoproteasomes, other than generating peptides for antigen presentation, are emerging from studies in immunoproteasome-deficient mice, and are complemented by recently described diseases linked to mutations or single-nucleotide polymorphisms in immunoproteasome subunits.  Thus, this growing body of literature suggests a more pleiotropic role in cell function for the immunoproteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB-ms47z5YWbVg90H21EOLACvtfcHk0ljZeG8Q4bWwsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2jtr7E&md5=dbddd6a20fe829739bb2acd037619376</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-397863-9.00003-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-397863-9.00003-1%26sid%3Dliteratum%253Aachs%26aulast%3DFerrington%26aufirst%3DD.%2BA.%26aulast%3DGregerson%26aufirst%3DD.%2BS.%26atitle%3DImmunoproteasomes%253A%2520structure%252C%2520function%252C%2520and%2520antigen%2520presentation%26jtitle%3DProg.%2520Mol.%2520Biol.%2520Transl%2520Sci.%26date%3D2012%26volume%3D109%26spage%3D75%26epage%3D112%26doi%3D10.1016%2FB978-0-12-397863-9.00003-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponder, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asbjornsdottir, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgington, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Validation of the proteasome as a therapeutic target in <i>Plasmodium</i> using an epoxyketone inhibitor with parasite-specific toxicity</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1535</span>– <span class="NLM_lpage">1545</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2Fj.chembiol.2012.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=23142757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GqtLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1535-1545&author=H.+Liauthor=E.+L.+Ponderauthor=M.+Verdoesauthor=K.+H.+Asbjornsdottirauthor=E.+Deuauthor=L.+E.+Edgingtonauthor=J.+T.+Leeauthor=C.+J.+Kirkauthor=S.+D.+Demoauthor=K.+C.+Williamsonauthor=M.+Bogyo&title=Validation+of+the+proteasome+as+a+therapeutic+target+in+Plasmodium+using+an+epoxyketone+inhibitor+with+parasite-specific+toxicity&doi=10.1016%2Fj.chembiol.2012.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of the Proteasome as a Therapeutic Target in Plasmodium Using an Epoxyketone Inhibitor with Parasite-Specific Toxicity</span></div><div class="casAuthors">Li, Hao; Ponder, Elizabeth L.; Verdoes, Martijn; Asbjornsdottir, Kristijana H.; Deu, Edgar; Edgington, Laura E.; Lee, Jeong Tae; Kirk, Christopher J.; Demo, Susan D.; Williamson, Kim C.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1535-1545</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Plasmodium proteasome has been suggested to be a potential antimalarial drug target; however, toxicity of inhibitors has prevented validation of this enzyme in vivo.  We report a screen of a library of 670 analogs of the recent US Food and Drug Administration-approved inhibitor, carfilzomib, to identify compds. that selectively kill parasites.  We identified one compd., PR3, that has significant parasite killing activity in vitro but dramatically reduced toxicity in host cells.  We found that this parasite-specific toxicity is not due to selective targeting of the Plasmodium proteasome over the host proteasome, but instead is due to a lack of activity against one of the human proteasome subunits.  Subsequently, we used PR3 to significantly reduce parasite load in Plasmodium berghei infected mice without host toxicity, thus validating the proteasome as a viable antimalarial drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrioM_fNpikeLVg90H21EOLACvtfcHk0ljZeG8Q4bWwsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GqtLjP&md5=676ae3dbb057ec1e0e3e42859ab20739</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DPonder%26aufirst%3DE.%2BL.%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DAsbjornsdottir%26aufirst%3DK.%2BH.%26aulast%3DDeu%26aufirst%3DE.%26aulast%3DEdgington%26aufirst%3DL.%2BE.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DWilliamson%26aufirst%3DK.%2BC.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DValidation%2520of%2520the%2520proteasome%2520as%2520a%2520therapeutic%2520target%2520in%2520Plasmodium%2520using%2520an%2520epoxyketone%2520inhibitor%2520with%2520parasite-specific%2520toxicity%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D1535%26epage%3D1545%26doi%3D10.1016%2Fj.chembiol.2012.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tschan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werkhoven, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knittel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aminake, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joanny, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liskamp, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordmuller, B.</span></span> <span> </span><span class="NLM_article-title">Broad-spectrum antimalarial activity of peptido sulfonyl fluorides, a new class of proteasome inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3576</span>– <span class="NLM_lpage">3584</span>, <span class="refDoi"> DOI: 10.1128/AAC.00742-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1128%2FAAC.00742-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=23689711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WgtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=3576-3584&author=S.+Tschanauthor=A.+J.+Brouwerauthor=P.+R.+Werkhovenauthor=A.+M.+Jonkerauthor=L.+Wagnerauthor=S.+Knittelauthor=M.+N.+Aminakeauthor=G.+Pradelauthor=F.+Joannyauthor=R.+M.+Liskampauthor=B.+Mordmuller&title=Broad-spectrum+antimalarial+activity+of+peptido+sulfonyl+fluorides%2C+a+new+class+of+proteasome+inhibitors&doi=10.1128%2FAAC.00742-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Broad-spectrum antimalarial activity of peptido sulfonyl fluorides, a new class of proteasome inhibitors</span></div><div class="casAuthors">Tschan, Serena; Brouwer, Arwin J.; Werkhoven, Paul R.; Jonker, Anika M.; Wagner, Lena; Knittel, Sarah; Aminake, Makoah Nigel; Pradel, Gabriele; Joanny, Fanny; Liskamp, Rob M. J.; Mordmueller, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3576-3584</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Despite declining nos. of cases and deaths, malaria remains a major public health problem in many parts of the world.  Today, case management relies heavily on a single class of antimalarial compds.: artemisinins.  Hence, development of resistance against artemisinins may destroy current malaria control strategies.  Beyond malaria control are elimination and eradication programs that will require drugs with good activity against acute infection but also with preventive and transmission-blocking properties.  Consequently, new antimalarials are needed not only to ensure malaria control but also for elimination and eradication efforts.  In this study, we introduce peptido sulfonyl fluorides (PSF) as a new class of compds. with antiplasmodial activity.  We show that PSF target the plasmodial proteasome and act on all asexual stages of the intraerythrocytic cycle and on gametocytes.  PSF showed activities at concns. as low as 20 nM against multidrug-resistant and chloroquine-sensitive Plasmodium falciparum lab. strains and clin. isolates from Gabon.  Structural requirements for activity were identified, and cytotoxicity in human HeLa or HEK 293 cells was low.  The lead PSF PW28 suppressed growth of Plasmodium berghei in vivo but showed signs of toxicity in mice.  Considering their modular structure and broad spectrum of activity against different stages of the plasmodial life cycle, proteasome inhibitors based on PSF have a great potential for further development as preclin. candidate compds. with improved species-specific activity and less toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZGX0bUt1lybVg90H21EOLACvtfcHk0li7RcnMX7N2Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WgtbzI&md5=7bf49f9fa35185f23d9cc075795e767f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FAAC.00742-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00742-12%26sid%3Dliteratum%253Aachs%26aulast%3DTschan%26aufirst%3DS.%26aulast%3DBrouwer%26aufirst%3DA.%2BJ.%26aulast%3DWerkhoven%26aufirst%3DP.%2BR.%26aulast%3DJonker%26aufirst%3DA.%2BM.%26aulast%3DWagner%26aufirst%3DL.%26aulast%3DKnittel%26aufirst%3DS.%26aulast%3DAminake%26aufirst%3DM.%2BN.%26aulast%3DPradel%26aufirst%3DG.%26aulast%3DJoanny%26aufirst%3DF.%26aulast%3DLiskamp%26aufirst%3DR.%2BM.%26aulast%3DMordmuller%26aufirst%3DB.%26atitle%3DBroad-spectrum%2520antimalarial%2520activity%2520of%2520peptido%2520sulfonyl%2520fluorides%252C%2520a%2520new%2520class%2520of%2520proteasome%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D3576%26epage%3D3584%26doi%3D10.1128%2FAAC.00742-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirkman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziedziech, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzual, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvaro, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiang, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindasamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumwebaze, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukenick, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendome, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhanot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kafsack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doggett, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span> <span> </span><span class="NLM_article-title">Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E6863</span>– <span class="NLM_lpage">E6870</span>, <span class="refDoi"> DOI: 10.1073/pnas.1806109115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1073%2Fpnas.1806109115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=29967165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCmtrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E6863-E6870&author=L.+A.+Kirkmanauthor=W.+Zhanauthor=J.+Visoneauthor=A.+Dziedziechauthor=P.+K.+Singhauthor=H.+Fanauthor=X.+Tongauthor=I.+Bruzualauthor=R.+Haraauthor=M.+Kawasakiauthor=T.+Imaedaauthor=R.+Okamotoauthor=K.+Satoauthor=M.+Michinoauthor=E.+F.+Alvaroauthor=L.+F.+Guiangauthor=L.+Sanzauthor=D.+J.+Motaauthor=K.+Govindasamyauthor=R.+Wangauthor=Y.+Lingauthor=P.+K.+Tumwebazeauthor=G.+Sukenickauthor=L.+Shiauthor=J.+Vendomeauthor=P.+Bhanotauthor=P.+J.+Rosenthalauthor=K.+Asoauthor=M.+A.+Foleyauthor=R.+A.+Cooperauthor=B.+Kafsackauthor=J.+S.+Doggettauthor=C.+F.+Nathanauthor=G.+Lin&title=Antimalarial+proteasome+inhibitor+reveals+collateral+sensitivity+from+intersubunit+interactions+and+fitness+cost+of+resistance&doi=10.1073%2Fpnas.1806109115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance</span></div><div class="casAuthors">Kirkman, Laura A.; Zhan, Wenhu; Visone, Joseph; Dziedziech, Alexis; Singh, Pradeep K.; Fan, Hao; Tong, Xinran; Bruzual, Igor; Hara, Ryoma; Kawasaki, Masanori; Imaeda, Toshihiro; Okamoto, Rei; Sato, Kenjiro; Michino, Mayako; Alvaro, Elena Fernandez; Guiang, Liselle F.; Sanz, Laura; Mota, Daniel J.; Govindasamy, Kavitha; Wang, Rong; Ling, Yan; Tumwebaze, Patrick K.; Sukenick, George; Shi, Lei; Vendome, Jeremie; Bhanot, Purnima; Rosenthal, Philip J.; Aso, Kazuyoshi; Foley, Michael A.; Cooper, Roland A.; Kafsack, Bjorn; Doggett, J. Stone; Nathan, Carl F.; Lin, Gang</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">E6863-E6870</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We describe noncovalent, reversible asparagine ethylenediamine (AsnEDA) inhibitors of the Plasmodium falciparum proteasome (Pf20S) β5 subunit that spare all active subunits of human constitutive and immuno-proteasomes.  The compds. are active against erythrocytic, sexual, and liver-stage parasites, against parasites resistant to current antimalarials, and against P. falciparum strains from patients in Africa.  The β5 inhibitors synergize with a β2 inhibitor in vitro and in mice and with artemisinin.  P. falciparum selected for resistance to an AsnEDA β5 inhibitor surprisingly harbored a point mutation in the noncatalytic β6 subunit.  The β6 mutant was resistant to the species-selective Pf20S β5 inhibitor but remained sensitive to the species-nonselective β5 inhibitors bortezomib and carfilzomib.  Moreover, resistance to the Pf20S β5 inhibitor was accompanied by increased sensitivity to a Pf20S β2 inhibitor.  Finally, the β5 inhibitor-resistant mutant had a fitness cost that was exacerbated by irradn.  Thus, used in combination, multistage-active inhibitors of the Pf20S β5 and β2 subunits afford synergistic antimalarial activity with a potential to delay the emergence of resistance to artemisinins and each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcBMtrslCvE7Vg90H21EOLACvtfcHk0li7RcnMX7N2Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCmtrfJ&md5=6addacc779527c9e4c6a265868f088fe</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1806109115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1806109115%26sid%3Dliteratum%253Aachs%26aulast%3DKirkman%26aufirst%3DL.%2BA.%26aulast%3DZhan%26aufirst%3DW.%26aulast%3DVisone%26aufirst%3DJ.%26aulast%3DDziedziech%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DBruzual%26aufirst%3DI.%26aulast%3DHara%26aufirst%3DR.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DImaeda%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DR.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DAlvaro%26aufirst%3DE.%2BF.%26aulast%3DGuiang%26aufirst%3DL.%2BF.%26aulast%3DSanz%26aufirst%3DL.%26aulast%3DMota%26aufirst%3DD.%2BJ.%26aulast%3DGovindasamy%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DTumwebaze%26aufirst%3DP.%2BK.%26aulast%3DSukenick%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DVendome%26aufirst%3DJ.%26aulast%3DBhanot%26aufirst%3DP.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DAso%26aufirst%3DK.%26aulast%3DFoley%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DR.%2BA.%26aulast%3DKafsack%26aufirst%3DB.%26aulast%3DDoggett%26aufirst%3DJ.%2BS.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26aulast%3DLin%26aufirst%3DG.%26atitle%3DAntimalarial%2520proteasome%2520inhibitor%2520reveals%2520collateral%2520sensitivity%2520from%2520intersubunit%2520interactions%2520and%2520fitness%2520cost%2520of%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE6863%26epage%3DE6870%26doi%3D10.1073%2Fpnas.1806109115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dogovski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridgford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnadig, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozdech, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foote, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klonis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span> <span> </span><span class="NLM_article-title">Targeting the cell stress response of <i>Plasmodium falciparum</i> to overcome artemisinin resistance</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">e1002132</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.1002132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1371%2Fjournal.pbio.1002132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=25901609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVGqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=e1002132&author=C.+Dogovskiauthor=S.+C.+Xieauthor=G.+Burgioauthor=J.+Bridgfordauthor=S.+Mokauthor=J.+M.+McCawauthor=K.+Chotivanichauthor=S.+Kennyauthor=N.+Gnadigauthor=J.+Straimerauthor=Z.+Bozdechauthor=D.+A.+Fidockauthor=J.+A.+Simpsonauthor=A.+M.+Dondorpauthor=S.+Footeauthor=N.+Klonisauthor=L.+Tilley&title=Targeting+the+cell+stress+response+of+Plasmodium+falciparum+to+overcome+artemisinin+resistance&doi=10.1371%2Fjournal.pbio.1002132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance</span></div><div class="casAuthors">Dogovski, Con; Xie, Stanley C.; Burgio, Gaetan; Bridgford, Jess; Mok, Sachel; McCaw, James M.; Chotivanich, Kesinee; Kenny, Shannon; Gnadig, Nina; Straimer, Judith; Bozdech, Zbynek; Fidock, David A.; Simpson, Julie A.; Dondorp, Arjen M.; Foote, Simon; Klonis, Nectarios; Tilley, Leann</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1002132/1-e1002132/26</span>CODEN:
                <span class="NLM_cas:coden">PBLIBG</span>;
        ISSN:<span class="NLM_cas:issn">1545-7885</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Successful control of falciparum malaria depends greatly on treatment with artemisinin combination therapies.  Thus, reports that resistance to artemisinins (ARTs) has emerged, and that the prevalence of this resistance is increasing, are alarming.  ART resistance has recently been linked to mutations in the K13 propeller protein.  The authors undertook a detailed kinetic anal. of the drug responses of K13 wild-type and mutant isolates of Plasmodium falciparum sourced from a region in Cambodia (Pailin).  They demonstrate that ART treatment induces growth retardation and an accumulation of ubiquitinated proteins, indicative of a cellular stress response that engages the ubiquitin/proteasome system.  They show that resistant parasites exhibit lower levels of ubiquitinated proteins and delayed onset of cell death, indicating an enhanced cell stress response.  The stress response could be targeted by inhibiting the proteasome.  Accordingly, clin. used proteasome inhibitors strongly synergize ART activity against both sensitive and resistant parasites, including isogenic lines expressing mutant or wild-type K13.  Synergy is also obsd. against Plasmodium berghei in vivo.  The authors developed a detailed model of parasite responses that enabled them to infer in vivo parasite clearance profiles from in vitro assessments of ART sensitivity.  They provide evidence that the clin. marker of resistance (delayed parasite clearance) is an indirect measure of drug efficacy because of the persistence of unviable parasites with unchanged morphol. in the circulation, and we suggest alternative approaches for the direct measurement of viability.  This model predicts that extending current three-day ART treatment courses to four days, or splitting the doses, will efficiently clear resistant parasite infections.  This work provides a rationale for improving the detection of ART resistance in the field and for treatment strategies that can be employed in areas with ART resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnq1k3owGeKbVg90H21EOLACvtfcHk0lgGSQ3e4-wp7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVGqu7c%253D&md5=acb11e532b67d900a54958ceebee8db1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1002132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1002132%26sid%3Dliteratum%253Aachs%26aulast%3DDogovski%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DS.%2BC.%26aulast%3DBurgio%26aufirst%3DG.%26aulast%3DBridgford%26aufirst%3DJ.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DMcCaw%26aufirst%3DJ.%2BM.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DKenny%26aufirst%3DS.%26aulast%3DGnadig%26aufirst%3DN.%26aulast%3DStraimer%26aufirst%3DJ.%26aulast%3DBozdech%26aufirst%3DZ.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DSimpson%26aufirst%3DJ.%2BA.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DFoote%26aufirst%3DS.%26aulast%3DKlonis%26aufirst%3DN.%26aulast%3DTilley%26aufirst%3DL.%26atitle%3DTargeting%2520the%2520cell%2520stress%2520response%2520of%2520Plasmodium%2520falciparum%2520to%2520overcome%2520artemisinin%2520resistance%26jtitle%3DPLoS%2520Biol.%26date%3D2015%26volume%3D13%26spage%3De1002132%26doi%3D10.1371%2Fjournal.pbio.1002132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foe, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Fonseca, P. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Structure and function based design of Plasmodium-selective proteasome inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>530</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/nature16936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fnature16936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=26863983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=530&publication_year=2016&pages=233-236&author=H.+Liauthor=A.+O%E2%80%99Donoghueauthor=W.+A.+van+der+Lindenauthor=S.+C.+Xieauthor=E.+Yooauthor=I.+T.+Foeauthor=L.+Tilleyauthor=C.+S.+Craikauthor=P.+C.+A.+da+Fonsecaauthor=M.+Bogyo&title=Structure+and+function+based+design+of+Plasmodium-selective+proteasome+inhibitors&doi=10.1038%2Fnature16936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and function-based design of Plasmodium-selective proteasome inhibitors</span></div><div class="casAuthors">Li, Hao; O'Donoghue, Anthony J.; van der Linden, Wouter A.; Xie, Stanley C.; Yoo, Euna; Foe, Ian T.; Tilley, Leann; Craik, Charles S.; da Fonseca, Paula C. A.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">530</span>
        (<span class="NLM_cas:issue">7589</span>),
    <span class="NLM_cas:pages">233-236</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The proteasome is a multi-component protease complex responsible for regulating key processes such as the cell cycle and antigen presentation.  Compds. that target the proteasome are potentially valuable tools for the treatment of pathogens that depend on proteasome function for survival and replication.  In particular, proteasome inhibitors have been shown to be toxic for the malaria parasite Plasmodium falciparum at all stages of its life cycle.  Most compds. that have been tested against the parasite also inhibit the mammalian proteasome, resulting in toxicity that precludes their use as therapeutic agents.  Therefore, better definition of the substrate specificity and structural properties of the Plasmodium proteasome could enable the development of compds. with sufficient selectivity to allow their use as anti-malarial agents.  To accomplish this goal, here the authors use a substrate profiling method to uncover differences in the specificities of the human and P. falciparum proteasome.  The authors design inhibitors based on amino-acid preferences specific to the parasite proteasome, and find that they preferentially inhibit the β2-subunit.  The authors det. the structure of the P. falciparum 20S proteasome bound to the inhibitor using cryo-electron microscopy and single-particle anal., to a resoln. of 3.6 Å.  These data reveal the unusually open P. falciparum β2 active site and provide valuable information about active-site architecture that can be used to further refine inhibitor design.  Furthermore, consistent with the recent finding that the proteasome is important for stress pathways assocd. with resistance of artemisinin family anti-malarials, the authors observe growth inhibition synergism with low doses of this β2-selective inhibitor in artemisinin-sensitive and -resistant parasites.  Finally, the authors demonstrate that a parasite-selective inhibitor could be used to attenuate parasite growth in vivo without appreciable toxicity to the host.  Thus, the Plasmodium proteasome is a chem. tractable target that could be exploited by next-generation anti-malarial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriK0Li_WncVrVg90H21EOLACvtfcHk0lgGSQ3e4-wp7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyrsr8%253D&md5=f24a562efb64dd533a7dbcfeff4171af</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature16936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16936%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DXie%26aufirst%3DS.%2BC.%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DFoe%26aufirst%3DI.%2BT.%26aulast%3DTilley%26aufirst%3DL.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3Dda%2BFonseca%26aufirst%3DP.%2BC.%2BA.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DStructure%2520and%2520function%2520based%2520design%2520of%2520Plasmodium-selective%2520proteasome%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D530%26spage%3D233%26epage%3D236%26doi%3D10.1038%2Fnature16936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kreidenweiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordmuller, B.</span></span> <span> </span><span class="NLM_article-title">Comprehensive study of proteasome inhibitors against <i>Plasmodium falciparum</i> laboratory strains and field isolates from Gabon</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">187</span>, <span class="refDoi"> DOI: 10.1186/1475-2875-7-187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1186%2F1475-2875-7-187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=18816382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BD1cnntV2luw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=187&author=A.+Kreidenweissauthor=P.+G.+Kremsnerauthor=B.+Mordmuller&title=Comprehensive+study+of+proteasome+inhibitors+against+Plasmodium+falciparum+laboratory+strains+and+field+isolates+from+Gabon&doi=10.1186%2F1475-2875-7-187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon</span></div><div class="casAuthors">Kreidenweiss Andrea; Kremsner Peter G; Mordmuller Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">187</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The emergence and spread of Plasmodium falciparum resistance to almost all available antimalarial drugs necessitates the search for new chemotherapeutic compounds.  The ubiquitin/proteasome system plays a major role in overall protein turnover, especially in fast dividing eukaryotic cells including plasmodia.  Previous studies show that the 20S proteasome is expressed and catalytically active in plasmodia and treatment with proteasome inhibitors arrests parasite growth.  This is the first comprehensive screening of proteasome inhibitors with different chemical modes of action against laboratory strains of P. falciparum.  Subsequently, a selection of inhibitors was tested in field isolates from Lambarene, Gabon.  METHODS:  Epoxomicin, YU101, YU102, MG132, MG115, Z-L(3)-VS, Ada-Ahx(3)-L(3)-VS, lactacystin, bortezomib (Velcade), gliotoxin, PR11 and PR39 were tested and compared to chloroquine- and artesunate-activities in a standardized in vitro drug susceptibility assay against P. falciparum laboratory strains 3D7, D10 and Dd2.  Freshly obtained field isolates from Lambarene, Gabon, were used to measure the activity of chloroquine, artesunate, epoxomicin, MG132, lactacystin and bortezomib.  Parasite growth was detected through histidine-rich protein 2 (HRP2) production.  Raw data were fitted by a four-parameter logistic model and individual inhibitory concentrations (50%, 90%, and 99%) were calculated.  RESULTS:  Amongst all proteasome inhibitors tested, epoxomicin showed the highest activity in chloroquine-susceptible (IC50: 6.8 nM [3D7], 1.7 nM [D10]) and in chloroquine-resistant laboratory strains (IC50: 10.4 nM [Dd2]) as well as in field isolates (IC50: 8.5 nM).  The comparator drug artesunate was even more active (IC50: 1.0 nM), whereas all strains were chloroquine-resistant (IC50: 113 nM).  CONCLUSION:  The peptide alpha',beta'-epoxyketone epoxomicin is highly active against P. falciparum regardless the grade of the parasite's chloroquine susceptibility.  Therefore, inhibition of the proteasome is a highly promising strategy to develop new antimalarials.  Epoxomicin can serve as a standard to compare new inhibitors with species-specific activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIl1PrcUBdeSXXDYhVZBdlfW6udTcc2eb0m4QV8vsIpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnntV2luw%253D%253D&md5=9ec8c38d3048e51bec85de327a1fb880</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1186%2F1475-2875-7-187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2875-7-187%26sid%3Dliteratum%253Aachs%26aulast%3DKreidenweiss%26aufirst%3DA.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26aulast%3DMordmuller%26aufirst%3DB.%26atitle%3DComprehensive%2520study%2520of%2520proteasome%2520inhibitors%2520against%2520Plasmodium%2520falciparum%2520laboratory%2520strains%2520and%2520field%2520isolates%2520from%2520Gabon%26jtitle%3DMalar.%2520J.%26date%3D2008%26volume%3D7%26spage%3D187%26doi%3D10.1186%2F1475-2875-7-187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesvizky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamadani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vescio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bacco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span> <span> </span><span class="NLM_article-title">Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1512</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(14)71125-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FS1470-2045%2814%2971125-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=25456369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFegt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1503-1512&author=S.+K.+Kumarauthor=J.+G.+Berdejaauthor=R.+Niesvizkyauthor=S.+Lonialauthor=J.+P.+Laubachauthor=M.+Hamadaniauthor=A.+K.+Stewartauthor=P.+Hariauthor=V.+Royauthor=R.+Vescioauthor=J.+L.+Kaufmanauthor=D.+Bergauthor=E.+Liaoauthor=A.+Di+Baccoauthor=J.+Estevamauthor=N.+Guptaauthor=A.+M.+Huiauthor=V.+Rajkumarauthor=P.+G.+Richardson&title=Safety+and+tolerability+of+ixazomib%2C+an+oral+proteasome+inhibitor%2C+in+combination+with+lenalidomide+and+dexamethasone+in+patients+with+previously+untreated+multiple+myeloma%3A+an+open-label+phase+1%2F2+study&doi=10.1016%2FS1470-2045%2814%2971125-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study</span></div><div class="casAuthors">Kumar, Shaji K.; Berdeja, Jesus G.; Niesvizky, Ruben; Lonial, Sagar; Laubach, Jacob P.; Hamadani, Mehdi; Stewart, A. Keith; Hari, Parameswaran; Roy, Vivek; Vescio, Robert; Kaufman, Jonathan L.; Berg, Deborah; Liao, Eileen; Di Bacco, Alessandra; Estevam, Jose; Gupta, Neeraj; Hui, Ai-Min; Rajkumar, Vincent; Richardson, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1503-1512</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma.  Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy.  In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma.  We enrolled patients newly diagnosed with multiple myeloma aged 18 years or older with measurable disease, Eastern Cooperative Oncol. Group performance status 0-2, and no grade 2 or higher peripheral neuropathy, and treated them with oral ixazomib (days 1, 8, 15) plus lenalidomide 25 mg (days 1-21) and dexamethasone 40 mg (days 1, 8, 15, 22) for up to 12 28-day cycles, followed by maintenance therapy with ixazomib alone.  In phase 1, we gave patients escalating doses of ixazomib (1·68-3·95 mg/m2) to establish the recommended dose for phase 2.  The primary endpoints were max. tolerated dose for phase 1, and the rate of very good partial response or better for phase 2.  Safety analyses were done in all patients who received at least one dose of study drug; efficacy analyses were done in all patients who received at least one dose of study drug at the phase 2 dose, had measurable disease at baseline, and had at least one post-baseline response assessment.  This study is registered at ClinicalTrials.gov, no. NCT01217957.  Between Nov 22, 2010, and Feb 28, 2012, we enrolled 65 patients (15 to phase 1 and 50 to phase 2).  Four dose-limiting toxic events were noted in phase 1: one at a dose of ixazomib of 2·97 mg/m2 and three at 3·95 mg/m2.  The max. tolerated dose of ixazomib was established as 2·97 mg/m2 and the recommended phase 2 dose was 2·23 mg/m2, which was converted to a 4·0 mg fixed dose based on population pharmacokinetic results.  Grade 3 or higher adverse events related to any drug were reported in 41 (63%) patients, including skin and s.c. tissue disorders (11 patients, 17%), neutropenia (eight patients, 12%), and thrombocytopenia (five patients, 8%); drug-related peripheral neuropathy of grade 3 or higher occurred in four (6%) patients.  Five patients discontinued because of adverse events.  In 64 response-evaluable patients, 37 (58%, 95% CI 45-70) had a very good partial response or better.  The all-oral combination of weekly ixazomib plus lenalidomide and dexamethasone was generally well tolerated and appeared active in newly diagnosed multiple myeloma.  These results support the phase 3 trial development of this combination for multiple myeloma.  Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical International Company.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh9Fp8bQp8sbVg90H21EOLACvtfcHk0ljQYwsbsidT7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFegt7zO&md5=59d0683d161783eaee2f9a3260ae7f34</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2971125-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252971125-8%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%2BK.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DNiesvizky%26aufirst%3DR.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DHamadani%26aufirst%3DM.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DRoy%26aufirst%3DV.%26aulast%3DVescio%26aufirst%3DR.%26aulast%3DKaufman%26aufirst%3DJ.%2BL.%26aulast%3DBerg%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DE.%26aulast%3DDi%2BBacco%26aufirst%3DA.%26aulast%3DEstevam%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DHui%26aufirst%3DA.%2BM.%26aulast%3DRajkumar%26aufirst%3DV.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520ixazomib%252C%2520an%2520oral%2520proteasome%2520inhibitor%252C%2520in%2520combination%2520with%2520lenalidomide%2520and%2520dexamethasone%2520in%2520patients%2520with%2520previously%2520untreated%2520multiple%2520myeloma%253A%2520an%2520open-label%2520phase%25201%252F2%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1503%26epage%3D1512%26doi%3D10.1016%2FS1470-2045%2814%2971125-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esseltine, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, K.</span></span> <span> </span><span class="NLM_article-title">Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1111/bcp.12542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1111%2Fbcp.12542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=25377318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2015&pages=789-800&author=N.+Guptaauthor=Y.+Zhaoauthor=A.+M.+Huiauthor=D.+L.+Esseltineauthor=K.+Venkatakrishnan&title=Switching+from+body+surface+area-based+to+fixed+dosing+for+the+investigational+proteasome+inhibitor+ixazomib%3A+a+population+pharmacokinetic+analysis&doi=10.1111%2Fbcp.12542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis</span></div><div class="casAuthors">Gupta, Neeraj; Zhao, Yuan; Hui, Ai-Min; Esseltine, Dixie-Lee; Venkatakrishnan, Karthik</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">789-800</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : This population pharmacokinetic anal. of the investigational oral proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates on ixazomib pharmacokinetics.  Methods : Data were pooled from 226 adult patients with multiple myeloma, lymphoma or solid tumors in four phase 1 studies, in which ixazomib dosing (oral/i.v., once/twice weekly) was based on BSA.  Population pharmacokinetic modeling was undertaken using nonmem version 7.2.  Results : Ixazomib pharmacokinetics were well described by a three compartment model with first order absorption and linear elimination.  Ixazomib was absorbed rapidly (Ka 0.5 h-1), with dose- and time-independent pharmacokinetics.  Estd. abs. bioavailability and clearance were 60% and 2 l h-1, resp.  Although a small effect of BSA (range 1.3-2.6 m2) was obsd. on the peripheral vol. of distribution (V4), reducing the corresponding inter-individual variability by 12.9%, there was no relationship between BSA and ixazomib clearance (the parameter that dictates total systemic exposure following fixed dosing).  Consistently, based on simulations (n = 1000), median AUCs (including interquartile range) were similar after BSA-based (2.23 mg m-2) and fixed (4 mg) oral dosing with no trend in simulated AUC vs.  BSA for fixed dosing (P = 0.42).  No other covariates, including creatinine clearance (22-213.7 mL min-1) and age (23-86 years), influenced ixazomib pharmacokinetics.  Conclusions : This anal. supports a switch from BSA-based to fixed dosing, without dose modification for mild/moderate renal impairment or age, in future adult studies of ixazomib, simplifying dosing guidance and clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvVv5ldaq2LLVg90H21EOLACvtfcHk0ljQYwsbsidT7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOnu7g%253D&md5=5f2414207e9f1bf46fe55a907b21a7be</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12542%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHui%26aufirst%3DA.%2BM.%26aulast%3DEsseltine%26aufirst%3DD.%2BL.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26atitle%3DSwitching%2520from%2520body%2520surface%2520area-based%2520to%2520fixed%2520dosing%2520for%2520the%2520investigational%2520proteasome%2520inhibitor%2520ixazomib%253A%2520a%2520population%2520pharmacokinetic%2520analysis%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2015%26volume%3D79%26spage%3D789%26epage%3D800%26doi%3D10.1111%2Fbcp.12542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skacel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, K.</span></span> <span> </span><span class="NLM_article-title">Dose and schedule selection of the oral proteasome inhibitor Ixazomib in relapsed/refractory multiple myeloma: Clinical and model-based analyses</span>. <i>Target Oncol</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1007/s11523-017-0524-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1007%2Fs11523-017-0524-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=28803351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BC1cfntV2quw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=643-654&author=N.+Guptaauthor=H.+Yangauthor=M.+J.+Hanleyauthor=S.+Zhangauthor=R.+Liuauthor=S.+Kumarauthor=P.+G.+Richardsonauthor=T.+Skacelauthor=K.+Venkatakrishnan&title=Dose+and+schedule+selection+of+the+oral+proteasome+inhibitor+Ixazomib+in+relapsed%2Frefractory+multiple+myeloma%3A+Clinical+and+model-based+analyses&doi=10.1007%2Fs11523-017-0524-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses</span></div><div class="casAuthors">Gupta Neeraj; Yang Huyuan; Hanley Michael J; Zhang Steven; Liu Rachael; Skacel Tomas; Venkatakrishnan Karthik; Kumar Shaji; Richardson Paul G; Skacel Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">643-654</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The oral proteasome inhibitor ixazomib has been approved by regulatory authorities around the world, including in the United States and the European Union, for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy, based on the pivotal phase III TOURMALINE-MM1 study.  OBJECTIVE:  The objective of this study was to quantitatively characterize the benefit-risk profile of ixazomib in relapsed/refractory MM in support of the approved dose and schedule.  METHODS:  We report early-phase study data and exposure-response analyses of TOURMALINE-MM1 data that support the selection of the recommended ixazomib dose and schedule.  RESULTS:  Single-agent ixazomib studies showed a favorable efficacy/safety profile with weekly versus twice-weekly dosing; a phase I/II study of ixazomib in combination with lenalidomide and dexamethasone (IRd) identified a weekly ixazomib dose that offered an acceptable efficacy/safety profile.  In IRd exposure-response analyses from TOURMALINE-MM1, ixazomib systemic exposure was not a significant predictor of progression-free survival or probability of response.  Significant associations were observed between ixazomib exposure and the probability of grade ≥3 anemia and thrombocytopenia, and grade ≥2 diarrhea, fatigue, nausea, peripheral neuropathy, and rash.  Additionally, higher ixazomib exposure was associated with lower lenalidomide relative dose intensity.  CONCLUSIONS:  These analyses support a favorable benefit-risk profile for weekly ixazomib 4.0 mg on days 1, 8, and 15 of 28-day cycles, which was selected for the phase III TOURMALINE registration program.  TRIAL REGISTRATION NUMBERS:  ClinicalTrials.gov NCT00932698, NCT00963820, NCT01217957, NCT01564537.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcfHg__x0c9gyMywPm6HgQfW6udTcc2eY51kjxgXgsxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfntV2quw%253D%253D&md5=b1724a7fcfbddeddeeef7a9d2e243b63</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs11523-017-0524-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-017-0524-3%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DHanley%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DSkacel%26aufirst%3DT.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26atitle%3DDose%2520and%2520schedule%2520selection%2520of%2520the%2520oral%2520proteasome%2520inhibitor%2520Ixazomib%2520in%2520relapsed%252Frefractory%2520multiple%2520myeloma%253A%2520Clinical%2520and%2520model-based%2520analyses%26jtitle%3DTarget%2520Oncol%26date%3D2017%26volume%3D12%26spage%3D643%26epage%3D654%26doi%3D10.1007%2Fs11523-017-0524-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Bissati, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandenburg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamoun, C. B.</span></span> <span> </span><span class="NLM_article-title">Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B</span>. <i>BMC Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13</span>, <span class="refDoi"> DOI: 10.1186/1472-6904-7-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1186%2F1472-6904-7-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=17956613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FlvFKjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=13&author=J.+M.+Reynoldsauthor=K.+El+Bissatiauthor=J.+Brandenburgauthor=A.+Gunzlauthor=C.+B.+Mamoun&title=Antimalarial+activity+of+the+anticancer+and+proteasome+inhibitor+bortezomib+and+its+analog+ZL3B&doi=10.1186%2F1472-6904-7-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B</span></div><div class="casAuthors">Reynolds Jennifer M; El Bissati Kamal; Brandenburg Jens; Gunzl Arthur; Mamoun Choukri Ben</div><div class="citationInfo"><span class="NLM_cas:title">BMC clinical pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The high rate of mortality due to malaria and the worldwide distribution of parasite resistance to the commonly used antimalarial drugs chloroquine and pyrimethamine emphasize the urgent need for the development of new antimalarial drugs.  An alternative approach to the long and uncertain process of designing and developing new compounds is to identify among the armamentarium of drugs already approved for clinical treatment of various human diseases those that may have strong antimalarial activity.  METHODS:  Proteasome inhibitor bortezomib (Velcade: [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid), which has been approved for treatment of patients with multiple myeloma, and a second boronate analog Z-Leu-Leu-Leu-B(OH)2 (ZL3B), were tested against four different strains of P. falciparum (3D7, HB3, W2 and Dd2) that are either sensitive or have different levels of resistance to the antimalarial drugs pyrimethamine and chloroquine.  RESULTS:  Bortezomib and ZL3B are equally effective against drug-sensitive and -resistant parasites and block intraerythrocytic development prior to DNA synthesis, but have no effect on parasite egress or invasion.  CONCLUSION:  The identification of bortezomib and its analog as potent antimalarial drugs will set the stage for the advancement of this class of compounds, either alone or in combination therapy, for treatment of malaria, and emphasize the need for large-scale screens to identify new antimalarials within the library of clinically approved compounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQljLNm0aFRXgyMywPm6HgQfW6udTcc2eY9GYk6Icks67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FlvFKjtQ%253D%253D&md5=e2281d7f721b80debc3aabad89e65234</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1186%2F1472-6904-7-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6904-7-13%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DJ.%2BM.%26aulast%3DEl%2BBissati%26aufirst%3DK.%26aulast%3DBrandenburg%26aufirst%3DJ.%26aulast%3DGunzl%26aufirst%3DA.%26aulast%3DMamoun%26aufirst%3DC.%2BB.%26atitle%3DAntimalarial%2520activity%2520of%2520the%2520anticancer%2520and%2520proteasome%2520inhibitor%2520bortezomib%2520and%2520its%2520analog%2520ZL3B%26jtitle%3DBMC%2520Clin.%2520Pharmacol.%26date%3D2007%26volume%3D7%26spage%3D13%26doi%3D10.1186%2F1472-6904-7-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, P. H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. R. S.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin proteasome system as a potential drug target for malaria</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.2174/1568026618666180427145308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.2174%2F1568026618666180427145308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=29701143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjnt1KrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=315-320&author=P.+H.+S.+Pereiraauthor=C.+Curraauthor=C.+R.+S.+Garcia&title=Ubiquitin+proteasome+system+as+a+potential+drug+target+for+malaria&doi=10.2174%2F1568026618666180427145308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin Proteasome System as a Potential Drug Target for Malaria</span></div><div class="casAuthors">Pereira Pedro H Scarpelli; Curra Chiara; Garcia Celia R S; Pereira Pedro H Scarpelli; Curra Chiara</div><div class="citationInfo"><span class="NLM_cas:title">Current topics in medicinal chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-320</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parasites of Plasmodium genus are responsible for causing malaria in humans.  Resistant strains to all available antimalarials can be found in several locations around the globe, including parasites resistant to the latest generation of combination drugs, such as piperaquine + artemisinin.  Plasmodium develops between two completely different hosts such as a vertebrate one and the mosquito vector, thus it has the ability to adapt to very extreme and different environments.  Through the complex life cycle in the hosts, Plasmodium invades and replicates in totally different cells thus making the study of the biology of the parasite and the identification of targets for drug development affecting all stages very difficult.  It was shown that host molecules, such as melatonin and derivatives, have a role in the progression and regulation of the parasite cell cycle; In fact, when the parasite is exposed to melatonin there is an increase in transcription levels of genes encoding for proteins related to the Ubiquitin Proteasome (UPS) System.  This system is essential for the survival of the parasite, and drugs such as bortezomib, MLN-273, ZL3B, epoxomicins and salinosporamides are capable of eliminating the parasite by inhibiting the degradation of proteins via the proteasome system.  In addition, the Plasmodium UPS shows low similarity to the ubiquitin proteasome system in Humans; the identification of unique targets to be used for therapeutic molecules development increases the importance of UPS studies in malaria challenging.  Drugs that cause oxidative stress, such as artemisinin, show a strong synergistic effect with proteasome inhibitors, increasing the possibilities of combined therapies, which are more effective with lower concentration of drugs.  Thus, the study of the mechanism of action of the UPS and the identification of potential targets for new drugs development are promising alternative strategies to fight the drug-resistance problem in malaria parasites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFuYTWOhkk5K-9TkgmBqTqfW6udTcc2eY9GYk6Icks67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjnt1KrsA%253D%253D&md5=cfcda145065cb7d3a9e17e4b9878a27e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1568026618666180427145308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026618666180427145308%26sid%3Dliteratum%253Aachs%26aulast%3DPereira%26aufirst%3DP.%2BH.%2BS.%26aulast%3DCurra%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DC.%2BR.%2BS.%26atitle%3DUbiquitin%2520proteasome%2520system%2520as%2520a%2520potential%2520drug%2520target%2520for%2520malaria%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2018%26volume%3D18%26spage%3D315%26epage%3D320%26doi%3D10.2174%2F1568026618666180427145308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span> <span> </span><span class="NLM_article-title">Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.2012.11-0302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.4269%2Fajtmh.2012.11-0302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=22232455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1ymu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=84-92&author=S.+Duffyauthor=V.+M.+Avery&title=Development+and+optimization+of+a+novel+384-well+anti-malarial+imaging+assay+validated+for+high-throughput+screening&doi=10.4269%2Fajtmh.2012.11-0302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening</span></div><div class="casAuthors">Duffy, Sandra; Avery, Vicky M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-92</span>CODEN:
                <span class="NLM_cas:coden">AJTHAB</span>;
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    
            (<span class="NLM_cas:orgname">American Society of Tropical Medicine and Hygiene</span>)
        </div><div class="casAbstract">With the increasing occurrence of drug resistance in the malaria parasite, Plasmodium falciparum, there is a great need for new and novel anti-malarial drugs.  We have developed a 384-well, high-throughput imaging assay for the detection of new anti-malarial compds., which was initially validated by screening a marine natural product library, and subsequently used to screen more than 3 million data points from a variety of compd. sources.  Founded on another fluorescence-based P. falciparum growth inhibition assay, the DNA-intercalating dye 4',6-diamidino-2-phenylindole, was used to monitor changes in parasite no.  Fluorescent images were acquired on the PerkinElmer Opera High Throughput confocal imaging system and analyzed with a spot detection algorithm using the Acapella data processing software.  Further optimization of this assay sought to increase throughput, assay stability, and compatibility with our high-throughput screening equipment platforms.  The assay typically yielded Z'-factor values of 0.5-0.6, with signal-to-noise ratios of 12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9mpHAvJlL67Vg90H21EOLACvtfcHk0lgICveRhPD8vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1ymu7k%253D&md5=60ae874f46758c03566acfdc948e1188</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.2012.11-0302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.2012.11-0302%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26atitle%3DDevelopment%2520and%2520optimization%2520of%2520a%2520novel%2520384-well%2520anti-malarial%2520imaging%2520assay%2520validated%2520for%2520high-throughput%2520screening%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D2012%26volume%3D86%26spage%3D84%26epage%3D92%26doi%3D10.4269%2Fajtmh.2012.11-0302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigstad, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sappal, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J. L.</span></span> <span> </span><span class="NLM_article-title">Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>430</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1042/BJ20100383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1042%2FBJ20100383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=20632995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=461-476&author=C.+Blackburnauthor=K.+M.+Gigstadauthor=P.+Halesauthor=K.+Garciaauthor=M.+Jonesauthor=F.+J.+Bruzzeseauthor=C.+Barrettauthor=J.+X.+Liuauthor=T.+A.+Soucyauthor=D.+S.+Sappalauthor=N.+Bumpauthor=E.+J.+Olhavaauthor=P.+Flemingauthor=L.+R.+Dickauthor=C.+Tsuauthor=M.+D.+Sintchakauthor=J.+L.+Blank&title=Characterization+of+a+new+series+of+non-covalent+proteasome+inhibitors+with+exquisite+potency+and+selectivity+for+the+20S+beta5-subunit&doi=10.1042%2FBJ20100383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit</span></div><div class="casAuthors">Blackburn, Christopher; Gigstad, Kenneth M.; Hales, Paul; Garcia, Khristofer; Jones, Matthew; Bruzzese, Frank J.; Barrett, Cynthia; Liu, Jane X.; Soucy, Teresa A.; Sappal, Darshan S.; Bump, Nancy; Olhava, Edward J.; Fleming, Paul; Dick, Lawrence R.; Tsu, Christopher; Sintchak, Michael D.; Blank, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-476</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The mammalian 26S proteasome is a 2500 kDa multi-catalytic complex involved in intracellular protein degrdn.  The authors describe the synthesis and properties of a novel series of non-covalent di-peptide inhibitors of the proteasome based on a capped tripeptide that was first identified by high-throughput screening of a library of approx. 350000 compds. for inhibitors of the ubiquitin-proteasome system in cells.  It is shown that these compds. are entirely selective for the β5 (chymotrypsin-like) site over the β1 (caspase-like) and β2 (trypsin-like) sites of the 20S core particle of the proteasome, and over a panel of less closely related proteases.  Compd. optimization, guided by x-ray crystallog. of the liganded 20S core particle, confirmed their non-covalent binding mode and provided a structural basis for their enhanced in vitro and cellular potencies.  The authors demonstrate that such compds. show low nanomolar IC50 values for the human 20S β5 site in vitro, and that pharmacol. inhibition of this site in cells is sufficient to potently inhibit the degrdn. of a tetra-ubiquitin-luciferase reporter, activation of NFκB (nuclear factor κB) in response to TNF-α (tumor necrosis factor-α) and the proliferation of cancer cells.  Finally, the authors identified capped dipeptides that show differential selectivity for the β5 site of the constitutively expressed proteasome and immunoproteasome in vitro and in B-cell lymphomas.  Collectively, these studies describe the synthesis, activity and binding mode of a new series of non-covalent proteasome inhibitors with unprecedented potency and selectivity for the β5 site, and which can discriminate between the constitutive proteasome and immunoproteasome in vitro and in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodAundpO9R0LVg90H21EOLACvtfcHk0lgICveRhPD8vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtb3O&md5=de750c60263f0ec83961326ae2b94445</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1042%2FBJ20100383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100383%26sid%3Dliteratum%253Aachs%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DGigstad%26aufirst%3DK.%2BM.%26aulast%3DHales%26aufirst%3DP.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DBarrett%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%2BX.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DSappal%26aufirst%3DD.%2BS.%26aulast%3DBump%26aufirst%3DN.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DBlank%26aufirst%3DJ.%2BL.%26atitle%3DCharacterization%2520of%2520a%2520new%2520series%2520of%2520non-covalent%2520proteasome%2520inhibitors%2520with%2520exquisite%2520potency%2520and%2520selectivity%2520for%2520the%252020S%2520beta5-subunit%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26spage%3D461%26epage%3D476%26doi%3D10.1042%2FBJ20100383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1016/j.str.2005.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2Fj.str.2005.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=16531229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=451-456&author=M.+Grollauthor=C.+R.+Berkersauthor=H.+L.+Ploeghauthor=H.+Ovaa&title=Crystal+structure+of+the+boronic+acid-based+proteasome+inhibitor+bortezomib+in+complex+with+the+yeast+20S+proteasome&doi=10.1016%2Fj.str.2005.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome</span></div><div class="casAuthors">Groll, Michael; Berkers, Celia R.; Ploegh, Hidde L.; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">451-456</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The dipeptide boronic acid bortezomib, also termed VELCADE is a proteasome inhibitor now in use for the treatment of multiple myeloma, and its use for the treatment of other malignancies is being explored.  We detd. the crystal structure of the yeast 20S proteasome in complex with bortezomib to establish the specificity and binding mode of bortezomib to the proteasome's different catalytically active sites.  This structure should enable the rational design of new boronic acid derivs. with improved affinities and specificities for individual active subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpusGzFSuveALVg90H21EOLACvtfcHk0lgICveRhPD8vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D&md5=d5b4e46e5a9f5259cce758770302b4fe</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2005.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2005.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DCrystal%2520structure%2520of%2520the%2520boronic%2520acid-based%2520proteasome%2520inhibitor%2520bortezomib%2520in%2520complex%2520with%2520the%2520yeast%252020S%2520proteasome%26jtitle%3DStructure%26date%3D2006%26volume%3D14%26spage%3D451%26epage%3D456%26doi%3D10.1016%2Fj.str.2005.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kupperman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1970</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-2766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1158%2F0008-5472.CAN-09-2766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=20160034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1970-1980&author=E.+Kuppermanauthor=E.+C.+Leeauthor=Y.+Caoauthor=B.+Bannermanauthor=M.+Fitzgeraldauthor=A.+Bergerauthor=J.+Yuauthor=Y.+Yangauthor=P.+Halesauthor=F.+Bruzzeseauthor=J.+Liuauthor=J.+Blankauthor=K.+Garciaauthor=C.+Tsuauthor=L.+Dickauthor=P.+Flemingauthor=L.+Yuauthor=M.+Manfrediauthor=M.+Rolfeauthor=J.+Bolen&title=Evaluation+of+the+proteasome+inhibitor+MLN9708+in+preclinical+models+of+human+cancer&doi=10.1158%2F0008-5472.CAN-09-2766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer</span></div><div class="casAuthors">Kupperman, Erik; Lee, Edmund C.; Cao, Yueying; Bannerman, Bret; Fitzgerald, Michael; Berger, Allison; Yu, Jie; Yang, Yu; Bruzzese, Frank; Liu, Jane; Blank, Jonathan; Garcia, Khristofer; Tsu, Christopher; Dick, Larry; Fleming, Paul; Yu, Li; Manfredi, Mark; Rolfe, Mark; Bolen, Joe</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1970-1980</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The proteasome was validated as an oncol. target following the clin. success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma.  Consequently, several groups are pursuing the development of addnl. small-mol. proteasome inhibitors for both hematol. and solid tumor indications.  Here, we describe MLN9708, a selective, orally bioavailable, second-generation proteasome inhibitor that is in phase I clin. development.  MLN9708 has a shorter proteasome dissocn. half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib.  MLN9708 has a larger blood vol. distribution at steady state, and anal. of 20S proteasome inhibition and markers of the unfolded protein response confirmed that MLN9708 has greater pharmacodynamic effects in tissues than bortezomib.  MLN9708 showed activity in both solid tumor and hematol. preclin. xenograft models, and we found a correlation between greater pharmacodynamic responses and improved antitumor activity.  Moreover, antitumor activity was shown via multiple dosing routes, including oral gavage.  Taken together, these data support the clin. development of MLN9708 for both hematol. and solid tumor indications.  Cancer Res; 70(5); 1970-80.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjauqAFEgDA7Vg90H21EOLACvtfcHk0lh3lWHHlONk6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWisro%253D&md5=45636404582fc0eb66581c6c19420458</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2766%26sid%3Dliteratum%253Aachs%26aulast%3DKupperman%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DE.%2BC.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DBannerman%26aufirst%3DB.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHales%26aufirst%3DP.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBlank%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520the%2520proteasome%2520inhibitor%2520MLN9708%2520in%2520preclinical%2520models%2520of%2520human%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1970%26epage%3D1980%26doi%3D10.1158%2F0008-5472.CAN-09-2766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banaszynski, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard-Smith, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooi, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandless, T. J.</span></span> <span> </span><span class="NLM_article-title">A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">995</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2Fj.cell.2006.07.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=16959577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvVKiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2006&pages=995-1004&author=L.+A.+Banaszynskiauthor=L.+C.+Chenauthor=L.+A.+Maynard-Smithauthor=A.+G.+Ooiauthor=T.+J.+Wandless&title=A+rapid%2C+reversible%2C+and+tunable+method+to+regulate+protein+function+in+living+cells+using+synthetic+small+molecules&doi=10.1016%2Fj.cell.2006.07.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules</span></div><div class="casAuthors">Banaszynski, Laura A.; Chen, Ling-chun; Maynard-Smith, Lystranne A.; Ooi, A. G. Lisa; Wandless, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">995-1004</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Rapid and reversible methods for perturbing the function of specific proteins are desirable tools for probing complex biol. systems.  We have developed a general technique to regulate the stability of specific proteins in mammalian cells using cell-permeable, synthetic mols.  We engineered mutants of the human FKBP12 protein that are rapidly and constitutively degraded when expressed in mammalian cells, and this instability is conferred to other proteins fused to these destabilizing domains.  Addn. of a synthetic ligand that binds to the destabilizing domains shields them from degrdn., allowing fused proteins to perform their cellular functions.  Genetic fusion of the destabilizing domain to a gene of interest ensures specificity, and the attendant small-mol. control confers speed, reversibility, and dose-dependence to this method.  This general strategy for regulating protein stability should enable conditional perturbation of specific proteins with unprecedented control in a variety of exptl. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPVF_0TfXfArVg90H21EOLACvtfcHk0lh3lWHHlONk6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvVKiurs%253D&md5=55b38d7804adfa794a0d991dd704fbde</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DBanaszynski%26aufirst%3DL.%2BA.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DMaynard-Smith%26aufirst%3DL.%2BA.%26aulast%3DOoi%26aufirst%3DA.%2BG.%26aulast%3DWandless%26aufirst%3DT.%2BJ.%26atitle%3DA%2520rapid%252C%2520reversible%252C%2520and%2520tunable%2520method%2520to%2520regulate%2520protein%2520function%2520in%2520living%2520cells%2520using%2520synthetic%2520small%2520molecules%26jtitle%3DCell%26date%3D2006%26volume%3D126%26spage%3D995%26epage%3D1004%26doi%3D10.1016%2Fj.cell.2006.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ariey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duru, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuor, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bout, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, W. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandeur, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringwald, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Bras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barale, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit-Vical, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercereau-Puijalon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, D.</span></span> <span> </span><span class="NLM_article-title">A molecular marker of artemisinin-resistant <i>Plasmodium falciparum</i> malaria</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>505</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1038/nature12876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fnature12876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=24352242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BC2c3ns1aqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2014&pages=50-55&author=F.+Arieyauthor=B.+Witkowskiauthor=C.+Amaratungaauthor=J.+Beghainauthor=A.+C.+Langloisauthor=N.+Khimauthor=S.+Kimauthor=V.+Duruauthor=C.+Bouchierauthor=L.+Maauthor=P.+Limauthor=R.+Leangauthor=S.+Duongauthor=S.+Srengauthor=S.+Suonauthor=C.+M.+Chuorauthor=D.+M.+Boutauthor=S.+Menardauthor=W.+O.+Rogersauthor=B.+Gentonauthor=T.+Fandeurauthor=O.+Miottoauthor=P.+Ringwaldauthor=J.+Le+Brasauthor=A.+Berryauthor=J.+C.+Baraleauthor=R.+M.+Fairhurstauthor=F.+Benoit-Vicalauthor=O.+Mercereau-Puijalonauthor=D.+Menard&title=A+molecular+marker+of+artemisinin-resistant+Plasmodium+falciparum+malaria&doi=10.1038%2Fnature12876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A molecular marker of artemisinin-resistant Plasmodium falciparum malaria</span></div><div class="casAuthors">Ariey Frederic; Beghain Johann; Barale Jean-Christophe; Witkowski Benoit; Khim Nimol; Kim Saorin; Duru Valentine; Amaratunga Chanaki; Langlois Anne-Claire; Bouchier Christiane; Ma Laurence; Lim Pharath; Leang Rithea; Duong Socheat; Sreng Sokunthea; Suon Seila; Chuor Char Meng; Bout Denis Mey; Menard Sandie; Berry Antoine; Rogers William O; Genton Blaise; Fandeur Thierry; Miotto Olivo; Ringwald Pascal; Le Bras Jacques; Fairhurst Rick M; Benoit-Vical Francoise; Mercereau-Puijalon Odile; Menard Didier</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">505</span>
        (<span class="NLM_cas:issue">7481</span>),
    <span class="NLM_cas:pages">50-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Plasmodium falciparum resistance to artemisinin derivatives in southeast Asia threatens malaria control and elimination activities worldwide.  To monitor the spread of artemisinin resistance, a molecular marker is urgently needed.  Here, using whole-genome sequencing of an artemisinin-resistant parasite line from Africa and clinical parasite isolates from Cambodia, we associate mutations in the PF3D7_1343700 kelch propeller domain ('K13-propeller') with artemisinin resistance in vitro and in vivo.  Mutant K13-propeller alleles cluster in Cambodian provinces where resistance is prevalent, and the increasing frequency of a dominant mutant K13-propeller allele correlates with the recent spread of resistance in western Cambodia.  Strong correlations between the presence of a mutant allele, in vitro parasite survival rates and in vivo parasite clearance rates indicate that K13-propeller mutations are important determinants of artemisinin resistance.  K13-propeller polymorphism constitutes a useful molecular marker for large-scale surveillance efforts to contain artemisinin resistance in the Greater Mekong Subregion and prevent its global spread.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTg24yBOxa0oSjiVMCqkKxVfW6udTcc2eaE_BBX1N1bs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3ns1aqtg%253D%253D&md5=e25f4dcc9ccc361de4c35e650391b7ca</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature12876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12876%26sid%3Dliteratum%253Aachs%26aulast%3DAriey%26aufirst%3DF.%26aulast%3DWitkowski%26aufirst%3DB.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DBeghain%26aufirst%3DJ.%26aulast%3DLanglois%26aufirst%3DA.%2BC.%26aulast%3DKhim%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DDuru%26aufirst%3DV.%26aulast%3DBouchier%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DLeang%26aufirst%3DR.%26aulast%3DDuong%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DChuor%26aufirst%3DC.%2BM.%26aulast%3DBout%26aufirst%3DD.%2BM.%26aulast%3DMenard%26aufirst%3DS.%26aulast%3DRogers%26aufirst%3DW.%2BO.%26aulast%3DGenton%26aufirst%3DB.%26aulast%3DFandeur%26aufirst%3DT.%26aulast%3DMiotto%26aufirst%3DO.%26aulast%3DRingwald%26aufirst%3DP.%26aulast%3DLe%2BBras%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DA.%26aulast%3DBarale%26aufirst%3DJ.%2BC.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DBenoit-Vical%26aufirst%3DF.%26aulast%3DMercereau-Puijalon%26aufirst%3DO.%26aulast%3DMenard%26aufirst%3DD.%26atitle%3DA%2520molecular%2520marker%2520of%2520artemisinin-resistant%2520Plasmodium%2520falciparum%2520malaria%26jtitle%3DNature%26date%3D2014%26volume%3D505%26spage%3D50%26epage%3D55%26doi%3D10.1038%2Fnature12876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Straimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnadig, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duru, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramadani, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dacheux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urnov, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercereau-Puijalon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit-Vical, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title">Drug resistance. K13-propeller mutations confer artemisinin resistance in <i>Plasmodium falciparum</i> clinical isolates</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1126/science.1260867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1126%2Fscience.1260867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=25502314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=428-431&author=J.+Straimerauthor=N.+F.+Gnadigauthor=B.+Witkowskiauthor=C.+Amaratungaauthor=V.+Duruauthor=A.+P.+Ramadaniauthor=M.+Dacheuxauthor=N.+Khimauthor=L.+Zhangauthor=S.+Lamauthor=P.+D.+Gregoryauthor=F.+D.+Urnovauthor=O.+Mercereau-Puijalonauthor=F.+Benoit-Vicalauthor=R.+M.+Fairhurstauthor=D.+Menardauthor=D.+A.+Fidock&title=Drug+resistance.+K13-propeller+mutations+confer+artemisinin+resistance+in+Plasmodium+falciparum+clinical+isolates&doi=10.1126%2Fscience.1260867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates</span></div><div class="casAuthors">Straimer, Judith; Gnaedig, Nina F.; Witkowski, Benoit; Amaratunga, Chanaki; Duru, Valentine; Ramadani, Arba Pramundita; Dacheux, Melanie; Khim, Nimol; Zhang, Lei; Lam, Stephen; Gregory, Philip D.; Urnov, Fyodor D.; Mercereau-Puijalon, Odile; Benoit-Vical, Francoise; Fairhurst, Rick M.; Menard, Didier; Fidock, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6220</span>),
    <span class="NLM_cas:pages">428-431</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The emergence of artemisinin resistance in Southeast Asia imperils efforts to reduce the global malaria burden.  We genetically modified the Plasmodium falciparum K13 locus using zinc-finger nucleases and measured ring-stage survival rates after drug exposure in vitro; these rates correlate with parasite clearance half-lives in artemisinin-treated patients.  With isolates from Cambodia, where resistance first emerged, survival rates decreased from 13 to 49% to 0.3 to 2.4% after the removal of K13 mutations.  Conversely, survival rates in wild-type parasites increased from ≤0.6% to 2 to 29% after the insertion of K13 mutations.  These mutations conferred elevated resistance to recent Cambodian isolates compared with that of ref. lines, suggesting a contemporary contribution of addnl. genetic factors.  Our data provide a conclusive rationale for worldwide K13-propeller sequencing to identify and eliminate artemisinin-resistant parasites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Ml-eUMKETLVg90H21EOLACvtfcHk0lg-52Bl1XCaKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCiur4%253D&md5=5776238fb78428d16bcaed8d16fa73af</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1126%2Fscience.1260867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1260867%26sid%3Dliteratum%253Aachs%26aulast%3DStraimer%26aufirst%3DJ.%26aulast%3DGnadig%26aufirst%3DN.%2BF.%26aulast%3DWitkowski%26aufirst%3DB.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DDuru%26aufirst%3DV.%26aulast%3DRamadani%26aufirst%3DA.%2BP.%26aulast%3DDacheux%26aufirst%3DM.%26aulast%3DKhim%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLam%26aufirst%3DS.%26aulast%3DGregory%26aufirst%3DP.%2BD.%26aulast%3DUrnov%26aufirst%3DF.%2BD.%26aulast%3DMercereau-Puijalon%26aufirst%3DO.%26aulast%3DBenoit-Vical%26aufirst%3DF.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DMenard%26aufirst%3DD.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DDrug%2520resistance.%2520K13-propeller%2520mutations%2520confer%2520artemisinin%2520resistance%2520in%2520Plasmodium%2520falciparum%2520clinical%2520isolates%26jtitle%3DScience%26date%3D2015%26volume%3D347%26spage%3D428%26epage%3D431%26doi%3D10.1126%2Fscience.1260867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells</span>. <i>Cancer Biol. Ther</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.4161%2Fcbt.2.6.573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=14688479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVCjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=694-699&author=J.+Yuauthor=S.+Tiwariauthor=P.+Steinerauthor=L.+Zhang&title=Differential+apoptotic+response+to+the+proteasome+inhibitor+Bortezomib+%5BVELCADE%2C+PS-341%5D+in+Bax-deficient+and+p21-deficient+colon+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Differential apoptotic response to the proteasome inhibitor bortezomib (VELCADE, PS-341) in Bax-deficient and p21-deficient colon cancer cells</span></div><div class="casAuthors">Yu, Jian; Tiwari, Sagarika; Steiner, Philipp; Zhang, Lin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">694-699</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Targeting the ubiquitin-proteasome pathway has emerged as a promising approach for treating cancer.  Bortezomib (VELCADE, formerly known as PS-341), a potent and reversible proteasome inhibitor, is being evaluated in clin. trials for treating multiple myeloma and various other types of hematol. and solid tumors.  Proteasome inhibitors are known to induce apoptosis in human cancer cells.  Nevertheless, the mechanisms of apoptosis induced by proteasome inhibitors remain unclear.  In this study, we investigated the role of p53 and its downstream targets in bortezomib-induced apoptosis in HCT1 16 human colon cancer cells.  We demonstrated that bortezomib induced p53 and activated its downstream genes p21, PUMA and Bax, in a p53-dependent fashion.  However, apoptotic response to bortezomib was not affected by the deletion of p53.  Surprisingly, we found that bortezomib-induced apoptosis was markedly enhanced in the p21-knockout cells, while significantly decreased in the BAX-knockout cells.  Furthermore, in the cells deficient for both Bax and p21, apoptosis was restored to the level in the parental or the p53-deficient cells.  The opposite effects of Bax and p21 were unrelated to the extent of proteasome inhibition and were also obsd. in cells treated with different proteasome inhibitors.  These results indicate that p53 downstream targets can collectively modulate apoptotic response to bortezomib and other proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPB13n2sQQQbVg90H21EOLACvtfcHk0lg-52Bl1XCaKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVCjsbo%253D&md5=7fa6e617dc5a3498cf164b1c8809b239</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.4161%2Fcbt.2.6.573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.2.6.573%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DTiwari%26aufirst%3DS.%26aulast%3DSteiner%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDifferential%2520apoptotic%2520response%2520to%2520the%2520proteasome%2520inhibitor%2520Bortezomib%2520%255BVELCADE%252C%2520PS-341%255D%2520in%2520Bax-deficient%2520and%2520p21-deficient%2520colon%2520cancer%2520cells%26jtitle%3DCancer%2520Biol.%2520Ther%26date%3D2003%26volume%3D2%26spage%3D694%26epage%3D699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baragana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallyburton, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norcross, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proto, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagborough, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porzelle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luksch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luksch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolscher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna-Cabello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakutansky, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noviyanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frearson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer-Bazaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinden, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebrevska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayner, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">A novel multiple-stage antimalarial agent that inhibits protein synthesis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>522</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1038/nature14451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fnature14451" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=522&publication_year=2015&pages=315-320&author=B.+Baraganaauthor=I.+Hallyburtonauthor=M.+C.+Leeauthor=N.+R.+Norcrossauthor=R.+Grimaldiauthor=T.+D.+Ottoauthor=W.+R.+Protoauthor=A.+M.+Blagboroughauthor=S.+Meisterauthor=G.+Wirjanataauthor=A.+Rueckerauthor=L.+M.+Uptonauthor=T.+S.+Abrahamauthor=M.+J.+Almeidaauthor=A.+Pradhanauthor=A.+Porzelleauthor=T.+Lukschauthor=M.+S.+Martinezauthor=T.+Lukschauthor=J.+M.+Bolscherauthor=A.+Woodlandauthor=S.+Norvalauthor=F.+Zuccottoauthor=J.+Thomasauthor=F.+Simeonsauthor=L.+Stojanovskiauthor=M.+Osuna-Cabelloauthor=P.+M.+Brockauthor=T.+S.+Churcherauthor=K.+A.+Salaauthor=S.+E.+Zakutanskyauthor=M.+B.+Jimenez-Diazauthor=L.+M.+Sanzauthor=J.+Rileyauthor=R.+Basakauthor=M.+Campbellauthor=V.+M.+Averyauthor=R.+W.+Sauerweinauthor=K.+J.+Decheringauthor=R.+Noviyantiauthor=B.+Campoauthor=J.+A.+Frearsonauthor=I.+Angulo-Barturenauthor=S.+Ferrer-Bazagaauthor=F.+J.+Gamoauthor=P.+G.+Wyattauthor=D.+Leroyauthor=P.+Sieglauthor=M.+J.+Delvesauthor=D.+E.+Kyleauthor=S.+Wittlinauthor=J.+Marfurtauthor=R.+N.+Priceauthor=R.+E.+Sindenauthor=E.+A.+Winzelerauthor=S.+A.+Charmanauthor=L.+Bebrevskaauthor=D.+W.+Grayauthor=S.+Campbellauthor=A.+H.+Fairlambauthor=P.+A.+Willisauthor=J.+C.+Raynerauthor=D.+A.+Fidockauthor=K.+D.+Readauthor=I.+H.+Gilbert&title=A+novel+multiple-stage+antimalarial+agent+that+inhibits+protein+synthesis&doi=10.1038%2Fnature14451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnature14451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14451%26sid%3Dliteratum%253Aachs%26aulast%3DBaragana%26aufirst%3DB.%26aulast%3DHallyburton%26aufirst%3DI.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DNorcross%26aufirst%3DN.%2BR.%26aulast%3DGrimaldi%26aufirst%3DR.%26aulast%3DOtto%26aufirst%3DT.%2BD.%26aulast%3DProto%26aufirst%3DW.%2BR.%26aulast%3DBlagborough%26aufirst%3DA.%2BM.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DUpton%26aufirst%3DL.%2BM.%26aulast%3DAbraham%26aufirst%3DT.%2BS.%26aulast%3DAlmeida%26aufirst%3DM.%2BJ.%26aulast%3DPradhan%26aufirst%3DA.%26aulast%3DPorzelle%26aufirst%3DA.%26aulast%3DLuksch%26aufirst%3DT.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DLuksch%26aufirst%3DT.%26aulast%3DBolscher%26aufirst%3DJ.%2BM.%26aulast%3DWoodland%26aufirst%3DA.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DSimeons%26aufirst%3DF.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DOsuna-Cabello%26aufirst%3DM.%26aulast%3DBrock%26aufirst%3DP.%2BM.%26aulast%3DChurcher%26aufirst%3DT.%2BS.%26aulast%3DSala%26aufirst%3DK.%2BA.%26aulast%3DZakutansky%26aufirst%3DS.%2BE.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DSanz%26aufirst%3DL.%2BM.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DBasak%26aufirst%3DR.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26aulast%3DDechering%26aufirst%3DK.%2BJ.%26aulast%3DNoviyanti%26aufirst%3DR.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DFrearson%26aufirst%3DJ.%2BA.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DFerrer-Bazaga%26aufirst%3DS.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DSiegl%26aufirst%3DP.%26aulast%3DDelves%26aufirst%3DM.%2BJ.%26aulast%3DKyle%26aufirst%3DD.%2BE.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DSinden%26aufirst%3DR.%2BE.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DBebrevska%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DWillis%26aufirst%3DP.%2BA.%26aulast%3DRayner%26aufirst%3DJ.%2BC.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DA%2520novel%2520multiple-stage%2520antimalarial%2520agent%2520that%2520inhibits%2520protein%2520synthesis%26jtitle%3DNature%26date%3D2015%26volume%3D522%26spage%3D315%26epage%3D320%26doi%3D10.1038%2Fnature14451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Cozar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandera, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peishoff, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Bustos, J. F.</span></span> <span> </span><span class="NLM_article-title">Thousands of chemical starting points for antimalarial lead identification</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1038/nature09107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fnature09107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=20485427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmt1Ois7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=305-310&author=F.+J.+Gamoauthor=L.+M.+Sanzauthor=J.+Vidalauthor=C.+de+Cozarauthor=E.+Alvarezauthor=J.+L.+Lavanderaauthor=D.+E.+Vanderwallauthor=D.+V.+Greenauthor=V.+Kumarauthor=S.+Hasanauthor=J.+R.+Brownauthor=C.+E.+Peishoffauthor=L.+R.+Cardonauthor=J.+F.+Garcia-Bustos&title=Thousands+of+chemical+starting+points+for+antimalarial+lead+identification&doi=10.1038%2Fnature09107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Thousands of chemical starting points for antimalarial lead identification</span></div><div class="casAuthors">Gamo, Francisco-Javier; Sanz, Laura M.; Vidal, Jaume; de Cozar, Cristina; Alvarez, Emilio; Lavandera, Jose-Luis; Vanderwall, Dana E.; Green, Darren V. S.; Kumar, Vinod; Hasan, Samiul; Brown, James R.; Peishoff, Catherine E.; Cardon, Lon R.; Garcia-Bustos, Jose F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7296</span>),
    <span class="NLM_cas:pages">305-310</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Malaria is a devastating infection caused by protozoa of the genus Plasmodium.  Drug resistance is widespread, no new chem. class of antimalarials has been introduced into clin. practice since 1996 and there is a recent rise of parasite strains with reduced sensitivity to the newest drugs.  We screened nearly 2 million compds. in GlaxoSmithKline's chem. library for inhibitors of P. falciparum, of which 13,533 were confirmed to inhibit parasite growth by at least 80% at 2 μM concn.  More than 8,000 also showed potent activity against the multidrug resistant strain Dd2.  Most (82%) compds. originate from internal company projects and are new to the malaria community.  Analyses using historic assay data suggest several novel mechanisms of antimalarial action, such as inhibition of protein kinases and host-pathogen interaction related targets.  Chem. structures and assocd. data are hereby made public to encourage addnl. drug lead identification efforts and further research into this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHijpWK_kBF7Vg90H21EOLACvtfcHk0liGV0UHmrOw-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmt1Ois7k%253D&md5=a1fd8c0b89a5650ecba31f5456928b42</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature09107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09107%26sid%3Dliteratum%253Aachs%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DSanz%26aufirst%3DL.%2BM.%26aulast%3DVidal%26aufirst%3DJ.%26aulast%3Dde%2BCozar%26aufirst%3DC.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DLavandera%26aufirst%3DJ.%2BL.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DGreen%26aufirst%3DD.%2BV.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DHasan%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DPeishoff%26aufirst%3DC.%2BE.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26aulast%3DGarcia-Bustos%26aufirst%3DJ.%2BF.%26atitle%3DThousands%2520of%2520chemical%2520starting%2520points%2520for%2520antimalarial%2520lead%2520identification%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D305%26epage%3D310%26doi%3D10.1038%2Fnature09107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wree, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Mutations in the <i>Plasmodium falciparum</i> Cyclic Amine Resistance Locus (PfCARL) confer multidrug resistance</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e00696-16</span>, <span class="refDoi"> DOI: 10.1128/mBio.00696-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1128%2FmBio.00696-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=27381290" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=e00696-16&author=G.+LaMonteauthor=M.+Y.+Limauthor=M.+Wreeauthor=C.+Reimerauthor=M.+Nachonauthor=V.+Coreyauthor=P.+Gedeckauthor=D.+Plouffeauthor=A.+Duauthor=N.+Figueroaauthor=B.+Yeungauthor=P.+Bifaniauthor=E.+A.+Winzeler&title=Mutations+in+the+Plasmodium+falciparum+Cyclic+Amine+Resistance+Locus+%28PfCARL%29+confer+multidrug+resistance&doi=10.1128%2FmBio.00696-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1128%2FmBio.00696-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00696-16%26sid%3Dliteratum%253Aachs%26aulast%3DLaMonte%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DM.%2BY.%26aulast%3DWree%26aufirst%3DM.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DNachon%26aufirst%3DM.%26aulast%3DCorey%26aufirst%3DV.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DA.%26aulast%3DFigueroa%26aufirst%3DN.%26aulast%3DYeung%26aufirst%3DB.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DMutations%2520in%2520the%2520Plasmodium%2520falciparum%2520Cyclic%2520Amine%2520Resistance%2520Locus%2520%2528PfCARL%2529%2520confer%2520multidrug%2520resistance%26jtitle%3DmBio%26date%3D2016%26volume%3D7%26spage%3De00696-16%26doi%3D10.1128%2FmBio.00696-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Using genetic methods to define the targets of compounds with antimalarial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7761</span>– <span class="NLM_lpage">7771</span>, <span class="refDoi"> DOI: 10.1021/jm400325j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400325j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Chs7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7761-7771&author=E.+L.+Flanneryauthor=D.+A.+Fidockauthor=E.+A.+Winzeler&title=Using+genetic+methods+to+define+the+targets+of+compounds+with+antimalarial+activity&doi=10.1021%2Fjm400325j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Using Genetic Methods To Define the Targets of Compounds with Antimalarial Activity</span></div><div class="casAuthors">Flannery, Erika L.; Fidock, David A.; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7761-7771</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Although phenotypic cellular screening has been used to drive antimalarial drug discovery in recent years, in some cases target-based drug discovery remains more attractive.  This is esp. true when appropriate high-throughput cellular assays are lacking, as is the case for drug discovery efforts that aim to provide a replacement for primaquine (4-N-(6-methoxyquinolin-8-yl)-pentane-1,4-diamine), the only drug that can block Plasmodium transmission to Anopheles mosquitoes and eliminate liver-stage hypnozoites.  At present, however, there are no known chem. validated parasite protein targets that are important in all Plasmodium parasite developmental stages and that can be used in traditional biochem. compd. screens.  We propose that a plethora of novel, chem. validated, cross-stage antimalarial targets still remain to be discovered from the ∼5,500 proteins encoded by the Plasmodium genomes.  Here we discuss how in vitro evolution of drug-resistant strains of Plasmodium falciparum and subsequent whole-genome anal. can be used to find the targets of some of the many compds. discovered in whole-cell phenotypic screens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKGylYC1n7jLVg90H21EOLACvtfcHk0liGV0UHmrOw-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Chs7bO&md5=89334c4fd625e02c7e8a949440ec6aa9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm400325j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400325j%26sid%3Dliteratum%253Aachs%26aulast%3DFlannery%26aufirst%3DE.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DUsing%2520genetic%2520methods%2520to%2520define%2520the%2520targets%2520of%2520compounds%2520with%2520antimalarial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7761%26epage%3D7771%26doi%3D10.1021%2Fjm400325j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schrader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henneberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mata, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tittmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourenkov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, A.</span></span> <span> </span><span class="NLM_article-title">The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1126/science.aaf8993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1126%2Fscience.aaf8993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=27493187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2016&pages=594-598&author=J.+Schraderauthor=F.+Hennebergauthor=R.+A.+Mataauthor=K.+Tittmannauthor=T.+R.+Schneiderauthor=H.+Starkauthor=G.+Bourenkovauthor=A.+Chari&title=The+inhibition+mechanism+of+human+20S+proteasomes+enables+next-generation+inhibitor+design&doi=10.1126%2Fscience.aaf8993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design</span></div><div class="casAuthors">Schrader, Jil; Henneberg, Fabian; Mata, Ricardo A.; Tittmann, Kai; Schneider, Thomas R.; Stark, Holger; Bourenkov, Gleb; Chari, Ashwin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">6299</span>),
    <span class="NLM_cas:pages">594-598</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The proteasome is a validated target for anticancer therapy, and proteasome inhibition is employed in the clinic for the treatment of tumors and hematol. malignancies.  Here, the authors describe crystal structures of the native human 20S proteasome and its complexes with inhibitors, which either are drugs approved for cancer treatment or are in clin. trials.  The structure of the native human 20S proteasome was detd. at an unprecedented resoln. of 1.8 angstroms.  Addnl., six inhibitor-proteasome complex structures were elucidated at resolns. between 1.9 and 2.1 angstroms.  Collectively, the high-resoln. structures provide new insights into the catalytic mechanisms of inhibition and necessitate a revised description of the proteasome active site.  Knowledge about inhibition mechanisms provides insights into peptide hydrolysis and can guide strategies for the development of next-generation proteasome-based cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZCuIDBbOXPLVg90H21EOLACvtfcHk0lhVQvaX540lmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oks7vL&md5=8216d0007cbf06c352e06fcb05d644a9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaf8993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaf8993%26sid%3Dliteratum%253Aachs%26aulast%3DSchrader%26aufirst%3DJ.%26aulast%3DHenneberg%26aufirst%3DF.%26aulast%3DMata%26aufirst%3DR.%2BA.%26aulast%3DTittmann%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DBourenkov%26aufirst%3DG.%26aulast%3DChari%26aufirst%3DA.%26atitle%3DThe%2520inhibition%2520mechanism%2520of%2520human%252020S%2520proteasomes%2520enables%2520next-generation%2520inhibitor%2520design%26jtitle%3DScience%26date%3D2016%26volume%3D353%26spage%3D594%26epage%3D598%26doi%3D10.1126%2Fscience.aaf8993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franke, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewerth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Meerloo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vojtekova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zantwijk, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweegman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geerke, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspers, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span> <span> </span><span class="NLM_article-title">Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fleu.2011.256" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=757-768&author=N.+E.+Frankeauthor=D.+Niewerthauthor=Y.+G.+Assarafauthor=J.+van+Meerlooauthor=K.+Vojtekovaauthor=C.+H.+van+Zantwijkauthor=S.+Zweegmanauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=D.+P.+Geerkeauthor=A.+D.+Schimmerauthor=G.+J.+Kaspersauthor=G.+Jansenauthor=J.+Cloos&title=Impaired+bortezomib+binding+to+mutant+beta5+subunit+of+the+proteasome+is+the+underlying+basis+for+bortezomib+resistance+in+leukemia+cells&doi=10.1038%2Fleu.2011.256"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.256%26sid%3Dliteratum%253Aachs%26aulast%3DFranke%26aufirst%3DN.%2BE.%26aulast%3DNiewerth%26aufirst%3DD.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3Dvan%2BMeerloo%26aufirst%3DJ.%26aulast%3DVojtekova%26aufirst%3DK.%26aulast%3Dvan%2BZantwijk%26aufirst%3DC.%2BH.%26aulast%3DZweegman%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DGeerke%26aufirst%3DD.%2BP.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DCloos%26aufirst%3DJ.%26atitle%3DImpaired%2520bortezomib%2520binding%2520to%2520mutant%2520beta5%2520subunit%2520of%2520the%2520proteasome%2520is%2520the%2520underlying%2520basis%2520for%2520bortezomib%2520resistance%2520in%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D757%26epage%3D768%26doi%3D10.1038%2Fleu.2011.256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrio, S.</span>; <span class="NLM_string-name">Stuhmer, T.</span>; <span class="NLM_string-name">Da-Via, M.</span>; <span class="NLM_string-name">Barrio-Garcia, C.</span>; <span class="NLM_string-name">Lehners, N.</span>; <span class="NLM_string-name">Besse, A.</span>; <span class="NLM_string-name">Cuenca, I.</span>; <span class="NLM_string-name">Garitano-Trojaola, A.</span>; <span class="NLM_string-name">Fink, S.</span>; <span class="NLM_string-name">Leich, E.</span>; <span class="NLM_string-name">Chatterjee, M.</span>; <span class="NLM_string-name">Driessen, C.</span>; <span class="NLM_string-name">Martinez-Lopez, J.</span>; <span class="NLM_string-name">Rosenwald, A.</span>; <span class="NLM_string-name">Beckmann, R.</span>; <span class="NLM_string-name">Bargou, R. C.</span>; <span class="NLM_string-name">Braggio, E.</span>; <span class="NLM_string-name">Stewart, A. K.</span>; <span class="NLM_string-name">Raab, M. S.</span>; <span class="NLM_string-name">Einsele, H.</span>; <span class="NLM_string-name">Kortum, K. M.</span></span> <span> </span><span class="NLM_article-title">Spectrum and functional validation of PSMB5 mutations in multiple myeloma</span>.  <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0216-8</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fs41375-018-0216-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Barrio&author=T.+Stuhmer&author=M.+Da-Via&author=C.+Barrio-Garcia&author=N.+Lehners&author=A.+Besse&author=I.+Cuenca&author=A.+Garitano-Trojaola&author=S.+Fink&author=E.+Leich&author=M.+Chatterjee&author=C.+Driessen&author=J.+Martinez-Lopez&author=A.+Rosenwald&author=R.+Beckmann&author=R.+C.+Bargou&author=E.+Braggio&author=A.+K.+Stewart&author=M.+S.+Raab&author=H.+Einsele&author=K.+M.+Kortum&title=Spectrum+and+functional+validation+of+PSMB5+mutations+in+multiple+myeloma&doi=10.1038%2Fs41375-018-0216-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0216-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0216-8%26sid%3Dliteratum%253Aachs%26aulast%3DBarrio%26aufirst%3DS.%26atitle%3DSpectrum%2520and%2520functional%2520validation%2520of%2520PSMB5%2520mutations%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2018%26doi%3D10.1038%2Fs41375-018-0216-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almaliti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibo-Verdugo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonova-Koch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orjuela-Sanchez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldgof, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, A.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span> <span> </span><span class="NLM_article-title">Development of a potent inhibitor of the Plasmodium proteasome with reduced mammalian toxicity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6721</span>– <span class="NLM_lpage">6732</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00671</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00671" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGitb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6721-6732&author=G.+M.+LaMonteauthor=J.+Almalitiauthor=B.+Bibo-Verdugoauthor=L.+Kellerauthor=B.+Y.+Zouauthor=J.+Yangauthor=Y.+Antonova-Kochauthor=P.+Orjuela-Sanchezauthor=C.+A.+Boyleauthor=E.+Vigilauthor=L.+Wangauthor=G.+M.+Goldgofauthor=L.+Gerwickauthor=A.%0AJ.+O%E2%80%99Donoghueauthor=E.+A.+Winzelerauthor=W.+H.+Gerwickauthor=S.+Ottilie&title=Development+of+a+potent+inhibitor+of+the+Plasmodium+proteasome+with+reduced+mammalian+toxicity&doi=10.1021%2Facs.jmedchem.7b00671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity</span></div><div class="casAuthors">LaMonte, Gregory M.; Almaliti, Jehad; Bibo-Verdugo, Betsaida; Keller, Lena; Zou, Bing Yu; Yang, Jennifer; Antonova-Koch, Yevgeniya; Orjuela-Sanchez, Pamela; Boyle, Colleen A.; Vigil, Edgar; Wang, Lawrence; Goldgof, Gregory M.; Gerwick, Lena; O'Donoghue, Anthony J.; Winzeler, Elizabeth A.; Gerwick, William H.; Ottilie, Sabine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6721-6732</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Naturally derived chem. compds. are the foundation of much of the authors' pharmacopeia, esp. in antiproliferative and anti-infective drug classes.  Here, the authors report that a naturally derived mol. called carmaphycin B is a potent inhibitor against both the asexual and sexual blood stages of malaria infection.  Using a combination of in silico mol. docking and in vitro directed evolution in a well-characterized drug-sensitive yeast model, the authors detd. that these compds. target the β5 subunit of the proteasome.  These studies were validated using in vitro inhibition assays with proteasomes isolated from Plasmodium falciparum.  As carmaphycin B is toxic to mammalian cells, the authors synthesized a series of chem. analogs that reduce host cell toxicity while maintaining blood-stage and gametocytocidal antimalarial activity and proteasome inhibition.  This study describes a promising new class of antimalarial compd. based on the carmaphycin B scaffold, as well as several chem. structural features that serve to enhance antimalarial specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe6ni2uoNcjrVg90H21EOLACvtfcHk0lhVQvaX540lmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGitb3K&md5=947e92a430c789d6f8e1e73abb834604</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00671%26sid%3Dliteratum%253Aachs%26aulast%3DLaMonte%26aufirst%3DG.%2BM.%26aulast%3DAlmaliti%26aufirst%3DJ.%26aulast%3DBibo-Verdugo%26aufirst%3DB.%26aulast%3DKeller%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DB.%2BY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DAntonova-Koch%26aufirst%3DY.%26aulast%3DOrjuela-Sanchez%26aufirst%3DP.%26aulast%3DBoyle%26aufirst%3DC.%2BA.%26aulast%3DVigil%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGoldgof%26aufirst%3DG.%2BM.%26aulast%3DGerwick%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DA.%2BJ.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DGerwick%26aufirst%3DW.%2BH.%26aulast%3DOttilie%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520a%2520potent%2520inhibitor%2520of%2520the%2520Plasmodium%2520proteasome%2520with%2520reduced%2520mammalian%2520toxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6721%26epage%3D6732%26doi%3D10.1021%2Facs.jmedchem.7b00671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span> <i>The PyMOL Molecular Graphics System</i>, version <span class="NLM_edition">1.8</span>; <span class="NLM_publisher-name">Schrödinger</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+PyMOL+Molecular+Graphics+System%2C+version+1.8%3B+Schr%C3%B6dinger%2C+2015."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menendez-Benito, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Nieuwendijk, A.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groothuis, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeuwenburgh, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefjes, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippov, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantuma, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1217</span>– <span class="NLM_lpage">1226</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2006.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2Fj.chembiol.2006.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=17114003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cis7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=1217-1226&author=M.+Verdoesauthor=B.+I.+Floreaauthor=V.+Menendez-Benitoauthor=C.+J.+Maynardauthor=M.+D.+Witteauthor=W.+A.+van+der+Lindenauthor=A.%0AM.+van+den+Nieuwendijkauthor=T.+Hofmannauthor=C.+R.+Berkersauthor=F.+W.+van+Leeuwenauthor=T.+A.+Groothuisauthor=M.+A.+Leeuwenburghauthor=H.+Ovaaauthor=J.+J.+Neefjesauthor=D.+V.+Filippovauthor=G.+A.+van+der+Marelauthor=N.+P.+Dantumaauthor=H.+S.+Overkleeft&title=A+fluorescent+broad-spectrum+proteasome+inhibitor+for+labeling+proteasomes+in+vitro+and+in+vivo&doi=10.1016%2Fj.chembiol.2006.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A Fluorescent Broad-Spectrum Proteasome Inhibitor for Labeling Proteasomes In Vitro and In Vivo</span></div><div class="casAuthors">Verdoes, Martijn; Florea, Bogdan I.; Menendez-Benito, Victoria; Maynard, Christa J.; Witte, Martin D.; van der Linden, Wouter A.; van den Nieuwendijk, Adrianus M. C. H.; Hofmann, Tanja; Berkers, Celia R.; van Leeuwen, Fijs W. B.; Groothuis, Tom A.; Leeuwenburgh, Michiel A.; Ovaa, Huib; Neefjes, Jacques J.; Filippov, Dmitri V.; van der Marel, Gijs A.; Dantuma, Nico P.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1217-1226</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The proteasome is an essential evolutionary conserved protease involved in many regulatory systems.  Here, the authors describe the synthesis and characterization of the activity-based, fluorescent, and cell-permeable inhibitor Bodipy TMR-Ahx3L3VS (MV151), which specifically targets all active subunits of the proteasome and immunoproteasome in living cells, allowing for rapid and sensitive in-gel detection.  The inhibition profile of a panel of commonly used proteasome inhibitors could be readily detd. by MV151 labeling.  Administration of MV151 to mice allowed for in vivo labeling of proteasomes, which correlated with inhibition of proteasomal degrdn. in the affected tissues.  This probe can be used for many applications ranging from clin. profiling of proteasome activity, to biochem. anal. of subunit specificity of inhibitors, and to cell biol. anal. of the proteasome function and dynamics in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMZq52j_0-wLVg90H21EOLACvtfcHk0liQkdOYnBnisA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cis7fN&md5=95b57d47d477020254a0fb2bd24fef87</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DMenendez-Benito%26aufirst%3DV.%26aulast%3DMaynard%26aufirst%3DC.%2BJ.%26aulast%3DWitte%26aufirst%3DM.%2BD.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%2BM.%26aulast%3DHofmann%26aufirst%3DT.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BW.%26aulast%3DGroothuis%26aufirst%3DT.%2BA.%26aulast%3DLeeuwenburgh%26aufirst%3DM.%2BA.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DNeefjes%26aufirst%3DJ.%2BJ.%26aulast%3DFilippov%26aufirst%3DD.%2BV.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DDantuma%26aufirst%3DN.%2BP.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DA%2520fluorescent%2520broad-spectrum%2520proteasome%2520inhibitor%2520for%2520labeling%2520proteasomes%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D1217%26epage%3D1226%26doi%3D10.1016%2Fj.chembiol.2006.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhanot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Assessing subunit dependency of the Plasmodium proteasome using small molecule inhibitors and active site probes</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1869</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1021/cb5001263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVKks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1869-1876&author=H.+Liauthor=W.+A.+van+der+Lindenauthor=M.+Verdoesauthor=B.+I.+Floreaauthor=F.+E.+McAllisterauthor=K.+Govindaswamyauthor=J.+E.+Eliasauthor=P.+Bhanotauthor=H.+S.+Overkleeftauthor=M.+Bogyo&title=Assessing+subunit+dependency+of+the+Plasmodium+proteasome+using+small+molecule+inhibitors+and+active+site+probes&doi=10.1021%2Fcb5001263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing Subunit Dependency of the Plasmodium Proteasome Using Small Molecule Inhibitors and Active Site Probes</span></div><div class="casAuthors">Li, Hao; van der Linden, Wouter A.; Verdoes, Martijn; Florea, Bogdan I.; McAllister, Fiona E.; Govindaswamy, Kavitha; Elias, Joshua E.; Bhanot, Purnima; Overkleeft, Herman S.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1869-1876</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system (UPS) is a potential pathway for therapeutic intervention for pathogens such as Plasmodium, the causative agent of malaria.  However, due to the essential nature of this proteolytic pathway, proteasome inhibitors must avoid inhibition of the host enzyme complex to prevent toxic side effects.  The Plasmodium proteasome is poorly characterized, making rational design of inhibitors that induce selective parasite killing difficult.  In this study, we developed a chem. probe designate BMV037 that labels all catalytic sites of the Plasmodium proteasome.  Using this probe, we identified several subunit-selective small mol. inhibitors of the parasite enzyme complex.  Treatment with an inhibitor that is specific for the β5 subunit during blood stage schizogony led to a dramatic decrease in parasite replication while short-term inhibition of the β2 subunit did not affect viability.  Interestingly, co-inhibition of both the β2 and β5 catalytic subunits resulted in enhanced parasite killing at all stages of the blood stage life cycle and reduced parasite levels in vivo to barely detectable levels.  Parasite killing was achieved with overall low host toxicity, something that has not been possible with existing proteasome inhibitors.  Our results highlight differences in the subunit dependency of the parasite and human proteasome, thus providing a strategy for development of potent antimalarial drugs with overall low host toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9qkR_VrNq2bVg90H21EOLACvtfcHk0liQkdOYnBnisA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVKks7s%253D&md5=811e1268d8285d4d2b0561f6b1123f6e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcb5001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5001263%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DMcAllister%26aufirst%3DF.%2BE.%26aulast%3DGovindaswamy%26aufirst%3DK.%26aulast%3DElias%26aufirst%3DJ.%2BE.%26aulast%3DBhanot%26aufirst%3DP.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DAssessing%2520subunit%2520dependency%2520of%2520the%2520Plasmodium%2520proteasome%2520using%2520small%2520molecule%2520inhibitors%2520and%2520active%2520site%2520probes%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1869%26epage%3D1876%26doi%3D10.1021%2Fcb5001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foe, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Fonseca, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Structure- and function-based design of Plasmodium-selective proteasome inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>530</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/nature16936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fnature16936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=26863983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=530&publication_year=2016&pages=233-236&author=H.+Liauthor=A.+J.+O%E2%80%99Donoghueauthor=W.+A.+van+der+Lindenauthor=S.+C.+Xieauthor=E.+Yooauthor=I.+T.+Foeauthor=L.+Tilleyauthor=C.+S.+Craikauthor=P.+C.+da+Fonsecaauthor=M.+Bogyo&title=Structure-+and+function-based+design+of+Plasmodium-selective+proteasome+inhibitors&doi=10.1038%2Fnature16936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and function-based design of Plasmodium-selective proteasome inhibitors</span></div><div class="casAuthors">Li, Hao; O'Donoghue, Anthony J.; van der Linden, Wouter A.; Xie, Stanley C.; Yoo, Euna; Foe, Ian T.; Tilley, Leann; Craik, Charles S.; da Fonseca, Paula C. A.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">530</span>
        (<span class="NLM_cas:issue">7589</span>),
    <span class="NLM_cas:pages">233-236</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The proteasome is a multi-component protease complex responsible for regulating key processes such as the cell cycle and antigen presentation.  Compds. that target the proteasome are potentially valuable tools for the treatment of pathogens that depend on proteasome function for survival and replication.  In particular, proteasome inhibitors have been shown to be toxic for the malaria parasite Plasmodium falciparum at all stages of its life cycle.  Most compds. that have been tested against the parasite also inhibit the mammalian proteasome, resulting in toxicity that precludes their use as therapeutic agents.  Therefore, better definition of the substrate specificity and structural properties of the Plasmodium proteasome could enable the development of compds. with sufficient selectivity to allow their use as anti-malarial agents.  To accomplish this goal, here the authors use a substrate profiling method to uncover differences in the specificities of the human and P. falciparum proteasome.  The authors design inhibitors based on amino-acid preferences specific to the parasite proteasome, and find that they preferentially inhibit the β2-subunit.  The authors det. the structure of the P. falciparum 20S proteasome bound to the inhibitor using cryo-electron microscopy and single-particle anal., to a resoln. of 3.6 Å.  These data reveal the unusually open P. falciparum β2 active site and provide valuable information about active-site architecture that can be used to further refine inhibitor design.  Furthermore, consistent with the recent finding that the proteasome is important for stress pathways assocd. with resistance of artemisinin family anti-malarials, the authors observe growth inhibition synergism with low doses of this β2-selective inhibitor in artemisinin-sensitive and -resistant parasites.  Finally, the authors demonstrate that a parasite-selective inhibitor could be used to attenuate parasite growth in vivo without appreciable toxicity to the host.  Thus, the Plasmodium proteasome is a chem. tractable target that could be exploited by next-generation anti-malarial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriK0Li_WncVrVg90H21EOLACvtfcHk0lj7IrvArJ6xNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyrsr8%253D&md5=f24a562efb64dd533a7dbcfeff4171af</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnature16936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16936%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DXie%26aufirst%3DS.%2BC.%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DFoe%26aufirst%3DI.%2BT.%26aulast%3DTilley%26aufirst%3DL.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3Dda%2BFonseca%26aufirst%3DP.%2BC.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DStructure-%2520and%2520function-based%2520design%2520of%2520Plasmodium-selective%2520proteasome%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D530%26spage%3D233%26epage%3D236%26doi%3D10.1038%2Fnature16936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Stelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">A set of sctivity-based probes to visualize human (immuno)proteasome activities</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4199</span>– <span class="NLM_lpage">4203</span>, <span class="refDoi"> DOI: 10.1002/anie.201509092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1002%2Fanie.201509092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=4199-4203&author=G.+de%0ABruinauthor=B.+T.+Xinauthor=M.+Krausauthor=M.+van+der%0ASteltauthor=G.+A.+van+der+Marelauthor=A.+F.+Kisselevauthor=C.+Driessenauthor=B.+I.+Floreaauthor=H.+S.+Overkleeft&title=A+set+of+sctivity-based+probes+to+visualize+human+%28immuno%29proteasome+activities&doi=10.1002%2Fanie.201509092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fanie.201509092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201509092%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DXin%26aufirst%3DB.%2BT.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DA%2520set%2520of%2520sctivity-based%2520probes%2520to%2520visualize%2520human%2520%2528immuno%2529proteasome%2520activities%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D4199%26epage%3D4203%26doi%3D10.1002%2Fanie.201509092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geurink, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyburne, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirabella, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silzle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabaneh, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haile, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rooden, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appenzeller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span> <span> </span><span class="NLM_article-title">The novel beta2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1360</span>, <span class="refDoi"> DOI: 10.3324/haematol.2014.109421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.3324%2Fhaematol.2014.109421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=26069288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVKitrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=1350-1360&author=M.+Krausauthor=J.+Baderauthor=P.+P.+Geurinkauthor=E.+S.+Weyburneauthor=A.+C.+Mirabellaauthor=T.+Silzleauthor=T.+B.+Shabanehauthor=W.+A.+van+der+Lindenauthor=G.+de+Bruinauthor=S.+R.+Haileauthor=E.+van+Roodenauthor=C.+Appenzellerauthor=N.+Liauthor=A.+F.+Kisselevauthor=H.+Overkleeftauthor=C.+Driessen&title=The+novel+beta2-selective+proteasome+inhibitor+LU-102+synergizes+with+bortezomib+and+carfilzomib+to+overcome+proteasome+inhibitor+resistance+of+myeloma+cells&doi=10.3324%2Fhaematol.2014.109421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells</span></div><div class="casAuthors">Kraus, Marianne; Bader, Juergen; Geurink, Paul P.; Weyburne, Emily S.; Mirabella, Anne C.; Silzle, Tobias; Shabaneh, Tamer B.; van der Linden, Wouter A.; de Bruin, Gerjan; Haile, Sarah R.; van Rooden, Eva; Appenzeller, Christina; Li, Nan; Kisselev, Alexei F.; Overkleeft, Herman; Driessen, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1350-1360</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Proteasome inhibitor resistance is a challenge for myeloma therapy.  Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome.  Bortezomib-resistant myeloma cells down-regulate the activation status of the unfolded protein response, and up-regulate β2 proteasome activity.  To improve proteasome inhibition in bortezomib-resistant myeloma and to achieve more efficient UPR activation, we have developed LU-102, a selective inhibitor of the β2 proteasome activity.  LU-102 inhibited the β2 activity in intact myeloma cells at low micromolar concns. without relevant co-inhibition of β1 and β5 proteasome subunits.  In protea-some inhibitor-resistant myeloma cells, significantly more potent proteasome inhibition was achieved by bortezomib or carfilzomib in combination with LU-102, compared to bortezomib/carfilzomib alone, resulting in highly synergistic cytotoxic activity of the drug combination via endoplasmatic reticulum stress-induced apoptosis.  Combining bortezomib/carfilzomib with LU-102 significantly prolonged proteasome inhibition and increased activation of the unfolded protein response and IRE1-α activity.  IRE1-α has recently been shown to control myeloma cell differentiation and bortezomib sensitivity (Leung-Hagesteijn, Cancer Cell 24:3, 289-304).  Thus, β2-selective proteasome inhibition by LU-102 in combination with bortezomib or carfilzomib re-sults in synergistic proteasome inhibition, activation of the unfolded protein response, and cytotoxicity, and overcomes bortezomib/carfilzomib resistance in myeloma cells in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhWaSEQ0aXHbVg90H21EOLACvtfcHk0lj7IrvArJ6xNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVKitrjE&md5=7895da9ac823a56178903ca149c8d39f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2014.109421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2014.109421%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DBader%26aufirst%3DJ.%26aulast%3DGeurink%26aufirst%3DP.%2BP.%26aulast%3DWeyburne%26aufirst%3DE.%2BS.%26aulast%3DMirabella%26aufirst%3DA.%2BC.%26aulast%3DSilzle%26aufirst%3DT.%26aulast%3DShabaneh%26aufirst%3DT.%2BB.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DHaile%26aufirst%3DS.%2BR.%26aulast%3Dvan%2BRooden%26aufirst%3DE.%26aulast%3DAppenzeller%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DOverkleeft%26aufirst%3DH.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DThe%2520novel%2520beta2-selective%2520proteasome%2520inhibitor%2520LU-102%2520synergizes%2520with%2520bortezomib%2520and%2520carfilzomib%2520to%2520overcome%2520proteasome%2520inhibitor%2520resistance%2520of%2520myeloma%2520cells%26jtitle%3DHaematologica%26date%3D2015%26volume%3D100%26spage%3D1350%26epage%3D1360%26doi%3D10.3324%2Fhaematol.2014.109421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheppeck, J. E.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosink, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheatley, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjerstad, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loftus, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubiria, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janc, J. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a statistically exhaustive fluorescent peptide substrate library for profiling protease specificity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2639</span>– <span class="NLM_lpage">2642</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(00)00545-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FS0960-894X%2800%2900545-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2639-2642&author=J.+E.+Sheppeckauthor=H.+Karauthor=L.+Gosinkauthor=J.+B.+Wheatleyauthor=E.+Gjerstadauthor=S.+M.+Loftusauthor=A.+R.+Zubiriaauthor=J.+W.+Janc&title=Synthesis+of+a+statistically+exhaustive+fluorescent+peptide+substrate+library+for+profiling+protease+specificity&doi=10.1016%2FS0960-894X%2800%2900545-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900545-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900545-X%26sid%3Dliteratum%253Aachs%26aulast%3DSheppeck%26aufirst%3DJ.%2BE.%26aulast%3DKar%26aufirst%3DH.%26aulast%3DGosink%26aufirst%3DL.%26aulast%3DWheatley%26aufirst%3DJ.%2BB.%26aulast%3DGjerstad%26aufirst%3DE.%26aulast%3DLoftus%26aufirst%3DS.%2BM.%26aulast%3DZubiria%26aufirst%3DA.%2BR.%26aulast%3DJanc%26aufirst%3DJ.%2BW.%26atitle%3DSynthesis%2520of%2520a%2520statistically%2520exhaustive%2520fluorescent%2520peptide%2520substrate%2520library%2520for%2520profiling%2520protease%2520specificity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2639%26epage%3D2642%26doi%3D10.1016%2FS0960-894X%2800%2900545-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span> <span> </span><span class="NLM_article-title">Distinct specificities of <i>Mycobacterium tuberculosis</i> and mammalian proteasomes for N-acetyl tripeptide substrates</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">34423</span>– <span class="NLM_lpage">34431</span>, <span class="refDoi"> DOI: 10.1074/jbc.M805324200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1074%2Fjbc.M805324200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=18829465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVelu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=34423-34431&author=G.+Linauthor=C.+Tsuauthor=L.+Dickauthor=X.+K.+Zhouauthor=C.+Nathan&title=Distinct+specificities+of+Mycobacterium+tuberculosis+and+mammalian+proteasomes+for+N-acetyl+tripeptide+substrates&doi=10.1074%2Fjbc.M805324200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Specificities of Mycobacterium tuberculosis and Mammalian Proteasomes for N-Acetyl Tripeptide Substrates</span></div><div class="casAuthors">Lin, Gang; Tsu, Christopher; Dick, Lawrence; Zhou, Xi K.; Nathan, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">34423-34431</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The proteasome of Mycobacterium tuberculosis (Mtb) is a validated and drug-treatable target for therapeutics.  To lay ground-work for developing peptide-based inhibitors with a useful degree of selectivity for the Mtb proteasome over those of the host, we used a library of 5920 N-acetyl tripeptide-aminomethylcoumarins to contrast the substrate preferences of the recombinant Mtb proteasome wild type and open gate mutant, the Rhodococcus erythropolis proteasome, and the bovine proteasome with activator PA28.  The Mtb proteasome was distinctive in strictly preferring P1 = tryptophan, particularly in combination with P3 = glycine, proline, lysine or arginine.  Screening results were validated with Michaelis-Menten kinetic analyses of 21 oligopeptide aminomethyl-coumarin substrates.  Bortezomib, a proteasome inhibitor in clin. use, and 17 analogs varying only at P1 were used to examine the differential impact of inhibitors on human and Mtb proteasomes.  The results with the inhibitor panel confirmed those with the substrate panel in demonstrating differential preferences of Mtb and mammalian proteasomes at the P1 amino acid.  Changing P1 in bortezomib from Leu to m-CF3-Phe led to a 220-fold increase in IC50 against the human proteasome, whereas changing a P1 Ala to m-F-Phe decreased the IC50 400-fold against the Mtb proteasome.  The change of a P1 Ala to m-Cl-Phe led to an 8000-fold shift in inhibitory potency in favor of the Mtb proteasome, resulting in 8-fold selectivity.  Combinations of preferred amino acids at different sites may thus improve the species selectivity of peptide-based inhibitors that target the Mtb proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVpCPunOb8tLVg90H21EOLACvtfcHk0liQ4wwkGhOviA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVelu7jP&md5=6f73b15a893fe094894ca3916882d834</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M805324200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M805324200%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DX.%2BK.%26aulast%3DNathan%26aufirst%3DC.%26atitle%3DDistinct%2520specificities%2520of%2520Mycobacterium%2520tuberculosis%2520and%2520mammalian%2520proteasomes%2520for%2520N-acetyl%2520tripeptide%2520substrates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D34423%26epage%3D34431%26doi%3D10.1074%2Fjbc.M805324200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Westhuyzen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momper, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Defining the determinants of specificity of <i>Plasmodium</i> proteasome inhibitors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">11424</span>– <span class="NLM_lpage">11437</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b06656</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b06656" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=11424-11437&author=E.+Yooauthor=B.+H.+Stokesauthor=H.+de+Jongauthor=M.+Vanaerschotauthor=T.+Kumarauthor=N.+Lawrenceauthor=M.+Njorogeauthor=A.+Garciaauthor=R.+Van+der+Westhuyzenauthor=J.+D.+Momperauthor=C.+L.+Ngauthor=D.+A.+Fidockauthor=M.+Bogyo&title=Defining+the+determinants+of+specificity+of+Plasmodium+proteasome+inhibitors&doi=10.1021%2Fjacs.8b06656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors</span></div><div class="casAuthors">Yoo, Euna; Stokes, Barbara H.; de Jong, Hanna; Vanaerschot, Manu; Kumar, T. R. S.; Lawrence, Nina; Njoroge, Mathew; Garcia, Arnold; Van der Westhuyzen, Renier; Momper, Jeremiah D.; Ng, Caroline L.; Fidock, David A.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">11424-11437</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Plasmodium proteasome is an emerging antimalarial target due to its essential role in all the major life cycle stages of the parasite and its contribution to the establishment of resistance to artemisinin (ART)-based therapies.  However, because of a similarly essential role for the host proteasome, the key property of any antiproteasome therapeutic is selectivity.  Several parasite-specific proteasome inhibitors have recently been reported, however, their selectivity must be improved to enable clin. development.  Here we describe screening of diverse libraries of non-natural synthetic fluorogenic substrates to identify determinants at multiple positions on the substrate that produce enhanced selectivity.  We find that selection of an optimal electrophilic "warhead" is essential to enable high selectivity that is driven by the peptide binding elements on the inhibitor.  We also find that host cell toxicity is dictated by the extent of coinhibition of the human β2 and β5 subunits.  Using this information, we identify compds. with over 3 orders of magnitude selectivity for the parasite enzyme.  Optimization of the pharmacol. properties resulted in mols. that retained high potency and selectivity, were sol., sufficiently metabolically stable and orally bioavailable.  These mols. are highly synergistic with ART and can clear parasites in a mouse model of infection, making them promising leads as antimalarial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzXchyqonWDrVg90H21EOLACvtfcHk0liQ4wwkGhOviA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbN&md5=990e0b5097087ff76681f901b2c8f35f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b06656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b06656%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DStokes%26aufirst%3DB.%2BH.%26aulast%3Dde%2BJong%26aufirst%3DH.%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DT.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DVan%2Bder%2BWesthuyzen%26aufirst%3DR.%26aulast%3DMomper%26aufirst%3DJ.%2BD.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DDefining%2520the%2520determinants%2520of%2520specificity%2520of%2520Plasmodium%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26spage%3D11424%26epage%3D11437%26doi%3D10.1021%2Fjacs.8b06656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostova, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mease, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denmeade, S. R.</span></span> <span> </span><span class="NLM_article-title">Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4224</span>– <span class="NLM_lpage">4235</span>, <span class="refDoi"> DOI: 10.1021/jm301718c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301718c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvFyis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4224-4235&author=M.+B.+Kostovaauthor=D.+M.+Rosenauthor=Y.+Chenauthor=R.+C.+Measeauthor=S.+R.+Denmeade&title=Structural+optimization%2C+biological+evaluation%2C+and+application+of+peptidomimetic+prostate+specific+antigen+inhibitors&doi=10.1021%2Fjm301718c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors</span></div><div class="casAuthors">Kostova, Maya B.; Rosen, D. Marc; Chen, Ying; Mease, Ronnie C.; Denmeade, Samuel R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4224-4235</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostate-specific antigen (PSA) is a serine protease produced at high levels by normal and malignant prostate epithelial cells that is used extensively as a biomarker in the clin. management of prostate cancer.  To better understand PSA's role in prostate cancer progression, we prepd. a library of peptidyl boronic acid-based inhibitors.  To enhance selectivity for PSA vs other serine proteases, we modified the P1 site of the inhibitors to incorporate a bromopropylglycine group.  This allowed the inhibitors to participate in halogen bond formation with the serine found at the bottom of the specificity pocket.  The best of these Ahx-FSQn(boro)Bpg had PSA Ki of 72 nM and chymotrypsin Ki of 580 nM.  In vivo studies using PSA-producing xenografts demonstrated that candidate inhibitors had minimal effect on growth but significantly altered serum levels of PSA.  Biodistribution of 125I labeled peptides showed low levels of uptake into tumors compared to other normal tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkTFZGJTbgAbVg90H21EOLACvtfcHk0liQ4wwkGhOviA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvFyis7g%253D&md5=20fdf7c185d3058335a1cb24ae7f652c</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm301718c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301718c%26sid%3Dliteratum%253Aachs%26aulast%3DKostova%26aufirst%3DM.%2BB.%26aulast%3DRosen%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMease%26aufirst%3DR.%2BC.%26aulast%3DDenmeade%26aufirst%3DS.%2BR.%26atitle%3DStructural%2520optimization%252C%2520biological%2520evaluation%252C%2520and%2520application%2520of%2520peptidomimetic%2520prostate%2520specific%2520antigen%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4224%26epage%3D4235%26doi%3D10.1021%2Fjm301718c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pickersgill, I. F.</span>; <span class="NLM_string-name">Bishop, J.</span>; <span class="NLM_string-name">Koellner, C.</span>; <span class="NLM_string-name">Gomez, J.-M.</span>; <span class="NLM_string-name">Geiser, A.</span>; <span class="NLM_string-name">Hett, R.</span>; <span class="NLM_string-name">Ammoscato, V.</span>; <span class="NLM_string-name">Munk, S.</span>; <span class="NLM_string-name">Lo, Y.</span>; <span class="NLM_string-name">Chui, F.-T.</span>; <span class="NLM_string-name">Kulkarni, V. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis Of Boronic Ester And Acid Compounds</span>. Patent Publication Number <span class="NLM_patent">WO 2005/097809</span>, <span class="NLM_year">2005</span>; Millenium Pharmaceuticals Inc.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=I.+F.+Pickersgill&author=J.+Bishop&author=C.+Koellner&author=J.-M.+Gomez&author=A.+Geiser&author=R.+Hett&author=V.+Ammoscato&author=S.+Munk&author=Y.+Lo&author=F.-T.+Chui&author=V.+R.+Kulkarni&title=Synthesis+Of+Boronic+Ester+And+Acid+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPickersgill%26aufirst%3DI.%2BF.%26atitle%3DSynthesis%2520Of%2520Boronic%2520Ester%2520And%2520Acid%2520Compounds%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dogovski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klonis, N.</span></span> <span> </span><span class="NLM_article-title">Optimal assay design for determining the in vitro sensitivity of ring stage <i>Plasmodium falciparum</i> to artemisinins</span>. <i>Int. J. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1016/j.ijpara.2014.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2Fj.ijpara.2014.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=25161101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2lt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=893-899&author=S.+C.+Xieauthor=C.+Dogovskiauthor=S.+Kennyauthor=L.+Tilleyauthor=N.+Klonis&title=Optimal+assay+design+for+determining+the+in+vitro+sensitivity+of+ring+stage+Plasmodium+falciparum+to+artemisinins&doi=10.1016%2Fj.ijpara.2014.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Optimal assay design for determining the in vitro sensitivity of ring stage Plasmodium falciparum to artemisinins</span></div><div class="casAuthors">Xie, Stanley C.; Dogovski, Con; Kenny, Shannon; Tilley, Leann; Klonis, Nectarios</div><div class="citationInfo"><span class="NLM_cas:title">International Journal for Parasitology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">893-899</span>CODEN:
                <span class="NLM_cas:coden">IJPYBT</span>;
        ISSN:<span class="NLM_cas:issn">0020-7519</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent reports demonstrate that failure of artemisinin-based antimalarial therapies is assocd. with an altered response of early blood stage Plasmodium falciparum.  This has led to increased interest in the use of pulse assays that mimic clin. drug exposure for analyzing artemisinin sensitivity of highly synchronised ring stage parasites.  We report a methodol. for the reliable execution of drug pulse assays and detail a synchronisation strategy that produces well-defined tightly synchronised ring stage cultures in a convenient time-frame.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKbGAjR2QHw7Vg90H21EOLACvtfcHk0lgdVKZqq3Fy8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2lt7vK&md5=dc166c5dd13df61df1bfbf18883bb391</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpara.2014.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpara.2014.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DS.%2BC.%26aulast%3DDogovski%26aufirst%3DC.%26aulast%3DKenny%26aufirst%3DS.%26aulast%3DTilley%26aufirst%3DL.%26aulast%3DKlonis%26aufirst%3DN.%26atitle%3DOptimal%2520assay%2520design%2520for%2520determining%2520the%2520in%2520vitro%2520sensitivity%2520of%2520ring%2520stage%2520Plasmodium%2520falciparum%2520to%2520artemisinins%26jtitle%3DInt.%2520J.%2520Parasitol.%26date%3D2014%26volume%3D44%26spage%3D893%26epage%3D899%26doi%3D10.1016%2Fj.ijpara.2014.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Istvan, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Lorenzo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata-Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magistrado, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linares, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arriaga, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bopp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnadig, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coburn-Flynn, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murithi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moura, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akidil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjalley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaseichuk, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Mapping the malaria parasite druggable genome by using <i>in vitro</i> evolution and chemogenomics</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1126/science.aan4472</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1126%2Fscience.aan4472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=29326268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmt1ehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2018&pages=191-199&author=A.+N.+Cowellauthor=E.+S.+Istvanauthor=A.+K.+Lukensauthor=M.+G.+Gomez-Lorenzoauthor=M.+Vanaerschotauthor=T.+Sakata-Katoauthor=E.+L.+Flanneryauthor=P.+Magistradoauthor=E.+Owenauthor=M.+Abrahamauthor=G.+LaMonteauthor=H.+J.+Painterauthor=R.+M.+Williamsauthor=V.+Francoauthor=M.+Linaresauthor=I.+Arriagaauthor=S.+Boppauthor=V.+C.+Coreyauthor=N.+F.+Gnadigauthor=O.+Coburn-Flynnauthor=C.+Reimerauthor=P.+Guptaauthor=J.+M.+Murithiauthor=P.+A.+Mouraauthor=O.+Fuchsauthor=E.+Sasakiauthor=S.+W.+Kimauthor=C.+H.+Tengauthor=L.+T.+Wangauthor=A.+Akidilauthor=S.+Adjalleyauthor=P.+A.+Willisauthor=D.+Siegelauthor=O.+Tanaseichukauthor=Y.+Zhongauthor=Y.+Zhouauthor=M.+Llinasauthor=S.+Ottilieauthor=F.+J.+Gamoauthor=M.+C.+S.+Leeauthor=D.+E.+Goldbergauthor=D.+A.+Fidockauthor=D.+F.+Wirthauthor=E.+A.+Winzeler&title=Mapping+the+malaria+parasite+druggable+genome+by+using+in+vitro+evolution+and+chemogenomics&doi=10.1126%2Fscience.aan4472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics</span></div><div class="casAuthors">Cowell, Annie N.; Istvan, Eva S.; Lukens, Amanda K.; Gomez-Lorenzo, Maria G.; Vanaerschot, Manu; Sakata-Kato, Tomoyo; Flannery, Erika L.; Magistrado, Pamela; Owen, Edward; Abraham, Matthew; La Monte, Gregory; Painter, Heather J.; Williams, Roy M.; Franco, Virginia; Linares, Maria; Arriaga, Ignacio; Bopp, Selina; Corey, Victoria C.; Gnaedig, Nina F.; Coburn-Flynn, Olivia; Reimer, Christin; Gupta, Purva; Murithi, James M.; Moura, Pedro A.; Fuchs, Olivia; Sasaki, Erika; Kim, Sang W.; Teng, Christine H.; Wang, Lawrence T.; Akidil, Asli; Adjalley, Sophie; Willis, Paul A.; Siegel, Dionicio; Tanaseichuk, Olga; Zhong, Yang; Zhou, Yingyao; Llinas, Manuel; Ottilie, Sabine; Gamo, Francisco-Javier; Lee, Marcus C. S.; Goldberg, Daniel E.; Fidock, David A.; Wirth, Dyann F.; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">6372</span>),
    <span class="NLM_cas:pages">191-199</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Chemogenetic characterization through in vitro evolution combined with whole-genome anal. can identify antimalarial drug targets and drug-resistance genes.  We performed a genome anal. of 262 Plasmodium falciparum parasites resistant to 37 diverse compds.  We found 159 gene amplifications and 148 nonsynonymous changes in 83 genes assocd. with drug-resistance acquisition, where gene amplifications contributed to one-third of resistance acquisition events.  Beyond confirming previously identified multidrug-resistance mechanisms, we discovered hitherto unrecognized drug target-inhibitor pairs, including thymidylate synthase and a benzoquinazolinone, farnesyltransferase and a pyrimidinedione, and a dipeptidylpeptidase and an arylurea.  This exploration of the P. falciparum resistome and druggable genome will likely guide drug discovery and structural biol. efforts, while also advancing our understanding of resistance mechanisms available to the malaria parasite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh05CQ_5D5nrVg90H21EOLACvtfcHk0lgdVKZqq3Fy8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmt1ehug%253D%253D&md5=fb3b3af094ea64e2b33df2371655282f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1126%2Fscience.aan4472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aan4472%26sid%3Dliteratum%253Aachs%26aulast%3DCowell%26aufirst%3DA.%2BN.%26aulast%3DIstvan%26aufirst%3DE.%2BS.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DGomez-Lorenzo%26aufirst%3DM.%2BG.%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DSakata-Kato%26aufirst%3DT.%26aulast%3DFlannery%26aufirst%3DE.%2BL.%26aulast%3DMagistrado%26aufirst%3DP.%26aulast%3DOwen%26aufirst%3DE.%26aulast%3DAbraham%26aufirst%3DM.%26aulast%3DLaMonte%26aufirst%3DG.%26aulast%3DPainter%26aufirst%3DH.%2BJ.%26aulast%3DWilliams%26aufirst%3DR.%2BM.%26aulast%3DFranco%26aufirst%3DV.%26aulast%3DLinares%26aufirst%3DM.%26aulast%3DArriaga%26aufirst%3DI.%26aulast%3DBopp%26aufirst%3DS.%26aulast%3DCorey%26aufirst%3DV.%2BC.%26aulast%3DGnadig%26aufirst%3DN.%2BF.%26aulast%3DCoburn-Flynn%26aufirst%3DO.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DMurithi%26aufirst%3DJ.%2BM.%26aulast%3DMoura%26aufirst%3DP.%2BA.%26aulast%3DFuchs%26aufirst%3DO.%26aulast%3DSasaki%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DTeng%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DL.%2BT.%26aulast%3DAkidil%26aufirst%3DA.%26aulast%3DAdjalley%26aufirst%3DS.%26aulast%3DWillis%26aufirst%3DP.%2BA.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DTanaseichuk%26aufirst%3DO.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLlinas%26aufirst%3DM.%26aulast%3DOttilie%26aufirst%3DS.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DGoldberg%26aufirst%3DD.%2BE.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DMapping%2520the%2520malaria%2520parasite%2520druggable%2520genome%2520by%2520using%2520in%2520vitro%2520evolution%2520and%2520chemogenomics%26jtitle%3DScience%26date%3D2018%26volume%3D359%26spage%3D191%26epage%3D199%26doi%3D10.1126%2Fscience.aan4472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labutti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span> <span> </span><span class="NLM_article-title">Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3052</span>– <span class="NLM_lpage">3061</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1158%2F1535-7163.MCT-06-0185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=17172407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlagsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=3052-3061&author=M.+J.+Williamsonauthor=J.+L.+Blankauthor=F.+J.+Bruzzeseauthor=Y.+Caoauthor=J.+S.+Danielsauthor=L.+R.+Dickauthor=J.+Labuttiauthor=A.+M.+Mazzolaauthor=A.+D.+Patilauthor=C.+L.+Reimerauthor=M.+S.+Solomonauthor=M.+Stirlingauthor=Y.+Tianauthor=C.+A.+Tsuauthor=G.+S.+Weatherheadauthor=J.+X.+Zhangauthor=M.+Rolfe&title=Comparison+of+biochemical+and+biological+effects+of+ML858+%28salinosporamide+A%29+and+bortezomib&doi=10.1158%2F1535-7163.MCT-06-0185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib</span></div><div class="casAuthors">Williamson, Mark J.; Blank, Jonathan L.; Bruzzese, Frank J.; Cao, Yueying; Daniels, J. Scott; Dick, Lawrence R.; Labutti, Jason; Mazzola, Anne M.; Patil, Ashok D.; Reimer, Corinne L.; Solomon, Marjorie S.; Stirling, Matthew; Tian, Yuan; Tsu, Christopher A.; Weatherhead, Gabriel S.; Zhang, Julie X.; Rolfe, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3052-3061</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Strains within the genus Salinospora have been shown to produce complex natural products having antibiotic and antiproliferative activities.  The biochem. basis for the cytotoxic effects of salinosporamide A has been linked to its ability to inhibit the proteasome.  Synthetically accessible salinosporamide A (ML858) was used to det. its biochem. and biol. activities and to compare its effects with those of bortezomib.  ML858 and bortezomib show time- and concn.-dependent inhibition of the proteasome in vitro.  However, unlike bortezomib, which is a reversible inhibitor, ML858 covalently binds to the proteasome, resulting in the irreversible inhibition of 20S proteasome activity.  ML858 was equipotent to bortezomib in cell-based reporter stabilization assays, but due to intramol. instability is less potent in long-term assays.  ML858 failed to maintain levels of proteasome inhibition necessary to achieve efficacy in tumor models responsive to bortezomib.  Our results show that ML858 and bortezomib exhibit different kinetic and pharmacol. profiles and suggest that addnl. characterization of ML858 is warranted before its therapeutic potential can be fully appreciated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGfUS2QJCMw7Vg90H21EOLACvtfcHk0lhAA2eTEsN3iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlagsbrN&md5=a8290c05f5e767604e4968dfff5498d8</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0185%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DM.%2BJ.%26aulast%3DBlank%26aufirst%3DJ.%2BL.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DLabutti%26aufirst%3DJ.%26aulast%3DMazzola%26aufirst%3DA.%2BM.%26aulast%3DPatil%26aufirst%3DA.%2BD.%26aulast%3DReimer%26aufirst%3DC.%2BL.%26aulast%3DSolomon%26aufirst%3DM.%2BS.%26aulast%3DStirling%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DTsu%26aufirst%3DC.%2BA.%26aulast%3DWeatherhead%26aufirst%3DG.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%2BX.%26aulast%3DRolfe%26aufirst%3DM.%26atitle%3DComparison%2520of%2520biochemical%2520and%2520biological%2520effects%2520of%2520ML858%2520%2528salinosporamide%2520A%2529%2520and%2520bortezomib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D3052%26epage%3D3061%26doi%3D10.1158%2F1535-7163.MCT-06-0185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjahjadi, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wintjens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malleret, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonamy, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span> <span> </span><span class="NLM_article-title">UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes</span>. <i>Nat. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">16166</span>, <span class="refDoi"> DOI: 10.1038/nmicrobiol.2016.166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fnmicrobiol.2016.166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=27642791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFyrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=16166&author=M.+Y.+Limauthor=G.+LaMonteauthor=M.+C.+Leeauthor=C.+Reimerauthor=B.+H.+Tanauthor=V.+Coreyauthor=B.+F.+Tjahjadiauthor=A.+Chuaauthor=M.+Nachonauthor=R.+Wintjensauthor=P.+Gedeckauthor=B.+Malleretauthor=L.+Reniaauthor=G.+M.+Bonamyauthor=P.+C.+Hoauthor=B.+K.+Yeungauthor=E.+D.+Chowauthor=L.+Limauthor=D.+A.+Fidockauthor=T.+T.+Diaganaauthor=E.+A.+Winzelerauthor=P.+Bifani&title=UDP-galactose+and+acetyl-CoA+transporters+as+Plasmodium+multidrug+resistance+genes&doi=10.1038%2Fnmicrobiol.2016.166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes</span></div><div class="casAuthors">Lim, Michelle Yi-Xiu; La Monte, Gregory; Lee, Marcus C. S.; Reimer, Christin; Tan, Bee Huat; Corey, Victoria; Tjahjadi, Bianca F.; Chua, Adeline; Nachon, Marie; Wintjens, Rene; Gedeck, Peter; Malleret, Benoit; Renia, Laurent; Bonamy, Ghislain M. C.; Ho, Paul Chi-Lui; Yeung, Bryan K. S.; Chow, Eric D.; Lim, Liting; Fidock, David A.; Diagana, Thierry T.; Winzeler, Elizabeth A.; Bifani, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Microbiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">16166</span>CODEN:
                <span class="NLM_cas:coden">NMAICH</span>;
        ISSN:<span class="NLM_cas:issn">2058-5276</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A mol. understanding of drug resistance mechanisms enables surveillance of the effectiveness of new antimicrobial therapies during development and deployment in the field.  We used conventional drug resistance selection as well as a regime of limiting diln. at early stages of drug treatment to probe 2 antimalarial imidazolopiperazines, KAF156 and GNF179.  The latter approach permits the isolation of low-fitness mutants that might otherwise be out-competed during selection.  Whole-genome sequencing of 24 independently derived resistant Plasmodium falciparum clones revealed 4 parasites with mutations in the known cyclic amine resistance locus (pfcarl) and a further 20 with mutations in 2 previously unreported P. falciparum drug resistance genes, an acetyl-CoA transporter (pfact) and a UDP-galactose transporter (pfugt).  Mutations were validated both in vitro by CRISPR editing in P. falciparum and in vivo by evolution of resistant Plasmodium berghei mutants.  Both PfACT and PfUGT were localized to the endoplasmic reticulum by fluorescence microscopy.  As mutations in pfact and pfugt conveyed resistance against addnl. unrelated chem. scaffolds, these genes are probably involved in broad mechanisms of antimalarial drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWucZl9WjFw7Vg90H21EOLACvtfcHk0lhAA2eTEsN3iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFyrtrw%253D&md5=c87d57996e20bb94d7d44c556553daf4</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnmicrobiol.2016.166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmicrobiol.2016.166%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DM.%2BY.%26aulast%3DLaMonte%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DB.%2BH.%26aulast%3DCorey%26aufirst%3DV.%26aulast%3DTjahjadi%26aufirst%3DB.%2BF.%26aulast%3DChua%26aufirst%3DA.%26aulast%3DNachon%26aufirst%3DM.%26aulast%3DWintjens%26aufirst%3DR.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DMalleret%26aufirst%3DB.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DBonamy%26aufirst%3DG.%2BM.%26aulast%3DHo%26aufirst%3DP.%2BC.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DChow%26aufirst%3DE.%2BD.%26aulast%3DLim%26aufirst%3DL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DBifani%26aufirst%3DP.%26atitle%3DUDP-galactose%2520and%2520acetyl-CoA%2520transporters%2520as%2520Plasmodium%2520multidrug%2520resistance%2520genes%26jtitle%3DNat.%2520Microbiol.%26date%3D2016%26volume%3D1%26spage%3D16166%26doi%3D10.1038%2Fnmicrobiol.2016.166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 29 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Melissa R. Rosenthal, <span class="NLM_string-name hlFld-ContribAuthor">Caroline L. Ng</span>. </span><span class="cited-content_cbyCitation_article-title">A Proteasome Mutation Sensitizes P. falciparum Cam3.II K13C580Y Parasites to DHA and OZ439. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2021,</strong> <em>7 </em>
                                    (7)
                                     , 1923-1931. <a href="https://doi.org/10.1021/acsinfecdis.0c00900" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00900</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00900%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DA%252BProteasome%252BMutation%252BSensitizes%252BP.%2525C2%2525A0falciparum%252BCam3.II%252BK13C580Y%252BParasites%252Bto%252BDHA%252Band%252BOZ439%26aulast%3DRosenthal%26aufirst%3DMelissa%2BR.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D22122020%26date%3D10052021%26volume%3D7%26issue%3D7%26spage%3D1923%26epage%3D1931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lydia Mata-Cantero, Stanley C. Xie, Mercedes García, Joanne Coyle, Raquel Fernandez, Alvaro Cortes Cabrera, David L. Gillett, Benigno Crespo, Francisco-Javier Gamo, Esther Fernández, Leann Tilley, <span class="NLM_string-name hlFld-ContribAuthor">Maria G. Gomez-Lorenzo</span>. </span><span class="cited-content_cbyCitation_article-title">High Throughput Screening to Identify Selective and Nonpeptidomimetic Proteasome Inhibitors As Antimalarials. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2021,</strong> <em>7 </em>
                                    (6)
                                     , 1818-1832. <a href="https://doi.org/10.1021/acsinfecdis.1c00110" title="DOI URL">https://doi.org/10.1021/acsinfecdis.1c00110</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.1c00110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.1c00110%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DHigh%252BThroughput%252BScreening%252Bto%252BIdentify%252BSelective%252Band%252BNonpeptidomimetic%252BProteasome%252BInhibitors%252BAs%252BAntimalarials%26aulast%3DMata-Cantero%26aufirst%3DLydia%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D04032021%26date%3D28052021%26volume%3D7%26issue%3D6%26spage%3D1818%26epage%3D1832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tatyana Almeida Tavella, Noeli Soares Melo da Silva, Natalie Spillman, Ana Carolina Andrade Vitor Kayano, Gustavo Capatti Cassiano, Adrielle Ayumi Vasconcelos, Antônio Pedro Camargo, Djane Clarys Baia da Silva, Diana Fontinha, Luis Carlos Salazar Alvarez, Letícia Tiburcio Ferreira, Kaira Cristina Peralis Tomaz, Bruno Junior Neves, Ludimila Dias Almeida, Daniel Youssef Bargieri, Marcus Vinicius Guimarães de Lacerda, Pedro Vitor Lemos Cravo, Per Sunnerhagen, Miguel Prudêncio, Carolina Horta Andrade, Stefanie Costa Pinto Lopes, Marcelo Falsarella Carazzolle, Leann Tilley, Elizabeth Bilsland, Júlio César Borges, <span class="NLM_string-name hlFld-ContribAuthor">Fabio Trindade Maranhão Costa</span>. </span><span class="cited-content_cbyCitation_article-title">Violacein-Induced Chaperone System Collapse Underlies Multistage Antiplasmodial Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2021,</strong> <em>7 </em>
                                    (4)
                                     , 759-776. <a href="https://doi.org/10.1021/acsinfecdis.0c00454" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00454</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00454%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DViolacein-Induced%252BChaperone%252BSystem%252BCollapse%252BUnderlies%252BMultistage%252BAntiplasmodial%252BActivity%26aulast%3DTavella%26aufirst%3DTatyana%2BAlmeida%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D27062020%26date%3D10032021%26volume%3D7%26issue%3D4%26spage%3D759%26epage%3D776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joshua H. Butler, Rodrigo P. Baptista, Ana L. Valenciano, Bin Zhou, Jessica C. Kissinger, Patrick K. Tumwebaze, Philip J. Rosenthal, Roland A. Cooper, Jian-Min Yue, <span class="NLM_string-name hlFld-ContribAuthor">Maria B. Cassera</span>. </span><span class="cited-content_cbyCitation_article-title">Resistance to Some But Not Other Dimeric Lindenane Sesquiterpenoid Esters Is Mediated by Mutations in a Plasmodium falciparum Esterase. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2020,</strong> <em>6 </em>
                                    (11)
                                     , 2994-3003. <a href="https://doi.org/10.1021/acsinfecdis.0c00487" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00487%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DResistance%252Bto%252BSome%252BBut%252BNot%252BOther%252BDimeric%252BLindenane%252BSesquiterpenoid%252BEsters%252BIs%252BMediated%252Bby%252BMutations%252Bin%252Ba%252BPlasmodium%252Bfalciparum%252BEsterase%26aulast%3DButler%26aufirst%3DJoshua%2BH.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09072020%26date%3D07102020%26date%3D24092020%26volume%3D6%26issue%3D11%26spage%3D2994%26epage%3D3003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Melissa R. Rosenthal, <span class="NLM_string-name hlFld-ContribAuthor">Caroline L. Ng</span>. </span><span class="cited-content_cbyCitation_article-title">Plasmodium falciparum Artemisinin Resistance: The Effect of Heme, Protein Damage, and Parasite Cell Stress Response. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2020,</strong> <em>6 </em>
                                    (7)
                                     , 1599-1614. <a href="https://doi.org/10.1021/acsinfecdis.9b00527" title="DOI URL">https://doi.org/10.1021/acsinfecdis.9b00527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.9b00527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.9b00527%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DPlasmodium%252Bfalciparum%252BArtemisinin%252BResistance%25253A%252BThe%252BEffect%252Bof%252BHeme%25252C%252BProtein%252BDamage%25252C%252Band%252BParasite%252BCell%252BStress%252BResponse%26aulast%3DRosenthal%26aufirst%3DMelissa%2BR.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D31122019%26date%3D06052020%26date%3D23042020%26volume%3D6%26issue%3D7%26spage%3D1599%26epage%3D1614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dongyang Fan, Jian Zhang, Yanhua Hu, Zhenfeng Zhang, Ilya D. Gridnev, <span class="NLM_string-name hlFld-ContribAuthor">Wanbin Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric Hydrogenation of α-Boryl Enamides Enabled by Nonbonding Interactions. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2020,</strong> <em>10 </em>
                                    (5)
                                     , 3232-3240. <a href="https://doi.org/10.1021/acscatal.9b04543" title="DOI URL">https://doi.org/10.1021/acscatal.9b04543</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.9b04543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.9b04543%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DAsymmetric%252BHydrogenation%252Bof%252B%2525CE%2525B1-Boryl%252BEnamides%252BEnabled%252Bby%252BNonbonding%252BInteractions%26aulast%3DFan%26aufirst%3DDongyang%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D2020%26date%3D22102019%26date%3D05022020%26date%3D20022020%26date%3D10022020%26volume%3D10%26issue%3D5%26spage%3D3232%26epage%3D3240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lydia Mata-Cantero, María Jesús Chaparro, Gonzalo Colmenarejo, Concepción Cid, Alvaro Cortes Cabrera, Manuel S. Rodriguez, Julio Martín, Francisco Javier Gamo, <span class="NLM_string-name hlFld-ContribAuthor">Maria G. Gomez-Lorenzo</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Small Molecules Disrupting the Ubiquitin Proteasome System in Malaria. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2019,</strong> <em>5 </em>
                                    (12)
                                     , 2105-2117. <a href="https://doi.org/10.1021/acsinfecdis.9b00216" title="DOI URL">https://doi.org/10.1021/acsinfecdis.9b00216</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.9b00216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.9b00216%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DIdentification%252Bof%252BSmall%252BMolecules%252BDisrupting%252Bthe%252BUbiquitin%252BProteasome%252BSystem%252Bin%252BMalaria%26aulast%3DMata-Cantero%26aufirst%3DLydia%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D11062019%26date%3D07112019%26date%3D23102019%26volume%3D5%26issue%3D12%26spage%3D2105%26epage%3D2117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Betsaida Bibo-Verdugo, Steven C Wang, Jehad Almaliti, Anh P. Ta, Zhenze Jiang, Derek A. Wong, Christopher B. Lietz, Brian M. Suzuki, Nelly El-Sakkary, Vivian Hook, Guy S. Salvesen, William H. Gerwick, Conor R. Caffrey, <span class="NLM_string-name hlFld-ContribAuthor">Anthony J. O’Donoghue</span>. </span><span class="cited-content_cbyCitation_article-title">The Proteasome as a Drug Target in the Metazoan Pathogen, Schistosoma mansoni. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2019,</strong> <em>5 </em>
                                    (10)
                                     , 1802-1812. <a href="https://doi.org/10.1021/acsinfecdis.9b00237" title="DOI URL">https://doi.org/10.1021/acsinfecdis.9b00237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.9b00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.9b00237%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DThe%252BProteasome%252Bas%252Ba%252BDrug%252BTarget%252Bin%252Bthe%252BMetazoan%252BPathogen%25252C%252BSchistosoma%252Bmansoni%26aulast%3DBibo-Verdugo%26aufirst%3DBetsaida%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D28062019%26date%3D12082019%26date%3D29072019%26volume%3D5%26issue%3D10%26spage%3D1802%26epage%3D1812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wenhu Zhan, Joseph Visone, Tierra Ouellette, Jacob C. Harris, Rong Wang, Hao Zhang, Pradeep K. Singh, John Ginn, George Sukenick, Tzu-Tshin Wong, Judith I. Okoro, Ryan M. Scales, Patrick K. Tumwebaze, Philip J. Rosenthal, Björn F. C. Kafsack, Roland A. Cooper, Peter T. Meinke, Laura A. Kirkman, <span class="NLM_string-name hlFld-ContribAuthor">Gang Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 6137-6145. <a href="https://doi.org/10.1021/acs.jmedchem.9b00363" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00363</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00363%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DImprovement%252Bof%252BAsparagine%252BEthylenediamines%252Bas%252BAnti-malarial%252BPlasmodium-Selective%252BProteasome%252BInhibitors%26aulast%3DZhan%26aufirst%3DWenhu%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26022019%26date%3D20062019%26date%3D09062019%26volume%3D62%26issue%3D13%26spage%3D6137%26epage%3D6145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hannah Michaela  Behrens</span>, <span class="hlFld-ContribAuthor ">Sabine  Schmidt</span>, <span class="hlFld-ContribAuthor ">Tobias  Spielmann</span>. </span><span class="cited-content_cbyCitation_article-title">The newly discovered role of endocytosis in artemisinin resistance. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2021,</strong> <em>17 </em><a href="https://doi.org/10.1002/med.21848" title="DOI URL">https://doi.org/10.1002/med.21848</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21848%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DThe%252Bnewly%252Bdiscovered%252Brole%252Bof%252Bendocytosis%252Bin%252Bartemisinin%252Bresistance%26aulast%3DBehrens%26aufirst%3DHannah%2BMichaela%26date%3D2021%26date%3D2021%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel  Sojka</span>, <span class="hlFld-ContribAuthor ">Pavla  Šnebergerová</span>, <span class="hlFld-ContribAuthor ">Luïse  Robbertse</span>. </span><span class="cited-content_cbyCitation_article-title">Protease Inhibition—An Established Strategy to Combat Infectious Diseases. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (11)
                                     , 5762. <a href="https://doi.org/10.3390/ijms22115762" title="DOI URL">https://doi.org/10.3390/ijms22115762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22115762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22115762%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DProtease%252BInhibition%2525E2%252580%252594An%252BEstablished%252BStrategy%252Bto%252BCombat%252BInfectious%252BDiseases%26aulast%3DSojka%26aufirst%3DDaniel%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D11%26spage%3D5762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Conor R.  Caffrey</span>, <span class="hlFld-ContribAuthor ">Dietmar  Steverding</span>, <span class="hlFld-ContribAuthor ">Rafaela S.  Ferreira</span>, <span class="hlFld-ContribAuthor ">Renata B.  Oliveira</span>, <span class="hlFld-ContribAuthor ">Anthony J.  O'Donoghue</span>, <span class="hlFld-ContribAuthor ">Ludovica  Monti</span>, <span class="hlFld-ContribAuthor ">Carlo  Ballatore</span>, <span class="hlFld-ContribAuthor ">Kelly A.  Bachovchin</span>, <span class="hlFld-ContribAuthor ">Lori  Ferrins</span>, <span class="hlFld-ContribAuthor ">Michael P.  Pollastri</span>, <span class="hlFld-ContribAuthor ">Kimberley M.  Zorn</span>, <span class="hlFld-ContribAuthor ">Daniel H.  Foil</span>, <span class="hlFld-ContribAuthor ">Alex M.  Clark</span>, <span class="hlFld-ContribAuthor ">Melina  Mottin</span>, <span class="hlFld-ContribAuthor ">Carolina H.  Andrade</span>, <span class="hlFld-ContribAuthor ">Jair L.  Siqueira‐Neto</span>, <span class="hlFld-ContribAuthor ">Sean  Ekins</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery and Development for Kinetoplastid Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-79. <a href="https://doi.org/10.1002/0471266949.bmc235.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc235.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc235.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc235.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DDrug%252BDiscovery%252Band%252BDevelopment%252Bfor%252BKinetoplastid%252BDiseases%26aulast%3DCaffrey%26aufirst%3DConor%2BR.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D79%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anu  Saini</span>, <span class="hlFld-ContribAuthor ">Sumit  Kumar</span>, <span class="hlFld-ContribAuthor ">Raghu  Raj</span>, <span class="hlFld-ContribAuthor ">Shefali  Chowdhary</span>, <span class="hlFld-ContribAuthor ">Mathieu  Gendrot</span>, <span class="hlFld-ContribAuthor ">Joel  Mosnier</span>, <span class="hlFld-ContribAuthor ">Isabelle  Fonta</span>, <span class="hlFld-ContribAuthor ">Bruno  Pradines</span>, <span class="hlFld-ContribAuthor ">Vipan  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antiplasmodial evaluation of 1H-1,2,3-triazole grafted 4-aminoquinoline-benzoxaborole hybrids and benzoxaborole analogues. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>109 </em>, 104733. <a href="https://doi.org/10.1016/j.bioorg.2021.104733" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104733</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104733%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Band%252Bantiplasmodial%252Bevaluation%252Bof%252B1H-1%25252C2%25252C3-triazole%252Bgrafted%252B4-aminoquinoline-benzoxaborole%252Bhybrids%252Band%252Bbenzoxaborole%252Banalogues%26aulast%3DSaini%26aufirst%3DAnu%26date%3D2021%26volume%3D109%26spage%3D104733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John  Okombo</span>, <span class="hlFld-ContribAuthor ">Mariko  Kanai</span>, <span class="hlFld-ContribAuthor ">Ioanna  Deni</span>, <span class="hlFld-ContribAuthor ">David A.  Fidock</span>. </span><span class="cited-content_cbyCitation_article-title">Genomic and Genetic Approaches to Studying Antimalarial Drug Resistance and Plasmodium Biology. </span><span class="cited-content_cbyCitation_journal-name">Trends in Parasitology</span><span> <strong>2021,</strong> <em>167 </em><a href="https://doi.org/10.1016/j.pt.2021.02.007" title="DOI URL">https://doi.org/10.1016/j.pt.2021.02.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pt.2021.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pt.2021.02.007%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Parasitology%26atitle%3DGenomic%252Band%252BGenetic%252BApproaches%252Bto%252BStudying%252BAntimalarial%252BDrug%252BResistance%252Band%252BPlasmodium%252BBiology%26aulast%3DOkombo%26aufirst%3DJohn%26date%3D2021%26volume%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tuo  Yang</span>, <span class="hlFld-ContribAuthor ">Sabine  Ottilie</span>, <span class="hlFld-ContribAuthor ">Eva S.  Istvan</span>, <span class="hlFld-ContribAuthor ">Karla P.  Godinez-Macias</span>, <span class="hlFld-ContribAuthor ">Amanda K.  Lukens</span>, <span class="hlFld-ContribAuthor ">Beatriz  Baragaña</span>, <span class="hlFld-ContribAuthor ">Brice  Campo</span>, <span class="hlFld-ContribAuthor ">Chris  Walpole</span>, <span class="hlFld-ContribAuthor ">Jacquin C.  Niles</span>, <span class="hlFld-ContribAuthor ">Kelly  Chibale</span>, <span class="hlFld-ContribAuthor ">Koen J.  Dechering</span>, <span class="hlFld-ContribAuthor ">Manuel  Llinás</span>, <span class="hlFld-ContribAuthor ">Marcus C.S.  Lee</span>, <span class="hlFld-ContribAuthor ">Nobutaka  Kato</span>, <span class="hlFld-ContribAuthor ">Susan  Wyllie</span>, <span class="hlFld-ContribAuthor ">Case W.  McNamara</span>, <span class="hlFld-ContribAuthor ">Francisco Javier  Gamo</span>, <span class="hlFld-ContribAuthor ">Jeremy  Burrows</span>, <span class="hlFld-ContribAuthor ">David A.  Fidock</span>, <span class="hlFld-ContribAuthor ">Daniel E.  Goldberg</span>, <span class="hlFld-ContribAuthor ">Ian H.  Gilbert</span>, <span class="hlFld-ContribAuthor ">Dyann F.  Wirth</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Winzeler</span>. </span><span class="cited-content_cbyCitation_article-title">MalDA, Accelerating Malaria Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Trends in Parasitology</span><span> <strong>2021,</strong> <em>10 </em><a href="https://doi.org/10.1016/j.pt.2021.01.009" title="DOI URL">https://doi.org/10.1016/j.pt.2021.01.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pt.2021.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pt.2021.01.009%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Parasitology%26atitle%3DMalDA%25252C%252BAccelerating%252BMalaria%252BDrug%252BDiscovery%26aulast%3DYang%26aufirst%3DTuo%26date%3D2021%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shu  Song</span>, <span class="hlFld-ContribAuthor ">Ping  Gao</span>, <span class="hlFld-ContribAuthor ">Lin  Sun</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments in the medicinal chemistry of single boron atom-containing compounds. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>73 </em><a href="https://doi.org/10.1016/j.apsb.2021.01.010" title="DOI URL">https://doi.org/10.1016/j.apsb.2021.01.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2021.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2021.01.010%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DRecent%252Bdevelopments%252Bin%252Bthe%252Bmedicinal%252Bchemistry%252Bof%252Bsingle%252Bboron%252Batom-containing%252Bcompounds%26aulast%3DSong%26aufirst%3DShu%26date%3D2021%26volume%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Krypton  Carolino</span>, <span class="hlFld-ContribAuthor ">Elizabeth A  Winzeler</span>. </span><span class="cited-content_cbyCitation_article-title">The antimalarial resistome – finding new drug targets and their modes of action. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Microbiology</span><span> <strong>2020,</strong> <em>57 </em>, 49-55. <a href="https://doi.org/10.1016/j.mib.2020.06.004" title="DOI URL">https://doi.org/10.1016/j.mib.2020.06.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mib.2020.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mib.2020.06.004%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Microbiology%26atitle%3DThe%252Bantimalarial%252Bresistome%252B%2525E2%252580%252593%252Bfinding%252Bnew%252Bdrug%252Btargets%252Band%252Btheir%252Bmodes%252Bof%252Baction%26aulast%3DCarolino%26aufirst%3DKrypton%26date%3D2020%26volume%3D57%26spage%3D49%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Swagata  Ghosh</span>, <span class="hlFld-ContribAuthor ">Laura  Farr</span>, <span class="hlFld-ContribAuthor ">Aditya  Singh</span>, <span class="hlFld-ContribAuthor ">Laura-Ann  Leaton</span>, <span class="hlFld-ContribAuthor ">Jay  Padalia</span>, <span class="hlFld-ContribAuthor ">Debbie-Ann  Shirley</span>, <span class="hlFld-ContribAuthor ">David  Sullivan</span>, <span class="hlFld-ContribAuthor ">Shannon  Moonah</span>, . </span><span class="cited-content_cbyCitation_article-title">COP9 signalosome is an essential and druggable parasite target that regulates protein degradation. </span><span class="cited-content_cbyCitation_journal-name">PLOS Pathogens</span><span> <strong>2020,</strong> <em>16 </em>
                                    (9)
                                     , e1008952. <a href="https://doi.org/10.1371/journal.ppat.1008952" title="DOI URL">https://doi.org/10.1371/journal.ppat.1008952</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.ppat.1008952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.ppat.1008952%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520Pathogens%26atitle%3DCOP9%252Bsignalosome%252Bis%252Ban%252Bessential%252Band%252Bdruggable%252Bparasite%252Btarget%252Bthat%252Bregulates%252Bprotein%252Bdegradation%26aulast%3DGhosh%26aufirst%3DSwagata%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D9%26spage%3De1008952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Judith L.  Green</span>, <span class="hlFld-ContribAuthor ">Yang  Wu</span>, <span class="hlFld-ContribAuthor ">Vesela  Encheva</span>, <span class="hlFld-ContribAuthor ">Edwin  Lasonder</span>, <span class="hlFld-ContribAuthor ">Adchara  Prommaban</span>, <span class="hlFld-ContribAuthor ">Simone  Kunzelmann</span>, <span class="hlFld-ContribAuthor ">Evangelos  Christodoulou</span>, <span class="hlFld-ContribAuthor ">Munira  Grainger</span>, <span class="hlFld-ContribAuthor ">Ngoc  Truongvan</span>, <span class="hlFld-ContribAuthor ">Sebastian  Bothe</span>, <span class="hlFld-ContribAuthor ">Vikram  Sharma</span>, <span class="hlFld-ContribAuthor ">Wei  Song</span>, <span class="hlFld-ContribAuthor ">Irene  Pinzuti</span>, <span class="hlFld-ContribAuthor ">Chairat  Uthaipibull</span>, <span class="hlFld-ContribAuthor ">Somdet  Srichairatanakool</span>, <span class="hlFld-ContribAuthor ">Veronique  Birault</span>, <span class="hlFld-ContribAuthor ">Gordon  Langsley</span>, <span class="hlFld-ContribAuthor ">Hermann  Schindelin</span>, <span class="hlFld-ContribAuthor ">Benjamin  Stieglitz</span>, <span class="hlFld-ContribAuthor ">Ambrosius P.  Snijders</span>, <span class="hlFld-ContribAuthor ">Anthony A.  Holder</span>, . </span><span class="cited-content_cbyCitation_article-title">Ubiquitin activation is essential for schizont maturation in Plasmodium falciparum blood-stage development. </span><span class="cited-content_cbyCitation_journal-name">PLOS Pathogens</span><span> <strong>2020,</strong> <em>16 </em>
                                    (6)
                                     , e1008640. <a href="https://doi.org/10.1371/journal.ppat.1008640" title="DOI URL">https://doi.org/10.1371/journal.ppat.1008640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.ppat.1008640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.ppat.1008640%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520Pathogens%26atitle%3DUbiquitin%252Bactivation%252Bis%252Bessential%252Bfor%252Bschizont%252Bmaturation%252Bin%252BPlasmodium%252Bfalciparum%252Bblood-stage%252Bdevelopment%26aulast%3DGreen%26aufirst%3DJudith%2BL.%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D6%26spage%3De1008640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hanh H. T.  Nguyen</span>, <span class="hlFld-ContribAuthor ">Lee M.  Yeoh</span>, <span class="hlFld-ContribAuthor ">Scott A.  Chisholm</span>, <span class="hlFld-ContribAuthor ">Michael F.  Duffy</span>. </span><span class="cited-content_cbyCitation_article-title">Developments in drug design strategies for bromodomain protein inhibitors to target
              Plasmodium falciparum
              parasites. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2020,</strong> <em>15 </em>
                                    (4)
                                     , 415-425. <a href="https://doi.org/10.1080/17460441.2020.1704251" title="DOI URL">https://doi.org/10.1080/17460441.2020.1704251</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2020.1704251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2020.1704251%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DDevelopments%252Bin%252Bdrug%252Bdesign%252Bstrategies%252Bfor%252Bbromodomain%252Bprotein%252Binhibitors%252Bto%252Btarget%252BPlasmodium%252Bfalciparum%252Bparasites%26aulast%3DNguyen%26aufirst%3DHanh%2BH.%2BT.%26date%3D2020%26date%3D2019%26volume%3D15%26issue%3D4%26spage%3D415%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">María  Álvarez-Bardón</span>, <span class="hlFld-ContribAuthor ">Yolanda  Pérez-Pertejo</span>, <span class="hlFld-ContribAuthor ">César  Ordóñez</span>, <span class="hlFld-ContribAuthor ">Daniel  Sepúlveda-Crespo</span>, <span class="hlFld-ContribAuthor ">Nestor M.  Carballeira</span>, <span class="hlFld-ContribAuthor ">Babu L.  Tekwani</span>, <span class="hlFld-ContribAuthor ">Sankaranarayanan  Murugesan</span>, <span class="hlFld-ContribAuthor ">Maria  Martinez-Valladares</span>, <span class="hlFld-ContribAuthor ">Carlos  García-Estrada</span>, <span class="hlFld-ContribAuthor ">Rosa M.  Reguera</span>, <span class="hlFld-ContribAuthor ">Rafael  Balaña-Fouce</span>. </span><span class="cited-content_cbyCitation_article-title">Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria. </span><span class="cited-content_cbyCitation_journal-name">Marine Drugs</span><span> <strong>2020,</strong> <em>18 </em>
                                    (4)
                                     , 187. <a href="https://doi.org/10.3390/md18040187" title="DOI URL">https://doi.org/10.3390/md18040187</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/md18040187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmd18040187%26sid%3Dliteratum%253Aachs%26jtitle%3DMarine%2520Drugs%26atitle%3DScreening%252BMarine%252BNatural%252BProducts%252Bfor%252BNew%252BDrug%252BLeads%252Bagainst%252BTrypanosomatids%252Band%252BMalaria%26aulast%3D%25C3%2581lvarez-Bard%25C3%25B3n%26aufirst%3DMar%25C3%25ADa%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D4%26spage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Graham L.  Patrick</span>. </span><span class="cited-content_cbyCitation_article-title">The Plasmodium falciparum proteasome as a drug target. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 403-432. <a href="https://doi.org/10.1016/B978-0-08-101210-9.00011-1" title="DOI URL">https://doi.org/10.1016/B978-0-08-101210-9.00011-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-101210-9.00011-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-101210-9.00011-1%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BPlasmodium%252Bfalciparum%252Bproteasome%252Bas%252Ba%252Bdrug%252Btarget%26aulast%3DPatrick%26aufirst%3DGraham%2BL.%26date%3D2020%26spage%3D403%26epage%3D432%26pub%3DElsevier%26atitle%3DAntimalarial%252BAgents%26date%3D2020%26volume%3D284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Annie N.  Cowell</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Winzeler</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in omics-based methods to identify novel targets for malaria and other parasitic protozoan infections. </span><span class="cited-content_cbyCitation_journal-name">Genome Medicine</span><span> <strong>2019,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13073-019-0673-3" title="DOI URL">https://doi.org/10.1186/s13073-019-0673-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13073-019-0673-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13073-019-0673-3%26sid%3Dliteratum%253Aachs%26jtitle%3DGenome%2520Medicine%26atitle%3DAdvances%252Bin%252Bomics-based%252Bmethods%252Bto%252Bidentify%252Bnovel%252Btargets%252Bfor%252Bmalaria%252Band%252Bother%252Bparasitic%252Bprotozoan%252Binfections%26aulast%3DCowell%26aufirst%3DAnnie%2BN.%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stanley C.  Xie</span>, <span class="hlFld-ContribAuthor ">Lawrence R.  Dick</span>, <span class="hlFld-ContribAuthor ">Alexandra  Gould</span>, <span class="hlFld-ContribAuthor ">Stephen  Brand</span>, <span class="hlFld-ContribAuthor ">Leann  Tilley</span>. </span><span class="cited-content_cbyCitation_article-title">The proteasome as a target for protozoan parasites. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Targets</span><span> <strong>2019,</strong> <em>23 </em>
                                    (11)
                                     , 903-914. <a href="https://doi.org/10.1080/14728222.2019.1685981" title="DOI URL">https://doi.org/10.1080/14728222.2019.1685981</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14728222.2019.1685981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14728222.2019.1685981%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Targets%26atitle%3DThe%252Bproteasome%252Bas%252Ba%252Btarget%252Bfor%252Bprotozoan%252Bparasites%26aulast%3DXie%26aufirst%3DStanley%2BC.%26date%3D2019%26date%3D2019%26volume%3D23%26issue%3D11%26spage%3D903%26epage%3D914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stanley C.  Xie</span>, <span class="hlFld-ContribAuthor ">Riley D.  Metcalfe</span>, <span class="hlFld-ContribAuthor ">Eric  Hanssen</span>, <span class="hlFld-ContribAuthor ">Tuo  Yang</span>, <span class="hlFld-ContribAuthor ">David L.  Gillett</span>, <span class="hlFld-ContribAuthor ">Andrew P.  Leis</span>, <span class="hlFld-ContribAuthor ">Craig J.  Morton</span>, <span class="hlFld-ContribAuthor ">Michael J.  Kuiper</span>, <span class="hlFld-ContribAuthor ">Michael W.  Parker</span>, <span class="hlFld-ContribAuthor ">Natalie J.  Spillman</span>, <span class="hlFld-ContribAuthor ">Wilson  Wong</span>, <span class="hlFld-ContribAuthor ">Christopher  Tsu</span>, <span class="hlFld-ContribAuthor ">Lawrence R.  Dick</span>, <span class="hlFld-ContribAuthor ">Michael D. W.  Griffin</span>, <span class="hlFld-ContribAuthor ">Leann  Tilley</span>. </span><span class="cited-content_cbyCitation_article-title">The structure of the PA28–20S proteasome complex from Plasmodium falciparum and implications for proteostasis. </span><span class="cited-content_cbyCitation_journal-name">Nature Microbiology</span><span> <strong>2019,</strong> <em>4 </em>
                                    (11)
                                     , 1990-2000. <a href="https://doi.org/10.1038/s41564-019-0524-4" title="DOI URL">https://doi.org/10.1038/s41564-019-0524-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41564-019-0524-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41564-019-0524-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Microbiology%26atitle%3DThe%252Bstructure%252Bof%252Bthe%252BPA28%2525E2%252580%25259320S%252Bproteasome%252Bcomplex%252Bfrom%252BPlasmodium%252Bfalciparum%252Band%252Bimplications%252Bfor%252Bproteostasis%26aulast%3DXie%26aufirst%3DStanley%2BC.%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D11%26spage%3D1990%26epage%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony J.  O’Donoghue</span>, <span class="hlFld-ContribAuthor ">Betsaida  Bibo-Verdugo</span>, <span class="hlFld-ContribAuthor ">Yukiko  Miyamoto</span>, <span class="hlFld-ContribAuthor ">Steven C  Wang</span>, <span class="hlFld-ContribAuthor ">Justin Z.  Yang</span>, <span class="hlFld-ContribAuthor ">Douglas E.  Zuill</span>, <span class="hlFld-ContribAuthor ">Shoun  Matsuka</span>, <span class="hlFld-ContribAuthor ">Zhenze  Jiang</span>, <span class="hlFld-ContribAuthor ">Jehad  Almaliti</span>, <span class="hlFld-ContribAuthor ">Conor R.  Caffrey</span>, <span class="hlFld-ContribAuthor ">William H.  Gerwick</span>, <span class="hlFld-ContribAuthor ">Lars  Eckmann</span>. </span><span class="cited-content_cbyCitation_article-title">20S Proteasome as a Drug Target in Trichomonas vaginalis. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2019,</strong> <em>63 </em>
                                    (11)
                                     <a href="https://doi.org/10.1128/AAC.00448-19" title="DOI URL">https://doi.org/10.1128/AAC.00448-19</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/AAC.00448-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FAAC.00448-19%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3D20S%252BProteasome%252Bas%252Ba%252BDrug%252BTarget%252Bin%252BTrichomonas%252Bvaginalis%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DAnthony%2BJ.%26date%3D2019%26volume%3D63%26issue%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara H.  Stokes</span>, <span class="hlFld-ContribAuthor ">Euna  Yoo</span>, <span class="hlFld-ContribAuthor ">James M.  Murithi</span>, <span class="hlFld-ContribAuthor ">Madeline R.  Luth</span>, <span class="hlFld-ContribAuthor ">Pavel  Afanasyev</span>, <span class="hlFld-ContribAuthor ">Paula C. A.  da Fonseca</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Winzeler</span>, <span class="hlFld-ContribAuthor ">Caroline L.  Ng</span>, <span class="hlFld-ContribAuthor ">Matthew  Bogyo</span>, <span class="hlFld-ContribAuthor ">David A.  Fidock</span>, . </span><span class="cited-content_cbyCitation_article-title">Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. </span><span class="cited-content_cbyCitation_journal-name">PLOS Pathogens</span><span> <strong>2019,</strong> <em>15 </em>
                                    (6)
                                     , e1007722. <a href="https://doi.org/10.1371/journal.ppat.1007722" title="DOI URL">https://doi.org/10.1371/journal.ppat.1007722</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.ppat.1007722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.ppat.1007722%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520Pathogens%26atitle%3DCovalent%252BPlasmodium%252Bfalciparum-selective%252Bproteasome%252Binhibitors%252Bexhibit%252Ba%252Blow%252Bpropensity%252Bfor%252Bgenerating%252Bresistance%252Bin%252Bvitro%252Band%252Bsynergize%252Bwith%252Bmultiple%252Bantimalarial%252Bagents%26aulast%3DStokes%26aufirst%3DBarbara%2BH.%26date%3D2019%26date%3D2019%26volume%3D15%26issue%3D6%26spage%3De1007722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elizabeth A.  Winzeler</span>, <span class="hlFld-ContribAuthor ">Sabine  Ottilie</span>. </span><span class="cited-content_cbyCitation_article-title">The proteasome as a target: How not tidying up can have toxic consequences for parasitic protozoa. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2019,</strong> <em>116 </em>
                                    (21)
                                     , 10198-10200. <a href="https://doi.org/10.1073/pnas.1904694116" title="DOI URL">https://doi.org/10.1073/pnas.1904694116</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.1904694116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.1904694116%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DThe%252Bproteasome%252Bas%252Ba%252Btarget%25253A%252BHow%252Bnot%252Btidying%252Bup%252Bcan%252Bhave%252Btoxic%252Bconsequences%252Bfor%252Bparasitic%252Bprotozoa%26aulast%3DWinzeler%26aufirst%3DElizabeth%2BA.%26date%3D2019%26date%3D2019%26volume%3D116%26issue%3D21%26spage%3D10198%26epage%3D10200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arduino  Mangoni</span>, <span class="hlFld-ContribAuthor ">Catherine  Guillou</span>, <span class="hlFld-ContribAuthor ">Jean  Vanden Eynde</span>, <span class="hlFld-ContribAuthor ">Christopher  Hulme</span>, <span class="hlFld-ContribAuthor ">Josef  Jampilek</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Katalin  Prokai-Tatrai</span>, <span class="hlFld-ContribAuthor ">Jarkko  Rautio</span>, <span class="hlFld-ContribAuthor ">Simona  Collina</span>, <span class="hlFld-ContribAuthor ">Tiziano  Tuccinardi</span>, <span class="hlFld-ContribAuthor ">Maria  Sousa</span>, <span class="hlFld-ContribAuthor ">Jean-Marc  Sabatier</span>, <span class="hlFld-ContribAuthor ">Stefania  Galdiero</span>, <span class="hlFld-ContribAuthor ">Rafik  Karaman</span>, <span class="hlFld-ContribAuthor ">George  Kokotos</span>, <span class="hlFld-ContribAuthor ">Giangiacomo  Torri</span>, <span class="hlFld-ContribAuthor ">F.  Luque</span>, <span class="hlFld-ContribAuthor ">M.  Vasconcelos</span>, <span class="hlFld-ContribAuthor ">Dimitra  Hadjipavlou-Litina</span>, <span class="hlFld-ContribAuthor ">Carlo  Siciliano</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>, <span class="hlFld-ContribAuthor ">Rino  Ragno</span>, <span class="hlFld-ContribAuthor ">Paula  Gomes</span>, <span class="hlFld-ContribAuthor ">Luigi  Agrofoglio</span>, <span class="hlFld-ContribAuthor ">Diego  Muñoz-Torrero</span>. </span><span class="cited-content_cbyCitation_article-title">Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–4. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (1)
                                     , 130. <a href="https://doi.org/10.3390/molecules24010130" title="DOI URL">https://doi.org/10.3390/molecules24010130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24010130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24010130%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBreakthroughs%252Bin%252BMedicinal%252BChemistry%25253A%252BNew%252BTargets%252Band%252BMechanisms%25252C%252BNew%252BDrugs%25252C%252BNew%252BHopes%2525E2%252580%2525934%26aulast%3DMangoni%26aufirst%3DArduino%26date%3D2019%26date%3D2018%26volume%3D24%26issue%3D1%26spage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/medium/jm-2018-01161a_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01161&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/medium/jm-2018-01161a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of MPI Pinane Esters<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01161&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc-<span class="smallcaps smallerCapital">l</span>-alanine, T3P, Et<sub>3</sub>N, DCM, room temperature, 73%; (b) 4 M HCl in dioxane, Et<sub>2</sub>O, DCM, room temperature, 93%; (c) (<i>R</i>)-(+)-<i>N</i>-acetylproline, T3P, Et<sub>3</sub>N, DCM, room temperature, 38%.</p></p></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/medium/jm-2018-01161a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures, proteasome inhibition, and isobologram analysis of selected compounds. (A) Structures of MPI-1, MPI-2, MPI-3, and MPI-4 (compounds <b>1</b>–<b>4</b>). (B) GFP-DD transfectants were maintained in Shield-1 for 24 h before wash-out prior to setting up experiments. Trophozoites were re-exposed to Shield-1 or exposed to indicated compounds for 3 h. Results are representative of four independent experiments. (i) Cell extracts were analyzed by Western blot using anti-GFP or anti-<i>Pf</i>BiP as a loading control. (ii) GFP fluorescence measured by flow cytometry. Dotted line represents background (fluorescence of sample after washout of Shield-1). Data are the mean ± range/2 for the readings in technical duplicate from one experiment. Curves are fitted with the sigmoidal four-parameter model. (C) Isobologram analysis of the interaction of test compounds and DHA. Cam3.II (DHA resistant) parasites at very early ring stages were subjected to 3 h pulses in the presence of different combinations of DHA and test compounds. The left side of each panel presents the isobolograms for the test compound–DHA pair at the 50% LD<sub>50</sub>(3 h) level. The right side of each panel shows the influence of sublethal concentrations of the test compounds (indicated in figure) on the dose–response profile of DHA. Data shown are representative of three independent experiments. Error bars, where present, correspond to the range of technical duplicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01161&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/medium/jm-2018-01161a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Sequence analysis of bortezomib-resistant parasites. (A) Comparison of sequences of β5 subunits of human and <i>Pf</i>20S. Residue positions are calculated at the start of the processed protein, and the first residue (Thr 1) is shown in red and underlined. Mutations that have been selected in human and <i>P. falciparum</i> cell lines are highlighted in yellow and green, respectively. (B) Molecular model of β5 subunit of <i>Pf</i>20S (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fmg">5fmg</a>) illustrating the Met45 and Leu53 residues that are mutated upon selection for resistance to bortezomib. (C) Mutations are located close to the anticipated bortezomib-binding pocket. Met45 and Leu53 residues are colored in gray. Residues shown in bold and underlined in (A) or marked with asterisks (T1, G47, A49, and A50) in (C) are identical in the yeast and human proteasome β5 subunit and/or have been shown to form direct hydrogen bonding interactions with bortezomib.<a onclick="showRef(event, 'ref22 ref33'); return false;" href="javascript:void(0);" class="ref ref22 ref33">(22,33)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01161&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/medium/jm-2018-01161a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Active site probe analysis of the proteasome subunit specificity of the selected compounds in 3D7 parent and bortezomib-resistant parasites. Purified <i>Pf</i>20S proteasome from wild-type 3D7 (A) and bortezomib-resistant (C) parasites or wild-type 3D7 (B) and bortezomib-resistant (D) trophozoite-infected erythrocytes were treated with compounds for 1 h, and activity-based probe (BMV037) labeling was performed (postlysis for the trophozoite samples). Fluorescent gel scans reveal subunits that remain active after treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01161&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/medium/jm-2018-01161a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>Pf</i>20S and human 20S constitutive (c20S) proteasome substrate profiling and validation of active and selective substrates for <i>P. falciparum</i> proteasome. Human and <i>P. falciparum</i> proteasome activity was measured using a library of AMC-based tripeptide substrates to determine cleavage preferences for each P position. Substrate specificity at P1, P2, and P3 positions was examined for <i>Pf</i>20S (A) and human constitutive (B) proteasomes. The <i>Y</i>-axis shows the average cleavage rate. Correlation between substrate sequence at each position and average cleavage activity by the proteasome is displayed. Cleavage rate for each substrate is normalized to Ac-WLR-AMC activity (×1000). B indicates either aspartic acid or asparagine. O is pyrrolysine. (C) Selectivity for <i>Pf</i>20S proteasome compared with human constitutive proteasome. The ratio of <i>Pf</i>20S to human constitutive proteasome cleavage activity is plotted based on the residues at P1, P2, and P3 positions. (D) Validation of selected substrates with <i>Pf</i>20S and human constitutive proteasomes. The cleavage rate for each substrate is normalized to Ac-WLR-AMC activity (×1000). Data shown are the mean ± SEM from three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01161/20181119/images/large/jm-2018-01161a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01161&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i38">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68061" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68061" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 50 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <i>World
Malaria Report 2017</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva, Switzerland</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+World%0AMalaria+Report+2017%3B+World+Health+Organization%3A+Geneva%2C+Switzerland%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DWorld%250AMalaria%2520Report%25202017%26pub%3DWorld%2520Health%2520Organization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lwin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanpithakpong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringwald, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silamut, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imwong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhasivanon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindegardh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Socheat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Artemisinin resistance in <i>Plasmodium falciparum</i> malaria</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0808859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1056%2FNEJMoa0808859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=19641202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1CrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=455-467&author=A.+M.+Dondorpauthor=F.+Nostenauthor=P.+Yiauthor=D.+Dasauthor=A.+P.+Phyoauthor=J.+Tarningauthor=K.+M.+Lwinauthor=F.+Arieyauthor=W.+Hanpithakpongauthor=S.+J.+Leeauthor=P.+Ringwaldauthor=K.+Silamutauthor=M.+Imwongauthor=K.+Chotivanichauthor=P.+Limauthor=T.+Herdmanauthor=S.+S.+Anauthor=S.+Yeungauthor=P.+Singhasivanonauthor=N.+P.+Dayauthor=N.+Lindegardhauthor=D.+Socheatauthor=N.+J.+White&title=Artemisinin+resistance+in+Plasmodium+falciparum+malaria&doi=10.1056%2FNEJMoa0808859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin resistance in Plasmodium falciparum malaria</span></div><div class="casAuthors">Dondorp, Arjen M.; Nosten, Francois; Yi, Poravuth; Das, Debashish; Phyo, Aung Phae; Tarning, Joel; Lwin, Khin Maung; Ariey, Frederic; Hanpithakpong, Warunee; Lee, Sue J.; Ringwald, Pascal; Silamut, Kamolrat; Imwong, Mallika; Chotivanich, Kesinee; Lim, Pharath; Herdman, Trent; Sam An, Sen; Yeung, Shunmay; Singhasivanon, Pratap; Day, Nicholas P. J.; Lindegardh, Niklas; Socheat, Duong; White, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-467</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Artemisinin-based combination therapies are the recommended first-line treatments of falciparum malaria in all countries with endemic disease.  There are recent concerns that the efficacy of such therapies has declined on the Thai-Cambodian border, historically a site of emerging antimalarial-drug resistance.  METHODS: In two open-label, randomized trials, we compared the efficacies of two treatments for uncomplicated falciparum malaria in Pailin, western Cambodia, and Wang Pha, northwestern Thailand: oral artesunate given at a dose of 2 mg per kg of body wt. per day, for 7 days, and artesunate given at a dose of 4 mg per kg per day, for 3 days, followed by mefloqine at two doses totaling 25 mg per kg.  We assessed in vitro and in vivo Plasmodium-falciparum susceptibility, artesunate pharmacokinetics, and mol. markers of resistance.  RESULTS: We studied 40 patients in each of the two locations.  The overall median parasite clearance times were 84 h (interquartile range, 60 to 96) in Pailin and 48 h (interquartile range, 36 to 66) in Wang Pha (P < 0.001).  Recrudescence confirmed by means of polymerase-chain-reaction assay occurred in 6 of 20 patients (30%) receiving artesunate monotherapy and 1 of 20 (5%) receiving artesunate-mefloqine therapy in Pailin, as compared with 2 of 20 (10%) and 1 of 20 (5%), resp., in Wang Pha (P = 0.31).  These markedly different parasitol. responses were not explained by differences in age, artesunate or dihydroartemisinin pharmacokinetics, results of isotopic in vitro sensitivity tests, or putative mol. correlates of P.falciparum drug resistance (mutations or amplifications of the gene encoding a multidrug resistance protein [PfMDR1] or mutations in the gene encoding sarco-endoplasmic reticulum calcium ATPase6 [PfSERCA]).  Adverse events were mild and did not differ significantly between the two treatment groups.  CONCLUSIONS: P.falciparum has reduced in vivo susceptibility to artesunate in western Cambodia as compared with northwestern Thailand.  Resistance is characterized by slow parasite clearance in vivo without corresponding redns. on conventional in vitro susceptibility testing.  Containment measures are urgently needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfVvi4ozTDSLVg90H21EOLACvtfcHk0ljdxZQwo2a1Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1CrsLk%253D&md5=ae3098a15e9fb82c80fa0ddd05378220</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0808859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0808859%26sid%3Dliteratum%253Aachs%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DNosten%26aufirst%3DF.%26aulast%3DYi%26aufirst%3DP.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DLwin%26aufirst%3DK.%2BM.%26aulast%3DAriey%26aufirst%3DF.%26aulast%3DHanpithakpong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DRingwald%26aufirst%3DP.%26aulast%3DSilamut%26aufirst%3DK.%26aulast%3DImwong%26aufirst%3DM.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DHerdman%26aufirst%3DT.%26aulast%3DAn%26aufirst%3DS.%2BS.%26aulast%3DYeung%26aufirst%3DS.%26aulast%3DSinghasivanon%26aufirst%3DP.%26aulast%3DDay%26aufirst%3DN.%2BP.%26aulast%3DLindegardh%26aufirst%3DN.%26aulast%3DSocheat%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DArtemisinin%2520resistance%2520in%2520Plasmodium%2520falciparum%2520malaria%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D455%26epage%3D467%26doi%3D10.1056%2FNEJMoa0808859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phyo, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkhoma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepniewska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGready, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ler Moo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Saai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lwin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singhasivanon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosten, F.</span></span> <span> </span><span class="NLM_article-title">Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1960</span>– <span class="NLM_lpage">1966</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)60484-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FS0140-6736%2812%2960484-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=22484134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BC38rjtFehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1960-1966&author=A.+P.+Phyoauthor=S.+Nkhomaauthor=K.+Stepniewskaauthor=E.+A.+Ashleyauthor=S.+Nairauthor=R.+McGreadyauthor=C.+ler+Mooauthor=S.+Al-Saaiauthor=A.+M.+Dondorpauthor=K.+M.+Lwinauthor=P.+Singhasivanonauthor=N.+P.+Dayauthor=N.+J.+Whiteauthor=T.+J.+Andersonauthor=F.+Nosten&title=Emergence+of+artemisinin-resistant+malaria+on+the+western+border+of+Thailand%3A+a+longitudinal+study&doi=10.1016%2FS0140-6736%2812%2960484-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study</span></div><div class="casAuthors">Phyo Aung Pyae; Nkhoma Standwell; Stepniewska Kasia; Ashley Elizabeth A; Nair Shalini; McGready Rose; ler Moo Carit; Al-Saai Salma; Dondorp Arjen M; Lwin Khin Maung; Singhasivanon Pratap; Day Nicholas P J; White Nicholas J; Anderson Tim J C; Nosten Francois</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">9830</span>),
    <span class="NLM_cas:pages">1960-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Artemisinin-resistant falciparum malaria has arisen in western Cambodia.  A concerted international effort is underway to contain artemisinin-resistant Plasmodium falciparum, but containment strategies are dependent on whether resistance has emerged elsewhere.  We aimed to establish whether artemisinin resistance has spread or emerged on the Thailand-Myanmar (Burma) border.  METHODS:  In malaria clinics located along the northwestern border of Thailand, we measured six hourly parasite counts in patients with uncomplicated hyperparasitaemic falciparum malaria (≥4% infected red blood cells) who had been given various oral artesunate-containing regimens since 2001.  Parasite clearance half-lives were estimated and parasites were genotyped for 93 single nucleotide polymorphisms.  FINDINGS:  3202 patients were studied between 2001 and 2010.  Parasite clearance half-lives lengthened from a geometric mean of 2·6 h (95% CI 2·5-2·7) in 2001, to 3·7 h (3·6-3·8) in 2010, compared with a mean of 5·5 h (5·2-5·9) in 119 patients in western Cambodia measured between 2007 and 2010.  The proportion of slow-clearing infections (half-life ≥6·2 h) increased from 0·6% in 2001, to 20% in 2010, compared with 42% in western Cambodia between 2007 and 2010.  Of 1583 infections genotyped, 148 multilocus parasite genotypes were identified, each of which infected between two and 13 patients.  The proportion of variation in parasite clearance attributable to parasite genetics increased from 30% between 2001 and 2004, to 66% between 2007 and 2010.  INTERPRETATION:  Genetically determined artemisinin resistance in P falciparum emerged along the Thailand-Myanmar border at least 8 years ago and has since increased substantially.  At this rate of increase, resistance will reach rates reported in western Cambodia in 2-6 years.  FUNDING:  The Wellcome Trust and National Institutes of Health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9gTXdi_aNKUcLvDNbOD4DfW6udTcc2eYlNzEGJnzOBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rjtFehsg%253D%253D&md5=9de4b3f2862332e0bf33d1d6612b06d0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960484-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960484-X%26sid%3Dliteratum%253Aachs%26aulast%3DPhyo%26aufirst%3DA.%2BP.%26aulast%3DNkhoma%26aufirst%3DS.%26aulast%3DStepniewska%26aufirst%3DK.%26aulast%3DAshley%26aufirst%3DE.%2BA.%26aulast%3DNair%26aufirst%3DS.%26aulast%3DMcGready%26aufirst%3DR.%26aulast%3Dler%2BMoo%26aufirst%3DC.%26aulast%3DAl-Saai%26aufirst%3DS.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DLwin%26aufirst%3DK.%2BM.%26aulast%3DSinghasivanon%26aufirst%3DP.%26aulast%3DDay%26aufirst%3DN.%2BP.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DAnderson%26aufirst%3DT.%2BJ.%26aulast%3DNosten%26aufirst%3DF.%26atitle%3DEmergence%2520of%2520artemisinin-resistant%2520malaria%2520on%2520the%2520western%2520border%2520of%2520Thailand%253A%2520a%2520longitudinal%2520study%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26spage%3D1960%26epage%3D1966%26doi%3D10.1016%2FS0140-6736%2812%2960484-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelps, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepniewska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindegardh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span> <span> </span><span class="NLM_article-title">Artemisinin-resistant <i>Plasmodium falciparum</i> in Pursat province, western Cambodia: a parasite clearance rate study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">851</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(12)70181-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FS1473-3099%2812%2970181-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=22940027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BC38bjt1Cqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=851-858&author=C.+Amaratungaauthor=S.+Srengauthor=S.+Suonauthor=E.+S.+Phelpsauthor=K.+Stepniewskaauthor=P.+Limauthor=C.+Zhouauthor=S.+Maoauthor=J.+M.+Andersonauthor=N.+Lindegardhauthor=H.+Jiangauthor=J.+Songauthor=X.+Z.+Suauthor=N.+J.+Whiteauthor=A.+M.+Dondorpauthor=T.+J.+Andersonauthor=M.+P.+Fayauthor=J.+Muauthor=S.+Duongauthor=R.+M.+Fairhurst&title=Artemisinin-resistant+Plasmodium+falciparum+in+Pursat+province%2C+western+Cambodia%3A+a+parasite+clearance+rate+study&doi=10.1016%2FS1473-3099%2812%2970181-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study</span></div><div class="casAuthors">Amaratunga Chanaki; Sreng Sokunthea; Suon Seila; Phelps Erika S; Stepniewska Kasia; Lim Pharath; Zhou Chongjun; Mao Sivanna; Anderson Jennifer M; Lindegardh Niklas; Jiang Hongying; Song Jianping; Su Xin-zhuan; White Nicholas J; Dondorp Arjen M; Anderson Tim J C; Fay Michael P; Mu Jianbing; Duong Socheat; Fairhurst Rick M</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">851-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Artemisinin-resistant Plasmodium falciparum has been reported in Pailin, western Cambodia, detected as a slow parasite clearance rate in vivo.  Emergence of this phenotype in western Thailand and possibly elsewhere threatens to compromise the effectiveness of all artemisinin-based combination therapies.  Parasite genetics is associated with parasite clearance rate but does not account for all variation.  We investigated contributions of both parasite genetics and host factors to the artemisinin-resistance phenotype in Pursat, western Cambodia.  METHODS:  Between June 19 and Nov 28, 2009, and June 26 and Dec 6, 2010, we enrolled patients aged 10 years or older with uncomplicated falciparum malaria, a density of asexual parasites of at least 10,000 per μL of whole blood, no symptoms or signs of severe malaria, no other cause of febrile illness, and no chronic illness.  We gave participants 4 mg/kg artesunate at 0, 24, and 48 h, 15 mg/kg mefloquine at 72 h, and 10 mg/kg mefloquine at 96 h.  We assessed parasite density on thick blood films every 6 h until undetectable.  The parasite clearance half-life was calculated from the parasite clearance curve.  We genotyped parasites with 18 microsatellite markers and patients for haemoglobin E, α-thalassaemia, and a mutation of G6PD, which encodes glucose-6-phosphate dehydrogenase.  To account for the possible effects of acquired immunity on half-life, we used three surrogates for increased likelihood of exposure to P falciparum: age, sex, and place of residence.  This study is registered with ClinicalTrials.gov, number NCT00341003.  FINDINGS:  We assessed 3504 individuals from all six districts of Pursat province seeking treatment for malaria symptoms.  We enrolled 168 patients with falciparum malaria who met inclusion criteria.  The geometric mean half-life was 5·85 h (95% CI 5·54-6·18) in Pursat, similar to that reported in Pailin (p=0·109).  We identified two genetically different parasite clone groups: parasite group 1 (PG1) and parasite group 2 (PG2).  Non-significant increases in parasite clearance half-life were seen in patients with haemoglobin E (0·55 h; p=0·078), those of male sex (0·96 h; p=0·064), and in 2010 (0·68 h; p=0·068); PG1 was associated with a significant increase (0·79 h; p=0·033).  The mean parasite heritability of half-life was 0·40 (SD 0·17).  INTERPRETATION:  Heritable artemisinin resistance is established in a second Cambodian province.  To accurately identify parasites that are intrinsically susceptible or resistant to artemisinins, future studies should explore the effect of erythrocyte polymorphisms and specific immune responses on half-life variation.  FUNDING:  Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRI09wVfIhndi-bLEOO4dYpfW6udTcc2eYlNzEGJnzOBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bjt1Cqsg%253D%253D&md5=3bb047418e6093e6b0d6ef8227de797a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2812%2970181-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252812%252970181-0%26sid%3Dliteratum%253Aachs%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DPhelps%26aufirst%3DE.%2BS.%26aulast%3DStepniewska%26aufirst%3DK.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DJ.%2BM.%26aulast%3DLindegardh%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DX.%2BZ.%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DAnderson%26aufirst%3DT.%2BJ.%26aulast%3DFay%26aufirst%3DM.%2BP.%26aulast%3DMu%26aufirst%3DJ.%26aulast%3DDuong%26aufirst%3DS.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26atitle%3DArtemisinin-resistant%2520Plasmodium%2520falciparum%2520in%2520Pursat%2520province%252C%2520western%2520Cambodia%253A%2520a%2520parasite%2520clearance%2520rate%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2012%26volume%3D12%26spage%3D851%26epage%3D858%26doi%3D10.1016%2FS1473-3099%2812%2970181-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sopha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Try, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blessborn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tullo, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span> <span> </span><span class="NLM_article-title">Dihydroartemisinin-piperaquine resistance in <i>Plasmodium falciparum</i> malaria in Cambodia: a multisite prospective cohort study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(15)00487-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FS1473-3099%2815%2900487-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=26774243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVWhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=357-365&author=C.+Amaratungaauthor=P.+Limauthor=S.+Suonauthor=S.+Srengauthor=S.+Maoauthor=C.+Sophaauthor=B.+Samauthor=D.+Dekauthor=V.+Tryauthor=R.+Amatoauthor=D.+Blessbornauthor=L.+Songauthor=G.+S.+Tulloauthor=M.+P.+Fayauthor=J.+M.+Andersonauthor=J.+Tarningauthor=R.+M.+Fairhurst&title=Dihydroartemisinin-piperaquine+resistance+in+Plasmodium+falciparum+malaria+in+Cambodia%3A+a+multisite+prospective+cohort+study&doi=10.1016%2FS1473-3099%2815%2900487-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study</span></div><div class="casAuthors">Amaratunga, Chanaki; Lim, Pharath; Suon, Seila; Sreng, Sokunthea; Mao, Sivanna; Sopha, Chantha; Sam, Baramey; Dek, Dalin; Try, Vorleak; Amato, Roberto; Blessborn, Daniel; Song, Lijiang; Tullo, Gregory S.; Fay, Michael P.; Anderson, Jennifer M.; Tarning, Joel; Fairhurst, Rick M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">357-365</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Artemisinin resistance in Plasmodium falciparum threatens to reduce the efficacy of artemisinin combination therapies (ACTs), thus compromising global efforts to eliminate malaria.  Recent treatment failures with dihydroartemisinin-piperaquine, the current first-line ACT in Cambodia, suggest that piperaquine resistance may be emerging in this country.  We explored the relation between artemisinin resistance and dihydroartemisinin-piperaquine failures, and sought to confirm the presence of piperaquine-resistant P falciparum infections in Cambodia.  In this prospective cohort study, we enrolled patients aged 2-65 years with uncomplicated P falciparum malaria in three Cambodian provinces: Pursat, Preah Vihear, and Ratanakiri.  Participants were given std. 3-day courses of dihydroartemisinin-piperaquine.  Peripheral blood parasite densities were measured until parasites cleared and then weekly to 63 days.  The primary outcome was recrudescent P falciparum parasitemia within 63 days.  We measured piperaquine plasma concns. at baseline, 7 days, and day of recrudescence.  We assessed phenotypic and genotypic markers of drug resistance in parasite isolates.  The study is registered with ClinicalTrials.gov, no. NCT01736319.  Between Sept 4, 2012, and Dec 31, 2013, we enrolled 241 participants.  In Pursat, where artemisinin resistance is entrenched, 37 (46%) of 81 patients had parasite recrudescence.  In Preah Vihear, where artemisinin resistance is emerging, ten (16%) of 63 patients had recrudescence and in Ratanakiri, where artemisinin resistance is rare, one (2%) of 60 patients did.  Patients with recrudescent P falciparum infections were more likely to have detectable piperaquine plasma concns. at baseline compared with non-recrudescent patients, but did not differ significantly in age, initial parasite d., or piperaquine plasma concns. at 7 days.  Recrudescent parasites had a higher prevalence of kelch13 mutations, higher piperaquine 50% inhibitory concn. (IC50) values, and lower mefloquine IC50 values; none had multiple pfmdr1 copies, a genetic marker of mefloquine resistance.  Dihydroartemisinin-piperaquine failures are caused by both artemisinin and piperaquine resistance, and commonly occur in places where dihydroartemisinin-piperaquine has been used in the private sector.  In Cambodia, artesunate plus mefloquine may be a viable option to treat dihydroartemisinin-piperaquine failures, and a more effective first-line ACT in areas where dihydroartemisinin-piperaquine failures are common.  The use of single low-dose primaquine to eliminate circulating gametocytes is needed in areas where artemisinin and ACT resistance is prevalent.  National Institute of Allergy and Infectious Diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd0RSM1qQzR7Vg90H21EOLACvtfcHk0ljDvWR0XoNjJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVWhsg%253D%253D&md5=b2b62ae0ef4f2b67f7446a2a5718654d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2815%2900487-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252815%252900487-9%26sid%3Dliteratum%253Aachs%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DSopha%26aufirst%3DC.%26aulast%3DSam%26aufirst%3DB.%26aulast%3DDek%26aufirst%3DD.%26aulast%3DTry%26aufirst%3DV.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DBlessborn%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DTullo%26aufirst%3DG.%2BS.%26aulast%3DFay%26aufirst%3DM.%2BP.%26aulast%3DAnderson%26aufirst%3DJ.%2BM.%26aulast%3DTarning%26aufirst%3DJ.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26atitle%3DDihydroartemisinin-piperaquine%2520resistance%2520in%2520Plasmodium%2520falciparum%2520malaria%2520in%2520Cambodia%253A%2520a%2520multisite%2520prospective%2520cohort%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2016%26volume%3D16%26spage%3D357%26epage%3D365%26doi%3D10.1016%2FS1473-3099%2815%2900487-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spring, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanachayangkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somethy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Se, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ittiverakul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sia-ngam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntawunginn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arsanok, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buathong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaorattanakawee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ta-aksorn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanarat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundrakes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heng, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teja-isavadharm, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichyangkul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phann, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juliano, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meshnick, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chour, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanteri, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. L.</span></span> <span> </span><span class="NLM_article-title">Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(15)70049-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FS1473-3099%2815%2970049-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=25877962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFSgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=683-691&author=M.+D.+Springauthor=J.+T.+Linauthor=J.+E.+Manningauthor=P.+Vanachayangkulauthor=S.+Somethyauthor=R.+Bunauthor=Y.+Seauthor=S.+Channauthor=M.+Ittiverakulauthor=P.+Sia-ngamauthor=W.+Kuntawunginnauthor=M.+Arsanokauthor=N.+Buathongauthor=S.+Chaorattanakaweeauthor=P.+Gosiauthor=W.+Ta-aksornauthor=N.+Chanaratauthor=S.+Sundrakesauthor=N.+Kongauthor=T.+K.+Hengauthor=S.+Nouauthor=P.+Teja-isavadharmauthor=S.+Pichyangkulauthor=S.+T.+Phannauthor=S.+Balasubramanianauthor=J.+J.+Julianoauthor=S.+R.+Meshnickauthor=C.+M.+Chourauthor=S.+Promauthor=C.+A.+Lanteriauthor=C.+Lonauthor=D.+L.+Saunders&title=Dihydroartemisinin-piperaquine+failure+associated+with+a+triple+mutant+including+kelch13+C580Y+in+Cambodia%3A+an+observational+cohort+study&doi=10.1016%2FS1473-3099%2815%2970049-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study</span></div><div class="casAuthors">Spring, Michele D.; Lin, Jessica T.; Manning, Jessica E.; Vanachayangkul, Pattaraporn; Somethy, Sok; Bun, Rathvicheth; Se, Youry; Chann, Soklyda; Ittiverakul, Mali; Sia-ngam, Piyaporn; Kuntawunginn, Worachet; Arsanok, Montri; Buathong, Nillawan; Chaorattanakawee, Suwanna; Gosi, Panita; Ta-aksorn, Winita; Chanarat, Nitima; Sundrakes, Siratchana; Kong, Nareth; Heng, Thay Kheang; Nou, Samon; Teja-isavadharm, Paktiya; Pichyangkul, Sathit; Phann, Sut Thang; Balasubramanian, Sujata; Juliano, Jonathan J.; Meshnick, Steven R.; Chour, Char Meng; Prom, Satharath; Lanteri, Charlotte A.; Lon, Chanthap; Saunders, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">683-691</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dihydroartemisinin-piperaquine has been adopted as first-line artemisinin combination therapy (ACT) for multidrug-resistant Plasmodium falciparum malaria in Cambodia because of few remaining alternatives.  We aimed to assess the efficacy of std. 3 day dihydroartemisinin-piperaquine treatment of uncomplicated P falciparum malaria, with and without the addn. of primaquine, focusing on the factors involved in drug resistance.  In this observational cohort study, we assessed 107 adults aged 18-65 years presenting to Anlong Veng District Hospital, Oddar Meanchey Province, Cambodia, with uncomplicated P falciparum or mixed P falciparum/Plasmodium vivax infection of between 1000 and 200 000 parasites per μL of blood, and participating in a randomized clin. trial in which all had received dihydroartemisinin-piperaquine for 3 days, after which they had been randomly allocated to receive either primaquine or no primaquine.  The trial was halted early due to poor dihydroartemisinin-piperaquine efficacy, and we assessed day 42 PCR-cor. therapeutic efficacy (proportion of patients with recurrence at 42 days) and evidence of drug resistance from the initial cohort.  We did analyses on both the intention to treat (ITT), modified ITT (withdrawals, losses to follow-up, and those with secondary outcomes [eg, new non-recrudescent malaria infection] were censored on the last day of follow-up), and per-protocol populations of the original trial.  The original trial was registered with ClinicalTrials.gov, no. NCT01280162.  Between Dec 10, 2012, and Feb 18, 2014, we had enrolled 107 patients in the original trial.  Enrolment was voluntarily halted on Feb 16, 2014, before reaching planned enrollment (n=150) because of poor efficacy.  We had randomly allocated 50 patients to primaquine and 51 patients to no primaquine groups.  PCR-adjusted Kaplan-Meier risk of P falciparum 42 day recrudescence was 54% (95% CI 45-63) in the modified ITT anal. population.  We found two kelch13 propeller gene mutations assocd. with artemisinin resistance-a non-synonymous Cys580Tyr substitution in 70 (65%) of 107 participants, an Arg539Thr substitution in 33 (31%), and a wild-type parasite in four (4%).  Unlike Arg539Thr, Cys580Tyr was accompanied by two other mutations assocd. with extended parasite clearance (MAL10:688956 and MAL13:1718319).  This combination triple mutation was assocd. with a 5·4 times greater risk of treatment failure (hazard ratio 5·4 [95% CI 2·4-12]; p<0·0001) and higher piperaquine 50% inhibitory concn. (triple mutant 34 nM [28-41]; non-triple mutant 24 nM [1-27]; p=0·003) than other infections had.  The drug was well tolerated, with gastrointestinal symptoms being the most common complaints.  The dramatic decline in efficacy of dihydroartemisinin-piperaquine compared with what was obsd. in a study at the same location in 2010 was strongly assocd. with a new triple mutation including the kelch13 Cys580Tyr substitution.  3 Days of artemisinin as part of an artemisinin combination therapy regimen might be insufficient.  Strict regulation and monitoring of antimalarial use, along with non-pharmacol. approaches to malaria resistance containment, must be integral parts of the public health response to rapidly accelerating drug resistance in the region.  Armed Forces Health Surveillance Center/Global Emerging Infections Surveillance and Response System, Military Infectious Disease Research Program, National Institute of Allergy and Infectious Diseases, and American Society of Tropical Medicine and Hygiene/Burroughs Wellcome Fund.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFjkvNekrUMrVg90H21EOLACvtfcHk0ljDvWR0XoNjJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFSgu78%253D&md5=6150b25babe19f91eb5971e030327681</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2815%2970049-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252815%252970049-6%26sid%3Dliteratum%253Aachs%26aulast%3DSpring%26aufirst%3DM.%2BD.%26aulast%3DLin%26aufirst%3DJ.%2BT.%26aulast%3DManning%26aufirst%3DJ.%2BE.%26aulast%3DVanachayangkul%26aufirst%3DP.%26aulast%3DSomethy%26aufirst%3DS.%26aulast%3DBun%26aufirst%3DR.%26aulast%3DSe%26aufirst%3DY.%26aulast%3DChann%26aufirst%3DS.%26aulast%3DIttiverakul%26aufirst%3DM.%26aulast%3DSia-ngam%26aufirst%3DP.%26aulast%3DKuntawunginn%26aufirst%3DW.%26aulast%3DArsanok%26aufirst%3DM.%26aulast%3DBuathong%26aufirst%3DN.%26aulast%3DChaorattanakawee%26aufirst%3DS.%26aulast%3DGosi%26aufirst%3DP.%26aulast%3DTa-aksorn%26aufirst%3DW.%26aulast%3DChanarat%26aufirst%3DN.%26aulast%3DSundrakes%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DN.%26aulast%3DHeng%26aufirst%3DT.%2BK.%26aulast%3DNou%26aufirst%3DS.%26aulast%3DTeja-isavadharm%26aufirst%3DP.%26aulast%3DPichyangkul%26aufirst%3DS.%26aulast%3DPhann%26aufirst%3DS.%2BT.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DJuliano%26aufirst%3DJ.%2BJ.%26aulast%3DMeshnick%26aufirst%3DS.%2BR.%26aulast%3DChour%26aufirst%3DC.%2BM.%26aulast%3DProm%26aufirst%3DS.%26aulast%3DLanteri%26aufirst%3DC.%2BA.%26aulast%3DLon%26aufirst%3DC.%26aulast%3DSaunders%26aufirst%3DD.%2BL.%26atitle%3DDihydroartemisinin-piperaquine%2520failure%2520associated%2520with%2520a%2520triple%2520mutant%2520including%2520kelch13%2520C580Y%2520in%2520Cambodia%253A%2520an%2520observational%2520cohort%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2015%26volume%3D15%26spage%3D683%26epage%3D691%26doi%3D10.1016%2FS1473-3099%2815%2970049-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">Proteasome inhibitors: an expanding army attacking a unique target</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2Fj.chembiol.2012.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=22284358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=99-115&author=A.+F.+Kisselevauthor=W.+A.+van+der+Lindenauthor=H.+S.+Overkleeft&title=Proteasome+inhibitors%3A+an+expanding+army+attacking+a+unique+target&doi=10.1016%2Fj.chembiol.2012.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome Inhibitors: An Expanding Army Attacking a Unique Target</span></div><div class="casAuthors">Kisselev, Alexei F.; van der Linden, Wouter A.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-115</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Proteasomes are large, multisubunit proteolytic complexes presenting multiple targets for therapeutic intervention.  The 26S proteasome consists of a 20S proteolytic core and one or two 19S regulatory particles.  The 20S core contains three types of active sites.  Many structurally diverse inhibitors of these active sites, both natural product and synthetic, have been discovered in the last two decades.  One, bortezomib, is used clin. for treatment of multiple myeloma, mantle cell lymphoma, and acute allograft rejection.  Five more recently developed proteasome inhibitors are in trials for treatment of myeloma and other cancers.  Proteasome inhibitors also have activity in animal models of autoimmune and inflammatory diseases, reperfusion injury, promote bone and hair growth, and can potentially be used as anti-infectives.  In addn., inhibitors of ATPases and deubiquitinases of 19S regulatory particles have been discovered in the last decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKc-6qcZILhrVg90H21EOLACvtfcHk0lgUOpmslxNJOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cqsbc%253D&md5=a4eca9d710b209d5455c2eaa58dfd0bc</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DProteasome%2520inhibitors%253A%2520an%2520expanding%2520army%2520attacking%2520a%2520unique%2520target%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D99%26epage%3D115%26doi%3D10.1016%2Fj.chembiol.2012.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregerson, D. S.</span></span> <span> </span><span class="NLM_article-title">Immunoproteasomes: structure, function, and antigen presentation</span>. <i>Prog. Mol. Biol. Transl Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-397863-9.00003-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FB978-0-12-397863-9.00003-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=22727420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2jtr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=75-112&author=D.+A.+Ferringtonauthor=D.+S.+Gregerson&title=Immunoproteasomes%3A+structure%2C+function%2C+and+antigen+presentation&doi=10.1016%2FB978-0-12-397863-9.00003-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoproteasomes: structure, function, and antigen presentation</span></div><div class="casAuthors">Ferrington, Deborah A.; Gregerson, Dale S.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Molecular Biology and Translational Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">Proteasomal System in Aging and Disease</span>),
    <span class="NLM_cas:pages">75-112, 1 plate</span>CODEN:
                <span class="NLM_cas:coden">PNARC5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Immunoproteasomes contain replacements for the three catalytic subunits of std. proteasomes.  In most cells, oxidative stress and proinflammatory cytokines are stimuli that lead to elevated prodn. of immunoproteasomes.  Immune system cells, esp. antigen-presenting cells, express a higher basal level of immunoproteasomes.  A well-described function of immunoproteasomes is to generate peptides with a hydrophobic C terminus that can be processed to fit in the groove of MHC class I mols.  This display of peptides on the cell surface allows surveillance by CD8 T cells of the adaptive immune system for pathogen-infected cells.  Functions of immunoproteasomes, other than generating peptides for antigen presentation, are emerging from studies in immunoproteasome-deficient mice, and are complemented by recently described diseases linked to mutations or single-nucleotide polymorphisms in immunoproteasome subunits.  Thus, this growing body of literature suggests a more pleiotropic role in cell function for the immunoproteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB-ms47z5YWbVg90H21EOLACvtfcHk0lgUOpmslxNJOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2jtr7E&md5=dbddd6a20fe829739bb2acd037619376</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-397863-9.00003-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-397863-9.00003-1%26sid%3Dliteratum%253Aachs%26aulast%3DFerrington%26aufirst%3DD.%2BA.%26aulast%3DGregerson%26aufirst%3DD.%2BS.%26atitle%3DImmunoproteasomes%253A%2520structure%252C%2520function%252C%2520and%2520antigen%2520presentation%26jtitle%3DProg.%2520Mol.%2520Biol.%2520Transl%2520Sci.%26date%3D2012%26volume%3D109%26spage%3D75%26epage%3D112%26doi%3D10.1016%2FB978-0-12-397863-9.00003-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponder, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asbjornsdottir, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgington, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demo, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Validation of the proteasome as a therapeutic target in <i>Plasmodium</i> using an epoxyketone inhibitor with parasite-specific toxicity</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1535</span>– <span class="NLM_lpage">1545</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2Fj.chembiol.2012.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=23142757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GqtLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1535-1545&author=H.+Liauthor=E.+L.+Ponderauthor=M.+Verdoesauthor=K.+H.+Asbjornsdottirauthor=E.+Deuauthor=L.+E.+Edgingtonauthor=J.+T.+Leeauthor=C.+J.+Kirkauthor=S.+D.+Demoauthor=K.+C.+Williamsonauthor=M.+Bogyo&title=Validation+of+the+proteasome+as+a+therapeutic+target+in+Plasmodium+using+an+epoxyketone+inhibitor+with+parasite-specific+toxicity&doi=10.1016%2Fj.chembiol.2012.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of the Proteasome as a Therapeutic Target in Plasmodium Using an Epoxyketone Inhibitor with Parasite-Specific Toxicity</span></div><div class="casAuthors">Li, Hao; Ponder, Elizabeth L.; Verdoes, Martijn; Asbjornsdottir, Kristijana H.; Deu, Edgar; Edgington, Laura E.; Lee, Jeong Tae; Kirk, Christopher J.; Demo, Susan D.; Williamson, Kim C.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1535-1545</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Plasmodium proteasome has been suggested to be a potential antimalarial drug target; however, toxicity of inhibitors has prevented validation of this enzyme in vivo.  We report a screen of a library of 670 analogs of the recent US Food and Drug Administration-approved inhibitor, carfilzomib, to identify compds. that selectively kill parasites.  We identified one compd., PR3, that has significant parasite killing activity in vitro but dramatically reduced toxicity in host cells.  We found that this parasite-specific toxicity is not due to selective targeting of the Plasmodium proteasome over the host proteasome, but instead is due to a lack of activity against one of the human proteasome subunits.  Subsequently, we used PR3 to significantly reduce parasite load in Plasmodium berghei infected mice without host toxicity, thus validating the proteasome as a viable antimalarial drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrioM_fNpikeLVg90H21EOLACvtfcHk0lgQYBqtDxXCeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GqtLjP&md5=676ae3dbb057ec1e0e3e42859ab20739</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DPonder%26aufirst%3DE.%2BL.%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DAsbjornsdottir%26aufirst%3DK.%2BH.%26aulast%3DDeu%26aufirst%3DE.%26aulast%3DEdgington%26aufirst%3DL.%2BE.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DWilliamson%26aufirst%3DK.%2BC.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DValidation%2520of%2520the%2520proteasome%2520as%2520a%2520therapeutic%2520target%2520in%2520Plasmodium%2520using%2520an%2520epoxyketone%2520inhibitor%2520with%2520parasite-specific%2520toxicity%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D1535%26epage%3D1545%26doi%3D10.1016%2Fj.chembiol.2012.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tschan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werkhoven, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knittel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aminake, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joanny, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liskamp, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordmuller, B.</span></span> <span> </span><span class="NLM_article-title">Broad-spectrum antimalarial activity of peptido sulfonyl fluorides, a new class of proteasome inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3576</span>– <span class="NLM_lpage">3584</span>, <span class="refDoi"> DOI: 10.1128/AAC.00742-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1128%2FAAC.00742-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=23689711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WgtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=3576-3584&author=S.+Tschanauthor=A.+J.+Brouwerauthor=P.+R.+Werkhovenauthor=A.+M.+Jonkerauthor=L.+Wagnerauthor=S.+Knittelauthor=M.+N.+Aminakeauthor=G.+Pradelauthor=F.+Joannyauthor=R.+M.+Liskampauthor=B.+Mordmuller&title=Broad-spectrum+antimalarial+activity+of+peptido+sulfonyl+fluorides%2C+a+new+class+of+proteasome+inhibitors&doi=10.1128%2FAAC.00742-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Broad-spectrum antimalarial activity of peptido sulfonyl fluorides, a new class of proteasome inhibitors</span></div><div class="casAuthors">Tschan, Serena; Brouwer, Arwin J.; Werkhoven, Paul R.; Jonker, Anika M.; Wagner, Lena; Knittel, Sarah; Aminake, Makoah Nigel; Pradel, Gabriele; Joanny, Fanny; Liskamp, Rob M. J.; Mordmueller, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3576-3584</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Despite declining nos. of cases and deaths, malaria remains a major public health problem in many parts of the world.  Today, case management relies heavily on a single class of antimalarial compds.: artemisinins.  Hence, development of resistance against artemisinins may destroy current malaria control strategies.  Beyond malaria control are elimination and eradication programs that will require drugs with good activity against acute infection but also with preventive and transmission-blocking properties.  Consequently, new antimalarials are needed not only to ensure malaria control but also for elimination and eradication efforts.  In this study, we introduce peptido sulfonyl fluorides (PSF) as a new class of compds. with antiplasmodial activity.  We show that PSF target the plasmodial proteasome and act on all asexual stages of the intraerythrocytic cycle and on gametocytes.  PSF showed activities at concns. as low as 20 nM against multidrug-resistant and chloroquine-sensitive Plasmodium falciparum lab. strains and clin. isolates from Gabon.  Structural requirements for activity were identified, and cytotoxicity in human HeLa or HEK 293 cells was low.  The lead PSF PW28 suppressed growth of Plasmodium berghei in vivo but showed signs of toxicity in mice.  Considering their modular structure and broad spectrum of activity against different stages of the plasmodial life cycle, proteasome inhibitors based on PSF have a great potential for further development as preclin. candidate compds. with improved species-specific activity and less toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZGX0bUt1lybVg90H21EOLACvtfcHk0lgQYBqtDxXCeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WgtbzI&md5=7bf49f9fa35185f23d9cc075795e767f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FAAC.00742-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00742-12%26sid%3Dliteratum%253Aachs%26aulast%3DTschan%26aufirst%3DS.%26aulast%3DBrouwer%26aufirst%3DA.%2BJ.%26aulast%3DWerkhoven%26aufirst%3DP.%2BR.%26aulast%3DJonker%26aufirst%3DA.%2BM.%26aulast%3DWagner%26aufirst%3DL.%26aulast%3DKnittel%26aufirst%3DS.%26aulast%3DAminake%26aufirst%3DM.%2BN.%26aulast%3DPradel%26aufirst%3DG.%26aulast%3DJoanny%26aufirst%3DF.%26aulast%3DLiskamp%26aufirst%3DR.%2BM.%26aulast%3DMordmuller%26aufirst%3DB.%26atitle%3DBroad-spectrum%2520antimalarial%2520activity%2520of%2520peptido%2520sulfonyl%2520fluorides%252C%2520a%2520new%2520class%2520of%2520proteasome%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D3576%26epage%3D3584%26doi%3D10.1128%2FAAC.00742-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirkman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziedziech, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzual, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaeda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvaro, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiang, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindasamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumwebaze, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukenick, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendome, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhanot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kafsack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doggett, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span> <span> </span><span class="NLM_article-title">Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E6863</span>– <span class="NLM_lpage">E6870</span>, <span class="refDoi"> DOI: 10.1073/pnas.1806109115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1073%2Fpnas.1806109115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=29967165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCmtrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E6863-E6870&author=L.+A.+Kirkmanauthor=W.+Zhanauthor=J.+Visoneauthor=A.+Dziedziechauthor=P.+K.+Singhauthor=H.+Fanauthor=X.+Tongauthor=I.+Bruzualauthor=R.+Haraauthor=M.+Kawasakiauthor=T.+Imaedaauthor=R.+Okamotoauthor=K.+Satoauthor=M.+Michinoauthor=E.+F.+Alvaroauthor=L.+F.+Guiangauthor=L.+Sanzauthor=D.+J.+Motaauthor=K.+Govindasamyauthor=R.+Wangauthor=Y.+Lingauthor=P.+K.+Tumwebazeauthor=G.+Sukenickauthor=L.+Shiauthor=J.+Vendomeauthor=P.+Bhanotauthor=P.+J.+Rosenthalauthor=K.+Asoauthor=M.+A.+Foleyauthor=R.+A.+Cooperauthor=B.+Kafsackauthor=J.+S.+Doggettauthor=C.+F.+Nathanauthor=G.+Lin&title=Antimalarial+proteasome+inhibitor+reveals+collateral+sensitivity+from+intersubunit+interactions+and+fitness+cost+of+resistance&doi=10.1073%2Fpnas.1806109115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance</span></div><div class="casAuthors">Kirkman, Laura A.; Zhan, Wenhu; Visone, Joseph; Dziedziech, Alexis; Singh, Pradeep K.; Fan, Hao; Tong, Xinran; Bruzual, Igor; Hara, Ryoma; Kawasaki, Masanori; Imaeda, Toshihiro; Okamoto, Rei; Sato, Kenjiro; Michino, Mayako; Alvaro, Elena Fernandez; Guiang, Liselle F.; Sanz, Laura; Mota, Daniel J.; Govindasamy, Kavitha; Wang, Rong; Ling, Yan; Tumwebaze, Patrick K.; Sukenick, George; Shi, Lei; Vendome, Jeremie; Bhanot, Purnima; Rosenthal, Philip J.; Aso, Kazuyoshi; Foley, Michael A.; Cooper, Roland A.; Kafsack, Bjorn; Doggett, J. Stone; Nathan, Carl F.; Lin, Gang</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">E6863-E6870</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We describe noncovalent, reversible asparagine ethylenediamine (AsnEDA) inhibitors of the Plasmodium falciparum proteasome (Pf20S) β5 subunit that spare all active subunits of human constitutive and immuno-proteasomes.  The compds. are active against erythrocytic, sexual, and liver-stage parasites, against parasites resistant to current antimalarials, and against P. falciparum strains from patients in Africa.  The β5 inhibitors synergize with a β2 inhibitor in vitro and in mice and with artemisinin.  P. falciparum selected for resistance to an AsnEDA β5 inhibitor surprisingly harbored a point mutation in the noncatalytic β6 subunit.  The β6 mutant was resistant to the species-selective Pf20S β5 inhibitor but remained sensitive to the species-nonselective β5 inhibitors bortezomib and carfilzomib.  Moreover, resistance to the Pf20S β5 inhibitor was accompanied by increased sensitivity to a Pf20S β2 inhibitor.  Finally, the β5 inhibitor-resistant mutant had a fitness cost that was exacerbated by irradn.  Thus, used in combination, multistage-active inhibitors of the Pf20S β5 and β2 subunits afford synergistic antimalarial activity with a potential to delay the emergence of resistance to artemisinins and each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcBMtrslCvE7Vg90H21EOLACvtfcHk0liDDe5BQDgxxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCmtrfJ&md5=6addacc779527c9e4c6a265868f088fe</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1806109115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1806109115%26sid%3Dliteratum%253Aachs%26aulast%3DKirkman%26aufirst%3DL.%2BA.%26aulast%3DZhan%26aufirst%3DW.%26aulast%3DVisone%26aufirst%3DJ.%26aulast%3DDziedziech%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DBruzual%26aufirst%3DI.%26aulast%3DHara%26aufirst%3DR.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DImaeda%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DR.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DMichino%26aufirst%3DM.%26aulast%3DAlvaro%26aufirst%3DE.%2BF.%26aulast%3DGuiang%26aufirst%3DL.%2BF.%26aulast%3DSanz%26aufirst%3DL.%26aulast%3DMota%26aufirst%3DD.%2BJ.%26aulast%3DGovindasamy%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DTumwebaze%26aufirst%3DP.%2BK.%26aulast%3DSukenick%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DVendome%26aufirst%3DJ.%26aulast%3DBhanot%26aufirst%3DP.%26aulast%3DRosenthal%26aufirst%3DP.%2BJ.%26aulast%3DAso%26aufirst%3DK.%26aulast%3DFoley%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DR.%2BA.%26aulast%3DKafsack%26aufirst%3DB.%26aulast%3DDoggett%26aufirst%3DJ.%2BS.%26aulast%3DNathan%26aufirst%3DC.%2BF.%26aulast%3DLin%26aufirst%3DG.%26atitle%3DAntimalarial%2520proteasome%2520inhibitor%2520reveals%2520collateral%2520sensitivity%2520from%2520intersubunit%2520interactions%2520and%2520fitness%2520cost%2520of%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE6863%26epage%3DE6870%26doi%3D10.1073%2Fpnas.1806109115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dogovski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridgford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaw, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chotivanich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnadig, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozdech, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondorp, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foote, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klonis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span> <span> </span><span class="NLM_article-title">Targeting the cell stress response of <i>Plasmodium falciparum</i> to overcome artemisinin resistance</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">e1002132</span>, <span class="refDoi"> DOI: 10.1371/journal.pbio.1002132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1371%2Fjournal.pbio.1002132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=25901609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVGqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=e1002132&author=C.+Dogovskiauthor=S.+C.+Xieauthor=G.+Burgioauthor=J.+Bridgfordauthor=S.+Mokauthor=J.+M.+McCawauthor=K.+Chotivanichauthor=S.+Kennyauthor=N.+Gnadigauthor=J.+Straimerauthor=Z.+Bozdechauthor=D.+A.+Fidockauthor=J.+A.+Simpsonauthor=A.+M.+Dondorpauthor=S.+Footeauthor=N.+Klonisauthor=L.+Tilley&title=Targeting+the+cell+stress+response+of+Plasmodium+falciparum+to+overcome+artemisinin+resistance&doi=10.1371%2Fjournal.pbio.1002132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance</span></div><div class="casAuthors">Dogovski, Con; Xie, Stanley C.; Burgio, Gaetan; Bridgford, Jess; Mok, Sachel; McCaw, James M.; Chotivanich, Kesinee; Kenny, Shannon; Gnadig, Nina; Straimer, Judith; Bozdech, Zbynek; Fidock, David A.; Simpson, Julie A.; Dondorp, Arjen M.; Foote, Simon; Klonis, Nectarios; Tilley, Leann</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1002132/1-e1002132/26</span>CODEN:
                <span class="NLM_cas:coden">PBLIBG</span>;
        ISSN:<span class="NLM_cas:issn">1545-7885</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Successful control of falciparum malaria depends greatly on treatment with artemisinin combination therapies.  Thus, reports that resistance to artemisinins (ARTs) has emerged, and that the prevalence of this resistance is increasing, are alarming.  ART resistance has recently been linked to mutations in the K13 propeller protein.  The authors undertook a detailed kinetic anal. of the drug responses of K13 wild-type and mutant isolates of Plasmodium falciparum sourced from a region in Cambodia (Pailin).  They demonstrate that ART treatment induces growth retardation and an accumulation of ubiquitinated proteins, indicative of a cellular stress response that engages the ubiquitin/proteasome system.  They show that resistant parasites exhibit lower levels of ubiquitinated proteins and delayed onset of cell death, indicating an enhanced cell stress response.  The stress response could be targeted by inhibiting the proteasome.  Accordingly, clin. used proteasome inhibitors strongly synergize ART activity against both sensitive and resistant parasites, including isogenic lines expressing mutant or wild-type K13.  Synergy is also obsd. against Plasmodium berghei in vivo.  The authors developed a detailed model of parasite responses that enabled them to infer in vivo parasite clearance profiles from in vitro assessments of ART sensitivity.  They provide evidence that the clin. marker of resistance (delayed parasite clearance) is an indirect measure of drug efficacy because of the persistence of unviable parasites with unchanged morphol. in the circulation, and we suggest alternative approaches for the direct measurement of viability.  This model predicts that extending current three-day ART treatment courses to four days, or splitting the doses, will efficiently clear resistant parasite infections.  This work provides a rationale for improving the detection of ART resistance in the field and for treatment strategies that can be employed in areas with ART resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnq1k3owGeKbVg90H21EOLACvtfcHk0liDDe5BQDgxxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVGqu7c%253D&md5=acb11e532b67d900a54958ceebee8db1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1002132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1002132%26sid%3Dliteratum%253Aachs%26aulast%3DDogovski%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DS.%2BC.%26aulast%3DBurgio%26aufirst%3DG.%26aulast%3DBridgford%26aufirst%3DJ.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DMcCaw%26aufirst%3DJ.%2BM.%26aulast%3DChotivanich%26aufirst%3DK.%26aulast%3DKenny%26aufirst%3DS.%26aulast%3DGnadig%26aufirst%3DN.%26aulast%3DStraimer%26aufirst%3DJ.%26aulast%3DBozdech%26aufirst%3DZ.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DSimpson%26aufirst%3DJ.%2BA.%26aulast%3DDondorp%26aufirst%3DA.%2BM.%26aulast%3DFoote%26aufirst%3DS.%26aulast%3DKlonis%26aufirst%3DN.%26aulast%3DTilley%26aufirst%3DL.%26atitle%3DTargeting%2520the%2520cell%2520stress%2520response%2520of%2520Plasmodium%2520falciparum%2520to%2520overcome%2520artemisinin%2520resistance%26jtitle%3DPLoS%2520Biol.%26date%3D2015%26volume%3D13%26spage%3De1002132%26doi%3D10.1371%2Fjournal.pbio.1002132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foe, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Fonseca, P. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Structure and function based design of Plasmodium-selective proteasome inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>530</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/nature16936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fnature16936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=26863983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=530&publication_year=2016&pages=233-236&author=H.+Liauthor=A.+O%E2%80%99Donoghueauthor=W.+A.+van+der+Lindenauthor=S.+C.+Xieauthor=E.+Yooauthor=I.+T.+Foeauthor=L.+Tilleyauthor=C.+S.+Craikauthor=P.+C.+A.+da+Fonsecaauthor=M.+Bogyo&title=Structure+and+function+based+design+of+Plasmodium-selective+proteasome+inhibitors&doi=10.1038%2Fnature16936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and function-based design of Plasmodium-selective proteasome inhibitors</span></div><div class="casAuthors">Li, Hao; O'Donoghue, Anthony J.; van der Linden, Wouter A.; Xie, Stanley C.; Yoo, Euna; Foe, Ian T.; Tilley, Leann; Craik, Charles S.; da Fonseca, Paula C. A.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">530</span>
        (<span class="NLM_cas:issue">7589</span>),
    <span class="NLM_cas:pages">233-236</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The proteasome is a multi-component protease complex responsible for regulating key processes such as the cell cycle and antigen presentation.  Compds. that target the proteasome are potentially valuable tools for the treatment of pathogens that depend on proteasome function for survival and replication.  In particular, proteasome inhibitors have been shown to be toxic for the malaria parasite Plasmodium falciparum at all stages of its life cycle.  Most compds. that have been tested against the parasite also inhibit the mammalian proteasome, resulting in toxicity that precludes their use as therapeutic agents.  Therefore, better definition of the substrate specificity and structural properties of the Plasmodium proteasome could enable the development of compds. with sufficient selectivity to allow their use as anti-malarial agents.  To accomplish this goal, here the authors use a substrate profiling method to uncover differences in the specificities of the human and P. falciparum proteasome.  The authors design inhibitors based on amino-acid preferences specific to the parasite proteasome, and find that they preferentially inhibit the β2-subunit.  The authors det. the structure of the P. falciparum 20S proteasome bound to the inhibitor using cryo-electron microscopy and single-particle anal., to a resoln. of 3.6 Å.  These data reveal the unusually open P. falciparum β2 active site and provide valuable information about active-site architecture that can be used to further refine inhibitor design.  Furthermore, consistent with the recent finding that the proteasome is important for stress pathways assocd. with resistance of artemisinin family anti-malarials, the authors observe growth inhibition synergism with low doses of this β2-selective inhibitor in artemisinin-sensitive and -resistant parasites.  Finally, the authors demonstrate that a parasite-selective inhibitor could be used to attenuate parasite growth in vivo without appreciable toxicity to the host.  Thus, the Plasmodium proteasome is a chem. tractable target that could be exploited by next-generation anti-malarial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriK0Li_WncVrVg90H21EOLACvtfcHk0lhXkoSMR3BBaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyrsr8%253D&md5=f24a562efb64dd533a7dbcfeff4171af</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature16936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16936%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DXie%26aufirst%3DS.%2BC.%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DFoe%26aufirst%3DI.%2BT.%26aulast%3DTilley%26aufirst%3DL.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3Dda%2BFonseca%26aufirst%3DP.%2BC.%2BA.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DStructure%2520and%2520function%2520based%2520design%2520of%2520Plasmodium-selective%2520proteasome%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D530%26spage%3D233%26epage%3D236%26doi%3D10.1038%2Fnature16936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kreidenweiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremsner, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordmuller, B.</span></span> <span> </span><span class="NLM_article-title">Comprehensive study of proteasome inhibitors against <i>Plasmodium falciparum</i> laboratory strains and field isolates from Gabon</span>. <i>Malar. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">187</span>, <span class="refDoi"> DOI: 10.1186/1475-2875-7-187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1186%2F1475-2875-7-187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=18816382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BD1cnntV2luw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=187&author=A.+Kreidenweissauthor=P.+G.+Kremsnerauthor=B.+Mordmuller&title=Comprehensive+study+of+proteasome+inhibitors+against+Plasmodium+falciparum+laboratory+strains+and+field+isolates+from+Gabon&doi=10.1186%2F1475-2875-7-187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon</span></div><div class="casAuthors">Kreidenweiss Andrea; Kremsner Peter G; Mordmuller Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Malaria journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">187</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The emergence and spread of Plasmodium falciparum resistance to almost all available antimalarial drugs necessitates the search for new chemotherapeutic compounds.  The ubiquitin/proteasome system plays a major role in overall protein turnover, especially in fast dividing eukaryotic cells including plasmodia.  Previous studies show that the 20S proteasome is expressed and catalytically active in plasmodia and treatment with proteasome inhibitors arrests parasite growth.  This is the first comprehensive screening of proteasome inhibitors with different chemical modes of action against laboratory strains of P. falciparum.  Subsequently, a selection of inhibitors was tested in field isolates from Lambarene, Gabon.  METHODS:  Epoxomicin, YU101, YU102, MG132, MG115, Z-L(3)-VS, Ada-Ahx(3)-L(3)-VS, lactacystin, bortezomib (Velcade), gliotoxin, PR11 and PR39 were tested and compared to chloroquine- and artesunate-activities in a standardized in vitro drug susceptibility assay against P. falciparum laboratory strains 3D7, D10 and Dd2.  Freshly obtained field isolates from Lambarene, Gabon, were used to measure the activity of chloroquine, artesunate, epoxomicin, MG132, lactacystin and bortezomib.  Parasite growth was detected through histidine-rich protein 2 (HRP2) production.  Raw data were fitted by a four-parameter logistic model and individual inhibitory concentrations (50%, 90%, and 99%) were calculated.  RESULTS:  Amongst all proteasome inhibitors tested, epoxomicin showed the highest activity in chloroquine-susceptible (IC50: 6.8 nM [3D7], 1.7 nM [D10]) and in chloroquine-resistant laboratory strains (IC50: 10.4 nM [Dd2]) as well as in field isolates (IC50: 8.5 nM).  The comparator drug artesunate was even more active (IC50: 1.0 nM), whereas all strains were chloroquine-resistant (IC50: 113 nM).  CONCLUSION:  The peptide alpha',beta'-epoxyketone epoxomicin is highly active against P. falciparum regardless the grade of the parasite's chloroquine susceptibility.  Therefore, inhibition of the proteasome is a highly promising strategy to develop new antimalarials.  Epoxomicin can serve as a standard to compare new inhibitors with species-specific activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIl1PrcUBdeSXXDYhVZBdlfW6udTcc2eaMU0Y-tyikJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnntV2luw%253D%253D&md5=9ec8c38d3048e51bec85de327a1fb880</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1186%2F1475-2875-7-187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2875-7-187%26sid%3Dliteratum%253Aachs%26aulast%3DKreidenweiss%26aufirst%3DA.%26aulast%3DKremsner%26aufirst%3DP.%2BG.%26aulast%3DMordmuller%26aufirst%3DB.%26atitle%3DComprehensive%2520study%2520of%2520proteasome%2520inhibitors%2520against%2520Plasmodium%2520falciparum%2520laboratory%2520strains%2520and%2520field%2520isolates%2520from%2520Gabon%26jtitle%3DMalar.%2520J.%26date%3D2008%26volume%3D7%26spage%3D187%26doi%3D10.1186%2F1475-2875-7-187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesvizky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamadani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vescio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bacco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span> <span> </span><span class="NLM_article-title">Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1512</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(14)71125-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FS1470-2045%2814%2971125-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=25456369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFegt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1503-1512&author=S.+K.+Kumarauthor=J.+G.+Berdejaauthor=R.+Niesvizkyauthor=S.+Lonialauthor=J.+P.+Laubachauthor=M.+Hamadaniauthor=A.+K.+Stewartauthor=P.+Hariauthor=V.+Royauthor=R.+Vescioauthor=J.+L.+Kaufmanauthor=D.+Bergauthor=E.+Liaoauthor=A.+Di+Baccoauthor=J.+Estevamauthor=N.+Guptaauthor=A.+M.+Huiauthor=V.+Rajkumarauthor=P.+G.+Richardson&title=Safety+and+tolerability+of+ixazomib%2C+an+oral+proteasome+inhibitor%2C+in+combination+with+lenalidomide+and+dexamethasone+in+patients+with+previously+untreated+multiple+myeloma%3A+an+open-label+phase+1%2F2+study&doi=10.1016%2FS1470-2045%2814%2971125-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study</span></div><div class="casAuthors">Kumar, Shaji K.; Berdeja, Jesus G.; Niesvizky, Ruben; Lonial, Sagar; Laubach, Jacob P.; Hamadani, Mehdi; Stewart, A. Keith; Hari, Parameswaran; Roy, Vivek; Vescio, Robert; Kaufman, Jonathan L.; Berg, Deborah; Liao, Eileen; Di Bacco, Alessandra; Estevam, Jose; Gupta, Neeraj; Hui, Ai-Min; Rajkumar, Vincent; Richardson, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1503-1512</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma.  Ixazomib is an investigational, oral, proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy.  In a phase 1/2 trial we aimed to assess the safety, tolerability, and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma.  We enrolled patients newly diagnosed with multiple myeloma aged 18 years or older with measurable disease, Eastern Cooperative Oncol. Group performance status 0-2, and no grade 2 or higher peripheral neuropathy, and treated them with oral ixazomib (days 1, 8, 15) plus lenalidomide 25 mg (days 1-21) and dexamethasone 40 mg (days 1, 8, 15, 22) for up to 12 28-day cycles, followed by maintenance therapy with ixazomib alone.  In phase 1, we gave patients escalating doses of ixazomib (1·68-3·95 mg/m2) to establish the recommended dose for phase 2.  The primary endpoints were max. tolerated dose for phase 1, and the rate of very good partial response or better for phase 2.  Safety analyses were done in all patients who received at least one dose of study drug; efficacy analyses were done in all patients who received at least one dose of study drug at the phase 2 dose, had measurable disease at baseline, and had at least one post-baseline response assessment.  This study is registered at ClinicalTrials.gov, no. NCT01217957.  Between Nov 22, 2010, and Feb 28, 2012, we enrolled 65 patients (15 to phase 1 and 50 to phase 2).  Four dose-limiting toxic events were noted in phase 1: one at a dose of ixazomib of 2·97 mg/m2 and three at 3·95 mg/m2.  The max. tolerated dose of ixazomib was established as 2·97 mg/m2 and the recommended phase 2 dose was 2·23 mg/m2, which was converted to a 4·0 mg fixed dose based on population pharmacokinetic results.  Grade 3 or higher adverse events related to any drug were reported in 41 (63%) patients, including skin and s.c. tissue disorders (11 patients, 17%), neutropenia (eight patients, 12%), and thrombocytopenia (five patients, 8%); drug-related peripheral neuropathy of grade 3 or higher occurred in four (6%) patients.  Five patients discontinued because of adverse events.  In 64 response-evaluable patients, 37 (58%, 95% CI 45-70) had a very good partial response or better.  The all-oral combination of weekly ixazomib plus lenalidomide and dexamethasone was generally well tolerated and appeared active in newly diagnosed multiple myeloma.  These results support the phase 3 trial development of this combination for multiple myeloma.  Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical International Company.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh9Fp8bQp8sbVg90H21EOLACvtfcHk0lib8XfboYtnhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFegt7zO&md5=59d0683d161783eaee2f9a3260ae7f34</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2971125-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252971125-8%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%2BK.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DNiesvizky%26aufirst%3DR.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DHamadani%26aufirst%3DM.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DRoy%26aufirst%3DV.%26aulast%3DVescio%26aufirst%3DR.%26aulast%3DKaufman%26aufirst%3DJ.%2BL.%26aulast%3DBerg%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DE.%26aulast%3DDi%2BBacco%26aufirst%3DA.%26aulast%3DEstevam%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DHui%26aufirst%3DA.%2BM.%26aulast%3DRajkumar%26aufirst%3DV.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520ixazomib%252C%2520an%2520oral%2520proteasome%2520inhibitor%252C%2520in%2520combination%2520with%2520lenalidomide%2520and%2520dexamethasone%2520in%2520patients%2520with%2520previously%2520untreated%2520multiple%2520myeloma%253A%2520an%2520open-label%2520phase%25201%252F2%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1503%26epage%3D1512%26doi%3D10.1016%2FS1470-2045%2814%2971125-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esseltine, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, K.</span></span> <span> </span><span class="NLM_article-title">Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1111/bcp.12542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1111%2Fbcp.12542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=25377318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2015&pages=789-800&author=N.+Guptaauthor=Y.+Zhaoauthor=A.+M.+Huiauthor=D.+L.+Esseltineauthor=K.+Venkatakrishnan&title=Switching+from+body+surface+area-based+to+fixed+dosing+for+the+investigational+proteasome+inhibitor+ixazomib%3A+a+population+pharmacokinetic+analysis&doi=10.1111%2Fbcp.12542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis</span></div><div class="casAuthors">Gupta, Neeraj; Zhao, Yuan; Hui, Ai-Min; Esseltine, Dixie-Lee; Venkatakrishnan, Karthik</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">789-800</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : This population pharmacokinetic anal. of the investigational oral proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates on ixazomib pharmacokinetics.  Methods : Data were pooled from 226 adult patients with multiple myeloma, lymphoma or solid tumors in four phase 1 studies, in which ixazomib dosing (oral/i.v., once/twice weekly) was based on BSA.  Population pharmacokinetic modeling was undertaken using nonmem version 7.2.  Results : Ixazomib pharmacokinetics were well described by a three compartment model with first order absorption and linear elimination.  Ixazomib was absorbed rapidly (Ka 0.5 h-1), with dose- and time-independent pharmacokinetics.  Estd. abs. bioavailability and clearance were 60% and 2 l h-1, resp.  Although a small effect of BSA (range 1.3-2.6 m2) was obsd. on the peripheral vol. of distribution (V4), reducing the corresponding inter-individual variability by 12.9%, there was no relationship between BSA and ixazomib clearance (the parameter that dictates total systemic exposure following fixed dosing).  Consistently, based on simulations (n = 1000), median AUCs (including interquartile range) were similar after BSA-based (2.23 mg m-2) and fixed (4 mg) oral dosing with no trend in simulated AUC vs.  BSA for fixed dosing (P = 0.42).  No other covariates, including creatinine clearance (22-213.7 mL min-1) and age (23-86 years), influenced ixazomib pharmacokinetics.  Conclusions : This anal. supports a switch from BSA-based to fixed dosing, without dose modification for mild/moderate renal impairment or age, in future adult studies of ixazomib, simplifying dosing guidance and clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvVv5ldaq2LLVg90H21EOLACvtfcHk0lib8XfboYtnhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOnu7g%253D&md5=5f2414207e9f1bf46fe55a907b21a7be</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12542%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHui%26aufirst%3DA.%2BM.%26aulast%3DEsseltine%26aufirst%3DD.%2BL.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26atitle%3DSwitching%2520from%2520body%2520surface%2520area-based%2520to%2520fixed%2520dosing%2520for%2520the%2520investigational%2520proteasome%2520inhibitor%2520ixazomib%253A%2520a%2520population%2520pharmacokinetic%2520analysis%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2015%26volume%3D79%26spage%3D789%26epage%3D800%26doi%3D10.1111%2Fbcp.12542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skacel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, K.</span></span> <span> </span><span class="NLM_article-title">Dose and schedule selection of the oral proteasome inhibitor Ixazomib in relapsed/refractory multiple myeloma: Clinical and model-based analyses</span>. <i>Target Oncol</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1007/s11523-017-0524-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1007%2Fs11523-017-0524-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=28803351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BC1cfntV2quw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=643-654&author=N.+Guptaauthor=H.+Yangauthor=M.+J.+Hanleyauthor=S.+Zhangauthor=R.+Liuauthor=S.+Kumarauthor=P.+G.+Richardsonauthor=T.+Skacelauthor=K.+Venkatakrishnan&title=Dose+and+schedule+selection+of+the+oral+proteasome+inhibitor+Ixazomib+in+relapsed%2Frefractory+multiple+myeloma%3A+Clinical+and+model-based+analyses&doi=10.1007%2Fs11523-017-0524-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses</span></div><div class="casAuthors">Gupta Neeraj; Yang Huyuan; Hanley Michael J; Zhang Steven; Liu Rachael; Skacel Tomas; Venkatakrishnan Karthik; Kumar Shaji; Richardson Paul G; Skacel Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">643-654</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The oral proteasome inhibitor ixazomib has been approved by regulatory authorities around the world, including in the United States and the European Union, for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy, based on the pivotal phase III TOURMALINE-MM1 study.  OBJECTIVE:  The objective of this study was to quantitatively characterize the benefit-risk profile of ixazomib in relapsed/refractory MM in support of the approved dose and schedule.  METHODS:  We report early-phase study data and exposure-response analyses of TOURMALINE-MM1 data that support the selection of the recommended ixazomib dose and schedule.  RESULTS:  Single-agent ixazomib studies showed a favorable efficacy/safety profile with weekly versus twice-weekly dosing; a phase I/II study of ixazomib in combination with lenalidomide and dexamethasone (IRd) identified a weekly ixazomib dose that offered an acceptable efficacy/safety profile.  In IRd exposure-response analyses from TOURMALINE-MM1, ixazomib systemic exposure was not a significant predictor of progression-free survival or probability of response.  Significant associations were observed between ixazomib exposure and the probability of grade ≥3 anemia and thrombocytopenia, and grade ≥2 diarrhea, fatigue, nausea, peripheral neuropathy, and rash.  Additionally, higher ixazomib exposure was associated with lower lenalidomide relative dose intensity.  CONCLUSIONS:  These analyses support a favorable benefit-risk profile for weekly ixazomib 4.0 mg on days 1, 8, and 15 of 28-day cycles, which was selected for the phase III TOURMALINE registration program.  TRIAL REGISTRATION NUMBERS:  ClinicalTrials.gov NCT00932698, NCT00963820, NCT01217957, NCT01564537.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcfHg__x0c9gyMywPm6HgQfW6udTcc2eZT3dM94dlQR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfntV2quw%253D%253D&md5=b1724a7fcfbddeddeeef7a9d2e243b63</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs11523-017-0524-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-017-0524-3%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DHanley%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DSkacel%26aufirst%3DT.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26atitle%3DDose%2520and%2520schedule%2520selection%2520of%2520the%2520oral%2520proteasome%2520inhibitor%2520Ixazomib%2520in%2520relapsed%252Frefractory%2520multiple%2520myeloma%253A%2520Clinical%2520and%2520model-based%2520analyses%26jtitle%3DTarget%2520Oncol%26date%3D2017%26volume%3D12%26spage%3D643%26epage%3D654%26doi%3D10.1007%2Fs11523-017-0524-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Bissati, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandenburg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamoun, C. B.</span></span> <span> </span><span class="NLM_article-title">Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B</span>. <i>BMC Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13</span>, <span class="refDoi"> DOI: 10.1186/1472-6904-7-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1186%2F1472-6904-7-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=17956613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FlvFKjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=13&author=J.+M.+Reynoldsauthor=K.+El+Bissatiauthor=J.+Brandenburgauthor=A.+Gunzlauthor=C.+B.+Mamoun&title=Antimalarial+activity+of+the+anticancer+and+proteasome+inhibitor+bortezomib+and+its+analog+ZL3B&doi=10.1186%2F1472-6904-7-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B</span></div><div class="casAuthors">Reynolds Jennifer M; El Bissati Kamal; Brandenburg Jens; Gunzl Arthur; Mamoun Choukri Ben</div><div class="citationInfo"><span class="NLM_cas:title">BMC clinical pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The high rate of mortality due to malaria and the worldwide distribution of parasite resistance to the commonly used antimalarial drugs chloroquine and pyrimethamine emphasize the urgent need for the development of new antimalarial drugs.  An alternative approach to the long and uncertain process of designing and developing new compounds is to identify among the armamentarium of drugs already approved for clinical treatment of various human diseases those that may have strong antimalarial activity.  METHODS:  Proteasome inhibitor bortezomib (Velcade: [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid), which has been approved for treatment of patients with multiple myeloma, and a second boronate analog Z-Leu-Leu-Leu-B(OH)2 (ZL3B), were tested against four different strains of P. falciparum (3D7, HB3, W2 and Dd2) that are either sensitive or have different levels of resistance to the antimalarial drugs pyrimethamine and chloroquine.  RESULTS:  Bortezomib and ZL3B are equally effective against drug-sensitive and -resistant parasites and block intraerythrocytic development prior to DNA synthesis, but have no effect on parasite egress or invasion.  CONCLUSION:  The identification of bortezomib and its analog as potent antimalarial drugs will set the stage for the advancement of this class of compounds, either alone or in combination therapy, for treatment of malaria, and emphasize the need for large-scale screens to identify new antimalarials within the library of clinically approved compounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQljLNm0aFRXgyMywPm6HgQfW6udTcc2eZT3dM94dlQR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FlvFKjtQ%253D%253D&md5=e2281d7f721b80debc3aabad89e65234</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1186%2F1472-6904-7-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6904-7-13%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DJ.%2BM.%26aulast%3DEl%2BBissati%26aufirst%3DK.%26aulast%3DBrandenburg%26aufirst%3DJ.%26aulast%3DGunzl%26aufirst%3DA.%26aulast%3DMamoun%26aufirst%3DC.%2BB.%26atitle%3DAntimalarial%2520activity%2520of%2520the%2520anticancer%2520and%2520proteasome%2520inhibitor%2520bortezomib%2520and%2520its%2520analog%2520ZL3B%26jtitle%3DBMC%2520Clin.%2520Pharmacol.%26date%3D2007%26volume%3D7%26spage%3D13%26doi%3D10.1186%2F1472-6904-7-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, P. H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. R. S.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin proteasome system as a potential drug target for malaria</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.2174/1568026618666180427145308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.2174%2F1568026618666180427145308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=29701143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjnt1KrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=315-320&author=P.+H.+S.+Pereiraauthor=C.+Curraauthor=C.+R.+S.+Garcia&title=Ubiquitin+proteasome+system+as+a+potential+drug+target+for+malaria&doi=10.2174%2F1568026618666180427145308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin Proteasome System as a Potential Drug Target for Malaria</span></div><div class="casAuthors">Pereira Pedro H Scarpelli; Curra Chiara; Garcia Celia R S; Pereira Pedro H Scarpelli; Curra Chiara</div><div class="citationInfo"><span class="NLM_cas:title">Current topics in medicinal chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-320</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parasites of Plasmodium genus are responsible for causing malaria in humans.  Resistant strains to all available antimalarials can be found in several locations around the globe, including parasites resistant to the latest generation of combination drugs, such as piperaquine + artemisinin.  Plasmodium develops between two completely different hosts such as a vertebrate one and the mosquito vector, thus it has the ability to adapt to very extreme and different environments.  Through the complex life cycle in the hosts, Plasmodium invades and replicates in totally different cells thus making the study of the biology of the parasite and the identification of targets for drug development affecting all stages very difficult.  It was shown that host molecules, such as melatonin and derivatives, have a role in the progression and regulation of the parasite cell cycle; In fact, when the parasite is exposed to melatonin there is an increase in transcription levels of genes encoding for proteins related to the Ubiquitin Proteasome (UPS) System.  This system is essential for the survival of the parasite, and drugs such as bortezomib, MLN-273, ZL3B, epoxomicins and salinosporamides are capable of eliminating the parasite by inhibiting the degradation of proteins via the proteasome system.  In addition, the Plasmodium UPS shows low similarity to the ubiquitin proteasome system in Humans; the identification of unique targets to be used for therapeutic molecules development increases the importance of UPS studies in malaria challenging.  Drugs that cause oxidative stress, such as artemisinin, show a strong synergistic effect with proteasome inhibitors, increasing the possibilities of combined therapies, which are more effective with lower concentration of drugs.  Thus, the study of the mechanism of action of the UPS and the identification of potential targets for new drugs development are promising alternative strategies to fight the drug-resistance problem in malaria parasites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFuYTWOhkk5K-9TkgmBqTqfW6udTcc2eZT3dM94dlQR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjnt1KrsA%253D%253D&md5=cfcda145065cb7d3a9e17e4b9878a27e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1568026618666180427145308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026618666180427145308%26sid%3Dliteratum%253Aachs%26aulast%3DPereira%26aufirst%3DP.%2BH.%2BS.%26aulast%3DCurra%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DC.%2BR.%2BS.%26atitle%3DUbiquitin%2520proteasome%2520system%2520as%2520a%2520potential%2520drug%2520target%2520for%2520malaria%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2018%26volume%3D18%26spage%3D315%26epage%3D320%26doi%3D10.2174%2F1568026618666180427145308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span> <span> </span><span class="NLM_article-title">Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.2012.11-0302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.4269%2Fajtmh.2012.11-0302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=22232455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1ymu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=84-92&author=S.+Duffyauthor=V.+M.+Avery&title=Development+and+optimization+of+a+novel+384-well+anti-malarial+imaging+assay+validated+for+high-throughput+screening&doi=10.4269%2Fajtmh.2012.11-0302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening</span></div><div class="casAuthors">Duffy, Sandra; Avery, Vicky M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-92</span>CODEN:
                <span class="NLM_cas:coden">AJTHAB</span>;
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    
            (<span class="NLM_cas:orgname">American Society of Tropical Medicine and Hygiene</span>)
        </div><div class="casAbstract">With the increasing occurrence of drug resistance in the malaria parasite, Plasmodium falciparum, there is a great need for new and novel anti-malarial drugs.  We have developed a 384-well, high-throughput imaging assay for the detection of new anti-malarial compds., which was initially validated by screening a marine natural product library, and subsequently used to screen more than 3 million data points from a variety of compd. sources.  Founded on another fluorescence-based P. falciparum growth inhibition assay, the DNA-intercalating dye 4',6-diamidino-2-phenylindole, was used to monitor changes in parasite no.  Fluorescent images were acquired on the PerkinElmer Opera High Throughput confocal imaging system and analyzed with a spot detection algorithm using the Acapella data processing software.  Further optimization of this assay sought to increase throughput, assay stability, and compatibility with our high-throughput screening equipment platforms.  The assay typically yielded Z'-factor values of 0.5-0.6, with signal-to-noise ratios of 12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9mpHAvJlL67Vg90H21EOLACvtfcHk0lhnDkH1Q0pvUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1ymu7k%253D&md5=60ae874f46758c03566acfdc948e1188</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.2012.11-0302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.2012.11-0302%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DS.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26atitle%3DDevelopment%2520and%2520optimization%2520of%2520a%2520novel%2520384-well%2520anti-malarial%2520imaging%2520assay%2520validated%2520for%2520high-throughput%2520screening%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D2012%26volume%3D86%26spage%3D84%26epage%3D92%26doi%3D10.4269%2Fajtmh.2012.11-0302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigstad, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sappal, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J. L.</span></span> <span> </span><span class="NLM_article-title">Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>430</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1042/BJ20100383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1042%2FBJ20100383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=20632995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=461-476&author=C.+Blackburnauthor=K.+M.+Gigstadauthor=P.+Halesauthor=K.+Garciaauthor=M.+Jonesauthor=F.+J.+Bruzzeseauthor=C.+Barrettauthor=J.+X.+Liuauthor=T.+A.+Soucyauthor=D.+S.+Sappalauthor=N.+Bumpauthor=E.+J.+Olhavaauthor=P.+Flemingauthor=L.+R.+Dickauthor=C.+Tsuauthor=M.+D.+Sintchakauthor=J.+L.+Blank&title=Characterization+of+a+new+series+of+non-covalent+proteasome+inhibitors+with+exquisite+potency+and+selectivity+for+the+20S+beta5-subunit&doi=10.1042%2FBJ20100383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit</span></div><div class="casAuthors">Blackburn, Christopher; Gigstad, Kenneth M.; Hales, Paul; Garcia, Khristofer; Jones, Matthew; Bruzzese, Frank J.; Barrett, Cynthia; Liu, Jane X.; Soucy, Teresa A.; Sappal, Darshan S.; Bump, Nancy; Olhava, Edward J.; Fleming, Paul; Dick, Lawrence R.; Tsu, Christopher; Sintchak, Michael D.; Blank, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-476</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The mammalian 26S proteasome is a 2500 kDa multi-catalytic complex involved in intracellular protein degrdn.  The authors describe the synthesis and properties of a novel series of non-covalent di-peptide inhibitors of the proteasome based on a capped tripeptide that was first identified by high-throughput screening of a library of approx. 350000 compds. for inhibitors of the ubiquitin-proteasome system in cells.  It is shown that these compds. are entirely selective for the β5 (chymotrypsin-like) site over the β1 (caspase-like) and β2 (trypsin-like) sites of the 20S core particle of the proteasome, and over a panel of less closely related proteases.  Compd. optimization, guided by x-ray crystallog. of the liganded 20S core particle, confirmed their non-covalent binding mode and provided a structural basis for their enhanced in vitro and cellular potencies.  The authors demonstrate that such compds. show low nanomolar IC50 values for the human 20S β5 site in vitro, and that pharmacol. inhibition of this site in cells is sufficient to potently inhibit the degrdn. of a tetra-ubiquitin-luciferase reporter, activation of NFκB (nuclear factor κB) in response to TNF-α (tumor necrosis factor-α) and the proliferation of cancer cells.  Finally, the authors identified capped dipeptides that show differential selectivity for the β5 site of the constitutively expressed proteasome and immunoproteasome in vitro and in B-cell lymphomas.  Collectively, these studies describe the synthesis, activity and binding mode of a new series of non-covalent proteasome inhibitors with unprecedented potency and selectivity for the β5 site, and which can discriminate between the constitutive proteasome and immunoproteasome in vitro and in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodAundpO9R0LVg90H21EOLACvtfcHk0lh1F1LppuNvUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtb3O&md5=de750c60263f0ec83961326ae2b94445</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1042%2FBJ20100383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100383%26sid%3Dliteratum%253Aachs%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DGigstad%26aufirst%3DK.%2BM.%26aulast%3DHales%26aufirst%3DP.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DBarrett%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%2BX.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DSappal%26aufirst%3DD.%2BS.%26aulast%3DBump%26aufirst%3DN.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DBlank%26aufirst%3DJ.%2BL.%26atitle%3DCharacterization%2520of%2520a%2520new%2520series%2520of%2520non-covalent%2520proteasome%2520inhibitors%2520with%2520exquisite%2520potency%2520and%2520selectivity%2520for%2520the%252020S%2520beta5-subunit%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26spage%3D461%26epage%3D476%26doi%3D10.1042%2FBJ20100383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1016/j.str.2005.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2Fj.str.2005.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=16531229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=451-456&author=M.+Grollauthor=C.+R.+Berkersauthor=H.+L.+Ploeghauthor=H.+Ovaa&title=Crystal+structure+of+the+boronic+acid-based+proteasome+inhibitor+bortezomib+in+complex+with+the+yeast+20S+proteasome&doi=10.1016%2Fj.str.2005.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome</span></div><div class="casAuthors">Groll, Michael; Berkers, Celia R.; Ploegh, Hidde L.; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">451-456</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The dipeptide boronic acid bortezomib, also termed VELCADE is a proteasome inhibitor now in use for the treatment of multiple myeloma, and its use for the treatment of other malignancies is being explored.  We detd. the crystal structure of the yeast 20S proteasome in complex with bortezomib to establish the specificity and binding mode of bortezomib to the proteasome's different catalytically active sites.  This structure should enable the rational design of new boronic acid derivs. with improved affinities and specificities for individual active subunits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpusGzFSuveALVg90H21EOLACvtfcHk0lh1F1LppuNvUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1ylsL8%253D&md5=d5b4e46e5a9f5259cce758770302b4fe</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2005.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2005.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DCrystal%2520structure%2520of%2520the%2520boronic%2520acid-based%2520proteasome%2520inhibitor%2520bortezomib%2520in%2520complex%2520with%2520the%2520yeast%252020S%2520proteasome%26jtitle%3DStructure%26date%3D2006%26volume%3D14%26spage%3D451%26epage%3D456%26doi%3D10.1016%2Fj.str.2005.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kupperman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannerman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1970</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-2766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1158%2F0008-5472.CAN-09-2766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=20160034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1970-1980&author=E.+Kuppermanauthor=E.+C.+Leeauthor=Y.+Caoauthor=B.+Bannermanauthor=M.+Fitzgeraldauthor=A.+Bergerauthor=J.+Yuauthor=Y.+Yangauthor=P.+Halesauthor=F.+Bruzzeseauthor=J.+Liuauthor=J.+Blankauthor=K.+Garciaauthor=C.+Tsuauthor=L.+Dickauthor=P.+Flemingauthor=L.+Yuauthor=M.+Manfrediauthor=M.+Rolfeauthor=J.+Bolen&title=Evaluation+of+the+proteasome+inhibitor+MLN9708+in+preclinical+models+of+human+cancer&doi=10.1158%2F0008-5472.CAN-09-2766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer</span></div><div class="casAuthors">Kupperman, Erik; Lee, Edmund C.; Cao, Yueying; Bannerman, Bret; Fitzgerald, Michael; Berger, Allison; Yu, Jie; Yang, Yu; Bruzzese, Frank; Liu, Jane; Blank, Jonathan; Garcia, Khristofer; Tsu, Christopher; Dick, Larry; Fleming, Paul; Yu, Li; Manfredi, Mark; Rolfe, Mark; Bolen, Joe</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1970-1980</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The proteasome was validated as an oncol. target following the clin. success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma.  Consequently, several groups are pursuing the development of addnl. small-mol. proteasome inhibitors for both hematol. and solid tumor indications.  Here, we describe MLN9708, a selective, orally bioavailable, second-generation proteasome inhibitor that is in phase I clin. development.  MLN9708 has a shorter proteasome dissocn. half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib.  MLN9708 has a larger blood vol. distribution at steady state, and anal. of 20S proteasome inhibition and markers of the unfolded protein response confirmed that MLN9708 has greater pharmacodynamic effects in tissues than bortezomib.  MLN9708 showed activity in both solid tumor and hematol. preclin. xenograft models, and we found a correlation between greater pharmacodynamic responses and improved antitumor activity.  Moreover, antitumor activity was shown via multiple dosing routes, including oral gavage.  Taken together, these data support the clin. development of MLN9708 for both hematol. and solid tumor indications.  Cancer Res; 70(5); 1970-80.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjauqAFEgDA7Vg90H21EOLACvtfcHk0lh1F1LppuNvUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWisro%253D&md5=45636404582fc0eb66581c6c19420458</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2766%26sid%3Dliteratum%253Aachs%26aulast%3DKupperman%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DE.%2BC.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DBannerman%26aufirst%3DB.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHales%26aufirst%3DP.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBlank%26aufirst%3DJ.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520the%2520proteasome%2520inhibitor%2520MLN9708%2520in%2520preclinical%2520models%2520of%2520human%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1970%26epage%3D1980%26doi%3D10.1158%2F0008-5472.CAN-09-2766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banaszynski, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard-Smith, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooi, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandless, T. J.</span></span> <span> </span><span class="NLM_article-title">A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">995</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2Fj.cell.2006.07.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=16959577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvVKiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2006&pages=995-1004&author=L.+A.+Banaszynskiauthor=L.+C.+Chenauthor=L.+A.+Maynard-Smithauthor=A.+G.+Ooiauthor=T.+J.+Wandless&title=A+rapid%2C+reversible%2C+and+tunable+method+to+regulate+protein+function+in+living+cells+using+synthetic+small+molecules&doi=10.1016%2Fj.cell.2006.07.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules</span></div><div class="casAuthors">Banaszynski, Laura A.; Chen, Ling-chun; Maynard-Smith, Lystranne A.; Ooi, A. G. Lisa; Wandless, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">995-1004</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Rapid and reversible methods for perturbing the function of specific proteins are desirable tools for probing complex biol. systems.  We have developed a general technique to regulate the stability of specific proteins in mammalian cells using cell-permeable, synthetic mols.  We engineered mutants of the human FKBP12 protein that are rapidly and constitutively degraded when expressed in mammalian cells, and this instability is conferred to other proteins fused to these destabilizing domains.  Addn. of a synthetic ligand that binds to the destabilizing domains shields them from degrdn., allowing fused proteins to perform their cellular functions.  Genetic fusion of the destabilizing domain to a gene of interest ensures specificity, and the attendant small-mol. control confers speed, reversibility, and dose-dependence to this method.  This general strategy for regulating protein stability should enable conditional perturbation of specific proteins with unprecedented control in a variety of exptl. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPVF_0TfXfArVg90H21EOLACvtfcHk0li-Gjj90MOwNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvVKiurs%253D&md5=55b38d7804adfa794a0d991dd704fbde</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DBanaszynski%26aufirst%3DL.%2BA.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DMaynard-Smith%26aufirst%3DL.%2BA.%26aulast%3DOoi%26aufirst%3DA.%2BG.%26aulast%3DWandless%26aufirst%3DT.%2BJ.%26atitle%3DA%2520rapid%252C%2520reversible%252C%2520and%2520tunable%2520method%2520to%2520regulate%2520protein%2520function%2520in%2520living%2520cells%2520using%2520synthetic%2520small%2520molecules%26jtitle%3DCell%26date%3D2006%26volume%3D126%26spage%3D995%26epage%3D1004%26doi%3D10.1016%2Fj.cell.2006.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ariey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duru, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuor, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bout, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, W. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandeur, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringwald, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Bras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barale, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit-Vical, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercereau-Puijalon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, D.</span></span> <span> </span><span class="NLM_article-title">A molecular marker of artemisinin-resistant <i>Plasmodium falciparum</i> malaria</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>505</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1038/nature12876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fnature12876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=24352242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A280%3ADC%252BC2c3ns1aqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2014&pages=50-55&author=F.+Arieyauthor=B.+Witkowskiauthor=C.+Amaratungaauthor=J.+Beghainauthor=A.+C.+Langloisauthor=N.+Khimauthor=S.+Kimauthor=V.+Duruauthor=C.+Bouchierauthor=L.+Maauthor=P.+Limauthor=R.+Leangauthor=S.+Duongauthor=S.+Srengauthor=S.+Suonauthor=C.+M.+Chuorauthor=D.+M.+Boutauthor=S.+Menardauthor=W.+O.+Rogersauthor=B.+Gentonauthor=T.+Fandeurauthor=O.+Miottoauthor=P.+Ringwaldauthor=J.+Le+Brasauthor=A.+Berryauthor=J.+C.+Baraleauthor=R.+M.+Fairhurstauthor=F.+Benoit-Vicalauthor=O.+Mercereau-Puijalonauthor=D.+Menard&title=A+molecular+marker+of+artemisinin-resistant+Plasmodium+falciparum+malaria&doi=10.1038%2Fnature12876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A molecular marker of artemisinin-resistant Plasmodium falciparum malaria</span></div><div class="casAuthors">Ariey Frederic; Beghain Johann; Barale Jean-Christophe; Witkowski Benoit; Khim Nimol; Kim Saorin; Duru Valentine; Amaratunga Chanaki; Langlois Anne-Claire; Bouchier Christiane; Ma Laurence; Lim Pharath; Leang Rithea; Duong Socheat; Sreng Sokunthea; Suon Seila; Chuor Char Meng; Bout Denis Mey; Menard Sandie; Berry Antoine; Rogers William O; Genton Blaise; Fandeur Thierry; Miotto Olivo; Ringwald Pascal; Le Bras Jacques; Fairhurst Rick M; Benoit-Vical Francoise; Mercereau-Puijalon Odile; Menard Didier</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">505</span>
        (<span class="NLM_cas:issue">7481</span>),
    <span class="NLM_cas:pages">50-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Plasmodium falciparum resistance to artemisinin derivatives in southeast Asia threatens malaria control and elimination activities worldwide.  To monitor the spread of artemisinin resistance, a molecular marker is urgently needed.  Here, using whole-genome sequencing of an artemisinin-resistant parasite line from Africa and clinical parasite isolates from Cambodia, we associate mutations in the PF3D7_1343700 kelch propeller domain ('K13-propeller') with artemisinin resistance in vitro and in vivo.  Mutant K13-propeller alleles cluster in Cambodian provinces where resistance is prevalent, and the increasing frequency of a dominant mutant K13-propeller allele correlates with the recent spread of resistance in western Cambodia.  Strong correlations between the presence of a mutant allele, in vitro parasite survival rates and in vivo parasite clearance rates indicate that K13-propeller mutations are important determinants of artemisinin resistance.  K13-propeller polymorphism constitutes a useful molecular marker for large-scale surveillance efforts to contain artemisinin resistance in the Greater Mekong Subregion and prevent its global spread.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTg24yBOxa0oSjiVMCqkKxVfW6udTcc2eYHPd1dzLlzSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3ns1aqtg%253D%253D&md5=e25f4dcc9ccc361de4c35e650391b7ca</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature12876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12876%26sid%3Dliteratum%253Aachs%26aulast%3DAriey%26aufirst%3DF.%26aulast%3DWitkowski%26aufirst%3DB.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DBeghain%26aufirst%3DJ.%26aulast%3DLanglois%26aufirst%3DA.%2BC.%26aulast%3DKhim%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DDuru%26aufirst%3DV.%26aulast%3DBouchier%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DLeang%26aufirst%3DR.%26aulast%3DDuong%26aufirst%3DS.%26aulast%3DSreng%26aufirst%3DS.%26aulast%3DSuon%26aufirst%3DS.%26aulast%3DChuor%26aufirst%3DC.%2BM.%26aulast%3DBout%26aufirst%3DD.%2BM.%26aulast%3DMenard%26aufirst%3DS.%26aulast%3DRogers%26aufirst%3DW.%2BO.%26aulast%3DGenton%26aufirst%3DB.%26aulast%3DFandeur%26aufirst%3DT.%26aulast%3DMiotto%26aufirst%3DO.%26aulast%3DRingwald%26aufirst%3DP.%26aulast%3DLe%2BBras%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DA.%26aulast%3DBarale%26aufirst%3DJ.%2BC.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DBenoit-Vical%26aufirst%3DF.%26aulast%3DMercereau-Puijalon%26aufirst%3DO.%26aulast%3DMenard%26aufirst%3DD.%26atitle%3DA%2520molecular%2520marker%2520of%2520artemisinin-resistant%2520Plasmodium%2520falciparum%2520malaria%26jtitle%3DNature%26date%3D2014%26volume%3D505%26spage%3D50%26epage%3D55%26doi%3D10.1038%2Fnature12876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Straimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnadig, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaratunga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duru, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramadani, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dacheux, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urnov, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercereau-Puijalon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit-Vical, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span> <span> </span><span class="NLM_article-title">Drug resistance. K13-propeller mutations confer artemisinin resistance in <i>Plasmodium falciparum</i> clinical isolates</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1126/science.1260867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1126%2Fscience.1260867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=25502314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=428-431&author=J.+Straimerauthor=N.+F.+Gnadigauthor=B.+Witkowskiauthor=C.+Amaratungaauthor=V.+Duruauthor=A.+P.+Ramadaniauthor=M.+Dacheuxauthor=N.+Khimauthor=L.+Zhangauthor=S.+Lamauthor=P.+D.+Gregoryauthor=F.+D.+Urnovauthor=O.+Mercereau-Puijalonauthor=F.+Benoit-Vicalauthor=R.+M.+Fairhurstauthor=D.+Menardauthor=D.+A.+Fidock&title=Drug+resistance.+K13-propeller+mutations+confer+artemisinin+resistance+in+Plasmodium+falciparum+clinical+isolates&doi=10.1126%2Fscience.1260867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates</span></div><div class="casAuthors">Straimer, Judith; Gnaedig, Nina F.; Witkowski, Benoit; Amaratunga, Chanaki; Duru, Valentine; Ramadani, Arba Pramundita; Dacheux, Melanie; Khim, Nimol; Zhang, Lei; Lam, Stephen; Gregory, Philip D.; Urnov, Fyodor D.; Mercereau-Puijalon, Odile; Benoit-Vical, Francoise; Fairhurst, Rick M.; Menard, Didier; Fidock, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6220</span>),
    <span class="NLM_cas:pages">428-431</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The emergence of artemisinin resistance in Southeast Asia imperils efforts to reduce the global malaria burden.  We genetically modified the Plasmodium falciparum K13 locus using zinc-finger nucleases and measured ring-stage survival rates after drug exposure in vitro; these rates correlate with parasite clearance half-lives in artemisinin-treated patients.  With isolates from Cambodia, where resistance first emerged, survival rates decreased from 13 to 49% to 0.3 to 2.4% after the removal of K13 mutations.  Conversely, survival rates in wild-type parasites increased from ≤0.6% to 2 to 29% after the insertion of K13 mutations.  These mutations conferred elevated resistance to recent Cambodian isolates compared with that of ref. lines, suggesting a contemporary contribution of addnl. genetic factors.  Our data provide a conclusive rationale for worldwide K13-propeller sequencing to identify and eliminate artemisinin-resistant parasites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Ml-eUMKETLVg90H21EOLACvtfcHk0lgE6KbGVh1OeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCiur4%253D&md5=5776238fb78428d16bcaed8d16fa73af</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1126%2Fscience.1260867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1260867%26sid%3Dliteratum%253Aachs%26aulast%3DStraimer%26aufirst%3DJ.%26aulast%3DGnadig%26aufirst%3DN.%2BF.%26aulast%3DWitkowski%26aufirst%3DB.%26aulast%3DAmaratunga%26aufirst%3DC.%26aulast%3DDuru%26aufirst%3DV.%26aulast%3DRamadani%26aufirst%3DA.%2BP.%26aulast%3DDacheux%26aufirst%3DM.%26aulast%3DKhim%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLam%26aufirst%3DS.%26aulast%3DGregory%26aufirst%3DP.%2BD.%26aulast%3DUrnov%26aufirst%3DF.%2BD.%26aulast%3DMercereau-Puijalon%26aufirst%3DO.%26aulast%3DBenoit-Vical%26aufirst%3DF.%26aulast%3DFairhurst%26aufirst%3DR.%2BM.%26aulast%3DMenard%26aufirst%3DD.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26atitle%3DDrug%2520resistance.%2520K13-propeller%2520mutations%2520confer%2520artemisinin%2520resistance%2520in%2520Plasmodium%2520falciparum%2520clinical%2520isolates%26jtitle%3DScience%26date%3D2015%26volume%3D347%26spage%3D428%26epage%3D431%26doi%3D10.1126%2Fscience.1260867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells</span>. <i>Cancer Biol. Ther</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.4161%2Fcbt.2.6.573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=14688479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVCjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=694-699&author=J.+Yuauthor=S.+Tiwariauthor=P.+Steinerauthor=L.+Zhang&title=Differential+apoptotic+response+to+the+proteasome+inhibitor+Bortezomib+%5BVELCADE%2C+PS-341%5D+in+Bax-deficient+and+p21-deficient+colon+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Differential apoptotic response to the proteasome inhibitor bortezomib (VELCADE, PS-341) in Bax-deficient and p21-deficient colon cancer cells</span></div><div class="casAuthors">Yu, Jian; Tiwari, Sagarika; Steiner, Philipp; Zhang, Lin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">694-699</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Targeting the ubiquitin-proteasome pathway has emerged as a promising approach for treating cancer.  Bortezomib (VELCADE, formerly known as PS-341), a potent and reversible proteasome inhibitor, is being evaluated in clin. trials for treating multiple myeloma and various other types of hematol. and solid tumors.  Proteasome inhibitors are known to induce apoptosis in human cancer cells.  Nevertheless, the mechanisms of apoptosis induced by proteasome inhibitors remain unclear.  In this study, we investigated the role of p53 and its downstream targets in bortezomib-induced apoptosis in HCT1 16 human colon cancer cells.  We demonstrated that bortezomib induced p53 and activated its downstream genes p21, PUMA and Bax, in a p53-dependent fashion.  However, apoptotic response to bortezomib was not affected by the deletion of p53.  Surprisingly, we found that bortezomib-induced apoptosis was markedly enhanced in the p21-knockout cells, while significantly decreased in the BAX-knockout cells.  Furthermore, in the cells deficient for both Bax and p21, apoptosis was restored to the level in the parental or the p53-deficient cells.  The opposite effects of Bax and p21 were unrelated to the extent of proteasome inhibition and were also obsd. in cells treated with different proteasome inhibitors.  These results indicate that p53 downstream targets can collectively modulate apoptotic response to bortezomib and other proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPB13n2sQQQbVg90H21EOLACvtfcHk0lgE6KbGVh1OeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVCjsbo%253D&md5=7fa6e617dc5a3498cf164b1c8809b239</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.4161%2Fcbt.2.6.573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.2.6.573%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DTiwari%26aufirst%3DS.%26aulast%3DSteiner%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDifferential%2520apoptotic%2520response%2520to%2520the%2520proteasome%2520inhibitor%2520Bortezomib%2520%255BVELCADE%252C%2520PS-341%255D%2520in%2520Bax-deficient%2520and%2520p21-deficient%2520colon%2520cancer%2520cells%26jtitle%3DCancer%2520Biol.%2520Ther%26date%3D2003%26volume%3D2%26spage%3D694%26epage%3D699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baragana, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallyburton, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norcross, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proto, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagborough, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirjanata, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porzelle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luksch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luksch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolscher, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna-Cabello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churcher, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakutansky, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Diaz, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerwein, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechering, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noviyanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frearson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer-Bazaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delves, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marfurt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinden, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebrevska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayner, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">A novel multiple-stage antimalarial agent that inhibits protein synthesis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>522</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1038/nature14451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fnature14451" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=522&publication_year=2015&pages=315-320&author=B.+Baraganaauthor=I.+Hallyburtonauthor=M.+C.+Leeauthor=N.+R.+Norcrossauthor=R.+Grimaldiauthor=T.+D.+Ottoauthor=W.+R.+Protoauthor=A.+M.+Blagboroughauthor=S.+Meisterauthor=G.+Wirjanataauthor=A.+Rueckerauthor=L.+M.+Uptonauthor=T.+S.+Abrahamauthor=M.+J.+Almeidaauthor=A.+Pradhanauthor=A.+Porzelleauthor=T.+Lukschauthor=M.+S.+Martinezauthor=T.+Lukschauthor=J.+M.+Bolscherauthor=A.+Woodlandauthor=S.+Norvalauthor=F.+Zuccottoauthor=J.+Thomasauthor=F.+Simeonsauthor=L.+Stojanovskiauthor=M.+Osuna-Cabelloauthor=P.+M.+Brockauthor=T.+S.+Churcherauthor=K.+A.+Salaauthor=S.+E.+Zakutanskyauthor=M.+B.+Jimenez-Diazauthor=L.+M.+Sanzauthor=J.+Rileyauthor=R.+Basakauthor=M.+Campbellauthor=V.+M.+Averyauthor=R.+W.+Sauerweinauthor=K.+J.+Decheringauthor=R.+Noviyantiauthor=B.+Campoauthor=J.+A.+Frearsonauthor=I.+Angulo-Barturenauthor=S.+Ferrer-Bazagaauthor=F.+J.+Gamoauthor=P.+G.+Wyattauthor=D.+Leroyauthor=P.+Sieglauthor=M.+J.+Delvesauthor=D.+E.+Kyleauthor=S.+Wittlinauthor=J.+Marfurtauthor=R.+N.+Priceauthor=R.+E.+Sindenauthor=E.+A.+Winzelerauthor=S.+A.+Charmanauthor=L.+Bebrevskaauthor=D.+W.+Grayauthor=S.+Campbellauthor=A.+H.+Fairlambauthor=P.+A.+Willisauthor=J.+C.+Raynerauthor=D.+A.+Fidockauthor=K.+D.+Readauthor=I.+H.+Gilbert&title=A+novel+multiple-stage+antimalarial+agent+that+inhibits+protein+synthesis&doi=10.1038%2Fnature14451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnature14451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14451%26sid%3Dliteratum%253Aachs%26aulast%3DBaragana%26aufirst%3DB.%26aulast%3DHallyburton%26aufirst%3DI.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DNorcross%26aufirst%3DN.%2BR.%26aulast%3DGrimaldi%26aufirst%3DR.%26aulast%3DOtto%26aufirst%3DT.%2BD.%26aulast%3DProto%26aufirst%3DW.%2BR.%26aulast%3DBlagborough%26aufirst%3DA.%2BM.%26aulast%3DMeister%26aufirst%3DS.%26aulast%3DWirjanata%26aufirst%3DG.%26aulast%3DRuecker%26aufirst%3DA.%26aulast%3DUpton%26aufirst%3DL.%2BM.%26aulast%3DAbraham%26aufirst%3DT.%2BS.%26aulast%3DAlmeida%26aufirst%3DM.%2BJ.%26aulast%3DPradhan%26aufirst%3DA.%26aulast%3DPorzelle%26aufirst%3DA.%26aulast%3DLuksch%26aufirst%3DT.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DLuksch%26aufirst%3DT.%26aulast%3DBolscher%26aufirst%3DJ.%2BM.%26aulast%3DWoodland%26aufirst%3DA.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DSimeons%26aufirst%3DF.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DOsuna-Cabello%26aufirst%3DM.%26aulast%3DBrock%26aufirst%3DP.%2BM.%26aulast%3DChurcher%26aufirst%3DT.%2BS.%26aulast%3DSala%26aufirst%3DK.%2BA.%26aulast%3DZakutansky%26aufirst%3DS.%2BE.%26aulast%3DJimenez-Diaz%26aufirst%3DM.%2BB.%26aulast%3DSanz%26aufirst%3DL.%2BM.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DBasak%26aufirst%3DR.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DAvery%26aufirst%3DV.%2BM.%26aulast%3DSauerwein%26aufirst%3DR.%2BW.%26aulast%3DDechering%26aufirst%3DK.%2BJ.%26aulast%3DNoviyanti%26aufirst%3DR.%26aulast%3DCampo%26aufirst%3DB.%26aulast%3DFrearson%26aufirst%3DJ.%2BA.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DFerrer-Bazaga%26aufirst%3DS.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DLeroy%26aufirst%3DD.%26aulast%3DSiegl%26aufirst%3DP.%26aulast%3DDelves%26aufirst%3DM.%2BJ.%26aulast%3DKyle%26aufirst%3DD.%2BE.%26aulast%3DWittlin%26aufirst%3DS.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DR.%2BN.%26aulast%3DSinden%26aufirst%3DR.%2BE.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DBebrevska%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DWillis%26aufirst%3DP.%2BA.%26aulast%3DRayner%26aufirst%3DJ.%2BC.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DA%2520novel%2520multiple-stage%2520antimalarial%2520agent%2520that%2520inhibits%2520protein%2520synthesis%26jtitle%3DNature%26date%3D2015%26volume%3D522%26spage%3D315%26epage%3D320%26doi%3D10.1038%2Fnature14451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanz, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Cozar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavandera, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peishoff, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardon, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Bustos, J. F.</span></span> <span> </span><span class="NLM_article-title">Thousands of chemical starting points for antimalarial lead identification</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1038/nature09107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fnature09107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=20485427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmt1Ois7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=305-310&author=F.+J.+Gamoauthor=L.+M.+Sanzauthor=J.+Vidalauthor=C.+de+Cozarauthor=E.+Alvarezauthor=J.+L.+Lavanderaauthor=D.+E.+Vanderwallauthor=D.+V.+Greenauthor=V.+Kumarauthor=S.+Hasanauthor=J.+R.+Brownauthor=C.+E.+Peishoffauthor=L.+R.+Cardonauthor=J.+F.+Garcia-Bustos&title=Thousands+of+chemical+starting+points+for+antimalarial+lead+identification&doi=10.1038%2Fnature09107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Thousands of chemical starting points for antimalarial lead identification</span></div><div class="casAuthors">Gamo, Francisco-Javier; Sanz, Laura M.; Vidal, Jaume; de Cozar, Cristina; Alvarez, Emilio; Lavandera, Jose-Luis; Vanderwall, Dana E.; Green, Darren V. S.; Kumar, Vinod; Hasan, Samiul; Brown, James R.; Peishoff, Catherine E.; Cardon, Lon R.; Garcia-Bustos, Jose F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7296</span>),
    <span class="NLM_cas:pages">305-310</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Malaria is a devastating infection caused by protozoa of the genus Plasmodium.  Drug resistance is widespread, no new chem. class of antimalarials has been introduced into clin. practice since 1996 and there is a recent rise of parasite strains with reduced sensitivity to the newest drugs.  We screened nearly 2 million compds. in GlaxoSmithKline's chem. library for inhibitors of P. falciparum, of which 13,533 were confirmed to inhibit parasite growth by at least 80% at 2 μM concn.  More than 8,000 also showed potent activity against the multidrug resistant strain Dd2.  Most (82%) compds. originate from internal company projects and are new to the malaria community.  Analyses using historic assay data suggest several novel mechanisms of antimalarial action, such as inhibition of protein kinases and host-pathogen interaction related targets.  Chem. structures and assocd. data are hereby made public to encourage addnl. drug lead identification efforts and further research into this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHijpWK_kBF7Vg90H21EOLACvtfcHk0lgVmNSCLyxavw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmt1Ois7k%253D&md5=a1fd8c0b89a5650ecba31f5456928b42</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature09107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09107%26sid%3Dliteratum%253Aachs%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DSanz%26aufirst%3DL.%2BM.%26aulast%3DVidal%26aufirst%3DJ.%26aulast%3Dde%2BCozar%26aufirst%3DC.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DLavandera%26aufirst%3DJ.%2BL.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DGreen%26aufirst%3DD.%2BV.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DHasan%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DPeishoff%26aufirst%3DC.%2BE.%26aulast%3DCardon%26aufirst%3DL.%2BR.%26aulast%3DGarcia-Bustos%26aufirst%3DJ.%2BF.%26atitle%3DThousands%2520of%2520chemical%2520starting%2520points%2520for%2520antimalarial%2520lead%2520identification%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D305%26epage%3D310%26doi%3D10.1038%2Fnature09107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wree, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plouffe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Mutations in the <i>Plasmodium falciparum</i> Cyclic Amine Resistance Locus (PfCARL) confer multidrug resistance</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e00696-16</span>, <span class="refDoi"> DOI: 10.1128/mBio.00696-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1128%2FmBio.00696-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=27381290" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=e00696-16&author=G.+LaMonteauthor=M.+Y.+Limauthor=M.+Wreeauthor=C.+Reimerauthor=M.+Nachonauthor=V.+Coreyauthor=P.+Gedeckauthor=D.+Plouffeauthor=A.+Duauthor=N.+Figueroaauthor=B.+Yeungauthor=P.+Bifaniauthor=E.+A.+Winzeler&title=Mutations+in+the+Plasmodium+falciparum+Cyclic+Amine+Resistance+Locus+%28PfCARL%29+confer+multidrug+resistance&doi=10.1128%2FmBio.00696-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1128%2FmBio.00696-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00696-16%26sid%3Dliteratum%253Aachs%26aulast%3DLaMonte%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DM.%2BY.%26aulast%3DWree%26aufirst%3DM.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DNachon%26aufirst%3DM.%26aulast%3DCorey%26aufirst%3DV.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DPlouffe%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DA.%26aulast%3DFigueroa%26aufirst%3DN.%26aulast%3DYeung%26aufirst%3DB.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DMutations%2520in%2520the%2520Plasmodium%2520falciparum%2520Cyclic%2520Amine%2520Resistance%2520Locus%2520%2528PfCARL%2529%2520confer%2520multidrug%2520resistance%26jtitle%3DmBio%26date%3D2016%26volume%3D7%26spage%3De00696-16%26doi%3D10.1128%2FmBio.00696-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Using genetic methods to define the targets of compounds with antimalarial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7761</span>– <span class="NLM_lpage">7771</span>, <span class="refDoi"> DOI: 10.1021/jm400325j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400325j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Chs7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7761-7771&author=E.+L.+Flanneryauthor=D.+A.+Fidockauthor=E.+A.+Winzeler&title=Using+genetic+methods+to+define+the+targets+of+compounds+with+antimalarial+activity&doi=10.1021%2Fjm400325j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Using Genetic Methods To Define the Targets of Compounds with Antimalarial Activity</span></div><div class="casAuthors">Flannery, Erika L.; Fidock, David A.; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7761-7771</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Although phenotypic cellular screening has been used to drive antimalarial drug discovery in recent years, in some cases target-based drug discovery remains more attractive.  This is esp. true when appropriate high-throughput cellular assays are lacking, as is the case for drug discovery efforts that aim to provide a replacement for primaquine (4-N-(6-methoxyquinolin-8-yl)-pentane-1,4-diamine), the only drug that can block Plasmodium transmission to Anopheles mosquitoes and eliminate liver-stage hypnozoites.  At present, however, there are no known chem. validated parasite protein targets that are important in all Plasmodium parasite developmental stages and that can be used in traditional biochem. compd. screens.  We propose that a plethora of novel, chem. validated, cross-stage antimalarial targets still remain to be discovered from the ∼5,500 proteins encoded by the Plasmodium genomes.  Here we discuss how in vitro evolution of drug-resistant strains of Plasmodium falciparum and subsequent whole-genome anal. can be used to find the targets of some of the many compds. discovered in whole-cell phenotypic screens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKGylYC1n7jLVg90H21EOLACvtfcHk0lgVmNSCLyxavw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Chs7bO&md5=89334c4fd625e02c7e8a949440ec6aa9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm400325j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400325j%26sid%3Dliteratum%253Aachs%26aulast%3DFlannery%26aufirst%3DE.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DUsing%2520genetic%2520methods%2520to%2520define%2520the%2520targets%2520of%2520compounds%2520with%2520antimalarial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7761%26epage%3D7771%26doi%3D10.1021%2Fjm400325j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schrader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henneberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mata, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tittmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourenkov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, A.</span></span> <span> </span><span class="NLM_article-title">The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1126/science.aaf8993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1126%2Fscience.aaf8993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=27493187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2016&pages=594-598&author=J.+Schraderauthor=F.+Hennebergauthor=R.+A.+Mataauthor=K.+Tittmannauthor=T.+R.+Schneiderauthor=H.+Starkauthor=G.+Bourenkovauthor=A.+Chari&title=The+inhibition+mechanism+of+human+20S+proteasomes+enables+next-generation+inhibitor+design&doi=10.1126%2Fscience.aaf8993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design</span></div><div class="casAuthors">Schrader, Jil; Henneberg, Fabian; Mata, Ricardo A.; Tittmann, Kai; Schneider, Thomas R.; Stark, Holger; Bourenkov, Gleb; Chari, Ashwin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">6299</span>),
    <span class="NLM_cas:pages">594-598</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The proteasome is a validated target for anticancer therapy, and proteasome inhibition is employed in the clinic for the treatment of tumors and hematol. malignancies.  Here, the authors describe crystal structures of the native human 20S proteasome and its complexes with inhibitors, which either are drugs approved for cancer treatment or are in clin. trials.  The structure of the native human 20S proteasome was detd. at an unprecedented resoln. of 1.8 angstroms.  Addnl., six inhibitor-proteasome complex structures were elucidated at resolns. between 1.9 and 2.1 angstroms.  Collectively, the high-resoln. structures provide new insights into the catalytic mechanisms of inhibition and necessitate a revised description of the proteasome active site.  Knowledge about inhibition mechanisms provides insights into peptide hydrolysis and can guide strategies for the development of next-generation proteasome-based cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZCuIDBbOXPLVg90H21EOLACvtfcHk0ligAzPacdkxjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oks7vL&md5=8216d0007cbf06c352e06fcb05d644a9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaf8993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaf8993%26sid%3Dliteratum%253Aachs%26aulast%3DSchrader%26aufirst%3DJ.%26aulast%3DHenneberg%26aufirst%3DF.%26aulast%3DMata%26aufirst%3DR.%2BA.%26aulast%3DTittmann%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DBourenkov%26aufirst%3DG.%26aulast%3DChari%26aufirst%3DA.%26atitle%3DThe%2520inhibition%2520mechanism%2520of%2520human%252020S%2520proteasomes%2520enables%2520next-generation%2520inhibitor%2520design%26jtitle%3DScience%26date%3D2016%26volume%3D353%26spage%3D594%26epage%3D598%26doi%3D10.1126%2Fscience.aaf8993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franke, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewerth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Meerloo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vojtekova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zantwijk, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweegman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geerke, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspers, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span> <span> </span><span class="NLM_article-title">Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fleu.2011.256" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=757-768&author=N.+E.+Frankeauthor=D.+Niewerthauthor=Y.+G.+Assarafauthor=J.+van+Meerlooauthor=K.+Vojtekovaauthor=C.+H.+van+Zantwijkauthor=S.+Zweegmanauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=D.+P.+Geerkeauthor=A.+D.+Schimmerauthor=G.+J.+Kaspersauthor=G.+Jansenauthor=J.+Cloos&title=Impaired+bortezomib+binding+to+mutant+beta5+subunit+of+the+proteasome+is+the+underlying+basis+for+bortezomib+resistance+in+leukemia+cells&doi=10.1038%2Fleu.2011.256"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.256%26sid%3Dliteratum%253Aachs%26aulast%3DFranke%26aufirst%3DN.%2BE.%26aulast%3DNiewerth%26aufirst%3DD.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3Dvan%2BMeerloo%26aufirst%3DJ.%26aulast%3DVojtekova%26aufirst%3DK.%26aulast%3Dvan%2BZantwijk%26aufirst%3DC.%2BH.%26aulast%3DZweegman%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DGeerke%26aufirst%3DD.%2BP.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DCloos%26aufirst%3DJ.%26atitle%3DImpaired%2520bortezomib%2520binding%2520to%2520mutant%2520beta5%2520subunit%2520of%2520the%2520proteasome%2520is%2520the%2520underlying%2520basis%2520for%2520bortezomib%2520resistance%2520in%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D757%26epage%3D768%26doi%3D10.1038%2Fleu.2011.256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrio, S.</span>; <span class="NLM_string-name">Stuhmer, T.</span>; <span class="NLM_string-name">Da-Via, M.</span>; <span class="NLM_string-name">Barrio-Garcia, C.</span>; <span class="NLM_string-name">Lehners, N.</span>; <span class="NLM_string-name">Besse, A.</span>; <span class="NLM_string-name">Cuenca, I.</span>; <span class="NLM_string-name">Garitano-Trojaola, A.</span>; <span class="NLM_string-name">Fink, S.</span>; <span class="NLM_string-name">Leich, E.</span>; <span class="NLM_string-name">Chatterjee, M.</span>; <span class="NLM_string-name">Driessen, C.</span>; <span class="NLM_string-name">Martinez-Lopez, J.</span>; <span class="NLM_string-name">Rosenwald, A.</span>; <span class="NLM_string-name">Beckmann, R.</span>; <span class="NLM_string-name">Bargou, R. C.</span>; <span class="NLM_string-name">Braggio, E.</span>; <span class="NLM_string-name">Stewart, A. K.</span>; <span class="NLM_string-name">Raab, M. S.</span>; <span class="NLM_string-name">Einsele, H.</span>; <span class="NLM_string-name">Kortum, K. M.</span></span> <span> </span><span class="NLM_article-title">Spectrum and functional validation of PSMB5 mutations in multiple myeloma</span>.  <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0216-8</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fs41375-018-0216-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Barrio&author=T.+Stuhmer&author=M.+Da-Via&author=C.+Barrio-Garcia&author=N.+Lehners&author=A.+Besse&author=I.+Cuenca&author=A.+Garitano-Trojaola&author=S.+Fink&author=E.+Leich&author=M.+Chatterjee&author=C.+Driessen&author=J.+Martinez-Lopez&author=A.+Rosenwald&author=R.+Beckmann&author=R.+C.+Bargou&author=E.+Braggio&author=A.+K.+Stewart&author=M.+S.+Raab&author=H.+Einsele&author=K.+M.+Kortum&title=Spectrum+and+functional+validation+of+PSMB5+mutations+in+multiple+myeloma&doi=10.1038%2Fs41375-018-0216-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0216-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0216-8%26sid%3Dliteratum%253Aachs%26aulast%3DBarrio%26aufirst%3DS.%26atitle%3DSpectrum%2520and%2520functional%2520validation%2520of%2520PSMB5%2520mutations%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2018%26doi%3D10.1038%2Fs41375-018-0216-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almaliti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibo-Verdugo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonova-Koch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orjuela-Sanchez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldgof, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, A.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span> <span> </span><span class="NLM_article-title">Development of a potent inhibitor of the Plasmodium proteasome with reduced mammalian toxicity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6721</span>– <span class="NLM_lpage">6732</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00671</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00671" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGitb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6721-6732&author=G.+M.+LaMonteauthor=J.+Almalitiauthor=B.+Bibo-Verdugoauthor=L.+Kellerauthor=B.+Y.+Zouauthor=J.+Yangauthor=Y.+Antonova-Kochauthor=P.+Orjuela-Sanchezauthor=C.+A.+Boyleauthor=E.+Vigilauthor=L.+Wangauthor=G.+M.+Goldgofauthor=L.+Gerwickauthor=A.%0AJ.+O%E2%80%99Donoghueauthor=E.+A.+Winzelerauthor=W.+H.+Gerwickauthor=S.+Ottilie&title=Development+of+a+potent+inhibitor+of+the+Plasmodium+proteasome+with+reduced+mammalian+toxicity&doi=10.1021%2Facs.jmedchem.7b00671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity</span></div><div class="casAuthors">LaMonte, Gregory M.; Almaliti, Jehad; Bibo-Verdugo, Betsaida; Keller, Lena; Zou, Bing Yu; Yang, Jennifer; Antonova-Koch, Yevgeniya; Orjuela-Sanchez, Pamela; Boyle, Colleen A.; Vigil, Edgar; Wang, Lawrence; Goldgof, Gregory M.; Gerwick, Lena; O'Donoghue, Anthony J.; Winzeler, Elizabeth A.; Gerwick, William H.; Ottilie, Sabine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6721-6732</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Naturally derived chem. compds. are the foundation of much of the authors' pharmacopeia, esp. in antiproliferative and anti-infective drug classes.  Here, the authors report that a naturally derived mol. called carmaphycin B is a potent inhibitor against both the asexual and sexual blood stages of malaria infection.  Using a combination of in silico mol. docking and in vitro directed evolution in a well-characterized drug-sensitive yeast model, the authors detd. that these compds. target the β5 subunit of the proteasome.  These studies were validated using in vitro inhibition assays with proteasomes isolated from Plasmodium falciparum.  As carmaphycin B is toxic to mammalian cells, the authors synthesized a series of chem. analogs that reduce host cell toxicity while maintaining blood-stage and gametocytocidal antimalarial activity and proteasome inhibition.  This study describes a promising new class of antimalarial compd. based on the carmaphycin B scaffold, as well as several chem. structural features that serve to enhance antimalarial specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe6ni2uoNcjrVg90H21EOLACvtfcHk0ligAzPacdkxjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGitb3K&md5=947e92a430c789d6f8e1e73abb834604</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00671%26sid%3Dliteratum%253Aachs%26aulast%3DLaMonte%26aufirst%3DG.%2BM.%26aulast%3DAlmaliti%26aufirst%3DJ.%26aulast%3DBibo-Verdugo%26aufirst%3DB.%26aulast%3DKeller%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DB.%2BY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DAntonova-Koch%26aufirst%3DY.%26aulast%3DOrjuela-Sanchez%26aufirst%3DP.%26aulast%3DBoyle%26aufirst%3DC.%2BA.%26aulast%3DVigil%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGoldgof%26aufirst%3DG.%2BM.%26aulast%3DGerwick%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DA.%2BJ.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DGerwick%26aufirst%3DW.%2BH.%26aulast%3DOttilie%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520a%2520potent%2520inhibitor%2520of%2520the%2520Plasmodium%2520proteasome%2520with%2520reduced%2520mammalian%2520toxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6721%26epage%3D6732%26doi%3D10.1021%2Facs.jmedchem.7b00671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span> <i>The PyMOL Molecular Graphics System</i>, version <span class="NLM_edition">1.8</span>; <span class="NLM_publisher-name">Schrödinger</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+PyMOL+Molecular+Graphics+System%2C+version+1.8%3B+Schr%C3%B6dinger%2C+2015."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menendez-Benito, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Nieuwendijk, A.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Leeuwen, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groothuis, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeuwenburgh, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefjes, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippov, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantuma, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1217</span>– <span class="NLM_lpage">1226</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2006.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2Fj.chembiol.2006.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=17114003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Cis7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=1217-1226&author=M.+Verdoesauthor=B.+I.+Floreaauthor=V.+Menendez-Benitoauthor=C.+J.+Maynardauthor=M.+D.+Witteauthor=W.+A.+van+der+Lindenauthor=A.%0AM.+van+den+Nieuwendijkauthor=T.+Hofmannauthor=C.+R.+Berkersauthor=F.+W.+van+Leeuwenauthor=T.+A.+Groothuisauthor=M.+A.+Leeuwenburghauthor=H.+Ovaaauthor=J.+J.+Neefjesauthor=D.+V.+Filippovauthor=G.+A.+van+der+Marelauthor=N.+P.+Dantumaauthor=H.+S.+Overkleeft&title=A+fluorescent+broad-spectrum+proteasome+inhibitor+for+labeling+proteasomes+in+vitro+and+in+vivo&doi=10.1016%2Fj.chembiol.2006.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A Fluorescent Broad-Spectrum Proteasome Inhibitor for Labeling Proteasomes In Vitro and In Vivo</span></div><div class="casAuthors">Verdoes, Martijn; Florea, Bogdan I.; Menendez-Benito, Victoria; Maynard, Christa J.; Witte, Martin D.; van der Linden, Wouter A.; van den Nieuwendijk, Adrianus M. C. H.; Hofmann, Tanja; Berkers, Celia R.; van Leeuwen, Fijs W. B.; Groothuis, Tom A.; Leeuwenburgh, Michiel A.; Ovaa, Huib; Neefjes, Jacques J.; Filippov, Dmitri V.; van der Marel, Gijs A.; Dantuma, Nico P.; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1217-1226</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The proteasome is an essential evolutionary conserved protease involved in many regulatory systems.  Here, the authors describe the synthesis and characterization of the activity-based, fluorescent, and cell-permeable inhibitor Bodipy TMR-Ahx3L3VS (MV151), which specifically targets all active subunits of the proteasome and immunoproteasome in living cells, allowing for rapid and sensitive in-gel detection.  The inhibition profile of a panel of commonly used proteasome inhibitors could be readily detd. by MV151 labeling.  Administration of MV151 to mice allowed for in vivo labeling of proteasomes, which correlated with inhibition of proteasomal degrdn. in the affected tissues.  This probe can be used for many applications ranging from clin. profiling of proteasome activity, to biochem. anal. of subunit specificity of inhibitors, and to cell biol. anal. of the proteasome function and dynamics in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMZq52j_0-wLVg90H21EOLACvtfcHk0ljxpSI7Sczhaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Cis7fN&md5=95b57d47d477020254a0fb2bd24fef87</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DMenendez-Benito%26aufirst%3DV.%26aulast%3DMaynard%26aufirst%3DC.%2BJ.%26aulast%3DWitte%26aufirst%3DM.%2BD.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%2BM.%26aulast%3DHofmann%26aufirst%3DT.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3Dvan%2BLeeuwen%26aufirst%3DF.%2BW.%26aulast%3DGroothuis%26aufirst%3DT.%2BA.%26aulast%3DLeeuwenburgh%26aufirst%3DM.%2BA.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DNeefjes%26aufirst%3DJ.%2BJ.%26aulast%3DFilippov%26aufirst%3DD.%2BV.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DDantuma%26aufirst%3DN.%2BP.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DA%2520fluorescent%2520broad-spectrum%2520proteasome%2520inhibitor%2520for%2520labeling%2520proteasomes%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D1217%26epage%3D1226%26doi%3D10.1016%2Fj.chembiol.2006.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhanot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Assessing subunit dependency of the Plasmodium proteasome using small molecule inhibitors and active site probes</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1869</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1021/cb5001263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVKks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1869-1876&author=H.+Liauthor=W.+A.+van+der+Lindenauthor=M.+Verdoesauthor=B.+I.+Floreaauthor=F.+E.+McAllisterauthor=K.+Govindaswamyauthor=J.+E.+Eliasauthor=P.+Bhanotauthor=H.+S.+Overkleeftauthor=M.+Bogyo&title=Assessing+subunit+dependency+of+the+Plasmodium+proteasome+using+small+molecule+inhibitors+and+active+site+probes&doi=10.1021%2Fcb5001263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing Subunit Dependency of the Plasmodium Proteasome Using Small Molecule Inhibitors and Active Site Probes</span></div><div class="casAuthors">Li, Hao; van der Linden, Wouter A.; Verdoes, Martijn; Florea, Bogdan I.; McAllister, Fiona E.; Govindaswamy, Kavitha; Elias, Joshua E.; Bhanot, Purnima; Overkleeft, Herman S.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1869-1876</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system (UPS) is a potential pathway for therapeutic intervention for pathogens such as Plasmodium, the causative agent of malaria.  However, due to the essential nature of this proteolytic pathway, proteasome inhibitors must avoid inhibition of the host enzyme complex to prevent toxic side effects.  The Plasmodium proteasome is poorly characterized, making rational design of inhibitors that induce selective parasite killing difficult.  In this study, we developed a chem. probe designate BMV037 that labels all catalytic sites of the Plasmodium proteasome.  Using this probe, we identified several subunit-selective small mol. inhibitors of the parasite enzyme complex.  Treatment with an inhibitor that is specific for the β5 subunit during blood stage schizogony led to a dramatic decrease in parasite replication while short-term inhibition of the β2 subunit did not affect viability.  Interestingly, co-inhibition of both the β2 and β5 catalytic subunits resulted in enhanced parasite killing at all stages of the blood stage life cycle and reduced parasite levels in vivo to barely detectable levels.  Parasite killing was achieved with overall low host toxicity, something that has not been possible with existing proteasome inhibitors.  Our results highlight differences in the subunit dependency of the parasite and human proteasome, thus providing a strategy for development of potent antimalarial drugs with overall low host toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9qkR_VrNq2bVg90H21EOLACvtfcHk0ljxpSI7Sczhaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVKks7s%253D&md5=811e1268d8285d4d2b0561f6b1123f6e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcb5001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5001263%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DMcAllister%26aufirst%3DF.%2BE.%26aulast%3DGovindaswamy%26aufirst%3DK.%26aulast%3DElias%26aufirst%3DJ.%2BE.%26aulast%3DBhanot%26aufirst%3DP.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DAssessing%2520subunit%2520dependency%2520of%2520the%2520Plasmodium%2520proteasome%2520using%2520small%2520molecule%2520inhibitors%2520and%2520active%2520site%2520probes%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1869%26epage%3D1876%26doi%3D10.1021%2Fcb5001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foe, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Fonseca, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Structure- and function-based design of Plasmodium-selective proteasome inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>530</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/nature16936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fnature16936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=26863983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=530&publication_year=2016&pages=233-236&author=H.+Liauthor=A.+J.+O%E2%80%99Donoghueauthor=W.+A.+van+der+Lindenauthor=S.+C.+Xieauthor=E.+Yooauthor=I.+T.+Foeauthor=L.+Tilleyauthor=C.+S.+Craikauthor=P.+C.+da+Fonsecaauthor=M.+Bogyo&title=Structure-+and+function-based+design+of+Plasmodium-selective+proteasome+inhibitors&doi=10.1038%2Fnature16936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and function-based design of Plasmodium-selective proteasome inhibitors</span></div><div class="casAuthors">Li, Hao; O'Donoghue, Anthony J.; van der Linden, Wouter A.; Xie, Stanley C.; Yoo, Euna; Foe, Ian T.; Tilley, Leann; Craik, Charles S.; da Fonseca, Paula C. A.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">530</span>
        (<span class="NLM_cas:issue">7589</span>),
    <span class="NLM_cas:pages">233-236</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The proteasome is a multi-component protease complex responsible for regulating key processes such as the cell cycle and antigen presentation.  Compds. that target the proteasome are potentially valuable tools for the treatment of pathogens that depend on proteasome function for survival and replication.  In particular, proteasome inhibitors have been shown to be toxic for the malaria parasite Plasmodium falciparum at all stages of its life cycle.  Most compds. that have been tested against the parasite also inhibit the mammalian proteasome, resulting in toxicity that precludes their use as therapeutic agents.  Therefore, better definition of the substrate specificity and structural properties of the Plasmodium proteasome could enable the development of compds. with sufficient selectivity to allow their use as anti-malarial agents.  To accomplish this goal, here the authors use a substrate profiling method to uncover differences in the specificities of the human and P. falciparum proteasome.  The authors design inhibitors based on amino-acid preferences specific to the parasite proteasome, and find that they preferentially inhibit the β2-subunit.  The authors det. the structure of the P. falciparum 20S proteasome bound to the inhibitor using cryo-electron microscopy and single-particle anal., to a resoln. of 3.6 Å.  These data reveal the unusually open P. falciparum β2 active site and provide valuable information about active-site architecture that can be used to further refine inhibitor design.  Furthermore, consistent with the recent finding that the proteasome is important for stress pathways assocd. with resistance of artemisinin family anti-malarials, the authors observe growth inhibition synergism with low doses of this β2-selective inhibitor in artemisinin-sensitive and -resistant parasites.  Finally, the authors demonstrate that a parasite-selective inhibitor could be used to attenuate parasite growth in vivo without appreciable toxicity to the host.  Thus, the Plasmodium proteasome is a chem. tractable target that could be exploited by next-generation anti-malarial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriK0Li_WncVrVg90H21EOLACvtfcHk0liSKC7a8USgCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyrsr8%253D&md5=f24a562efb64dd533a7dbcfeff4171af</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnature16936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16936%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3DXie%26aufirst%3DS.%2BC.%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DFoe%26aufirst%3DI.%2BT.%26aulast%3DTilley%26aufirst%3DL.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3Dda%2BFonseca%26aufirst%3DP.%2BC.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DStructure-%2520and%2520function-based%2520design%2520of%2520Plasmodium-selective%2520proteasome%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D530%26spage%3D233%26epage%3D236%26doi%3D10.1038%2Fnature16936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Stelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">A set of sctivity-based probes to visualize human (immuno)proteasome activities</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4199</span>– <span class="NLM_lpage">4203</span>, <span class="refDoi"> DOI: 10.1002/anie.201509092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1002%2Fanie.201509092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=4199-4203&author=G.+de%0ABruinauthor=B.+T.+Xinauthor=M.+Krausauthor=M.+van+der%0ASteltauthor=G.+A.+van+der+Marelauthor=A.+F.+Kisselevauthor=C.+Driessenauthor=B.+I.+Floreaauthor=H.+S.+Overkleeft&title=A+set+of+sctivity-based+probes+to+visualize+human+%28immuno%29proteasome+activities&doi=10.1002%2Fanie.201509092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fanie.201509092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201509092%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DXin%26aufirst%3DB.%2BT.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DA%2520set%2520of%2520sctivity-based%2520probes%2520to%2520visualize%2520human%2520%2528immuno%2529proteasome%2520activities%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D4199%26epage%3D4203%26doi%3D10.1002%2Fanie.201509092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geurink, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyburne, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirabella, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silzle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabaneh, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haile, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rooden, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appenzeller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span> <span> </span><span class="NLM_article-title">The novel beta2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1360</span>, <span class="refDoi"> DOI: 10.3324/haematol.2014.109421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.3324%2Fhaematol.2014.109421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=26069288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVKitrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=1350-1360&author=M.+Krausauthor=J.+Baderauthor=P.+P.+Geurinkauthor=E.+S.+Weyburneauthor=A.+C.+Mirabellaauthor=T.+Silzleauthor=T.+B.+Shabanehauthor=W.+A.+van+der+Lindenauthor=G.+de+Bruinauthor=S.+R.+Haileauthor=E.+van+Roodenauthor=C.+Appenzellerauthor=N.+Liauthor=A.+F.+Kisselevauthor=H.+Overkleeftauthor=C.+Driessen&title=The+novel+beta2-selective+proteasome+inhibitor+LU-102+synergizes+with+bortezomib+and+carfilzomib+to+overcome+proteasome+inhibitor+resistance+of+myeloma+cells&doi=10.3324%2Fhaematol.2014.109421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells</span></div><div class="casAuthors">Kraus, Marianne; Bader, Juergen; Geurink, Paul P.; Weyburne, Emily S.; Mirabella, Anne C.; Silzle, Tobias; Shabaneh, Tamer B.; van der Linden, Wouter A.; de Bruin, Gerjan; Haile, Sarah R.; van Rooden, Eva; Appenzeller, Christina; Li, Nan; Kisselev, Alexei F.; Overkleeft, Herman; Driessen, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1350-1360</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Proteasome inhibitor resistance is a challenge for myeloma therapy.  Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome.  Bortezomib-resistant myeloma cells down-regulate the activation status of the unfolded protein response, and up-regulate β2 proteasome activity.  To improve proteasome inhibition in bortezomib-resistant myeloma and to achieve more efficient UPR activation, we have developed LU-102, a selective inhibitor of the β2 proteasome activity.  LU-102 inhibited the β2 activity in intact myeloma cells at low micromolar concns. without relevant co-inhibition of β1 and β5 proteasome subunits.  In protea-some inhibitor-resistant myeloma cells, significantly more potent proteasome inhibition was achieved by bortezomib or carfilzomib in combination with LU-102, compared to bortezomib/carfilzomib alone, resulting in highly synergistic cytotoxic activity of the drug combination via endoplasmatic reticulum stress-induced apoptosis.  Combining bortezomib/carfilzomib with LU-102 significantly prolonged proteasome inhibition and increased activation of the unfolded protein response and IRE1-α activity.  IRE1-α has recently been shown to control myeloma cell differentiation and bortezomib sensitivity (Leung-Hagesteijn, Cancer Cell 24:3, 289-304).  Thus, β2-selective proteasome inhibition by LU-102 in combination with bortezomib or carfilzomib re-sults in synergistic proteasome inhibition, activation of the unfolded protein response, and cytotoxicity, and overcomes bortezomib/carfilzomib resistance in myeloma cells in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhWaSEQ0aXHbVg90H21EOLACvtfcHk0liSKC7a8USgCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVKitrjE&md5=7895da9ac823a56178903ca149c8d39f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2014.109421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2014.109421%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DBader%26aufirst%3DJ.%26aulast%3DGeurink%26aufirst%3DP.%2BP.%26aulast%3DWeyburne%26aufirst%3DE.%2BS.%26aulast%3DMirabella%26aufirst%3DA.%2BC.%26aulast%3DSilzle%26aufirst%3DT.%26aulast%3DShabaneh%26aufirst%3DT.%2BB.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DHaile%26aufirst%3DS.%2BR.%26aulast%3Dvan%2BRooden%26aufirst%3DE.%26aulast%3DAppenzeller%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DOverkleeft%26aufirst%3DH.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DThe%2520novel%2520beta2-selective%2520proteasome%2520inhibitor%2520LU-102%2520synergizes%2520with%2520bortezomib%2520and%2520carfilzomib%2520to%2520overcome%2520proteasome%2520inhibitor%2520resistance%2520of%2520myeloma%2520cells%26jtitle%3DHaematologica%26date%3D2015%26volume%3D100%26spage%3D1350%26epage%3D1360%26doi%3D10.3324%2Fhaematol.2014.109421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheppeck, J. E.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosink, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheatley, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gjerstad, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loftus, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubiria, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janc, J. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a statistically exhaustive fluorescent peptide substrate library for profiling protease specificity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2639</span>– <span class="NLM_lpage">2642</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(00)00545-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2FS0960-894X%2800%2900545-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2639-2642&author=J.+E.+Sheppeckauthor=H.+Karauthor=L.+Gosinkauthor=J.+B.+Wheatleyauthor=E.+Gjerstadauthor=S.+M.+Loftusauthor=A.+R.+Zubiriaauthor=J.+W.+Janc&title=Synthesis+of+a+statistically+exhaustive+fluorescent+peptide+substrate+library+for+profiling+protease+specificity&doi=10.1016%2FS0960-894X%2800%2900545-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900545-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900545-X%26sid%3Dliteratum%253Aachs%26aulast%3DSheppeck%26aufirst%3DJ.%2BE.%26aulast%3DKar%26aufirst%3DH.%26aulast%3DGosink%26aufirst%3DL.%26aulast%3DWheatley%26aufirst%3DJ.%2BB.%26aulast%3DGjerstad%26aufirst%3DE.%26aulast%3DLoftus%26aufirst%3DS.%2BM.%26aulast%3DZubiria%26aufirst%3DA.%2BR.%26aulast%3DJanc%26aufirst%3DJ.%2BW.%26atitle%3DSynthesis%2520of%2520a%2520statistically%2520exhaustive%2520fluorescent%2520peptide%2520substrate%2520library%2520for%2520profiling%2520protease%2520specificity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2639%26epage%3D2642%26doi%3D10.1016%2FS0960-894X%2800%2900545-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, C.</span></span> <span> </span><span class="NLM_article-title">Distinct specificities of <i>Mycobacterium tuberculosis</i> and mammalian proteasomes for N-acetyl tripeptide substrates</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">34423</span>– <span class="NLM_lpage">34431</span>, <span class="refDoi"> DOI: 10.1074/jbc.M805324200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1074%2Fjbc.M805324200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=18829465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVelu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=34423-34431&author=G.+Linauthor=C.+Tsuauthor=L.+Dickauthor=X.+K.+Zhouauthor=C.+Nathan&title=Distinct+specificities+of+Mycobacterium+tuberculosis+and+mammalian+proteasomes+for+N-acetyl+tripeptide+substrates&doi=10.1074%2Fjbc.M805324200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Specificities of Mycobacterium tuberculosis and Mammalian Proteasomes for N-Acetyl Tripeptide Substrates</span></div><div class="casAuthors">Lin, Gang; Tsu, Christopher; Dick, Lawrence; Zhou, Xi K.; Nathan, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">34423-34431</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The proteasome of Mycobacterium tuberculosis (Mtb) is a validated and drug-treatable target for therapeutics.  To lay ground-work for developing peptide-based inhibitors with a useful degree of selectivity for the Mtb proteasome over those of the host, we used a library of 5920 N-acetyl tripeptide-aminomethylcoumarins to contrast the substrate preferences of the recombinant Mtb proteasome wild type and open gate mutant, the Rhodococcus erythropolis proteasome, and the bovine proteasome with activator PA28.  The Mtb proteasome was distinctive in strictly preferring P1 = tryptophan, particularly in combination with P3 = glycine, proline, lysine or arginine.  Screening results were validated with Michaelis-Menten kinetic analyses of 21 oligopeptide aminomethyl-coumarin substrates.  Bortezomib, a proteasome inhibitor in clin. use, and 17 analogs varying only at P1 were used to examine the differential impact of inhibitors on human and Mtb proteasomes.  The results with the inhibitor panel confirmed those with the substrate panel in demonstrating differential preferences of Mtb and mammalian proteasomes at the P1 amino acid.  Changing P1 in bortezomib from Leu to m-CF3-Phe led to a 220-fold increase in IC50 against the human proteasome, whereas changing a P1 Ala to m-F-Phe decreased the IC50 400-fold against the Mtb proteasome.  The change of a P1 Ala to m-Cl-Phe led to an 8000-fold shift in inhibitory potency in favor of the Mtb proteasome, resulting in 8-fold selectivity.  Combinations of preferred amino acids at different sites may thus improve the species selectivity of peptide-based inhibitors that target the Mtb proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVpCPunOb8tLVg90H21EOLACvtfcHk0lgKJPc3zKEIfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVelu7jP&md5=6f73b15a893fe094894ca3916882d834</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M805324200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M805324200%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DX.%2BK.%26aulast%3DNathan%26aufirst%3DC.%26atitle%3DDistinct%2520specificities%2520of%2520Mycobacterium%2520tuberculosis%2520and%2520mammalian%2520proteasomes%2520for%2520N-acetyl%2520tripeptide%2520substrates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D34423%26epage%3D34431%26doi%3D10.1074%2Fjbc.M805324200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Westhuyzen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momper, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogyo, M.</span></span> <span> </span><span class="NLM_article-title">Defining the determinants of specificity of <i>Plasmodium</i> proteasome inhibitors</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">11424</span>– <span class="NLM_lpage">11437</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b06656</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b06656" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=11424-11437&author=E.+Yooauthor=B.+H.+Stokesauthor=H.+de+Jongauthor=M.+Vanaerschotauthor=T.+Kumarauthor=N.+Lawrenceauthor=M.+Njorogeauthor=A.+Garciaauthor=R.+Van+der+Westhuyzenauthor=J.+D.+Momperauthor=C.+L.+Ngauthor=D.+A.+Fidockauthor=M.+Bogyo&title=Defining+the+determinants+of+specificity+of+Plasmodium+proteasome+inhibitors&doi=10.1021%2Fjacs.8b06656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors</span></div><div class="casAuthors">Yoo, Euna; Stokes, Barbara H.; de Jong, Hanna; Vanaerschot, Manu; Kumar, T. R. S.; Lawrence, Nina; Njoroge, Mathew; Garcia, Arnold; Van der Westhuyzen, Renier; Momper, Jeremiah D.; Ng, Caroline L.; Fidock, David A.; Bogyo, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">11424-11437</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Plasmodium proteasome is an emerging antimalarial target due to its essential role in all the major life cycle stages of the parasite and its contribution to the establishment of resistance to artemisinin (ART)-based therapies.  However, because of a similarly essential role for the host proteasome, the key property of any antiproteasome therapeutic is selectivity.  Several parasite-specific proteasome inhibitors have recently been reported, however, their selectivity must be improved to enable clin. development.  Here we describe screening of diverse libraries of non-natural synthetic fluorogenic substrates to identify determinants at multiple positions on the substrate that produce enhanced selectivity.  We find that selection of an optimal electrophilic "warhead" is essential to enable high selectivity that is driven by the peptide binding elements on the inhibitor.  We also find that host cell toxicity is dictated by the extent of coinhibition of the human β2 and β5 subunits.  Using this information, we identify compds. with over 3 orders of magnitude selectivity for the parasite enzyme.  Optimization of the pharmacol. properties resulted in mols. that retained high potency and selectivity, were sol., sufficiently metabolically stable and orally bioavailable.  These mols. are highly synergistic with ART and can clear parasites in a mouse model of infection, making them promising leads as antimalarial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzXchyqonWDrVg90H21EOLACvtfcHk0lgKJPc3zKEIfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbN&md5=990e0b5097087ff76681f901b2c8f35f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b06656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b06656%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DStokes%26aufirst%3DB.%2BH.%26aulast%3Dde%2BJong%26aufirst%3DH.%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DT.%26aulast%3DLawrence%26aufirst%3DN.%26aulast%3DNjoroge%26aufirst%3DM.%26aulast%3DGarcia%26aufirst%3DA.%26aulast%3DVan%2Bder%2BWesthuyzen%26aufirst%3DR.%26aulast%3DMomper%26aufirst%3DJ.%2BD.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DBogyo%26aufirst%3DM.%26atitle%3DDefining%2520the%2520determinants%2520of%2520specificity%2520of%2520Plasmodium%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26spage%3D11424%26epage%3D11437%26doi%3D10.1021%2Fjacs.8b06656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostova, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mease, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denmeade, S. R.</span></span> <span> </span><span class="NLM_article-title">Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4224</span>– <span class="NLM_lpage">4235</span>, <span class="refDoi"> DOI: 10.1021/jm301718c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301718c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvFyis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4224-4235&author=M.+B.+Kostovaauthor=D.+M.+Rosenauthor=Y.+Chenauthor=R.+C.+Measeauthor=S.+R.+Denmeade&title=Structural+optimization%2C+biological+evaluation%2C+and+application+of+peptidomimetic+prostate+specific+antigen+inhibitors&doi=10.1021%2Fjm301718c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors</span></div><div class="casAuthors">Kostova, Maya B.; Rosen, D. Marc; Chen, Ying; Mease, Ronnie C.; Denmeade, Samuel R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4224-4235</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostate-specific antigen (PSA) is a serine protease produced at high levels by normal and malignant prostate epithelial cells that is used extensively as a biomarker in the clin. management of prostate cancer.  To better understand PSA's role in prostate cancer progression, we prepd. a library of peptidyl boronic acid-based inhibitors.  To enhance selectivity for PSA vs other serine proteases, we modified the P1 site of the inhibitors to incorporate a bromopropylglycine group.  This allowed the inhibitors to participate in halogen bond formation with the serine found at the bottom of the specificity pocket.  The best of these Ahx-FSQn(boro)Bpg had PSA Ki of 72 nM and chymotrypsin Ki of 580 nM.  In vivo studies using PSA-producing xenografts demonstrated that candidate inhibitors had minimal effect on growth but significantly altered serum levels of PSA.  Biodistribution of 125I labeled peptides showed low levels of uptake into tumors compared to other normal tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkTFZGJTbgAbVg90H21EOLACvtfcHk0lgKJPc3zKEIfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvFyis7g%253D&md5=20fdf7c185d3058335a1cb24ae7f652c</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm301718c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301718c%26sid%3Dliteratum%253Aachs%26aulast%3DKostova%26aufirst%3DM.%2BB.%26aulast%3DRosen%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMease%26aufirst%3DR.%2BC.%26aulast%3DDenmeade%26aufirst%3DS.%2BR.%26atitle%3DStructural%2520optimization%252C%2520biological%2520evaluation%252C%2520and%2520application%2520of%2520peptidomimetic%2520prostate%2520specific%2520antigen%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4224%26epage%3D4235%26doi%3D10.1021%2Fjm301718c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pickersgill, I. F.</span>; <span class="NLM_string-name">Bishop, J.</span>; <span class="NLM_string-name">Koellner, C.</span>; <span class="NLM_string-name">Gomez, J.-M.</span>; <span class="NLM_string-name">Geiser, A.</span>; <span class="NLM_string-name">Hett, R.</span>; <span class="NLM_string-name">Ammoscato, V.</span>; <span class="NLM_string-name">Munk, S.</span>; <span class="NLM_string-name">Lo, Y.</span>; <span class="NLM_string-name">Chui, F.-T.</span>; <span class="NLM_string-name">Kulkarni, V. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis Of Boronic Ester And Acid Compounds</span>. Patent Publication Number <span class="NLM_patent">WO 2005/097809</span>, <span class="NLM_year">2005</span>; Millenium Pharmaceuticals Inc.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=I.+F.+Pickersgill&author=J.+Bishop&author=C.+Koellner&author=J.-M.+Gomez&author=A.+Geiser&author=R.+Hett&author=V.+Ammoscato&author=S.+Munk&author=Y.+Lo&author=F.-T.+Chui&author=V.+R.+Kulkarni&title=Synthesis+Of+Boronic+Ester+And+Acid+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPickersgill%26aufirst%3DI.%2BF.%26atitle%3DSynthesis%2520Of%2520Boronic%2520Ester%2520And%2520Acid%2520Compounds%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dogovski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klonis, N.</span></span> <span> </span><span class="NLM_article-title">Optimal assay design for determining the in vitro sensitivity of ring stage <i>Plasmodium falciparum</i> to artemisinins</span>. <i>Int. J. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1016/j.ijpara.2014.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1016%2Fj.ijpara.2014.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=25161101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2lt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=893-899&author=S.+C.+Xieauthor=C.+Dogovskiauthor=S.+Kennyauthor=L.+Tilleyauthor=N.+Klonis&title=Optimal+assay+design+for+determining+the+in+vitro+sensitivity+of+ring+stage+Plasmodium+falciparum+to+artemisinins&doi=10.1016%2Fj.ijpara.2014.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Optimal assay design for determining the in vitro sensitivity of ring stage Plasmodium falciparum to artemisinins</span></div><div class="casAuthors">Xie, Stanley C.; Dogovski, Con; Kenny, Shannon; Tilley, Leann; Klonis, Nectarios</div><div class="citationInfo"><span class="NLM_cas:title">International Journal for Parasitology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">893-899</span>CODEN:
                <span class="NLM_cas:coden">IJPYBT</span>;
        ISSN:<span class="NLM_cas:issn">0020-7519</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent reports demonstrate that failure of artemisinin-based antimalarial therapies is assocd. with an altered response of early blood stage Plasmodium falciparum.  This has led to increased interest in the use of pulse assays that mimic clin. drug exposure for analyzing artemisinin sensitivity of highly synchronised ring stage parasites.  We report a methodol. for the reliable execution of drug pulse assays and detail a synchronisation strategy that produces well-defined tightly synchronised ring stage cultures in a convenient time-frame.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKbGAjR2QHw7Vg90H21EOLACvtfcHk0lhMlmk4ejQBVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2lt7vK&md5=dc166c5dd13df61df1bfbf18883bb391</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpara.2014.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpara.2014.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DS.%2BC.%26aulast%3DDogovski%26aufirst%3DC.%26aulast%3DKenny%26aufirst%3DS.%26aulast%3DTilley%26aufirst%3DL.%26aulast%3DKlonis%26aufirst%3DN.%26atitle%3DOptimal%2520assay%2520design%2520for%2520determining%2520the%2520in%2520vitro%2520sensitivity%2520of%2520ring%2520stage%2520Plasmodium%2520falciparum%2520to%2520artemisinins%26jtitle%3DInt.%2520J.%2520Parasitol.%26date%3D2014%26volume%3D44%26spage%3D893%26epage%3D899%26doi%3D10.1016%2Fj.ijpara.2014.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowell, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Istvan, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukens, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Lorenzo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanaerschot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata-Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magistrado, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linares, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arriaga, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bopp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnadig, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coburn-Flynn, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murithi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moura, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akidil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjalley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaseichuk, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottilie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamo, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span> <span> </span><span class="NLM_article-title">Mapping the malaria parasite druggable genome by using <i>in vitro</i> evolution and chemogenomics</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1126/science.aan4472</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1126%2Fscience.aan4472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=29326268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmt1ehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2018&pages=191-199&author=A.+N.+Cowellauthor=E.+S.+Istvanauthor=A.+K.+Lukensauthor=M.+G.+Gomez-Lorenzoauthor=M.+Vanaerschotauthor=T.+Sakata-Katoauthor=E.+L.+Flanneryauthor=P.+Magistradoauthor=E.+Owenauthor=M.+Abrahamauthor=G.+LaMonteauthor=H.+J.+Painterauthor=R.+M.+Williamsauthor=V.+Francoauthor=M.+Linaresauthor=I.+Arriagaauthor=S.+Boppauthor=V.+C.+Coreyauthor=N.+F.+Gnadigauthor=O.+Coburn-Flynnauthor=C.+Reimerauthor=P.+Guptaauthor=J.+M.+Murithiauthor=P.+A.+Mouraauthor=O.+Fuchsauthor=E.+Sasakiauthor=S.+W.+Kimauthor=C.+H.+Tengauthor=L.+T.+Wangauthor=A.+Akidilauthor=S.+Adjalleyauthor=P.+A.+Willisauthor=D.+Siegelauthor=O.+Tanaseichukauthor=Y.+Zhongauthor=Y.+Zhouauthor=M.+Llinasauthor=S.+Ottilieauthor=F.+J.+Gamoauthor=M.+C.+S.+Leeauthor=D.+E.+Goldbergauthor=D.+A.+Fidockauthor=D.+F.+Wirthauthor=E.+A.+Winzeler&title=Mapping+the+malaria+parasite+druggable+genome+by+using+in+vitro+evolution+and+chemogenomics&doi=10.1126%2Fscience.aan4472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics</span></div><div class="casAuthors">Cowell, Annie N.; Istvan, Eva S.; Lukens, Amanda K.; Gomez-Lorenzo, Maria G.; Vanaerschot, Manu; Sakata-Kato, Tomoyo; Flannery, Erika L.; Magistrado, Pamela; Owen, Edward; Abraham, Matthew; La Monte, Gregory; Painter, Heather J.; Williams, Roy M.; Franco, Virginia; Linares, Maria; Arriaga, Ignacio; Bopp, Selina; Corey, Victoria C.; Gnaedig, Nina F.; Coburn-Flynn, Olivia; Reimer, Christin; Gupta, Purva; Murithi, James M.; Moura, Pedro A.; Fuchs, Olivia; Sasaki, Erika; Kim, Sang W.; Teng, Christine H.; Wang, Lawrence T.; Akidil, Asli; Adjalley, Sophie; Willis, Paul A.; Siegel, Dionicio; Tanaseichuk, Olga; Zhong, Yang; Zhou, Yingyao; Llinas, Manuel; Ottilie, Sabine; Gamo, Francisco-Javier; Lee, Marcus C. S.; Goldberg, Daniel E.; Fidock, David A.; Wirth, Dyann F.; Winzeler, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">6372</span>),
    <span class="NLM_cas:pages">191-199</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Chemogenetic characterization through in vitro evolution combined with whole-genome anal. can identify antimalarial drug targets and drug-resistance genes.  We performed a genome anal. of 262 Plasmodium falciparum parasites resistant to 37 diverse compds.  We found 159 gene amplifications and 148 nonsynonymous changes in 83 genes assocd. with drug-resistance acquisition, where gene amplifications contributed to one-third of resistance acquisition events.  Beyond confirming previously identified multidrug-resistance mechanisms, we discovered hitherto unrecognized drug target-inhibitor pairs, including thymidylate synthase and a benzoquinazolinone, farnesyltransferase and a pyrimidinedione, and a dipeptidylpeptidase and an arylurea.  This exploration of the P. falciparum resistome and druggable genome will likely guide drug discovery and structural biol. efforts, while also advancing our understanding of resistance mechanisms available to the malaria parasite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh05CQ_5D5nrVg90H21EOLACvtfcHk0lhMlmk4ejQBVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmt1ehug%253D%253D&md5=fb3b3af094ea64e2b33df2371655282f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1126%2Fscience.aan4472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aan4472%26sid%3Dliteratum%253Aachs%26aulast%3DCowell%26aufirst%3DA.%2BN.%26aulast%3DIstvan%26aufirst%3DE.%2BS.%26aulast%3DLukens%26aufirst%3DA.%2BK.%26aulast%3DGomez-Lorenzo%26aufirst%3DM.%2BG.%26aulast%3DVanaerschot%26aufirst%3DM.%26aulast%3DSakata-Kato%26aufirst%3DT.%26aulast%3DFlannery%26aufirst%3DE.%2BL.%26aulast%3DMagistrado%26aufirst%3DP.%26aulast%3DOwen%26aufirst%3DE.%26aulast%3DAbraham%26aufirst%3DM.%26aulast%3DLaMonte%26aufirst%3DG.%26aulast%3DPainter%26aufirst%3DH.%2BJ.%26aulast%3DWilliams%26aufirst%3DR.%2BM.%26aulast%3DFranco%26aufirst%3DV.%26aulast%3DLinares%26aufirst%3DM.%26aulast%3DArriaga%26aufirst%3DI.%26aulast%3DBopp%26aufirst%3DS.%26aulast%3DCorey%26aufirst%3DV.%2BC.%26aulast%3DGnadig%26aufirst%3DN.%2BF.%26aulast%3DCoburn-Flynn%26aufirst%3DO.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DMurithi%26aufirst%3DJ.%2BM.%26aulast%3DMoura%26aufirst%3DP.%2BA.%26aulast%3DFuchs%26aufirst%3DO.%26aulast%3DSasaki%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DTeng%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DL.%2BT.%26aulast%3DAkidil%26aufirst%3DA.%26aulast%3DAdjalley%26aufirst%3DS.%26aulast%3DWillis%26aufirst%3DP.%2BA.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DTanaseichuk%26aufirst%3DO.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLlinas%26aufirst%3DM.%26aulast%3DOttilie%26aufirst%3DS.%26aulast%3DGamo%26aufirst%3DF.%2BJ.%26aulast%3DLee%26aufirst%3DM.%2BC.%2BS.%26aulast%3DGoldberg%26aufirst%3DD.%2BE.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26atitle%3DMapping%2520the%2520malaria%2520parasite%2520druggable%2520genome%2520by%2520using%2520in%2520vitro%2520evolution%2520and%2520chemogenomics%26jtitle%3DScience%26date%3D2018%26volume%3D359%26spage%3D191%26epage%3D199%26doi%3D10.1126%2Fscience.aan4472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labutti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span> <span> </span><span class="NLM_article-title">Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3052</span>– <span class="NLM_lpage">3061</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1158%2F1535-7163.MCT-06-0185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=17172407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlagsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=3052-3061&author=M.+J.+Williamsonauthor=J.+L.+Blankauthor=F.+J.+Bruzzeseauthor=Y.+Caoauthor=J.+S.+Danielsauthor=L.+R.+Dickauthor=J.+Labuttiauthor=A.+M.+Mazzolaauthor=A.+D.+Patilauthor=C.+L.+Reimerauthor=M.+S.+Solomonauthor=M.+Stirlingauthor=Y.+Tianauthor=C.+A.+Tsuauthor=G.+S.+Weatherheadauthor=J.+X.+Zhangauthor=M.+Rolfe&title=Comparison+of+biochemical+and+biological+effects+of+ML858+%28salinosporamide+A%29+and+bortezomib&doi=10.1158%2F1535-7163.MCT-06-0185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib</span></div><div class="casAuthors">Williamson, Mark J.; Blank, Jonathan L.; Bruzzese, Frank J.; Cao, Yueying; Daniels, J. Scott; Dick, Lawrence R.; Labutti, Jason; Mazzola, Anne M.; Patil, Ashok D.; Reimer, Corinne L.; Solomon, Marjorie S.; Stirling, Matthew; Tian, Yuan; Tsu, Christopher A.; Weatherhead, Gabriel S.; Zhang, Julie X.; Rolfe, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3052-3061</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Strains within the genus Salinospora have been shown to produce complex natural products having antibiotic and antiproliferative activities.  The biochem. basis for the cytotoxic effects of salinosporamide A has been linked to its ability to inhibit the proteasome.  Synthetically accessible salinosporamide A (ML858) was used to det. its biochem. and biol. activities and to compare its effects with those of bortezomib.  ML858 and bortezomib show time- and concn.-dependent inhibition of the proteasome in vitro.  However, unlike bortezomib, which is a reversible inhibitor, ML858 covalently binds to the proteasome, resulting in the irreversible inhibition of 20S proteasome activity.  ML858 was equipotent to bortezomib in cell-based reporter stabilization assays, but due to intramol. instability is less potent in long-term assays.  ML858 failed to maintain levels of proteasome inhibition necessary to achieve efficacy in tumor models responsive to bortezomib.  Our results show that ML858 and bortezomib exhibit different kinetic and pharmacol. profiles and suggest that addnl. characterization of ML858 is warranted before its therapeutic potential can be fully appreciated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGfUS2QJCMw7Vg90H21EOLACvtfcHk0lgwpOtjDQZ59A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlagsbrN&md5=a8290c05f5e767604e4968dfff5498d8</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0185%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DM.%2BJ.%26aulast%3DBlank%26aufirst%3DJ.%2BL.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DLabutti%26aufirst%3DJ.%26aulast%3DMazzola%26aufirst%3DA.%2BM.%26aulast%3DPatil%26aufirst%3DA.%2BD.%26aulast%3DReimer%26aufirst%3DC.%2BL.%26aulast%3DSolomon%26aufirst%3DM.%2BS.%26aulast%3DStirling%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DTsu%26aufirst%3DC.%2BA.%26aulast%3DWeatherhead%26aufirst%3DG.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%2BX.%26aulast%3DRolfe%26aufirst%3DM.%26atitle%3DComparison%2520of%2520biochemical%2520and%2520biological%2520effects%2520of%2520ML858%2520%2528salinosporamide%2520A%2529%2520and%2520bortezomib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D3052%26epage%3D3061%26doi%3D10.1158%2F1535-7163.MCT-06-0185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaMonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjahjadi, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wintjens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malleret, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonamy, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winzeler, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span> <span> </span><span class="NLM_article-title">UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes</span>. <i>Nat. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">16166</span>, <span class="refDoi"> DOI: 10.1038/nmicrobiol.2016.166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=10.1038%2Fnmicrobiol.2016.166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=27642791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFyrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=16166&author=M.+Y.+Limauthor=G.+LaMonteauthor=M.+C.+Leeauthor=C.+Reimerauthor=B.+H.+Tanauthor=V.+Coreyauthor=B.+F.+Tjahjadiauthor=A.+Chuaauthor=M.+Nachonauthor=R.+Wintjensauthor=P.+Gedeckauthor=B.+Malleretauthor=L.+Reniaauthor=G.+M.+Bonamyauthor=P.+C.+Hoauthor=B.+K.+Yeungauthor=E.+D.+Chowauthor=L.+Limauthor=D.+A.+Fidockauthor=T.+T.+Diaganaauthor=E.+A.+Winzelerauthor=P.+Bifani&title=UDP-galactose+and+acetyl-CoA+transporters+as+Plasmodium+multidrug+resistance+genes&doi=10.1038%2Fnmicrobiol.2016.166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes</span></div><div class="casAuthors">Lim, Michelle Yi-Xiu; La Monte, Gregory; Lee, Marcus C. S.; Reimer, Christin; Tan, Bee Huat; Corey, Victoria; Tjahjadi, Bianca F.; Chua, Adeline; Nachon, Marie; Wintjens, Rene; Gedeck, Peter; Malleret, Benoit; Renia, Laurent; Bonamy, Ghislain M. C.; Ho, Paul Chi-Lui; Yeung, Bryan K. S.; Chow, Eric D.; Lim, Liting; Fidock, David A.; Diagana, Thierry T.; Winzeler, Elizabeth A.; Bifani, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Microbiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">16166</span>CODEN:
                <span class="NLM_cas:coden">NMAICH</span>;
        ISSN:<span class="NLM_cas:issn">2058-5276</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A mol. understanding of drug resistance mechanisms enables surveillance of the effectiveness of new antimicrobial therapies during development and deployment in the field.  We used conventional drug resistance selection as well as a regime of limiting diln. at early stages of drug treatment to probe 2 antimalarial imidazolopiperazines, KAF156 and GNF179.  The latter approach permits the isolation of low-fitness mutants that might otherwise be out-competed during selection.  Whole-genome sequencing of 24 independently derived resistant Plasmodium falciparum clones revealed 4 parasites with mutations in the known cyclic amine resistance locus (pfcarl) and a further 20 with mutations in 2 previously unreported P. falciparum drug resistance genes, an acetyl-CoA transporter (pfact) and a UDP-galactose transporter (pfugt).  Mutations were validated both in vitro by CRISPR editing in P. falciparum and in vivo by evolution of resistant Plasmodium berghei mutants.  Both PfACT and PfUGT were localized to the endoplasmic reticulum by fluorescence microscopy.  As mutations in pfact and pfugt conveyed resistance against addnl. unrelated chem. scaffolds, these genes are probably involved in broad mechanisms of antimalarial drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWucZl9WjFw7Vg90H21EOLACvtfcHk0lgwpOtjDQZ59A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFyrtrw%253D&md5=c87d57996e20bb94d7d44c556553daf4</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnmicrobiol.2016.166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmicrobiol.2016.166%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DM.%2BY.%26aulast%3DLaMonte%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DReimer%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DB.%2BH.%26aulast%3DCorey%26aufirst%3DV.%26aulast%3DTjahjadi%26aufirst%3DB.%2BF.%26aulast%3DChua%26aufirst%3DA.%26aulast%3DNachon%26aufirst%3DM.%26aulast%3DWintjens%26aufirst%3DR.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DMalleret%26aufirst%3DB.%26aulast%3DRenia%26aufirst%3DL.%26aulast%3DBonamy%26aufirst%3DG.%2BM.%26aulast%3DHo%26aufirst%3DP.%2BC.%26aulast%3DYeung%26aufirst%3DB.%2BK.%26aulast%3DChow%26aufirst%3DE.%2BD.%26aulast%3DLim%26aufirst%3DL.%26aulast%3DFidock%26aufirst%3DD.%2BA.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DWinzeler%26aufirst%3DE.%2BA.%26aulast%3DBifani%26aufirst%3DP.%26atitle%3DUDP-galactose%2520and%2520acetyl-CoA%2520transporters%2520as%2520Plasmodium%2520multidrug%2520resistance%2520genes%26jtitle%3DNat.%2520Microbiol.%26date%3D2016%26volume%3D1%26spage%3D16166%26doi%3D10.1038%2Fnmicrobiol.2016.166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fmg" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fmg','PDB','5fmg'); return false;">PDB: 5fmg</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5lf3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5lf3','PDB','5lf3'); return false;">PDB: 5lf3</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i34"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01161">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_77313"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01161">10.1021/acs.jmedchem.8b01161</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_001.csv">CSV</a>)</p></li><li><p class="inline">Tables S1 and S2 listing sequencing statistics and summary of single nucleotide variants and insertion-deletions for bortezomib resistant <i>P. falciparum</i> clones; Figure S1–S9 showing purification of <i>Pf</i>20S proteasome; optimization of <i>Pf</i>20S proteasome activities; kinetic analysis of MPI-4; in vitro evolution of resistance to bortezomib; structure analysis of β5 mutations associated with bortezomib resistance; active site probe analysis of the selected compounds; proteasome substrate profiling of human 20S immunoproteasome and <i>P. falciparum</i> proteasome; substrate preferences of human constitutive and <i>Pf</i>20S proteasomes; NMR structural assignments of MPI compounds; synthesis of BMV037 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_001.csv">jm8b01161_si_001.csv (1.72 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01161/suppl_file/jm8b01161_si_002.pdf">jm8b01161_si_002.pdf (2.07 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01161&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-22%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01161%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01161" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a4e71dc123cac","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
